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Posttraumatic stress disorder (PTSD) is a severe, chronic and debilitating psychiatric disorder that can 
present after the experience of a life-threatening traumatic event. D-cycloserine (DCS), a partial N-
methyl-D-aspartate (NMDA) receptor agonist, has been found to augment cognitive behavioural 
therapy by facilitating fear extinction; however, the precise mechanisms whereby DCS ameliorates 
fear triggered by a traumatic context remains to be fully elucidated. This study aimed to (i) identify 
the molecular mechanisms of intrahippocampally administered DCS in facilitating fear extinction in a 
rat model of PTSD by investigating gene expression profiles in the left dorsal hippocampus (LDH) of 
male Sprague Dawley rats and (ii) determine whether microRNA (miRNA) expression and DNA 
methylation mediated these gene expression changes. 
 
An adapted version of the PTSD animal model described by Siegmund and Wotjak (2007) was 
utilised. The total number of 120 rats were grouped into four experimental groups (of 30 rats per 
group) based on fear conditioning and the intrahippocampal administration of either DCS or saline: 
(1) fear conditioned + intrahippocampal saline administration (FS), (2) fear conditioned + 
intrahippocampal DCS administration (FD), (3) control + intrahippocampal saline administration (CS) 
and (4) control + intrahippocampal DCS administration (CD). Behavioural tests (the light/dark [L/D] 
avoidance test, forced swim test and open field test) were conducted to assess anxiety and PTSD-like 
behaviours. The L/D avoidance test was the most sensitive behavioural test of anxiety and was 
subsequently used to differentiate maladapted (animals that displayed anxiety-like behaviour) and 
well-adapted (animals that did not display anxiety-like behaviour) subgroups. In order to identify 
genes that were differentially expressed between FS maladapted (FSM) (n = 6) vs. FD well-adapted 
(FDW) (n = 6) groups, RNA sequencing was performed on the Illumina HiSeq 2000 which generated 
more than 60 million reads per sample. This was followed by subsequent bioinformatics analyses 
(using the software programs TopHat, Bowtie, Cuffdiff and Bio-Ontological Relationship Graph 
(BORG) database (that identifies genes that may be biologically relevant) to identify biologically 
relevant differentially expressed genes between the treatment groups. Epigenetic mechanisms 
mediating observed differences in gene expression were investigated by conducting DNA methylation 
and miRNAseq analyses in the FDW and FSM experimental groups. DNA methylation was 
investigated using real-time quantitative PCR (qPCR) amplification followed by high resolution melt 
analysis on the Rotor-GeneTM 6000. Differences in miRNA expression levels between the FDW and 
FSM groups were investigated by sequencing the miRNA fraction on the MiSeq platform.  
The bioinformatics pipeline used to analyse the RNAseq data identified 93 genes that were 
significantly downregulated in the FDW group compared to the FSM group. Forty-two of these 
genes were predicted to be biologically relevant (based on BORG analysis). Integrative network 
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analyses revealed subsets of differentially expressed genes common across biological functions, 
pathways and disorders. The co-administration of DCS and behavioural fear extinction 
downregulated immune system genes and genes that transcribe proinflammatory and oxidative 
stress molecules. These molecules mediate neuroinflammation and subsequently cause neuronal 
damage. DCS also regulated genes involved in learning and memory processes. Additionally, a 
subset of the genes, which have been found to be associated with disorders that commonly co-occur 
with PTSD (such as cardiovascular disease, metabolic disease, Alzheimer’s and Parkinson’s 
disease), was downregulated by the co-administration of DCS and behavioural fear extinction.  
 
In order to determine whether real-time qPCR analysis would be sensitive enough to detect 
differential expression in those genes found to be differentially expressed in RNAseq analysis, the 
expression of nine genes was analysed using SYBR Green qPCR technology. In the LDH, six of the 
nine genes were found to be differentially expressed between FDW and FSM groups and one gene, 
matrix metallopeptidase 9 (MMP9), was observed to be differentially expressed between these two 
groups in the blood.  
 
Three of the nine genes for which differential expression levels were investigated using SYBR 
Green real-time qPCR, contained CpG islands and were used for CpG island DNA methylation 
analysis. Results indicated that CpG island DNA methylation did not mediate differential gene 
expression of TRH, NPY or MT2A. Bioinformatics analysis of miRNAseq data identified 23 
miRNAs that were differentially expressed between the FDW and FSM groups. Several of these 
miRNAs have previously been found to be involved in brain development and behavioural 
measures of anxiety. Furthermore, functional luciferase analysis indicated that the upregulation of 
rno-mi31a-5p could have facilitated the downregulation of interleukin 1 receptor antagonist gene 
(IL1RN) as detected in RNAseq.  
 
RNAseq and miRNAseq analyses in this PTSD animal model identified differentially expressed 
genes and miRNAs that serve to broaden our understanding of the mechanism whereby DCS 
facilitates fear extinction. To this end, immune system genes and genes transcribing 
proinflammatory and oxidative stress molecules were among the genes that were found to be 
differentially expressed between the FDW and FSM groups. Based on the results obtained, it can be 
hypothesised that DCS attenuates neuroinflammation and subsequent neuronal damage, and also 
regulates genes involved in learning and memory processes. Concomitantly, these gene expression 
alterations mediate optimal neuronal functioning, plasticity, learning and memory (such as fear 
extinction memory) which contribute to the fear extinction process. Furthermore, biologically 
relevant differentially expressed genes that were associated with DCS facilitation of fear extinction 
and with other chronic medical conditions, such as cardiovascular disease and metabolic diseases, 
Stellenbosch University  https://scholar.sun.ac.za
iv 
 
might help to explain the co-occurrence of these disorders with PTSD. In conclusion, Identifying 
the molecular underpinnings of DCS-mediated fear extinction brings us closer to understanding the 
process of fear extinction and could, in future work be used to explore novel therapeutic targets to 
effectively treat PTSD and related disorders. 
  





Posttraumatiese stressindroom is ‘n ernstige, kroniese aftakelende psigiatriese toestand wat kan 
ontwikkel na ‘n lewensgevaarlike traumatiese gebeurtenis. Daar is bevind dat die gesamentlike 
toediening van D-sikloserien (DCS), ‘n N-metiel-D-aspartaat (NMDA) reseptor agonis, en kognitiewe 
gedragsterapie effektief is in die bemiddeling van vrees uitwissing; maar die presiese meganisme waar 
deur DCS die vrees wat deur ‘n traumatiese konteks ontlok word verminder, is egter onduidelik. 
Hierdie studie het beoog om (i) die molekulêre meganismes te identifiseer waardeur intra-
hippokampaal toegediende DCS vrees uitwissing fasiliteer, in ‘n rot model van posttraumatiese 
stressindroom, deur geen uitdrukkingsprofiele in the linker dorsale hippokampus (LDH) van manlike 
Sprague Dawley rotte te ondersoek en (ii) om te bepaal of mikroRNA (miRNA) uitdrukking en DNA 
metilering die veranderinge in geen uitdrukking bemiddel het. 
 
‘n Gewysigde weergawe van die posttraumatiese stressindroom diere model, beskryf deur Siegmund 
en Wotjak (2007), was gebruik tydens die studie. Rotte was in vier groepe verdeel, vrees 
kondisionering + soutwater (FS), vrees kondisionering + DCS (FD), kontrole + soutwater (CS) en 
kontrole + DCS (CD). Gedragstoetse was uitgevoer om angstige, vreesvolle en posttraumatiese 
stressindroom-tipe gedrag te evalueer. Gedurende die lig/donker (L/D) vermydingstoets het die FS 
groep aansienlik meer tyd in die donker kompartement deurgebring (‘n indikasie van vreesvolle 
gedrag) in vergelyking met die CS en die FD groepe wat meer tyd in die verligte kompartement 
deurgebring het (‘n indikasie van vreeslose gedrag). Die L/D toets was die mees sensitiewe 
gedragstoets vir angstige en vreesvolle gedrag en was gevolglik gebruik om die diere te sub-groepeer 
in wanaangepaste (diere wat angstige en vreesvolle gedrag vertoon het) en goedaangepaste (diere wat 
nie angstige en vreesvolle gedrag vertoon het nie) subgroepe. Nuwe generasie RNA volgordebepaling 
(RNAseq) van die LDH RNA en daaropvolgende bioinformatiese analise was uitgevoer om gene te 
identifiseer wat differensieel uitgedruk is tussen die twee behandelingsgroepe van belang in die 
betrokke studie, naamlik FS wanaangepaste (FSM) teenoor FD goedaangepaste (FDW) groepe. 
Epigenetiese analises was uitgevoer om te bepaal of differensieel uitgedrukte miRNAs of CpG-eiland 
DNA metilasie die differensiële geenuitdrukking bemiddel het.  
Bioinformatiese analises van die RNAseq data het 93 gene geïdentifiseer waarvan die geen 
uitdrukking beduidend onderdruk was in die FDW groep in vergelyking met die FSM groep; 42 van 
hierdie gene was voorspel om biologies relevant te wees. Geïntegreerde netwerk analise het onthul dat 
sekere van die differensieel uitgedrukte gene gemeenskaplik was tussen verskeie biologiese funksies, 
padweë en versteurings. DCS het die uitdrukking van immuun-sisteem gene en pro-inflammatoriese 
en oksidatiewe stres gene verlaag. Hierdie molekules medieer neuro-inflammasie wat gevolglik tot 
neurale skade lei. DCS het ook gene gereguleer wat betrokke is by leer en geheue prosesse. DCS het 
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onder meer ook die geenuitdrukking verlaag van ‘n sub-groep van gene wat voorheen geassosier is 
met komorbiede versteurings van PTSD. SYBR Green real-time qPCR (werklike tyd kwantitatiewe 
polimerase ketting reaksie) analise was ondersoek om te bepaal of hierdie metode sensitief genoeg 
sou wees om die verlaagde geen-uitdrukking van verskeie van die biologies relevante differensieel 
uitgedrukte gene te identifiseer, in dieselfde LDH komplementêre DNA (cDNA) monsters as wat in 
die RNAseq gebruik is, asook in die bloed cDNA monsters. SYBR Green real-time qPCR was in staat 
om ses, van die nege, differensieel uitgedrukte gene in die LDH cDNA monsters en een geen, matriks 
metallopeptidase 9 (MMP9), in die bloed cDNA monsters op te tel.  
Drie van die gene waarvoor SYBR Green real-time qPCR gebruik is om differensiële 
geenuitdrukking te toets, het CpG eilande bevat en was gevolglik gebruik in CpG eiland DNA 
metilering analises. Resultate het getoon dat CpG eiland DNA metilering nie die differensiële 
geenuitdrukking van TRH, NPY of MT2A gedryf het nie. Bioinformatiese analises van die 
miRNAseq data het 23 miRNAs geïdentifiseer wat differensieël uitgedruk was tussen die FDW en 
FSM groepe. Verskeie van hierdie miRNAs is reeds voorheen beskryf om betrokke te wees in brein 
ontwikkeling en angs gedrags metings. Funksionele luciferase analises het verder aangedui dat die 
verhoogde uitdrukking van rno-mi31a-5p moontlik die verlaagde geen uitdrukking van IL1RN, soos 
waargeneem in die RNAseq data, kon bewerkstellig het.  
RNAseq en miRNAseq analises in hierdie posttraumatiese stressindroom dieremodel het differensieël 
uitgedrukte gene en miRNAs geïdentifiseer wat dien om die verstaanswyse te verbreed van hoe DCS 
die vrees uitwissings proses fasiliteer. Die meganismes waardeur DCS vrees uitwissings bewerkstellig 
het sluit die verlaging van immuun-sisteem geen-uitdrukking in, sowel as verlaagde uitdrukking van 
gene wat pro-inflammatoriese en oksidatiewe stress gene transkribeer. DCS het daardeur neuro-
inflammasie en gevolglike neurale skade voorkom. DCS het daarmee saam ook gene gereguleer wat 
betrokke is by leer en geheue prosesse. Hierdie gesamentlike veranderings in geen uitdrukking het 
gelei tot die uiteindelike bewerkstelling van optimale neurale funksionering, plastisiteit, leer en 
geheue prosesse wat uiteindelik bygedra het tot vrees uitwissing. Biologies relevante differensieël 
uitgedrukte gene wat ook geassosieer was met ander kondisies, soos middel verwante versteurings en 
metaboliese versteurings, kan help om die komorbiditeit met posttraumatiese stressindroom te 
verklaar. Identifisering van die molekulêre grondslae van DCS bemiddelde vrees uitwissing verbreed 
ons begrip en verstaan van vrees uitwissing en kan moontlik, in toekomstige navorsing gebruik word 
om nuwe innoverende terapeutiese teikens te verken om sodoende posttraumatiese stressindroom 
meer effektief te kan behandel. 
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Posttraumatic stress disorder (PTSD) is a severe, chronic and debilitating psychiatric disorder that can 
occur after exposure to a potentially traumatic event (DSM-5, APA 2013)1, significantly impairing 
normal functioning and quality of life. PTSD is classified as a trauma- and stress-related disorder in the 
DSM-5 (APA, 2013), and is characterized by the presence of four distinct diagnostic symptom clusters, 
namely re-experiencing, avoidance and negative cognitions and mood, and arousal (DSM-5, APA 2013). 
The disorder occurs in about 7% of the general population (Kessler et al., 2005). Stress-related diseases, 
such as depression and anxiety disorders, place a heavy health and economic burden on society. 
However, there is a limited range of available pharmacotherapies to treat these disorders and the majority 
of treatments are suboptimal with regard to efficacy and tolerability (Holmes et al., 2003; Kessler et al., 
2005; Kasper et al., 2010).  
 
The development of PTSD is associated with learned fear-conditioned responses, which serve as 
reminders of traumatic events, and which can persist for several years after the occurrence of the 
traumatic event (Orr et al., 2000; Blechert et al., 2007). In fact, several forms of psychotherapy, 
especially cognitive behavioural therapy (CBT), form part of the current recommendations for the 
treatment of PTSD (Foa et al., 2000), as well as psycho-education and supportive measures (Cohen et al., 
2004; Oflaz et al., 2008). Exposure-based CBT is the most commonly used approach for PTSD treatment 
and relies on extinction-based methods (Norton and Price, 2007). This therapy involves exposing the 
patient to an anxiety-producing stimulus repeatedly in a controlled setting, thereby reducing the 
uncontrolled fear associated with the anxiety (Foa and Kozak, 1986).  
Pharmacological strategies for the treatment of established PTSD that target the emotional response or 
other non-cognitive symptoms include selective serotonin re-uptake inhibitors (SSRIs) (Van der Kolk et 
al., 1994; Connor et al., 1999; Brady et al., 2000; Martenyi et al., 2002), other antidepressants (such as 
serotonin–norepinephrine reuptake inhibitors (SNRIs), tricyclic and tetracyclic antidepressants (TCAs) 
and monoamine oxidase inhibitors (MAOIs)) Benzodiazepines) (Davidson et al., 1990,2006; Frank et al., 
1988; Onder et al., 2006), adrenoceptor agonists and antagonists (Peskind et al., 2003; Raskind et al., 
2003, 2007; Taylor et al., 2008) as well as anticonvulsants and antipsychotics (Hageman et al.,2001; 
Berlin, 2007). 
                                                     
1 American Psychiatric Association. (2013). Diagnostic and   statistical manual of mental disorders (5th ed.). Arlington, 
VA:  American Psychiatric Publishing. 
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D-cycloserine (DCS) is an antibiotic and partial N-methyl-D-aspartate receptor (NMDAR) agonist at the 
glycine site on the NMDAR1 receptor subunit and has been found to be effective in facilitating 
extinction learning in rats when administered before or immediately after extinction training 
(Ledgerwood et al., 2003; 2005; Walker et al., 2002; Yang and Lu, 2005; Philbert et al., 2013). 
Administration of DCS has been found to result in generalized extinction of fear (Legderwood et al., 
2005), a characteristic which could be of clinical benefit to PTSD, as the extinction of a single cue might 
generalize to other fear-associated cues simultaneously. Additionally, DCS treatment has been found to 
augment exposure therapy (Smits et al., 2013), especially in patients suffering from more severe PTSD 
that require longer treatment (de Kleine et al., 2012). DCS has furthermore been shown to reduce the rate 
of relapse following successful exposure-based CBT (Richardson et al., 2004). DCS has also been shown 
to be effective in human trials of various anxiety disorders, such as phobias (Ressler et al., 2004), social 
anxiety disorder (SAD) (Hofmann et al., 2006; Guastella et al., 2008), obsessive-compulsive disorder 
(OCD) (Kushner et al., 2007; Wilhelm et al., 2008; Storch et al., 2010) and panic disorder (Otto et al., 
2010). However, the precise mechanisms by which co-administration of DCS reduces the fear triggered 
by a traumatic context remain to be fully elucidated. It is therefore imperative to identify the molecular 
mechanisms that are involved in DCS-induced fear extinction, as this could facilitate a better 
understanding of PTSD and anxiety disorders.  
Animal models provide researchers with the opportunity to perform brain-specific genetic analyses in 
order to determine the molecular mechanisms involved in disorders or to determine the molecular 
mechanisms of therapeutic drugs. Gene expression profiling is one of the approaches followed to 
elucidate the genetic underpinnings of complex disorders or processes, such as fear extinction. Genes 
that are differentially expressed between trauma-exposed individuals who develop PTSD and those who 
do not, have extensively been investigated in PTSD and anxiety disorder research and have the potential 
to unravel the molecular underpinnings of these disorders. 
Although quantifying gene expression provides one with an idea of the biological pathways involved in 
the disorder, it does not provide knowledge of the mechanisms that contribute to observed alterations in 
gene expression. The term epigenetics literally means 'outside conventional genetics', and is currently 
used to describe the study of stable alterations in gene expression that are not brought about by changes 
in DNA sequence (Bjornsson et al., 2004). These epigenetic changes are heritable and potentially 
reversible, (Jaenisch and Bird 2003) and provide an additional layer of transcriptional control that may 
mediate the interaction between genetic predisposition, changes in neural functioning and environmental 
factors (Bjornsson et al., 2004). Epigenetic modifications may thus explain the interindividual variation 
and the long-lasting effects of trauma exposure (Yehuda and Bierer 2009). Such epigenetic mechanisms 
include DNA methylation, posttranscriptional modifications of histone proteins (acetylation, 
methylation, phosphorylation, ubiquitination and sumoylation) and non-coding RNA-mediated 
alterations (such as micro-RNAs (miRNAs) and small interfering RNAs (siRNAs)) (Yehuda and Bierer 
2009).  
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1.2 Significance of the study 
 
Although studies have been conducted to investigate the mechanism whereby DCS may facilitate fear 
extinction, the majority of these studies have focused on either intra-amygdalar (Mao et al., 2006; 2008) 
or systemic (Polese et al., 2002; Yamamoto et al., 2007; Wu et al., 2008; Gabriele and Packard, 2007) 
administration of the drug. The novelty of the proposed research rests in the fact that DCS was 
administered intrahippocampally, allowing the direct assessment of the effects of the drug in this brain 
region. In addition, the study will shed more light on the role that the hippocampus plays in fear 
extinction. The hippocampus is an important brain region in fear extinction (Barad, 2005; Szapiro et al., 
2003) and numerous studies have observed a reduced hippocampal volume in PTSD patients compared 
to controls (Bremner et al., 1995; 2003; Gurvits et al., 1996; Vythilingam et al., 2005). It is not known 
whether this reduced volume is a consequence of the disorder, or a pre-existing vulnerability factor 
(Gilbertson et al., 2006). In addition, recent investigations have indicated enhanced hippocampal 
activation during associative memory and learning in PTSD patients compared to trauma-exposed 
(Geuze et al., 2008) and trauma-unexposed controls (Werner et al., 2009). The hippocampus furthermore 
plays an important role in the processing of emotional behaviour (Kjelstrup et al., 2002; Bannerman et 
al., 2004; McHugh et al., 2004).  
 
Understanding the molecular mechanisms underlying the fear extinction process mediated by DCS in a 
PTSD animal model, is crucial to understanding stress-related disorders and the development of effective 
treatment strategies. Due to the complexity of the fear extinction process and PTSD, it is important to 
obtain a comprehensive representation of the whole transcriptome and relevant factors that could affect 
gene transcription. By investigating genes that are differentially regulated in the left dorsal hippocampus 
(LDH) in a rat animal model of PTSD, we can delineate what is happening on a genomic level during the 
fear extinction process. Investigating the epigenetic mechanisms involved in the fear extinction process 
will provide us with insight into how the epigenome mediates gene expression changes, induced by 
DCS, to facilitate the fear extinction process. The present study represents one of the first to investigate 
the possible epigenetic effects involved in fear extinction as mediated by intrahippocampal DCS 
administration. In light of the potentially reversible nature of epigenetic alterations; the epigenetic 
information gained in this study may provide researchers with exciting and tractable new avenues for 
pharmacological treatment of PTSD.  
  




1.3 Aims & Objectives 
 
Aim 
To investigate the molecular mechanism of action of intrahippocampally administered D-cycloserine in 
facilitating fear extinction in an animal model of PTSD by performing gene expression and epigenetic 
analyses. 
Objectives 
1. To identify genes that are differentially expressed in the LDH of male Sprague Dawley rats 
following fear conditioning, fear extinction and intrahippocampal DCS administration. 
2. To determine whether CpG island DNA methylation mediated the differential gene expression 
observed in the LDH of fear-saline maladapted (FSM) and fear-DCS well-adapted FDW male 
Sprague-Dawley rats. 
3. To identify differentially expressed microRNAs in the LDH of male Sprague Dawley rats following 
fear conditioning, fear extinction and intrahippocampal DCS administration, in order to identify 
miRNAs that are involved in DCS-induced fear extinction (comparing expression profiles of FSM 
vs. FDW animals). 
4. To correlate LDH gene and miRNA expression profiles in order to elucidate which miRNAs 
possibly mediated expression changes of which genes to facilitate DCS-induced fear extinction 
1.4  Brief overview of chapters 
 
The second chapter provides an overview of the PTSD literature, with a brief introduction to the disease 
pathology, aetiology, prevalence rates, the hypothalamic–pituitary–adrenal (HPA) axis as well as 
neurobiology of the disorder. An overview of fear conditioning and extinction is also provided followed 
by neuropeptides and neurotransmitters that play a role in PTSD. The section thereafter focusses on the 
genetics of PTSD, covering twin and family studies, candidate genes and gene-environment studies. 
The larger part of the literature review is dedicated to gene expression studies as well as DNA 
methylation and miRNA expression studies in PTSD animal models and human studies. The chapter 
concludes with the treatment strategies of PTSD, with the focus on DCS. 
 
The third chapter outlines the methods utilised in the present study, including the PTSD animal model, 
animal behavioural tests (note that animal behavioural work was performed by another student for her 
PhD), statistical analyses of behavioural data and animal selection based on behavioural data. Thereafter, 
the genetic laboratory methods are described. This methodology includes nucleic acid isolation, gene 
expression analyses with next generation RNA sequencing, bioinformatics analyses for differential gene 
Stellenbosch University  https://scholar.sun.ac.za
5 
 
expression analysis and gene enrichment analyses and clustering to facilitate the biological interpretation 
of the results. Information regarding SYBR Green real-time qPCR techniques is also provided. SYBR 
Green qPCR technology was assessed for its sensitivity to detect a subset of differentially expressed 
genes. This is followed by a description of epigenetic methodology used in the present study, including 
CpG island DNA methylation analysis, as well as miRNA sequencing and bioinformatics analyses to 
identify differentially expressed miRNAs. SYBR Green real-time qPCR was again investigated to 
determine its sensitivity to detect differential expression of a particular miRNA of interest. Chapter 3 
concludes with a description of the functional luciferase assay that was performed to determine whether 
a specific miRNA interacted with its predicted mRNA target region. The fourth chapter provides the 
relevant results generated during the study. This includes the animal behavioural data, gene expression 
data together with gene enrichment analyses and clustering as well as epigenetic data. Furthermore, gene 
and miRNA expression data was correlated to determine whether any differentially expressed miRNAs 
may have mediated the differential expression of certain genes. Lastly, the data of the functional 
luciferase assay is provided. 
The fifth chapter provides a discussion and interpretation of the results of the current study. Note that 
certain sections in the discussion are italicized to emphasise the main findings of the current study in 
light of previous literature. This is followed by the sixth and final chapter, which provides a conclusion 
of the results of the study as well as limitations and proposed future research. Two appendices are 
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2. Literature review 
2.1 PTSD 
 
The global prevalence of anxiety disorders, as reported in 2012, was estimated at 7.3 % (4.8–10.9 %) (Baxter 
et al., 2012). Prevalence rates range from 5.3 % (3.5–8.1 %) in African cultures to 10.4 % (7.0–15.5 %) in 
Euro/Anglo cultures (Baxter et al., 2012). South Africa is considered to be among the most violent countries 
globally and is a county with the unfortunate title of “rape capital of the world” (Human Rights Watch, 
1995). Kaminer et al. (2008) found that approximately 75% of South Africans had experienced at least one 
traumatic event in their lifetime, and that the experience of multiple traumas was the rule rather than the 
exception. Studies internationally have found that violent trauma, compared with other types of trauma, is 
more likely to be associated with posttraumatic stress disorder (PTSD) (Breslau et al., 1998; Creamer et al., 
2001; Norris et al., 2003; Zlotnick et al., 2006), suggesting that South Africans are particularly at risk for 
developing PTSD. This underscores the importance of research into the disease aetiology of PTSD. 
 
PTSD is a severe, chronic and debilitating psychiatric disorder that can occur after exposure to a potentially 
traumatic event (DSM-5, APA 2013). Failure of extinction of fear memories can result in PTSD symptoms 
that persist for extended periods of time following the traumatic event (Bremner et al., 1996). These 
symptoms can significantly impair normal functioning and quality of life (Zatzick et al., 1997; Mendlowicz 
and Stein 2000). PTSD is classified as a trauma- and stress-related disorder in the DSM-5 (APA, 2013), and 
is characterized by the presence of four distinct diagnostic symptom clusters, namely re-experiencing, 
avoidance, negative cognitions and mood, and arousal (DSM-5, APA 2013).  
 
Development of the disorder involves a fear conditioning process during which fear and anxiety responses 
are exaggerated and/or are resistant to extinction (Keane et al., 1985; Cohen et al., 2006; Amstadter et al., 
2009). During classical fear conditioning, a neutral (conditioned) stimulus (CS) is temporarily paired with an 
aversive (unconditioned) stimulus (US). After sufficient pairing of the CS and the US, the CS alone will 
eventually elicit the same response as the US. This response is referred to as the conditioned response (CR). 
The US can elicit a natural, physiological fear response, the unconditioned responses (UR). The CS 
subsequently acquires the ability to elicit a conditioned fear response which can be triggered upon 
encountering the harmless stimuli associated with the trauma. Analogous to Pavlovian fear-conditioning 
models, in PTSD, the trauma is considered to be the US, and the conditioned fear response experienced by 
PTSD patients, even in the presence of seemingly harmless stimuli, is the CR (Foa and Steketee 1989; 
Grillon et al., 1998; Skelton et al., 2012). This process plays an important evolutionary role by enabling an 
organism to identify and react to threatening stimuli. Excessive activation of fear responses, however, to 
non-threatening stimuli forms the basis of PTSD. Furthermore, emotional and physiological responses to 
stimuli that resemble the original traumatic event are a central characteristic of PTSD. 
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2.1.1 HPA axis in PTSD 
A key feature of PTSD is an inability to initiate a normal stress response that results in part from the 
dysregulation of the hypothalamic–pituitary–adrenal (HPA) axis. The HPA-axis is a key stress response 
system that interacts with the immune system to maintain homeostasis (Wong et al., 2002). Corticotropin-
releasing hormone (CRH) (also known as corticotropin-releasing factor [CRF]) regulates the stress-induced 
activation of the HPA axis and mediates autonomic and behavioural changes associated with anxiety 
disorders (Chrousos 1998). CRH and vasopressin are secreted by the hypothalamus in response to stress. 
These neuropeptides are secreted into the portal vessels and stimulate the anterior pituitary to synthesise and 
release adrenocorticotropin hormone (ACTH) into the bloodstream, which in turn leads to the release of 
glucocorticoids (GCs) (such as cortisol or corticosterone in rodents) by the adrenal cortex. GCs help to 
control the processes of adaptation to and recovery from stress due to the role they play in the restoration of 
biological homeostasis (de Kloet et al., 2009; McEwen et al., 2002). The HPA axis is regulated by a negative 
feedback mechanism; excess cortisol binds to GC receptors in the hypothalamus and pituitary and this 
subsequently suppresses the release of CRH and ACTH (Fig. 2.1).  
 
The HPA axis plays a vital role in regulating the normal response to stress. Malfunctioning of this system 
underlies susceptibility to certain anxiety disorders (McEwen et al., 2002). In addition, studies have indicated 
a link between elevated cortisol and both chronic stress and depression (Cowen et al., 2002). However, more 
recent evidence suggests that abnormal HPA axis functioning may characterize a subset of anxiety disorders 
that distinguish them from mood disorders. For example, traditional stress models (which included anxiety 
disorders and depression) predict HPA axis overactivity, characterized by hypercortisolemia and reduced 
negative feedback inhibition (as described in mood disorders) (Holsboer, 2003). 
 
To date, there is no consensus regarding the exact nature of HPA alterations in PTSD. Certain studies 
reported decreased urinary cortisol levels collected over 24 hours (Mason et al., 1986; Yehuda et al., 1990) 
and in blood plasma collected repeatedly over 24 hours (Yehuda et al., 1994, 1996). Other studies did not 
find differences in urinary cortisol levels (over 24-hours) between patients and controls (Mason et al., 2002), 
or a difference between baseline plasma cortisol levels and PTSD symptoms (Goenjian et al., 2003), and 
even higher cortisol levels have been reported in PTSD urine samples (Lemieux and Coe 1995; Pitman and 
Orr 1990). A model described by Yehuda proposed that enhanced negative feedback inhibition of cortisol by 
the pituitary could be involved (Yehuda, 2006). Initial drug sensitivity studies in PTSD (using 
Dexamethasone, which measures the response of the adrenal glands to ACTH) did not consider the 
possibility of hypersuppression to DEX, but rather tested non-suppression of cortisol in PTSD patients, 
similar to patients with major depressive disorder. Halbreich et al. (1989) found lower post-DEX cortisol 
levels in the PTSD group compared to subjects with depression and controls (Halbreich et al., 1989), leading 
Yehuda et al. (1993, 1995) to hypothesize that PTSD patients might exhibit enhanced, rather than reduced 
cortisol suppression to DEX. Indeed, a hyperresponsiveness to low doses of DEX was observed (indicated by 
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significantly lower post-DEX cortisol levels), was observed in several studies (Stein et al., 1997; Kellner et 
al., 1997; Yehuda et al., 2002; Yehuda et al., 2004; Newport et al., 2004).  
 
Reports of elevated CRH and subsequent HPA axis alterations in clinically anxious samples have spurred the 
investigation of CRH-1 receptor antagonists as novel anxiolytics (refer to Section 2.4 Treatment of PTSD, 
for more detail).  
 
 
Figure 2.1: Schematic representation of the effect of stress on the HPA axis. CRH is secreted by the hypothalamus 
in response to stress. CRH is subsequently transported to the pituitary gland, where it stimulates the synthesis and 
release of ACTH into the bloodstream. ACTH enters the adrenal glands, inducing the release of glucocorticoids (GCs) 
(such as cortisol or corticosterone in rodents) by the adrenal cortex. This process creates a negative feedback loop 
whereby the hypothalamus responds to the amount of cortisol it detects and either reduces or increases CRH production 
(Total Body Psychology website: http://total-body-psychology.com.au/stress-response-hpa-axis/) (copyright granted). 
ACTH - adrenocorticotropin hormone, CRH - corticotropin-releasing hormone, GCs - glucocorticoid 
2.1.2 Neurobiology of PTSD 
Processes of fear extinction and retention have been postulated to be deficient in PTSD (Bremner et al., 
1996) (refer to Section 2.1.2.3 for more detail regarding fear conditioning and extinction). A network of 
dysfunctional brain regions, including the hippocampus, amygdala and sub-regions of the medial prefrontal 
cortex (mPFC) (including ventromedial prefrontal cortex (vmPFC) and dorsal anterior cingulate cortex 
(dACC)) have been found to contribute to fear extinction and retention abnormalities in PTSD (Fredrikson et 
al., 1976; Quirk and Mueller 2008). During extinction learning, conditioned fear responses gradually 
diminish, whilst during extinction recall, the learned extinction memory is retrieved and expressed after a 
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delay (Quirk et al., 2000). One fear extinction study using a rat model found that extinction recall lasted up 
to 6 days (Quirk 2002). Behavioural treatment of PTSD (viz. exposure therapy), relies on extinction-based 
mechanisms (Rothbaum and Foa 2002, Rothbaum and Davis 2003). Thus, a comprehensive understanding of 
these processes is important to better understand and treat PTSD. 
2.1.2.1 Amygdala and hippocampus 
 
Several neurobiological systems are hypothesized to be involved in the aetiology and maintenance of fear 
conditioning associated with PTSD. These systems include the HPA axis, the locus coeruleus (LC)-
noradrenergic (LC-NA) system and connections between the limbic system and frontal cortex. The neural 
and endocrine structures of the HPA axis coordinate the hormonal response to stress and activate the LC-NA 
system (Claes, 2004). This system has been implicated in the over-consolidation of fear memories in the 
aftermath of traumatic exposure (O’Carroll et al., 1999; Southwick et al., 1999; Southwick et al., 2002). The 
amygdala, located within the temporal lobe, is part of the limbic system. It plays a major role in the detection 
of threats and in the induction of conditioned and unconditioned fear responses, such as behavioural 
responses and HPA axis activation. The amygdala consists of several nuclei, including the central nucleus of 
the amygdala (CeA) and the basolateral nucleus (BLA) which functions in different ways during fear 
conditioning (Davis 1992).  
 
The fear response is mostly regulated by the CeA. The fear response controls the release of cortisol through 
the paraventricular nucleus of the hypothalamus, regulates the increase in startle response via the pons in the 
midbrain, and modulates the autonomic nervous system through the lateral hypothalamus (Davis 1992). 
Studies in animal models have revealed that lesions in the CeA abolish fear-conditioned responses, such as 
freezing (LeDoux 1992) and fear-potentiated startle (Davis et al., 1982). The CeA, which receives inputs 
from BLA projections, is the main locus for associations between the CS and US that ultimately results in 
fear acquisition (Fanselow and LeDoux 1999). Amygdala activity is regulated in a ‘top-down’ fashion by the 
mPFC (including orbitofrontal cortex, subgenual anterior cingulate cortex and hippocampus). The CeA, 
through an inhibitory or excitatory manner, can either abolish or induce conditioned fear responses (Ehrlich 
et al., 2009; Milad and Quirk, 2002; Vidal-Gonzalez et al., 2006; Quirk et al., 2006; Peters et al., 2009). This 
mode of regulation allows appropriate information (such as context, explicit memory representations, and 
conscious self-regulation) to impact the response to threats. Fear behaviour and inhibition is controlled by 
complex inhibitory neural circuitry, dysregulation of these circuits are typical in pathological states that are 














Figure 2.2: Inhibitory control of the amygdala in fear regulation. (A) A schematic diagram of the interaction of the 
BLA and CeA of the amygdala and the modulatory region, the mPFC. The BLA compares inputs from the CS and US 
and regulates CeA activation of the fear and stress circuitry. This ultimately leads to inhibition or activation of the fear 
response. (B) A schematic diagram that illustrates the role of the inhibitory neural circuitry that modulates the fear 
response at a cellular level. Sensory and associative inputs from the hippocampus and cortex project directly and 
indirectly to the CeA. Within the CeA “on” and “off” inhibitory circuits are postulated to differentially modulate fear 
output and fear extinction. In addition, direct projections from the infralimbic region of the mPFC activate inhibitory 
neurons in the intercalated region between the CeA and BLA, which inhibits the fear output of the CeA in a top-down 
manner (Adapted from Jovanovic and Ressler 2010).  
The hippocampus has been found to be region-specific with regard to its function, the major distinction being 
between the dorsal hippocampus (DH) (posterior hippocampus in humans) and ventral hippocampus (VH) 
(anterior hippocampus in humans) (Greicius et al., 2003). For example, the dorsal and ventral regions of the 
hippocampus have been proposed to play different roles in the processing of emotional behaviour 
(Bannerman et al., 2004; McHugh et al., 2004; Zhu et al., 2006; Oomen et al., 2010; Korosi et al., 2012). 
Notably, Bonne et al. (2008) indicated a significant reduction in posterior hippocampal volume in PTSD 
patients compared to controls, with no significant differences in the size of the anterior hippocampus (Bonne 
et al. 2008). The DH has exhibited a distinct role in the reconsolidation process of fear memories, indicating 
that generalization of fear inhibition could be achieved through disruption of memory reconsolidation 
processes in the DH (Yang et al., 2011).  
 
A related part of the extended amygdala is the bed nucleus of the stria terminalis. This region seems to be 
associated with nonspecific fear, such as anxiety, which is unrelated to a CS used during fear conditioning. 
The anxiogenic effects of bright lights and CRH infusions in rodents are eliminated by abrasions to the bed 
nucleus of the stria terminalis (Davis et al., 1997). This region is postulated to be involved in general, 
nonspecific anxiety and depression symptoms, whereas the CeA is more involved in cue-specific stress 
responses, fear and panic. Positron emission tomography (PET) and functional magnetic resonance imaging 
(fMRI) studies in healthy individuals have shown amygdala activation in response to fearful stimuli (Whalen 
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et al., 2001; Pine et al., 2001; LaBar et al., 1998; Knight 2005). These findings indicate the extensive role of 
the amygdala in regulating the fear response in humans as well as in animals. 
 
2.1.2.2 Prefrontal cortex and insula 
 
The prefrontal cortex (PFC) is believed to be important in behavioural inhibition. Animal studies show that 
lesions of the mPFC, inflicted prior to fear conditioning, delay extinction to a tone (Morgan et al., 1993). 
Furthermore, studies demonstrate that PFC neurons may elicit inhibitory action on the amygdala (Phelps et 
al., 2004, Grace and Rosenkranz 2002). Similar to the amygdala, the PFC consists of many subregions, such 
as the mPFC, anterior cingulate cortex (ACC) and orbitofrontal prefrontal cortex (OFC). The ACC contains 
ventromedial and dorsolateral components, which may have different functions during expression and 
inhibition of fear. A study of the rodent neuroanatomical equivalent to the mPFC, the infralimbic prefrontal 
cortex (ILPFC), showed enhanced activity following learning of an extinguished CS (Milad and Quirk 
2002). In addition, fear responses were inhibited when ILPFC activity was enhanced (Milad and Quirk 
2002). The authors proposed that during extinction consolidation, a neural circuit running from the BLA to 
the PFC and back to the amygdala’s inhibitory neurons, may be enhanced. This enhancement occurs in such 
a fashion that during re-experiencing of the extinguished CS, the ILPFC elicits a feed-forward inhibitory 
projection that competes with the fear pathway elicited by the BLA-to-CeA nucleus projection (Fig. 2.2) 
(Peters et al., 2009; Vidal-Gonzalez et al., 2006). 
 
Although the majority of research on anxiety disorders has focused on the amygdala and its connections to 
the PFC, an emerging region of interest is the insula. This region is mainly known for its role in interoception 
(the sense of the physiological condition of the body) (Critchley et al., 2004). Paulus and Stein (2006) 
proposed that information from the amygdala, orbitofrontal cortex and nucleus accumbens is integrated by 
the anterior insula which generates an interoceptive prediction signal (difference between the current body 
state and a predicted future state). This prediction signal may be increased in anxiety-prone individuals, due 
to an exaggerated aversive expectation that drives responses such as cognitive and behavioural avoidance. 
Indeed, brain imaging studies have revealed altered insular function in OCD, PTSD, specific phobia (Rauch 
et al., 1997; Wright et al., 2003), SAD (Lorberbaum et al., 2004), GAD (Hoehn-Saric et al., 2004), panic 
disorder (Malizia et al., 1998) patients and individuals with elevated trait anxiety (Paulus and Stein 2006). 
These studies underscore the importance of detecting and investigating nuances in the neurocircuitry to 
better understand anxiety disorders.  
2.1.2.3 Fear conditioning and extinction 
 
Bremner et al. (2005) were the first to examine fear conditioning and extinction learning in PTSD using 
positron emission tomography (PET). The study, performed in women with childhood sexual-abuse-related 
PTSD indicated a reduction in vmPFC activity and an increase in amygdala activity in PTSD cases compared 
Stellenbosch University  https://scholar.sun.ac.za
12 
 
to controls (Bremner et al., 2005). These results were later confirmed in a study by Milad et al. (2009) whose 
data suggested that the deficient extinction retention in PTSD might be attributed to dysfunctional responses 
in brain regions implicated in the recall of fear extinction. To this end, they found reduced hippocampal and 
bilateral vmPFC activation and increased dACC activation during extinction recall in PTSD cases vs. 
trauma-exposed non-PTSD controls (TENC). They described a positive correlation between the amount of 
extinction retention and activation in both the vmPFC and hippocampus and a trend towards a significant 
negative correlation with activation in dACC (Milad et al., 2009). Their data suggest that dysfunctional 
activation of particular brain regions in the PTSD group (i.e., increased amygdala activity and decreased 
vmPFC activity compared with the TENC group) during extinction learning might contribute to inadequate 
consolidation of extinction memory in PTSD patients. Furthermore, they proposed that a failure to activate 
vmPFC and hippocampus during recall could contribute to insufficient extinction memory expression in 
PTSD (Milad et al., 2009). 
 
The molecular mechanism of fear conditioning involves learning, primarily mediated by synaptic plasticity 
in the amygdala. Associative fear conditioning and extinction of conditioned fear are both learning 
processes; during extinction of conditioned fear, a CS becomes less associated with the US (refer to Sections 
2.1 PTSD and 2.1.2.1 Amygdala and hippocampus). This learning process is dependent on activation of 
glutamate NMDAR. Extinction of fear memories become blocked by the systemic administration of 
NMDAR antagonists (Baker and Azorlosa 1996; Cox and Westbrook 1994) or direct infusion of NMDAR 
antagonists into the BLA (Falls et al., 1992; Lee and Kim 1998). This impairment in extinction training 
occurs when NMDAR antagonists are administered prior to (Falls et al., 1992; Lee and Kim 1998) or after 
extinction training, which suggests that NMDARs are involved in the consolidation of extinction memories 
(Santini et al., 2001). Furthermore, scientists found that 24-hour recall of extinction was impaired following 
infusion of an NMDAR antagonist into the vmPFC prior to, or immediately after, extinction training 
(Burgos-Robles et al., 2007). They observed that the NMDAR antagonist selectively reduced burst firing in 
the neurons of the vmPFC suggesting that extinction memory is stabilized and successful extinction recall is 
facilitated through NMDAR-dependent bursting in the vmPFC, which subsequently initiates calcium-
dependent molecular cascades (Burgos-Robles et al., 2007) (Refer to Section 2.4.1 N-methyl-D-aspartate 
receptors).  
 
Morris and colleagues established a link between NMDAR activity, hippocampal long-term potentiation 
(LTP) and learning and memory when they developed the Morris water maze (MWM) task for rodents 
(Morris 1981). The device consists of a large round pool with a small escape platform. The pool is filled with 
opaque water which obscures the platform. Visual cues (for example coloured shapes) are placed around the 
pool in plain sight of the animal. During the basic procedure the animal is placed in the pool (at different 
starting positions) and they have several training trials where they learn to find the platform and escape from 
the pool (Morris 1981) (more sophisticated variations have also been developed from the basic model) 
(D’Hooge and De Deyn 2001). During the trials various parameters are recorded, including the time taken to 
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reach the platform (latency), time spent in each quadrant of the pool and total distance travelled (Morris 
1981). With subsequent trials (with the platform in the same position) the animals should be able to locate 
the platform more rapidly. This performance improvement occurs as a result of learning and memorizing 
where the hidden platform is located relative to the visual cues. This task evaluates spatial learning and 
memory in the model organism and is particularly sensitive to the effects of hippocampal lesions in rats. 
Findings by Morris and colleagues (using rats with hippocampal lesions) suggested that hippocampal 
NMDAR activity and NMDAR-dependent plasticity are crucial for spatial learning (Morris 1981; Morris et 
al., 1982). The subregional specificity of NMDAR function was investigated by Lee and Kesner (2002) who 
found that the Cornu Ammonis region 3 (CA3) hippocampal subfield NMDARs are required in situations 
requiring reorganization of spatial representation, whereas CA1 and/or the dentate gyrus NMDARs are more 
involved in memory acquisition that requires retrieval after a delay period (exceeding a short-term range) 
(Lee and Kesner 2002). The hippocampus is thus an important brain region in PTSD due to high expression 
levels of NMDARs in this region.  
 
In addition to NMDARs, there are numerous other factors that play a role in the plasticity of learning. 
Research points to the involvement of voltage-gated calcium channels in the mediation of calcium-dependent 
synaptic plasticity, a process that is involved in fear extinction (Cain et al., 2002; Cain et al., 2005). Brain-
derived neurotrophic factor (BDNF) and its receptor, tropomyosin receptor kinase B (TrkB) (Chhatwal et al., 
2006; Rattiner et al., 2004) have also been implicated in plasticity underlying fear and extinction learning. 
Additionally, regulation of the inhibitory neurotransmitter γ-aminobutyric acid (GABA) was found to be 
differentially altered during fear acquisition compared to extinction (Harris and Westbrook 1998). Decreased 
levels of gephyrin (a scaffolding protein that facilitates insertion of GABA into the surface membrane) and 
decreased surface expression of GABAA receptors have been found in the BLA after fear acquisition and 
increased levels of gephyrin and GABAA receptors have also been observed after extinction learning 
(Chhatwal et al., 2005; Heldt and Ressler 2007). These results correlate with heightened amygdala 
excitability during fear learning and amygdala inhibition following extinction. Furthermore, the results 
indicate that the gephyrin protein is involved in both fear acquisition and extinction and suggest that 
variation in BLA gephyrin and GABAA receptor expression contributes to experience-dependent plasticity 
underlying both types of learning (fear acquisition and extinction). Finally, these results demonstrate that 
during the consolidation phase of BLA-dependent learning, dynamic alterations of GABAergic synapses 
occur which may interact with previously described changes in glutamatergic transmission to initiate and 
stabilize memory formation (Chhatwal et al., 2005).  
 
The expression of genes involved in neural plasticity (such as glutamate receptors and BDNF), stress 
responsiveness (such as glucocorticoid receptors and corticotropin receptor) and neural inhibition (such as 
GABA receptors), may be associated with extinction learning or impaired fear inhibition. In-depth 
investigations into these genes are important in PTSD research as the disorder seems to be associated with 
abnormal fear acquisition or inhibition, either as vulnerability factors prior to trauma exposure or as a result 
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of trauma-related fear conditioning (Jovanovic and Ressler 2010) (refer to Section 2.2.4 Gene expression 
analyses in PTSD). 
 
All of the abovementioned neural systems interact during the development and maintenance of fear 
conditioning, and have been investigated as target regions where candidate genes may be involved in the 
aetiology of PTSD (Skelton et al., 2012) (refer to Section 2.2.2 Candidate genes in PTSD).  
2.1.3 Neuropeptides and neurotransmitters 
Neuropeptides are short-chain amino acids which function as neurotransmitters. They are often located in 
brain regions that mediate emotional behaviours and stress responses, and are subsequently involved in 
numerous brain functions, including behaviour, learning and memory (Hӧkfelt et al., 2000). Neuropeptides 
and peptide hormones are related (both are small protein-like signalling molecules). Occasionally peptides 
that function as hormones in the periphery also function as neuropeptides with neuronal functions. The 
difference between peptide hormones and neuropeptides lies in the cell type that release and respond to these 
molecules. Peptide hormones are secreted by neuroendocrine cells, transported through the blood and elicit a 
response in distant tissues. Conversely, neuropeptides are secreted by neuronal cells (primarily neurons and 
sometimes glia) and signal to neighbouring cells (mostly neurons) (Migaud et al., 1995). However, 
neuropeptides and peptide hormones are synthesized by the same enzymes, including carboxypeptidases and 
prohormone convertases that cut the peptide precursors at specific sites to generate bioactive peptides 
(Steiner, 1998). There is a growing list of neuropeptides implicated in stress-related functions. The most 
extensively studied neuropeptides include tachykinins (substance P (SP) and neurokinin A), vasopressin, 
CRH and neuropeptide Y (NPY). These molecules and their respective targets have gained popularity as 
potential novel therapeutic targets to treat stress-related disorders (Varty et al., 2002; Heinrichs et al., 2002; 
Griebel et al., 2002; Sajdyk et al., 2002), and are discussed in more detail below.  
2.1.3.1 Substance P 
 
Substance P (SP) has been one of the most comprehensively studied neuropeptides since its discovery in the 
1930s. It elicits its biological actions through G-protein-coupled tachykinin receptors (Neurokinin 1 [NK1]). 
Levels of SP have been found to be increased in the amygdala of guinea pigs following maternal separation 
(an early life stressor) (Kramer et al., 1998). In addition, augmented levels of SP were detected at baseline in 
the cerebrospinal fluid (CSF) of PTSD patients, and increased SP levels accompanied symptom provocation 
in PTSD patients who viewed a trauma-related video (Geracioti et al., 2006). NK1 receptor antagonists were 
subsequently investigated as a treatment for PTSD. NK1 receptor antagonists produced anxiolytic responses 
in various preclinical tests, including elevated plus-maze, transient maternal separation and the social 
interaction test (Kramer et al., 1998; File, 2000; Varty et al., 2002). A phase II trial of NK1 antagonist, 
GR205171, has been conducted in chronic PTSD patients (Mathew et al., 2011). This investigational 
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Vasopressin is a nonapeptide synthesized in the paraventricular nucleus (PVN) and supraoptic nucleus and is 
known for its role in fluid metabolism and regulation of the HPA axis. As in the case of CRH, vasopressin 
release is induced by stress; it is released from the hypothalamus median eminence into the pituitary portal 
circulation where it enhances the effects of CRF on ACTH release (Aguilera, et al., 2000). Once released 
from these neurons, the effects of vasopressin are exerted via a dense localization of vasopressin receptors 
mainly expressed in limbic areas and the hypothalamus (Lolait et al., 1995). This distribution pattern 
suggests that vasopressin might have a regulatory effect on limbic function and stress responses (Holmes et 
al., 2003). 
 
Vasopressin release predicts anxious reactions to stress provocation in healthy individuals (Abelson et al., 
2001). Increased vasopressin-mediated control of the HPA axis may therefore contribute to HPA axis 
dysregulation associated with depression and anxiety disorders (Holsboer and Barden 1996; Dinan et al., 
1999). Vasopressin receptor antagonists have consequently been investigated as a treatment option for these 
disorders. Indeed, the Vasopressin V1b receptor (V1bR) antagonist (SSR149415) has been found to exert 
noticeable anxiolytic and antidepressant effects in rodent models (Griebel et al., 2002; Serradeil-Le Gal et 
al., 2002). The antidepressant activity of this compound is comparable to that of reference antidepressant 
(imipramine); however, the overall anxiety tests profile appears to differ from classical anxiolytics. For 
example, benzodiazepines are active in a broad range of anxiety models, whereas SSR149415 shows definite 
effects only in the more stressful test situations (Stemmelin et al., 2005).  
 
2.1.3.3 Corticotropin-releasing factor 
 
Corticotropin-releasing factor (CRF) consists of 41 amino acids and initiates the HPA axis stress response. It 
has thus been extensively investigated in anxiety disorders and depression. The CRF system in the 
mammalian brain comprises of CRF-related peptides (urocortin 1, urocortin 2, and urocortin 3) and G-
protein-coupled CRF receptor subtypes (CRF1 and CRF2). Neurons containing CRF and CRF receptors are 
located in brain regions involved in stress responses, including the amygdala, LC, lateral septum and 
brainstem raphe nuclei as well as the major projections from the PVN to the pituitary corticotropes (Steckler 
and Holsboer 1999). CRF infusion into rodent brains or constitutive transgenic overexpression of CRF in 
mice, reproduce certain neuroendocrine and behavioural consequences of stress exposure, such as HPA 
dysfunction and increased anxiety-like behaviour (Van Gaalen et al., 2002a; Van Gaalen et al., 2002b). 
PTSD is associated with increased CRF levels in CSF (Bremner et al., 1997; Baker et al., 1999; Sautter et al., 
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2003) (as discussed in Section 2.1.1 HPA axis in PTSD), and this has prompted investigation into CRF-1 
receptor antagonists as novel anxiolytics. These compounds seem to selectively block CRF- and stress-
induced ACTH release without disruption of basal ACTH release (Heinrichs et al., 2002; Gutman et al., 
2011; Gully et al., 2002). Preclinical studies suggest that CRF-1 antagonists may reverse stress-related 
behaviours (Lelas et al., 2004; Timpl et al., 2008; Habib et al., 2000; Heinrichs et al., 2002; Gutman et al., 
2011) and similar findings are evident in preliminary data of small clinical trials (Zobel et al., 2001). 
2.1.3.4 Neuropeptide Y 
 
Neuropeptide Y (NPY), the most abundant peptide in mammalian brains, constitutes 36-amino-acid 
polypeptides (Wahlestedt and Reis, 1993) and functions as a sympathetic co-transmitter. NPY is abundantly 
expressed throughout the brain, including the hypothalamus, LC, hippocampus, amygdala, nucleus 
accumbens and neocortex. Central NPY is colocalized with GABA, noradrenaline, agouti-related protein and 
somatostatin (Kask et al., 2002). Heterogeneous G-protein-coupled receptors mediate the actions of NPY 
with the receptor subtypes Y1, Y2 and Y,5 mediating central nervous system (CNS) effects. NPY is co-
released with epinephrine from the cardiac sympathetic nerves and is present in measurable amounts in 
coronary sinus venous blood (Esler et al., 2004). This is of particular importance in anxiety disorders, where 
sympathetic hyperactivity occurs during symptoms such as panic attacks (Esler et al., 2004).  
 
NPY may also be involved in the consolidation of fear memories. NPY infusion into the amygdala results in 
impaired memory retention in a foot-shock avoidance paradigm in rodents (Flood et al., 1989). In combat 
veterans diagnosed with PTSD, reduced levels of baseline NPY were detected compared to healthy, non-
traumatized controls (Rasmusson et al., 2000). In another study, reduced baseline plasma NPY levels were 
found to be associated with repeated exposure to traumatic stress, rather than the presence of PTSD or 
PTSD-type symptoms (Morgan et al., 2003). In numerous preclinical models, NPY has been noted to have 
anxiolytic effects (Heilig et al., 2004). Amygdalar NPY mRNA levels were upregulated in response to 
chronic stress, suggesting involvement in the adaptive responses to stress exposure (Thorsell et al., 1999). To 
this end, elevated levels of plasma NPY were found in combat-exposed veterans without current PTSD 
compared to noncombat-exposed veterans (Yehuda et al., 2006). Recovery from previous PTSD symptoms 
was correlated with NPY elevation (Yehuda et al., 2006).  
2.1.3.5 Serotonin 
 
Neurotransmitters are endogenous chemical compounds which transmit signals from neurons to their target 
cells across synapses, and are thus involved in complex neuronal communication (Sugimori et al., 1994; Lee 
et al., 2005). Serotonin is one of the neurotransmitters involved in the pathophysiology of PTSD. Graeff et 
al. (1996) have proposed a “dual serotonin fear hypothesis” based on animal behavioural data. They 
postulate that in the amygdala, serotonin may augment conditioned fear, whilst in the dorsal periaqueductal 
gray (PAG), it may inhibit innate fear. The ascending serotonergic pathway, which originates in the dorsal 
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raphe nucleus and stimulates the amygdala and frontal cortex, facilitates conditioned fear, while instinctive 
fight-or-flight reactions in response to imminent danger are inhibited by the dorsal raphe-nucleus-
periventricular pathway. Finally, the pathway that connects the median raphe nucleus to the dorsal 
hippocampus facilitates resistance to chronic, unavoidable stress (Graeff et al., 1996). In the region of the 
LC, serotonin may exert an inhibitory effect on norepinephrine (NE) neurons. Moreover, NE terminals (from 
the LC) and serotonin terminals (from the dorsal raphe) converge on the amygdala to regulate fear responses. 
Disruptions in the serotonergic circuits play a role in the aetiology of PTSD (Davis et al., 1997) especially 




Dopamine is another neurotransmitter that has been well studied in PTSD. Animal studies have found that 
dopaminergic innervation of the amygdala, BLA, mPFC and other limbic regions are highly responsive and 
susceptible to stress (Goldstein et al., 1996; Inglis and Moghaddam, 1999). Administration of dopamine D1 
receptor agonists in rats has resulted in an enhanced acoustic startle response, one of the symptoms of PTSD 
in animal models (Meloni and Davis, 1999). On the other hand, investigation of the D2 receptor revealed that 
intraperitoneal injection of the dopamine D2 receptor agonist, quinpirole, and the D2 antagonist, sulpiride, 
resulted in a significant dose-dependent reduction of contextual conditioned freezing. A reduction in the 
conditioned freezing response was also evident following quinpirole administration into the ventral 
tegmental area (VTA) and sulpiride injections in the BLA. The data show that the expression of contextual 
conditioned freezing is influenced by dopamine D2-like receptors. Dopaminergic mechanisms in the 
mesolimbic circuit should be investigated as potential pharmacological targets for the treatment of fear-
related disorders, especially PTSD (de Souza Caetano et al., 2013).  
 
In human studies, a relationship between urinary excreted dopamine and plasma dopamine and severity of 
PTSD symptoms has also been observed (Yehuda et al., 1992; Hamner and Diamond, 1993). A recent study 
investigated the levels of the dopamine metabolite, homovanillic acid (HVA), in CSF of individuals with 
war-related chronic PTSD in response to video provocation (either a trauma-related or neutral video) 
(Geracioti et al., 2013). A significant increase in anxiety and a drop in mood and blood pressure were evident 
in the CSF sample taken during the traumatic video screening relative to the neutral video. This was 
accompanied by significantly reduced concentrations of CSF HVA. The authors concluded that an acute 
decrease in the concentrations of HVA in the CNS is associated with laboratory-induced symptoms in 
chronic PTSD patients. Their data suggests that elevation of dopaminergic neurotransmission should be 
investigated as a potential therapy for PTSD (Geracioti et al., 2013).  
 
Neurotransmitters, neuropeptides and their receptors play a major role in maintaining CNS homeostasis. 
Significant deviations in the levels of neurotransmitters and neuropeptides in certain brain regions have been 
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implicated in PTSD aetiology. What then is the underlying cause of these alterations? Assessment of 
causation leads one to genetic investigations of genes that transcribe these neurotransmitters, neuropeptides 
and their receptors.  
2.2 Genetics of PTSD 
 
Not everybody who experiences a traumatic event will go on to develop PTSD (Monroe et al., 1991; Costello 
et al., 2002). Thus, traumatic exposure alone cannot account for the development of the disorder. Individuals 
with an existing genetic vulnerability may have a higher risk of PTSD development, following a traumatic 
experience and twin and family studies provide evidence for this. 
2.2.1 Twin and family studies 
Twin and family studies offer the opportunity to delineate the contribution of genetics to the susceptibility of 
complex disorders, such as PTSD, and although the number of twin and family studies in PTSD is small in 
relation to other psychiatric disorders, results from studies that have been conducted point towards a genetic 
aetiology of PTSD. One family study found that as adults, children of Holocaust survivors who suffered 
from PTSD possessed a higher risk of developing PTSD after experiencing trauma compared to children of 
Holocaust survivors without PTSD (Yehuda et al., 2001). Furthermore, children of Cambodian refugees were 
found to be five-fold more likely to develop PTSD when both parents suffered from PTSD compared to 
refugee children whose parents did not have PTSD (Sack et al., 1995). Similarly, the parents of children who 
suffered from PTSD following serious physical injury were more susceptible to develop PTSD themselves 
(Hall et al., 2006). However, since families do not only share genetic material but also similar environments, 
family studies cannot discriminate whether a disorder that runs in families is due to common genetic or 
environmental factors. Therefore, twin studies have been conducted to disentangle the role of environmental 
and genetic influences in PTSD aetiology.  
 
Heritability refers to the amount of variance in a characteristic or disorder that can be explained by genetic 
factors. Twin studies can be used to calculate the heritability of a disorder. The concordance rate of identical 
or monozygotic (MZ) twin pairs is compared with that of fraternal or dizygotic (DZ) twin pairs. If MZ twins 
have a significantly higher concordance rate for a characteristic or disorder compared to DZ twins, then this 
characteristic is genetically influenced (Koenen et al., 2007).  
 
True et al. (1993) investigated PTSD in a large sample of MZ and DZ US Vietnam War Veteran twins. They 
reported estimated heritabilities ranging from 0.13 – 0.34 for various PTSD symptoms (including re-
experiencing, avoidance and arousal). While the study by True et al. (1993) only included male combat 
veterans, Stein et al. (2002) broadened the scope by investigating the heritability of trauma exposure and 
PTSD symptoms in a sample that included female twin pairs (from the general population) and by measuring 
a wider range of traumatic events (including robbery, sexual assault, motor vehicle accidents, physical 
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assault, sudden family death and natural disasters). Heritability estimates for the different PTSD symptoms 
ranged from 0.28 – 0.38 (Stein et al., 2002).  
 
In a study of PTSD in MZ twin pairs who were discordant for combat exposure, similar deficits in verbal 
memory were evident in the identical co-twins of combat veterans with PTSD, who had no combat exposure 
or PTSD themselves. To this effect, both the combat veterans with PTSD and their co-twins possessed 
significantly smaller hippocampal tissue (Gilbertson et al., 2002). These findings suggest that memory 
impairments and smaller hippocampal size may represent a pre-existing, genetic vulnerability to PTSD 
(Gilbertson et al., 2006).  
 
A recent study investigated the relative genetic and environmental contributions to trauma exposure, PTSD 
and major depressive disorder (MDD) in adult twin-pairs who experienced childhood trauma and control 
twin pairs who did not (Sartor et al., 2012). Additive genetic effects accounted for 47% of the variance 
observed in low-risk trauma exposure and 60% of the variance in high-risk trauma exposure, while 46% of 
the variance in PTSD and 27% of the variance in MDD was attributable to heritable influences. High-risk 
trauma exposure had a high degree of genetic overlap with both PTSD and MDD, suggesting that most of the 
heritable influences on high-risk trauma exposure, PTSD, and MDD, can be attributed to the same genetic 
factors.  
 
Results from twin studies underscore the genetic contribution to PTSD. However, twin studies are unable to 
indicate which genes confer the risk of developing PTSD. Thus in order to identify candidate genes, 
molecular genetic studies are required (Koenen et al., 2007). 
2.2.2 Candidate genes in PTSD 
The majority of human genetic variation is attributed to single nucleotide polymorphisms (SNPs), which 
occur in at least 1% of the population. The human genome harbours about 3 million SNPs; SNPs are one of 
the most commonly screened for polymorphisms in case-control candidate gene-association studies of PTSD 
(Risch and Merikangas, 1996; Koenen et al., 2007). These studies rely on the selection of candidate genes 
based on the current knowledge regarding the neurobiology of the disorder. In PTSD research, such genes 
typically include those involved in the HPA regulation, noradrenergic system and limbic–frontal brain 
systems (especially genes that are involved in fear conditioning). Association studies in PTSD have mainly 
focussed on the following key candidate genes: BDNF (Zhang et al., 2006a, Zhang et al., 2006b; Rasmusson 
et al., 2002; Hemmings et al., 2013), NPY (Lappalainen et al., 2002), the serotonin transporter gene 
(SLC6A4) (Stahl, 2005; Davis et al., 1997; Caspi et al., 2003; Mendlewicz et al., 2004; Murphy et al., 2001; 
Bennett et al., 2002) dopamine (DRD2, DAT) (Lawford et al., 2003; Young et al., 2002; Gelernter et al., 
1999; Comings et al., 1996; Segman et al., 2002; Hemmings et al., 2013), glucocorticoid (GR) (Bachmann et 
al., 2005), GABA (GABRB) (Feusner et al., 2001) and the apolipoprotein systems (APOE2). Many of these 
studies have yielded non-replicated or conflicting results, some of which could be attributed to differences in 
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methodological approaches, different sample populations, different index traumas, variations in confounding 
factors and, in some cases, small sample sizes that result in insufficient statistical power. In addition, the 
complex aetiology of PTSD complicates the identification of specific genes that contribute significantly to 
the disorder (Broekman and Boer 2007). 
 
Genome-wide association studies (GWAS) represent an alternative, more robust and hypothesis-neutral 
approach that can be followed for case-control studies. In GWAS, SNPs (frequencies of SNPs) across the 
entire genome of cases are compared to controls (Hirschhorn and Daly, 2005). However, to date, very few 
GWAS studies have been conducted in anxiety disorders and in PTSD. This could be due to difficulties in 
methodological design, such as requiring very large sample sizes (Koenen et al., 2007), adequate matching of 
risk factors in cases and controls (especially with regards to trauma exposure and the type of trauma) and 
small effect sizes (Skelton et al., 2012). Only two GWAS studies were performed thus far in PTSD. In the 
study by Logue et al., in 2012 the sample population consisted of trauma-exposed Caucasian (non-Hispanic) 
military veterans and their intimate partners. Several SNPs showed evidence of an association with PTSD. 
They identified one SNP that reached genome-wide significance (after correcting for multiple testing); 
rs8042149 is located in the retinoid-related orphan receptor alpha gene (RORA) and was significantly 
associated with a lifetime diagnosis of PTSD (Logue et al., 2012). Recently, Xie et al. (2013) conducted a 
GWAS study in a study population consisting of European Americans and African Americans in order to 
find novel common risk alleles for PTSD. They identified a SNP on chromosome 7p12, rs406001, which 
exceeded genome-wide significance. Furthermore, a SNP that maps to the first intron of the Tolloid-Like 1 
gene (TLL1) also showed strong evidence of association; however, it did not reach genome-wide 
significance. However, further analysis of two SNPs in the first intron of TLL1, rs6812849 and rs7691872 in 
2000 European Americans, replicated the association findings from the GWAS.  
 
Table 2.1 provides a summary of association studies performed in PTSD, also see the review by Cornelis et 
al., 2010 for more detail. 
 
Table 2.1: Candidate genes that have been investigated in PTSD (adapted from Cornelis et al., 2010) 
Gene  Name Selected feferences 
RD2 Dopamine receptor D2 Dragan and Oniszczenko 2009; Gelernter et al., 1999; Voisey al., 2009; 
Comings et al., 1991; Hemmings et al., 2013; Bailey et al., 2010 
DRD4 Dopamine receptor D4 Dragan and Oniszczenko 2009 
SLC6A3 
(DAT1) 
Dopamine transporter Segman et al., 2002; Drury et al., 2009; Bailey et al., 2010; Chang et al., 
2012; Drury et al., 2013; Valente et al., 2011 
SLC6A4 Serotonin transporter Lee et al., 2005; Kolassa et al., 2010; Kilpatrick et al., 2007; Koenen et 
al., 2009; Thakur et al., 2009; Xie et al., 2009; Grabe et al., 2009; 
Mellman et al., 2009; Sayin et al., 2010; Valente et al., 2011; Pietrzak et 
al., 2013 




(serotonin) receptor 2A 
Lee et al.,2007; Mellman et al., 2009 
FKBP5 FK506 binding protein 5 Binder et al., 2008; Xie et al., 2010; Sarapas et al., 2011; Boscarino et 
al., 2011; 2012; 2013; Mehta et al., 2011; van Zuiden et al., 2012 
BDNF Brain-derived neurotrophic 
factor 
Lee et al., 2006; Zhang et al., 2006; Valente et al., 2011; Hemmings te 
al., 2013; Zhang et al., 2013; Felmingham et al., 2013; Rakofsky et al., 
2012 
NPY Neuropeptide Y Lappalainen et al., 2002  
GCCR 
(NR3C1) 
Glucocorticoid receptor Bachmann et al., 2005; van Zuiden et al., 2012; Hauer et al., 2011 
DBH Dopamine β-hydroxylase Mustapic et al., 2007 
CNR1 Cannabinoid receptor 1 
(brain) 
Lu et al., 2008 
GABRA2 γ-aminobutyric acid 
receptor subunit alpha-2 
Nelson et al., 2009 
COMT Catechol-O-
methyltransferase 
Kolassa et al., 2010; Boscarino et al., 2011; 2012; 2013 
APOE Apolipoprotein E Freeman et al., 2005; Kim et al., 2013 
RGS2 Regulator of G-protein 
signaling 2 
Amstadter et al., 2009 
CHRNA5 Cholinergic receptor, 
nicotinic, alpha 5 
(neuronal) 
Boscarino et al., 2011; 2012; 2013 
CRHR1 Corticotropin releasing 
hormone receptor 1 
Boscarino et al., 2012; 2013 
RORA Retinoid-related orphan 
receptor alpha 
Logue et al., 2012 
2.2.3 Gene-environment interaction studies 
As PTSD by definition requires exposure to a traumatic event and only a subset of individuals develop PTSD 
after trauma, studies of gene-environment (G x E) interactions might be better suited to elucidate the genetic 
underpinnings of the disorder. These studies have provided evidence that PTSD is influenced by interactive 
effects from both environmental and genetic factors (Table 2.2). In one of the first G x E studies to be 
conducted in PTSD, four polymorphisms in FKBP5 (rs9296158, rs3800373, rs1360780, and rs9470080) 
were shown to interact with severity of childhood trauma to predict adult PTSD symptom severity in 
traumatized African-American subjects (Binder et al., 2008). Moreover, these polymorphisms were found to 
be functional; individuals with PTSD that carried the risk alleles showed enhanced suppression of cortisol in 
response to dexamethasone (Binder et al., 2008). More recently Xie et al. (2010) partially replicated these 
findings in an African-American cohort; they found that one of the FKBP5 polymorphisms (rs9470080) 
moderated the risk of PTSD associated with childhood adversity. In individuals with a history of childhood 
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trauma, the TT genotype was found to be associated with the highest risk of developing PTSD, whereas it 
was found to be associated with the lowest risk for PTSD development in individuals with no history of 
childhood trauma. When Xie et al. (2010) investigated these G x E interactions in a European-American 
population, they were not significant, however, interactions between alcohol dependence, FKBP5 
polymorphisms (rs3800373, rs9296158, rs1360780 and rs9470080) and childhood adversity were found to 
increase the risk for PTSD diagnosis.  
 
Furthermore, another polymorphism in FKBP5 (rs9296158) was found to interact with childhood 
environment to predict PTSD severity (Mehta and Binder 2012; Mehta et al., 2011). Individuals with adult 
PTSD, who experienced childhood trauma and were carriers of the risk allele of rs9296158 (A allele), 
displayed excessive GC negative feedback of HPA secretion (Mehta et al., 2011). FKBP5 regulates GR 
activity and subsequently influences HPA axis functioning; it also forms part of the mature GR 
heterocomplex. Furthermore, FKBP5 is a co-chaperone protein that interacts with heat shock protein 90 
(hsp90), another molecular chaperone (Hubler and Scammell, 2004), and controls sensitivity and nuclear 
translocation of GRs so that reduced FKBP5 activity increases GR sensitivity (refer to Table 2.2 for more G 
x E studies conducted in PTSD) (Binder, 2009). These results suggest that various population characteristics, 
as well as childhood and adult trauma measurements need to be accounted for in the robust identification of 
G x E effects in PTSD.  
 
Table 2.2: Published G x E studies in PTSD and PTSD phenotypes (adapted from Mehta and Binder 2012) 
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Binder et al., 2008 
 rs9296158, 
rs737054, 
    
 rs1334894, 
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War GR sensitivity (low dose 
dexamethasone 
suppression test and 
dermal vasoconstrictor 
assay) 
Vietnamese Bachmann et al., 2005 
 
Serotonergic neurotransmission is influenced by the serotonin transporter (SERT, transcribed by the SLC6A4 
gene). The duration and magnitude of serotonergic neurotransmission is regulated by SERT, which also 
serves as an initial target site for antidepressants (Graham and Langer, 1992; Schloss and Williams, 1998). A 
SERT-linked polymorphic region (SERTPR) has been identified in the SERT promoter. This repeat length 
polymorphism affects the rate of serotonin uptake; the SERTPR consists of repeats of a 20-23-bp-long GC-
rich element. The short (S) and long (L) alleles (14- and 16-repeats, respectively) was reported to originate 
from an insertion/deletion in the SERTPR (Nakamura et al., 2000). Basal SERT activity in SERTPR long (L) 
allele carriers has been found to be more than twice that of short (S) allele carriers (Heils et al., 1996; Lesch 
et al., 1996). These allelic variants have been shown to be associated with various anxiety responses to 
stressful events (Table 2.2) (Glatz et al., 2003; Kilpatrick et al., 2007; Koenen et al., 2009; Kolassa et al., 
2010; Lee et al., 2005; Xie et al., 2009 Grabe et al., 2009; Sayin et al., 2010; Thakur et al., 2009 Mellman et 
al., 2009; Valente et al., 2011). Lee et al. (2005) found that the frequency of the S/S genotype was 
significantly higher in the PTSD patients compared to controls (Lee et al., 2005). In a study that investigated 
post-hurricane PTSD and major depression, the S-allele was found to increase the risk of developing post-
hurricane PTSD and MDD; however, this was observed only under conditions of high hurricane exposure 
and low social support. High-risk individuals (high hurricane exposure, S-allele with low social support) had 
a 4.5-fold increased risk of developing PTSD and MDD compared to low-risk individuals (low hurricane 
exposure L-allele) (Kilpatrick et al., 2007). Similar findings were published by Xie et al. (2010), who 
investigated the SERTPR in European American and African American populations. Individuals who 
experienced childhood adversity and adult traumatic events and who possessed at least one S-allele were 
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significantly more likely to develop lifetime PTSD compared to individuals who only experienced one type 
of adverse event, and were homozygous for the L-allele.  
  
The dopamine receptor gene (DRD2) and the dopamine transporter gene (DAT) directly affect the 
dopaminergic system (since it transcribes proteins that release dopamine and that regulate transport of 
dopamine) and are therefore important PTSD candidate genes. Comings et al. (1996) published the first 
study on the function of DRD2 in PTSD. They reported a significant association between the DRD2 A1 allele 
and PTSD; this was however not confirmed in a later study by Gelernter et al. (1999). Another study later 
found an association between the DRD2 A1 allele and PTSD; it was however only seen in individuals who 
consumed harmful amounts of alcohol on a daily basis (Young et al., 2002). Results on the relationship 
between DRD2 and PTSD are thus conflicting. In order to gain more insight into the link between PTSD and 
DRD2, alcohol consumption must be clearly documented in future association studies. Furthermore, research 
into the role of DAT in relation to PTSD should also be explored (Broekman et al., 2007). 
  
An alternative approach to understanding the genetic underpinnings of complex disorders, such as PTSD, 
includes gene expression profiling studies. Genes that show differential expression profiles between trauma-
exposed individuals who develop PTSD and those who don’t, also provide good candidate genes for further 
investigation (Segman et al., 2005). The following sections will review gene expression studies performed in 
model organisms as well as in human participants.  
2.2.4 Gene expression analyses in PTSD  
During the process of memory consolidation, short term memory (STM) is converted into stable long-term 
memory (LTM) over a period of time (Davis and Squire 1984). Fearful experiences and fear conditioning 
memories are rapidly acquired and therefore easily consolidated into LTM, this is important for survival 
since these experiences convey vital information regarding danger in the environment (Schafe et al., 2001). 
LTM is accompanied by long-lasting alterations of synaptic plasticity in particular brain structures (Garcia 
2001), such as the hippocampus (Fonta´n-Lozano et al., 2007). In the context of PTSD, cognitive 
behavioural therapies (CBTs), one of the treatment strategies for PTSD, are based on regulating the 
processes of fear extinction (McNally, 2007; Otto et al., 2007). Changes in synaptic plasticity also occur 
during extinction learning to promote long-term memory of extinction. However, the absence of such 
alterations in synaptic plasticity (during or after the treatment) may lead to the development of PTSD (Herry 
and Garcia 2002). 
 
The activation of specific signalling cascades contribute to stable, prolonged synaptic changes through the 
activation of inducible immediate-early gene (IEG) transcription and de novo protein synthesis (Davis and 
Squire, 1984; Bailey et al., 1999; Guzowski, 2002; Ressler et al., 2002). Spontaneous recovery of 
conditioned fear is a PTSD-like phenotype in animal models, and refers to impaired fear extinction or 
relapse. Spontaneous recovery of conditioned fear was found to be associated with prolonged long-term 
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depression of synaptic transmission in the mPFC and the failure to induce the IEGs c-Fos and zif268 in the 
BLA of the amygdala and the mPFC. These findings suggest that long-term extinction of conditioned fear 
can be achieved through activity-dependent changes in gene expression in the mPFC and the amygdala 
(Herry et al., 2004). Given that gene expression alterations mediate fear conditioning and extinction 
processes, investigating differential gene expression patterns in these brain regions may broaden our 
understanding of fear extinction as well as the development and maintenance of PTSD.  
2.2.4.1 Gene expression analyses in PTSD animal models 
 
Exposing model organisms to acute or chronic stress can alter the activity of the neuroendocrine and 
neurotransmitter systems that affect behaviour. Stress induces enhanced fear, anxiety and depression in 
rodents; therefore they have been used extensively in the study of the pathophysiology of PTSD (Bekris et al. 
2005; Bergstrom et al. 2008; D’Aquila et al. 1994; Wood et al. 2008; Goswami et al., 2013). Owing to the 
high degree of similarity between the human genome and that of other mammals, animal studies often 
identify potential candidates for human genetic studies. Animal models, therefore, provide researchers with 
the opportunity to perform brain-specific genetic analyses in order to determine the molecular mechanisms 
involved in disorders such as PTSD (refer to Table 2.3 for an overview of tests performed in PTSD animal 
models, also refer to reviews by Sousa et al. (2006) and Goswami et al. (2013) for more detail).  
  
Table 2.3: Tests commonly used in animal models of PTSD (adapted from Sousa et al., 2006) 
Tests that measure reflexes and 
sensory function 
Measurement References 
Acoustic startle response (ASR) The magnitude of the reflexive response Koch (1999); Swerdlow et al. (2000);  
 (muscle contraction) to a loud auditory 
stimulus is measured. 
Serova et al. (2013) 
Prepulse inhibition (PPI) Prepulse inhibition includes presentation of a Yeomans and Frankland (1995) 
 brief subliminal sound stimulus prior to the Baisley et al. (2011); Conti 2012 
 reflex-eliciting stimulus. Prepulse stimuli 
inhibit the startle reflex. PPI is a functional 
measure of sensorimotor gating which could 
be impaired in PTSD 
 
Tests that measure motor 
function and co-ordination 
Measurement References 
Motor activity Measures horizontal and/or vertical 
movements in a test environment (e.g. open 
field, home cage). 
Crusio (2001); Drai and Golani (2001); 
Holmes et al. (2002); Prut and Belzung 
(2003); Imanaka et al. (2006); Qiu et al., 2013 
   
Tests that measure exploratory 
and emotional behaviour 
Measurement References 
Exploration- and Interaction-
based anxiety tests (elevated plus-
maze test, light/dark test, open 
field, social interaction) 
Measures approach and avoidance behaviour 
of potentially dangerous environments/stimuli 
(e.g. open, brightly lit, elevated areas; 
conspecifics). 
Rodgers and Dalvi (1997);File (2001); 
Hascoet et al. (2001); Prut and Belzung 
(2003); File and Seth (2003); Kung et al. 
(2010); Adamec et al. (2010); Krishnamurthy 
et al. (2013) 
Response-based anxiety tests 
(fear-potentiated startle, 
unconditioned freezing) 
Measures the potentiation of the reflexive 
startle or freezing response by anxiogenic 
stimuli or drugs (e.g. bright light). 
Davis (1998); Walker et al. (2003); Missig et 
al. (2010); Norrholm et al. (2013); 
Defense-based anxiety tests (rat/ 
mouse defense test battery) 
Measures flight, fight, freezing, defensive 
threat, defensive attack and risk assessment in 
Blanchard et al. (1997, 2003); Borsini et al. 
(2002); Griebel et al. (1995) 
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response to an unconditioned predator 
stimulus. 
Conflict-based anxiety tests 
(vogel conflict test) 
Measures water consumption in water-
deprived animals that receive a mild electric 
shock to the tongue after a certain number of 
licks. Measure of anxiolytic-like activity 
Vogel et al. (1971); Heilig et al. (1989); 
Thorsell et al. (2000); Lotarski et al. (2011) 
Non-conflict-based conditioned 
anxiety tests (fear conditioning) 
Measures emotional memories by means of 
potentiation of startle responses, conditioned 
eyelid closures or conditioned freezing. 
LeDoux (2000); Siegmund and Wotjak 
(2007); Cordero et al. (2003); Takahashi, et 
al. (2006) 
Tests that measure social 
behaviour 
Measurement References 
Social interaction test Animal is confronted with an unknown 
conspecific (animal of the same species) in a 
novel environment. Measures latencies, 
frequencies and duration of social behavior 
(approach, avoidance, exploration, aggression, 
submission, sexual behavior). 
Huhman et al.,(1992); File and Seth (2003); 
Lijam et al.(1997); Miczek et al. (2001); 
Strekalova et al. (2004); Huhman (2006) 
Nanda et al. (2008) 
Maternal behaviour Measures nest building, suckling, active vs. 
passive nursing. 
Levine (1957); Heim et al. (2001); Meaney 
(2001); Champagne et al. (2003); Siegmund 
et al. (2009) 
Tests that measure cognitive 
behaviour 
Measurement References 
Passive avoidance (step-down 
avoidance, step-through 
avoidance) 
Animals are taught to withhold a response 
following pairing of a cue/test context with the 
presentation of a mild electric shock. Memory 
is assessed by the duration of withholding the 
response following training. 
Izquierdo and Medina (1997); Picciotto and 
Wickman (1998); Szapiro et al. (2003); 
Padilla et al. (2010) 
Spatial learning (Morris water 
maze, Barnes maze, T-maze)  
Animals are taught to navigate in a maze to 
obtain positive reinforcement (e.g. food) or to 
avoid negative reinforcement (e.g. escape from 
water). Measures choice/escape latencies, 
response accuracy and selectivity of searching. 
D’Hooge and De Deyn (2001); Lipp and 
Wolfer (1998); Graeff et al. (1998); Silva et 
al. (1998); Whishaw (1998) ; Gerlai (2001); 
Reisel et al. (2002); Lutz (2009); Diehl et al. 
(2012) 
Recognition memory Measures frequency and duration of 
exploration of novel stimuli (e.g. objects, 
odors, conspecifics) as opposed to exploration 
of familiar stimuli of the same modality. 
Brown and Aggleton (2001); Kogan et al. 
(2000); Steckler et al. (1998a, 1998b, 1998c); 
Wang et al. (2012); Goswami et al. (2012) 
Classical (Pavlovian) conditioning 
(fear conditioning) 
Measures duration and frequency of 
conditioned responses (e.g. freezing, fear-
potentiated startle, eyelid closures in fear 
conditioning tasks). 
Kamprath and Wotjak (2004); LeDoux 
(2000); Maren (2001); Medina et al. (2002); 
Rudy et al. (2004); Norrholm et al. (2013) 
 
In animal models of PTSD, a variety of stressors (physical, psychosocial or psychogenic) are used to 
examine the long-term effects of severe trauma. Models that use physical stressors include inescapable foot- 
shocks (Rudy et al., 2004), single prolonged stress (SPS) (Yamamoto et al., 2009), underwater trauma 
(Moore et al., 2012), restraint stress (Vyas et al., 2002) and variable stress (Molina et al., 1990; McGuire et 
al., 2010). The models that use psychosocial stressors include housing instability (Rollins et al. 2012; Park et 
al., 2001; Zoladz et al., 2008, 2012), social defeat (Huhman et al., 1992, 2006) and social isolation 
(Matsumoto et al., 1999). Models incorporating early life stressors are used to mimic childhood trauma. 
These models usually use maternal separation (Young et al., 1973; Zhang et al., 2011) either alone or in 
conjunction with other stressors such as isolation (Diehl et al., 2012). Maternal separation animal models 
mimic early life stressors by removing rat of mice pups from the dam (for different periods of time 
depending on the model) (Plotsky and Meaney, 1993; Mourlon et al., 2010; Reus et al., 2011; Leussis et al., 
2012). Models that use psychogenic stressors usually involve threat, but not pain. These models include 
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predator stress or predator threat (usually an odour) (Blanchard and Blanchard, 1988; Dielenberg and 
McGregor, 2001). 
 
The main aim of the current study was to determine the molecular mechanisms of DCS in facilitating fear 
extinction in a PTSD animal model; therefore studies that have investigated gene expression profiles 
following DCS administration will be discussed (refer to Section 2.4.1.1 D-cycloserine, for more information 
regarding DCS). Several animal studies have investigated the effects of anxiolytic drugs on gene expression 
profiles in different brain tissues in order to determine the molecular mechanism whereby these drugs 
facilitate fear extinction. D-cycloserine (DCS) was originally used as an effective antimycobacterial agent 
used for the treatment of tuberculosis, due to its ability to inhibit mycobacterial cell wall synthesis (Trias and 
Benz 1994). However, it is rarely prescribed for tuberculosis treatment nowadays and is mostly used in 
combination with other therapies due to its adverse side-effects at high dosages (Heifets and Iseman 1991; 
Yew et al., 1993). These side-effects were attributed to the binding of DCS to the NMDAR1 as a partial 
agonist at the glycine site (Thompson et al., 1992), it also inhibits enzymes that metabolize and synthesize 
the neurotransmitter γ-aminobutyric acid (GABA) (Wood et al., 1978). It is due to this binding of DCS to the 
NMDARs that the administration of DCS has been found to facilitate extinction learning in rats when 
administered before or immediately after extinction training (Ledgerwood et al., 2003; 2005; Walker et al., 
2002; Yang and Lu, 2005).  
 
Yamamoto et al. (2008; 2010) investigated the effects of SPS and DCS on hippocampal NMDAR expression 
in rats. They found a sustained increase in hippocampal NMDAR expression in response to fear conditioning 
in SPS rats. The increased NMDAR expression was found to be reduced by oral administration of DCS 
suggesting that DCS may help to reverse hippocampal plasticity, and thus reverse the NMDA compensatory 
alterations during fear extinction (Yamamoto et al., 2008). In addition, fear conditioning was found to 
increase the expression of the glycine transporter 1 (GLYT-1) gene in the hippocampus and resulted in a 
reducted extracellular hippocampal glycine concentration (Yamamoto et al., 2010). However, repeated 
extinction training significantly reduced the enhancement of GLYT-1 mRNA levels in SPS rats in response to 
fear conditioning. These findings suggest that impaired fear extinction in SPS rats may be due to reduced 
activity of the hippocampal glycinergic system (Yamamoto et al., 2010). 
 
Another study also used the SPS model, but combined it with contextual fear and investigated its effects on 
gene expression in the rat hippocampus (Iwamoto et al. 2007). As with the studies by Yamamoto et al, 
(2010) the authors reported elevated levels of GLYT-1 in the SPS treated rats. In addition, they also found a 
significant increase in levels of vesicle-associated membrane protein 2 (VAMP2) mRNA in rats subjected to 
SPS relative to sham-treated rats. SPS administration alone did not affect the expression of these two genes, 
suggesting that the upregulation of GLYT-1 and VAMP2 in the hippocampus might be involved in enhanced 
susceptibility to contextual fear in rats subjected to SPS (Iwamoto et al. 2007). Harada et al. (2008) 
investigated the molecular changes associated with SPS-induced behavioural changes. Their microarray 
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analysis revealed that the serotonin 5-HT2C receptor gene was overexpressed in the amygdala of SPS rats; 
these results were confirmed with qPCR analysis. Administration of a selective 5-HT2C receptor antagonist, 
FR260010, showed a definite anxiolytic effect in the SPS treated rats. Their results were the first to 
demonstrate that brain-specific 5-HT2C receptor activation is involved in the behavioural abnormalities seen 
in the SPS exposure model. Selective 5-HT2C receptor antagonists might provide novel therapeutic options 
for PTSD treatment (Harada et al., 2008).  
 
The majority of earlier PTSD animal models investigated the exposed group of animals as a homogenous 
PTSD-like population (Pynoos et al., 1996, Koba et al., 2001, Korte et al., 2003). A study by Cohen et al., in 
2003 showed that, like humans, animals exhibit heterogeneous reactions to stress, therefore grouping animals 
accordingly is imperative (Cohen et al., 2003). Kesner et al. (2009) followed this approach in their study 
where they used exposure to predator odor as an unconditioned stressor. Furthermore, they monitored 
individual rat behaviour for up to a month, after which animals were grouped into two groups, namely 
‘exposed PTSD-like’ and ‘exposed non-PTSD-like’. They then treated the PTSD-like animals with 
citalopram. They found elevated expression levels of the Wolframin gene (WFS1) in the CA1 hippocampal 
region and basolateral amygdala of PTSD rats compared to control saline-treated rats. Expression levels of 
WFS1 in trauma-exposed animals who did not exhibit PTSD-like phenotypes (non-PTSD-like rats) were 
identical to that of non-trauma exposed controls. Administration of citalopram to PTSD-like animals for 14 
days normalized elevated WFS1 levels in both brain regions (Kesner et al., 2009).  
 
An important neurotrophin involved in plasticity and neuronal survival is BDNF. BDNF mRNA expression 
levels in the CNS are sensitive to factors such as stress (Hyman et al., 1991). Previous studies have reported 
reduced hippocampal BDNF expression levels in the rat pituitary following single or repeated 
immobilization stress (Givalois et al., 2001; Hyman et al., 1991). Similar results have also been found 
following psychological and unconditioned physical stress (Rasmusson et al; 2002), where hippocampal 
BDNF expression was found to be reduced. The adrenal hormone, corticosterone, has been hypothesized to 
be involved in this stress-associated down-regulation of BDNF, as exogenous administration of 
corticosterone reduced BDNF expression (Nibuya et al., 1999). Kozlovsky et al. (2007) also observed BDNF 
downregulation and upregulation of the BDNF receptor, TrkB, in the CA1 sub-region of the hippocampus of 
animals that exhibited fearful behaviour in response to predator stress.  
 
A recent study investigated the effects of chronic mild stress (CMS) on PFC gene expression profiles by 
using gene expression profiling and bioinformatics analyses on previously studied mice samples (Lisowski et 
al., 2013; Błaszczyk et al. 2000; Juszczak et al. 2008a; Juszczak et al. 2008b, 2006; Panocka et al. 2001). 
They used two mice strains that were bred for high (HA) and low (LA) swim stress-induced analgesia 
(insensibility to or relief from pain). Animals were grouped into two treatment groups: control animals 
(control HA mice and control LA mice) and stressed animals that received 5 weeks of CMS (CMS HA mice 
and CMS LA mice). Increased acoustic startle responses (Błaszczyk et al. 2000; Juszczak et al. 2008a), 
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longer periods of immobility in the tail suspension test (TST) and forced swim tests (FST) were evident in 
the CMS HA strain (Juszczak et al. 2008b, 2006; Panocka et al. 2001) compared to the CMS LA strain. CMS 
HA mice thus represent a maladapted group and CMS LA a well-adapted group. CMS induced differential 
expression in 96 and 92 genes respectively in HA and LA mice compared to the control groups (Lisowski et 
al., 2013). In the CMS group they found that vesicular glutamate transporter 1(VGLUT1) and solute carrier 
family 17 (sodium-dependent inorganic phosphate cotransporter), member 7 (SLC17A7) was significantly 
upregulated in HA mice and metabotropic glutamate receptor 5 (GRM5) was downregulated in LA mice. 
These results correlated with those from a previous study that also found VGLUT1 and VGLUT2 to be 
significantly upregulated in the hippocampus of LA mice after CMS (Lisowski et al. 2011). Metabotropic 
glutamate receptor 5 (GRM5), a subtype of group I GRs, exhibits high expression levels in limbic forebrain 
regions, and possibly modulates anxiety-related processes. The specific antagonist 2-methyl- 6-
(phenylethynyl) pyridine, blocks GRM5, thereby reducing extracellular norepinephrine, which may 
contribute to its anxiolytic effect (Page et al. 2005). The authors suggest that GRM5 down-regulation and 
VGLUT1 up-regulation in LA CMS mice could be involved in a mechanism of adaptation to stress in stress-
resistant individuals (Lisowski et al., 2013).  
Lisowski et al. (2013) also detected significant up-regulation of the arginine vasopressin (AVP) gene in HA 
mice. Previous research indicates that repeated stress induces increased AVP expression in paraventricular 
CRH neurons, which acts to enhance the ACTH-releasing capacity of these cells. AVP acts on wide array of 
neurons throughout the brain. Acute immobilization also induced significant upregulation of AVP and CRF 
mRNA expression in the medial parvocellular subdivisions of the paraventricular nucleus (PVN) (Aubry et 
al. 1999). Makino et al. (1995) found that PVN AVP expression levels were more sensitive to GC negative 
feedback than CRH levels. Koob (2008) also suggested that AVP possibly modulates emotional memory and 
anxiety. Lisowski et al. (2013) concluded that in CMS, increased expression of AVP in the PFC is a 
mechanism that contributes to the maintenance of HPA response following repeated stress. In addition to the 
amygdala and hypothalamus, the PFC excitatory actions of increased expression of AVP may also contribute 
to the behavioural stress response (Lisowski et al., 2013).  
The endocannabinoid system (ECS) is not only a crucial mediator of emotional learning but also forms part 
of the intricate circuitry that regulates stress and anxiety (Ganon-Elazar et al., 2012; Marsicano et al., 2002; 
Abush and Akirav 2012; Akirav 2011; Hill et al., 2009; Viveros et al., 2005), and is a therapeutic target for 
the treatment of stress and anxiety-related disorders such as PTSD (Marsicano et al., 2002). Indeed, the 
potential benefits of nabilone, the synthetic cannabinoid, have been demonstrated in PTSD patients (Fraser 
2009). Campos et al. (2013) investigated whether the expression of the cannabinoid receptor 1 (CB1) and the 
synaptic protein, synaptophysin (SYP), were involved in the lasting behavioural effects induced by predator 
exposure. They investigated this in brain regions implicated in PTSD symptoms, such as the hippocampus, 
frontal cortex and amygdaloid complex. Male Wistar rats were exposed to predator stress and were evaluated 
seven days later on the elevated plus-maze test. The authors measured CB1 receptor and SYP expression 
levels in the hippocampus, frontal cortex and amygdaloid complex. Long-term anxiogenic effects were 
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evident following single predator exposure. Expression levels of CB1 were downregulated in the frontal 
cortex and amygdaloid complex seven days after predator threat exposure, while SYP was upregulated in the 
amygdaloid complex. These results suggest that the persistent anxiogenic effects induced by predator 
exposure are associated with amygdaloid complex hyperactivation and CB1 receptor modulation in brain 
regions associated with PTSD symptoms (Campos et al., 2013).  
 
Another important aspect to keep in mind when conducting studies in PTSD is comorbidity with other 
disorders. Comorbidity of PTSD and diabetes has recently become the focus of numerous studies (Goodwin 
and Davidson 2005; Trief et al., 2006; Boyko et al., 2010). In the brain, insulin influences the structural 
responses to stressors; insulin deprivation causes a decrease in dentate gyrus neurons and leads to increased 
remodelling of CA3 neuron dendrites, this effect is further accelerated by exposure to repeated restraint 
stress. Stress and hyperglycemia both increase oxidative stress in the brain and this is likely to contribute, 
over time, to impaired neural function in chronic stress and diabetes Lisowski et al. (2013).  
 
Table 2.4 provides a summary of genes that were found to be differentially expressed in PTSD animal 
models. The majority of these studies have focussed on specific brain regions implicated in the disorder, 
whereas peripheral blood mononuclear cells (PBMCs) have mainly been used in human expression studies 
(Zieker et al., 2007; Segman et al., 2005). This raises the question of whether it is possible to obtain 
consistent expression results from both brain and blood samples. Gene expression analysis in blood provides 
a much less invasive method of detecting expression changes associated with PTSD. By using animal models 
to identify stress-related gene expression profiles in the brain that are also reflected in the blood, provide 
relevant candidate genes to investigate in human studies of the disease (where mostly PBMCs or other 
peripheral tissues are available for testing). Van Heerden et al. (2009) compared gene expression profiles in 
PBMCs and brain tissue from a mouse maternal separation model. They found that in the 50 genes selected 
from the PBMC microarray, the stress-related transcriptome differences in PBMCs were paralleled by stress-
related gene expression changes in the CNS target tissues. Similar investigations are required in different 
animal models and different brain regions to clearly determine the correlation between gene expression 
profiles in the CNS and in blood.  
 
Gene expression profiles that were found to be associated with anxiety-like behaviours in animal models of 
PTSD could be further investigated in human samples to unravel the pathophysiology and aetiology of PTSD 
and direct novel drug targets.  
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Table 2.4: Summary of differentially expressed genes in animal studies of PTSD 
Gene Association with PTSD Species Reference 
NPY Upregulated in amygdala in response to chronic stress Rattus norvegicus Thorsell et al., 1999 
c-Fos  Failure to induce expression of this IEG in basolateral 
nucleus of amygdala and mPFC lead to spontaneous 
recovery of conditioned fear  
Mus musculus Herry et al., 2004 
zif268 Failure to induce expression of this IEG in basolateral 
nucleus of amygdala and mPFC lead to spontaneous 
recovery of conditioned fear 
Mus musculus Herry et al., 2004 
NMDAR Increased hippocampal expression in response to SPS fear 
conditioning  
Rattus norvegicus Yamamoto et al. (2008) 
GLYT-1 Increased hippocampal expression in response to SPS fear 
conditioning 
Rattus norvegicus Yamamoto et al. (2010) 
 Elevated levels in hippocampal in response to SPS 
combined with contextual fear 
Rattus norvegicus Iwamoto et al. (2007) 
VAMP2 Significant increase in expression in response to SPS 
combined with contextual fear 
Rattus norvegicus Iwamoto et al. (2007) 
WFS1 Elevated expression levels in CA1 and BLA in PTSD-like 
animals vs. stressed animals with no PTSD-like symptoms 
exposed to repeated stress. 14 day citalopram treatment 
corrected this effect.  
Rattus norvegicus Kesner et al. (2009) 
BDNF Reduced expression in pituitary gland following acute 
immobilisation stress 
Rattus norvegicus Givalois et al., 2001 
 Decreased expression following psychological and 
unconditioned physical stress 
Rattus norvegicus Rasmusson et al; 2002 
 Downregulated in CA1 of fearful animals following 
predator stress 
Rattus norvegicus Kozlovsky et al., 2007 
TRKB Upregulated in CA1 of fearful animals following predator 
stress 
Rattus norvegicus Kozlovsky et al., 2007 
 Reduced expression in pituitary gland following acute 
immobilisation stress 
Rattus norvegicus Givalois et al., 2001 
5-HT2C  Overexpressed in amygdala following SPS  Rattus norvegicus Harada et al., 2008 
P11 (S100a10) Upregulated in the PFC rats exposed to inescapable tail 
shock 
Zhang et al., 2008  
VGLUT1 Upregulated in PFC of fearful animals in response to CMS  Mus musculus Lisowski et al., 2013 
 Upregulated in hippocampus of LA mice after CMS Mus musculus Lisowski et al. 2011 
SLC17A7 Upregulated in PFC of HA animals following CMS Mus musculus Lisowski et al., 2013 
GRM5 Downregulated in PFC of LA animals following CMS  Mus musculus Lisowski et al., 2013 
VGLUT2 Upregulated in hippocampus of LA mice after CMS Mus musculus Lisowski et al. 2011 
AVP Upregulated in PFC of HA mi animals following CMS  Mus musculus Lisowski et al., 2013 
 Upregulated in PVN following acute immobilization  Rattus norvegicus Aubry et al. 1999 
CRH Upregulated in PVN following acute immobilization Rattus norvegicus Aubry et al. 1999 
CB1 Downregulated in frontal cortex and amygdaloid complex 7 
days after predator threat exposure 
Rattus norvegicus Campos et al., 2013 
SYP Upregulated in amygdaloid complex 7 days after predator 
threat exposure 
Rattus norvegicus Campos et al., 2013 
PRLR Upregulated in PFC of HA animals following CMS Mus musculus Lisowski et al., 2013 
 
Please refer to list of abbreviations for full gene names 
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2.2.4.2 Gene expression analyses in human studies of PTSD 
 
Distinct differences in gene expression patterns have been observed between PTSD-affected and unaffected 
individuals in genes involved in HPA axis and immune function and genes that transcribe neural and 
endocrine proteins (Weaver et al., 2002; Segman et al., 2005; Zieker et al., 2007; Uddin et al., 2010; Yehuda 
et al., 2009, 2010) (Table 2.5). Identification of differentially expressed genes involved in the aetiology of 
PTSD could help identify pathways that are involved in the disorder. In addition, factors that contribute to 
altered gene expression patterns may unravel the complex biological underpinnings of PTSD. Table 2.5 
provides a summary of the differentially expressed genes that have been described in human PTSD samples. 
 
Table 2.5: Summary of differentially expressed genes in human studies of PTSD 
Genes Association with PTSD Reference 
FKPB5 Baseline differential expression in PBMCs of trauma survivors was 
predicative of PTSD outcome in later life  
Segman et al. 2005 
 Low pre-deployment expression levels in PBMCs predictive of PTSD 
development in response to deployment 
Van Zuiden et al., 2013 
GILZ High pre-deployment expression levels in PBMCs predictive of PTSD 
development in response to deployment 
Van Zuiden et al., 2013 
*FKBP5, STAT5B, MHC-II Reduced expression in PTSD patients vs. trauma exposed controls 
following the 9/11 attacks  
Yehuda et al., 2009 
*ROS and immune related 
genes (TXR, SOD, IL-16, IL-18, 
EDG1)  
Downregulated in whole blood of PTSD patients following the 
Ramstein air show catastrophe, 1989 
Zieker et al., 2007 
P11 (S100a10) Upregulated in the post-mortem PFC of individuals who had PTSD Zhang et al., 2008 
 Reduced expression in PBMC of PTSD patients vs. controls. Expression 
levels can distinguish PTSD from MDD, BP and SCZ. 
Su et al., 2009 
NFI-A Reduced expression in PTSD patients vs. trauma exposed controls 
following the 9/11 attacks 
Sarapas et al., 2011 
EDG1 - endothelial differentiation gene 1, FKBP5 - FK506 binding protein 5, GILZ - glucocorticoid-induced leucine zipper, 
interleukin 16 (IL-16) and interleukin 18 (IL-18), MHC-II - major histocompatibility complex class II, NFI-A - nuclear factor 1 A, 
ROS - reactive oxygen species, SOD - superoxide dismutase, STAT5B - signal transducer and activator of transcription 5B, TXR - 




GWAS and smaller case-control studies have yielded numerous disease-associated variants; however most of 
these variants have a minor effect on disease and explain only a small amount of the heritability of complex 
disorders. The search for the missing heritability has shifted attention to rare variants, copy number variants 
(CNVs), copy neutral variants and epigenetic modifications. 
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Although quantifying gene expression provides one with an idea of the biological pathways involved in the 
disorder, it does not provide knowledge of the mechanisms that contribute to observed alterations in gene 
expression. The question of whether it is transcription of the gene itself that is altered, or whether differences 
in expression are due to mRNA turnover in the cell, remains unanswered (Akbarian and Huang, 2009). 
 
The term epigenetics literally means 'outside conventional genetics', and is currently used to describe the 
study of stable alterations in gene expression that are not brought about by changes in DNA sequence 
(Bjornsson et al., 2004). These epigenetic changes are heritable and potentially reversible, (Jaenisch and Bird 
2003) and provide an additional layer of transcriptional control that may mediate the interaction between 
genetic predisposition, changes in neural functioning and environmental factors (Bjornsson et al., 2004). 
Epigenetic modifications may thus explain the interindividual variation and the long-lasting effects of trauma 
exposure (Yehuda and Bierer 2009). Such epigenetic mechanisms include DNA methylation, 
posttranscriptionional modifications of histone proteins (acetylation, methylation, phosphorylation, 
ubiquitination and sumoylation) and non-coding RNA-mediated alterations (such as microRNAs (miRNAs) 
and small interfering RNAs (siRNAs)) (Yehuda and Bierer 2009).  
Epigenetic remodelling has been found to be a crucial component of the neuronal changes that underlie 
memory and learning processes (Bredy et al., 2007; Chwang et al., 2006; Miller and Sweatt, 2007). It has 
been postulated that epigenetic factors play an important role in the regulation of activity-dependent neuronal 
gene expression (Martinowich et al., 2003; Chen et al., 2003). In addition, it has been found that contextual 
fear conditioning can lead to histone H3 acetylation and H3 phosphorylation changes in the hippocampus 
(Chwang et al., 2006), implicating the role of histone modifications in memory formation. A study by Miller 
and Sweatt (2007) found that the transcription of DNA methyltransferases (DNMTs), which catalyse DNA 
methylation, were upregulated in the rat hippocampus during contextual fear conditioning, and that inhibition 
of DNMT blocked memory formation. Studies have also found various miRNAs in the CNS and they are 
believed to be crucial in regulating a variety of neurobiological processes that could pertain to the 
development of PTSD (Parsons et al., 2008; Hunsberger et al., 2009; Uchida et al. 2010; Meerson et al., 
2010; Muiños-Gimeno et al., 2011; Malan-Müller et al., 2013; Barbash et al., 2013; Schmidt et al., 2013).  
Epigenetic regulation may be particularly important in shaping the effect that the early environment has on 
the development of dysfunctional fear extinction. It is thought that epigenetic regulation of gene expression 
underlying neural plasticity is important in the event of early-life adversity. For example, it has been found 
that early life experience in the form of maternal care results in stable epigenetic markings that contribute 
towards the anxiety-like phenotype in adult rats (Weaver et al., 2004; 2005; 2006; Szyf et al., 2005; 
Murgatroyd et al. 2009). These results have recently been extrapolated to human subjects (McGowan et al., 
2009; Franklin et al., 2010).  
Epigenetic mechanisms represents an exciting frontier to investigate in psychiatric disorders because of the 
ability to define specific molecular pathways by which environmental risk factors might directly change the 
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expression of a gene, thus forming a basis for individual differences in gene function and even vulnerability 
to a specific disorder. This is likely to be the case in PTSD and might explain the origin of GC-related 
alterations associated with PTSD and PTSD risk (Yehuda and LeDoux, 2007). Indeed, infants of mothers 
who developed PTSD as a result of direct exposure to the 9/11 World Trade Centre terrorist attacks were 
found to have lower salivary cortisol levels, reflecting an increase in number of GR, and thus possibly an 
alteration in in utero glucocorticoid programming, thought to be central in susceptibility to PTSD (Yehuda 
and Bierer, 2009; Yehuda et al., 2005). Exposure to GCs as a result of maternal stress has been found to 
reduce the birth weight of offspring, which is associated with, amongst others, the development of 
behavioural and psychiatric problems (Susser et al., 1996). Unpacking the role of the epigenome in PTSD 
vulnerability is thus of great importance (Kajantie 2006; Seckl 1994; Chertkow-Deutsher et al., 2010; 
Stankiewicz et al., 2013).  
2.3.1 DNA Methylation 
The central role of epigenetics, and specifically DNA methylation, in disease susceptibility and progression 
has become more apparent in recent years. Epigenetic mechanisms facilitate the response to environmental 
changes and challenges by regulating gene expression (Jaenisch and Bird 2003). This makes the study of 
DNA methylation in psychiatric disorders such as PTSD highly salient, as the environment plays such a vital 
role in disease aetiology. The epigenome is dynamic and can be modulated by numerous factors, including 
learning and memory (Roth et al., 2010), which is important in the context of PTSD. Indeed, numerous 
studies have shown the effects of early life events, such as maternal separation, as well as traumas during 
adulthood, on DNA methylation patterns and subsequent gene expression profiles (Mullen et al., 1996; 
MacMillan et al., 2001; Weaver et al., 2002; Szyf et al., 2005; Han and Kim, 2008; Murgatroyd et al. 2009; 
Lee et al., 2010; Yang et al., 2012;). Furthermore, aberrations in adaptive DNA methylation contribute to 
disease susceptibility when an organism is unable to effectively respond to environmental demands (Ozanne 
and Constância 2007). Epigenetic mechanisms are also involved in higher-order brain functions (Feng et al., 
2007). Dysregulation of methylation is associated with neurodevelopmental (Robertson and Wolffe 2000) 
and neurodegenerative cognitive diseases (Mattson, 2003), affective disorders (McMahon et al., 1995), 
addictive behaviours (Robison and Nestler 2011) and altered stress resistance. A thorough understanding of 
how the environment, methylome and transcriptome interact and influence each other in the context of stress 
and anxiety is integral to our understanding and treatment of anxiety disorders such as PTSD. 
2.3.1.1 DNA Methylation (5mC) 
 
In mammals, DNA methylation occurs mainly at the C-5 position of cytosine residues within CpG 
dinucleotides (Fig. 2.3). However, it was also shown that sequences other than CpG may also be methylated 
(as seen in the embryonic stem cell) (Salomon et al., 1970; Grafstrom et al., 1985; Ramsahoye et al., 2000). 
Globally, about 70% – 80 % of all CpG dinucleotides in the human genome are methylated (Ehrlich 1982); 
however, numerous temporal and spatial variations are evident, especially during early development (Reik et 
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al. 2001). DNA methylation regulates developmental genes, such as the pluripotency genes NANOG 
(Homeobox Transcription Factor) and the octamer-binding transcription factor 4 gene (OCT4), and is vital 
for genomic imprinting. During specific stages of mammalian development, CpG methylation undergoes 
dramatic global changes. New methylation patterns are acquired during early development; primordial germ 
cells (PGCs) are characterised by genome-wide removal of DNA methylation marks, and, following 
fertilization, the sperm-derived genome is stripped of DNA methylation (Sasaki and Matsui 2008). DNA 
methylation patterns are maintained after cell division and are consequently passed from parent to daughter 
cells (Turner, 2001; Taylor and Jones, 1985; Razin, 1998). Dysregulation of methylation can lead to aberrant 
transcriptional control, and subsequent alterations in gene expression (Yehuda and LeDoux, 2007). Another 
essential role of DNA methylation is the repression of retrotransposons and other foreign elements (Sasaki 
and Matsui 2008).  
 
The process of DNA methylation is strongly dependent on DNMTs, namely DNMT1 and de novo DNA 
methyltransferase enzymes DNMT3A and DNMT3B (essential for DNA methylation patterns in early 
development). DNMT1 acts as a maintenance DNMT which acts on hemimethylated CpG sites (Turek-
Plewa and Jagodzinski 2005), whereas DNMT3A and 3B are responsible for de novo DNA methylation by 
acting on hemimethylated and unmethylated CpG sites (Xie et al., 1999). DNMT1 and DNMT3A are 
abundant in the mature brain (Feng et al., 2010), whereas DNMT3B and DNMT3L are almost undetectable 
in mature brain. DNMT3L is an accessory protein; it is catalytically inactive and is required to stimulate the 
DNA methylation activity of DNMT3A and 3B in embryonic stem cells (Turek-Plewa and Jagodzinski 
2005). De novo methylation in cells that express DNMT3L, requires a tetrameric complex of two DNMT3A2 
and DNMT3L molecules as well as the nucleosome. The nucleosome forms the fundamental units of 
eukaryotic chromatin and consists of DNA wound around eight histone protein cores (McGhee and 
Felsenfeld 1980).  
 
Active transcription start sites (TSSs) lack nucleosomes and as a result do not contain this substrate for de 
novo methylation (Ooi et al. 2007). A family of methyl CpG-binding domain (MBD) proteins (including 
methyl CpG binding protein 2 [MeCP2] and methyl-CpG binding domain 1-4 [MBD1-4]) interpret DNA 
methylation by interacting with histone deactylases and DNA-methyltransferases to induce gene silencing. In 
addition, the binding of these proteins to methylated DNA seems to be important in maintaining the DNA 
methylation status since site-specific demethylation is associated with the dissociation of this complex 
(specifically MeCP2) (Murgatroyd et al., 2009; Chen et al., 2003; Martinowich et al., 2003). The process of 
active demethylation requires a mechanism that involves cell division or DNA repair and the removal of the 
base rather than the methyl group directly from the 5mC unit (Bhutani et al., 2010; Popp et al., 2010). Recent 
studies indicate the involvement of enzymes such as ten-eleven translocation (TET) methylcytosine 
dioxygenases, thymine DNA glycosylase (TDG) and activation-induced cytidine deaminase (AID) in active 
and passive demethylation as well as in gene activation (Bhutani et al., 2010; Inoue and Zhang 2011; Iqbal et 
al., 2011).  




It has been hypothesised that DNA methylation and histone deacetylation may function along a common 
pathway to induce transcriptional repression (Nan et al., 1998; Jones et al., 1998; Cameron et al., 1999). 
Proteins that contain MBD recognize methylated DNA and recruit a histone deacetylase (HDAC) complex to 
remodel the chromatin (Nan et al., 1998; Jones et al., 1998; Zhang et al., 1999). Fuks et al. (2000) showed 
that the association between DNA methylation and histone deacetylation was more direct than originally 
anticipated. DNMT1 was shown to be directly associated with histone deacetylase activity  in vivo (Fuks et 
al., 2000). Results showed that HDAC1 has the ability to bind DNMT1 and to purify methyltransferase 
activity from nuclear extracts. Furthermore, a transcriptional repression domain in DNMT1 identified which 
functions partly by recruiting histone deacetylase activity (Fuks et al., 2000). The authors suggested that 
DNMT1 -mediated DNA methylation may generate, or depend on, a transformed chromatin state through 
histone deacetylase activity. 
 
 
Figure 2.3: Graphical representation of unmethylated and methylated cytosine residues and their respective 
effects on mRNA transcription. The process of methylation, whereby a methyl group (CH3) is added to the C-5 
position of cytosine residues within CpG dinucleotides, is strongly dependent on the DNA methyltransferases (DNMT) 
enzymes. The methyl group, together with the methyl binding protein, prevents transcription factors (TF) from binding 
to transcription start site (TSS) or promoters and hinders transcription of the gene 
 
Methylation in close proximity to the TSS prevents transcription factors and RNA polymerase from 
accessing the DNA, resulting in silencing of the gene (Fig. 2.3). In addition to gene silencing, these methyl 
groups also attract other protein complexes which promote histone deacetylation, further inhibiting gene 
expression (Strathdee and Brown, 2002; Turner, 2001). The bond between the methyl group and the cytosine 
nucleotide is very strong, resulting in stable, yet potentially reversible, changes in gene expression. It has 
been well established that transcription cannot be initiated at methylated CpG islands (CGIs) of TSSs after 
the DNA has been assembled into nucleosomes (Hashimshony et al., 2003; Kass et al., 1997; Venolia and 
Gartler 1983). However, the question of which comes first, silencing or methylation, has resulted in 
longstanding and active discussion. In 1987, Lock et al. clearly showed that methylation of the hypoxanthine 
phosphoribosyltransferase (HPRT) gene (on the inactive X chromosome) occurred only after inactivation of 
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the chromosome. Consequently, it was postulated that methylation serves as a lock that reinforces a 
previously silenced state of X-linked genes (Lock et al. 1987). However, results from a study by Challen et 
al. (2011), which investigated the role of DNMT3A in haematopoietic stem cell differentiation have raised 
questions about the universality of the long-term locking model. Their results indicated that methylase was 
vital for differentiation of a short-lived cell type. It is thus probable that DNA methylation instructs rather 
than reinforces gene silencing. It therefore seems likely that there is a general mechanism whereby silencing 
precedes methylation, although more data is required to confirm this. Nonetheless, it is evident that the 
process of DNA methylation is a more complex process than initially anticipated, requiring more in-depth 
research to address a number of unanswered questions.  
 
It is also important to note that the position of methylation affects gene expression. Methylation in the TSS 
prevents initiation of transcription (as discussed above), whereas methylation in the gene body does not 
necessarily block transcription, and may even stimulate transcription elongation. It has been suggested that 
gene body methylation may play a role in splicing (Moarefi and Chedin, 2011). Gene body methylation is a 
feature of transcribed genes (Wolf et al., 1984), the majority of gene bodies contain a limited amount of CpG 
dinucleotides, numerous repetitive and transposable elements, and they are extensively methylated. One of 
the main causes of C→T transition mutations is CpG methylation in gene exons which could result in 
disease-causing mutations in the germline and cancer-causing mutations in somatic cells (Rideout et al., 
1990; Jones et al., 2012). A ‘methylation paradox’ thus exists, whereby promoter methylation is inversely 
correlated with gene expression, and gene body methylation is positively correlated with gene expression 
(Jones et al., 1999). Therefore, initiation of transcription, and not transcription elongation, appears to be 
sensitive to DNA methylation silencing in mammals. The presence of a 5mC does not, of itself, elicit a 
transcriptional effect; this effect is elicited by the interpretation of the 5mC in a particular genomic and 
cellular context (Jones et al., 2012). 
 
Since most genes have at least two TSSs, it has also been suggested that methylation could help to regulate 
the process of alternative promoter usage (Maunakea et al., 2010). CpG-rich sequences are abundant in the 
genome and are referred to as CpG islands (CGIs), most often situated in promoter regions. These CGIs are 
usually protected from methylation (Yehuda and LeDoux, 2007). A fraction of these CGIs, present in certain 
tissues during ageing (Issa 2000) or in abnormal cells (such as cancer cells) (Baylin and Herman 2000), are 
susceptible to progressive methylation. In mammals, the GC-content of CGIs is roughly 65% compared to 
40% for the entire genome (Suzuki and Bird 2008). CpG island shores and shelves are regions outside CpG 
islands. Shores are 0 - 2000 bp outside CpG islands, while CpG shelves flank CpG shores and are 2000 - 
4000 bp adjacent to CpG islands (Pastor et al., 2011). Methylation mostly occurs a short distance from the 
CpG islands, at the CpG island shores.  
 
CpG islands can also exist within the gene bodies and within gene deserts (long stretches of the genome 
devoid of protein-coding genes) (Jones 1999; Venter et al., 2001). In the human brain, up to 34% of all 
Stellenbosch University  https://scholar.sun.ac.za
38 
 
intragenic CGIs are methylated (Maunakea et al., 2010), however, the exact function of this remains to be 
fully elucidated. One hypothesis is that these regions may represent ‘orphan promoters’ that have escaped 
methylation in the germline, thus maintaining their high CpG density. It is therefore plausible that they play a 
functional role during development (Illingworth et al., 2010). The function of gene body methylation outside 
CGIs was initially assumed to be a mechanism for silencing repetitive DNA elements, such as retroviruses, 
LINE1 and Alu elements (Yoder et al., 1997). However, more recent whole-genome studies, suggest it may 
play a role in regulating splicing (Laurent et al., 2010). 
 
Assembly of the spliceosome occurs during the process of transcription and is influenced by the elongation 
rate of RNA polymerase II (RNAPII) (Kornblihtt 2007). Researchers have hypothesized that exon definition 
could be promoted by chromatin which alters elongation kinetics or act as an adaptor for the recruitment of 
splicing factors (Alló et al., 2010; Luco et al., 2010). There is a growing body of evidence that link histone 
modifications to both these levels of regulation (refer to Alló et al. (2010) and Luco et al. (2010) for a 
thorough review). Exon definition could thus be directly promoted through the interaction of intragenic DNA 
methylation with auxiliary proteins and/or through kinetic regulation of RNAPII elongation. Deviations to 
intragenic DNA methylation could therefore result in alternative pre-mRNA splicing. Intragenic DNA 
methylation can thus be regarded as an emerging critical determinant of pre-mRNA processing (Oberdoerffer 
2012).  
 
In addition to the epigenetic mechanisms themselves, the various enzymes that regulate these mechanisms 
have also been linked to memory formation (Day and Sweatt, 2010; Ma et al., 2010). One such example is 
the regulation of active DNA demethylation, with focus on the gadd45 (growth arrest and DNA-damage-
inducible, beta) family (Sultan et al., 2012; Leach et al., 2012). In particular, gadd45b has been found to be 
involved in activity-dependent demethylation in the adult CNS (Sultan et al., 2012). The deletion of gadd45b 
(gadd45b−/−) (the gene that encodes the growth arrest and DNA-damage-inducible, beta protein) leads to the 
abolishment of neuronal activity-induced DNA demethylation in the adult mouse dentate gyrus at specific 
genomic loci, including the promoters of the brain-derived neurotrophic factor gene (BDNF) and fibroblast 
growth factor 1 (FGF1). This reduces activity-induced adult hippocampal neurogenesis (Ma et al., 2009b). In 
addition, studies have shown that pharmacological inhibition of changes in DNA methylation also affect 
synaptic plasticity, learning and memory (Day and Sweatt, 2010).  
 
Two research groups investigated the effects that the deletion of the gadd45b gene would have on fear 
conditioning and memory. Both studies found that gadd45b transcription is regulated in an experience-
dependent manner and suggested its involvement in regulating memory capacity (Sultan et al., 2012; Leach 
et al., 2012). However, some conflicting results have emerged from these two studies with regards to the 
involvement of gadd45b in fear conditioning. On the one hand Sultan and colleagues observed enhanced 
contextual fear conditioning in gadd45b−/− (Sultan et al., 2012) whereas Leach et al. (2012) observed a 
deficit in contextual fear conditioning. Although there is no clear explanation for these conflicting results, 
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Sultan et al. (2012) hypothesised that a loss of such a potent epigenomic regulator could be sensitive to the 
background genome, where strain differences could have arisen during backcrossing. Different training 
facilities or housing environments could have augmented background genome or epigenome differences in 
the mutant mice (Crews, 2010). Another factor that could have contributed to the discrepant results between 
these two studies, are the differences in training paradigms; Leach et. al. (2012) utilized a foreground 
training paradigm whereas Sultan et al. (2012) used background training for contextual memory assessment. 
Irrespective of these differences, both of these studies emphasized the importance of epigenetic DNA 
modification mechanisms in the adult nervous system. They showed that the transcription of gadd45b is 
regulated by experience and that gadd45b may play an important role in long-term hippocampal-dependent 
memory.  
 
However, it is not only a methyl group that occur on the C-5 position of cytosine residues, but also 5-
hydroxymethylcytosine (5hmC), and although these two groups are very similar, they could have distinct 
effects on gene expression. The exact biological function of 5hmC is not fully elucidated but due to its 
identification in mouse embryonic stem (ES) and neuronal cells (Davis and Vaisvila 2011) it has generated 
interest as a potential biomarker. It has been postulated to play an important role in the process of 
demethylation (Guo et al., 2011), where 5hmC facilitates passive demethylation and in turn promotes gene 
transcription.  
 
Most research techniques aimed at investigating methylation, including the current gold standard bisulfite 
sequencing, are unable to accurately distinguish between 5mC and 5hmC. This is because bisulfite 
conversion only converts unmethylated cytosines to uracil, thus both 5mC and 5hmC remain unaffected and 
cannot be distinguished. This could present some difficulties in identifying which methyl group is present 
and determining the effect it has on gene expression as these two methylation states can have opposite effects 
on gene expression (Davis and Vaisvila 2011). It is imperative to accurately discriminate between these 
methylation states, especially if gene expression studies are to be correlated with methylation status. 
Although a discussion of the methodologies that can be used to distinguish between 5hmC and 5mc is 
beyond the scope of this review, the reader is directed towards a review by Booth et al., (2012), which 
discusses methods that can be used to investigate 5hmC, such as thin layer chromatography, liquid 
chromatography and mass spectrometry, glucosylation, antibody detection and chemical labelling (Booth et 
al., 2012). 
2.3.1.2 Neuronal DNA methylation in PTSD: animal studies  
 
A key clinical feature of PTSD is dysfunctional fear extinction, which results from, amongst other things, 
dysregulation of the HPA axis. The HPA axis, arguably the key stress response system, interacts with the 
immune system in order to maintain homeostasis (Wong et al., 2002). Studies have shown that maternal care 
in rodents influences the development of HPA axis responses to stress in the pups. Adult offspring of 
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mothers that exhibit increased levels of licking/grooming and arched back nursing (high LG-ABN mothers) 
display more modest HPA responses to stress (Weaver et al., 2002). Little is known about the molecular 
mechanisms by which early environmental influences alter anxiety circuits in the brain. However, 
researchers have found that these alterations are, in part, mediated by changes in hippocampal GR 
expression, which mediates the negative feedback regulation of CRF expression. The effects on GR 
expression have been found to be associated with increased expression of the transcription factor, nerve 
growth factor-inducible protein A gene (NGFI-A), and increased activation of GR gene expression via a 
promoter on exon 1 (exon lZ) of the GR gene. Adult offspring of the high LG-ABN mothers had reduced 
methylation levels of exon lZ, which was associated with increased NGFI-A (transcription factor) binding to 
the GR promoter. Therefore, better maternal care increased NGFI-A expression in the offspring, resulting in 
differential methylation of specific DNA sequences with subsequent stable, long-term alterations in gene 
expression (Weaver et al., 2002).  
 
Numerous studies have confirmed the abovementioned results, with reduced expression of GRs in the 
hippocampal tissue of pups raised by dams exhibiting low rates of maternal licking and grooming, compared 
to the offspring of mothers exhibiting high rates of maternal care (Weaver at al., 2004; Szyf et al., 2005). The 
reduced expression of GRs was attributed to increased methylation of the GR gene promoter (Weaver at al., 
2004; Szyf et al., 2005). Long-term transcriptional alteration is established within the first week of life and 
may persist long-term and even be passed to the next generation (Champagne 2008). To this end, these 
alterations are effectively reversed by cross-fostering the rats with dams who exhibit high maternal care, or 
by infusion of trichostatin A, a histone deacetylase (HDAC) inhibitor (Weaver at al., 2004). 
 
Lee et al. (2010) investigated glucocorticoid (GC) induced epigenetic changes in candidate HPA axis genes. 
FKBP5 mediates GR translocation; this GR co-chaperone protein is associated with hsp90 and together they 
form a chaperone complex that regulates GR dynamics (Hubler and Scammell 2004). Lee and colleagues 
(2010) found reduced DNA methylation levels in the FKBP5 gene in brain and blood samples following GC 
administration. These alterations persisted for up to 4 weeks following GC withdrawal. In addition, these 
DNA methylation changes were associated with behavioural deficits (such as anxiety-like behaviour in the 
elevated plus-maze task) in an animal model of Cushing’s syndrome (Lee et al., 2010). FKBP5 genotype and 
methylation profiles have recently been found to be associated with GR sensitivity and exposure to early 
childhood trauma (Klengel et al., 2013). Here, a functional polymorphism in FKBP5 altered the chromatin 
interaction between the TSS and long-range enhancers. This resulted in an increased risk of developing 
stress-related psychiatric disorders during adulthood through early-life trauma-dependent DNA 
demethylation in FKBP5 functional glucocorticoid response elements (Klengel et al., 2013).  
 
Yang et al. (2012) focused their investigation on the mouse hippocampal dentate gyrus, a vital region in the 
HPA-axis stress response, to determine if epigenetic alterations are enriched in this region compared to the 
entire hippocampus. They observed an overall greater decrease in DNA methylation in the dentate gyrus 
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compared to the entire hippocampal region. Moreover, they assessed whether DNMT1, was involved in these 
epigenetic alterations. They found that dexamethasone treatment resulted in a dose-dependent decrease in 
DNMT1 expression in a pituitary adenoma cell line and corticosterone-treated mouse hippocampus. Their 
research identified methylation as a potential epigenetic mediator of the stress response. In addition, they 
illustrated that GC-induced loss of methylation in pituitary cells can occur. A thorough understanding of the 
molecular mechanisms of GC-induced changes in gene function is crucial for improved therapeutic strategies 
for mood and trauma-related disorders. 
 
Another early life stress study in mice has suggested that vasopressin-induced gene hyperactivity could 
possibly be involved in the aetiology of PTSD (Murgatroyd et al. 2009). In this study of maternally separated 
mice, a stable increase in GCs, vasopressin and depressive behaviour was observed in the separated pups. 
This behaviour was reversed by administration of a vasopressin receptor antagonist. Further investigations 
revealed that this effect was attributable to a reduction in DNA methylation of the transcription factor that 
increases vasopressin gene activity. Increased release of vasopressin into brain regions involved in anxiety 
and fear induced increased anxiety-like behaviour. DNA methylation could, therefore, act as an additional 
putative neurobiological marker for vulnerability to PTSD development in the context of early life stress 
(Murgatroyd et al. 2009).  
 
It is clear that early life stress has a profound impact on gene expression profiles and subsequent behavioural 
abnormalities. This is further supported by the fact that some of these effects are heritable. Franklin and 
colleagues (2010) investigated the transgenerational effects of early stress on behavioural traits and the 
modes of inheritance in mice. They found that only when maternal separation was unpredictable and 
combined with unpredictable maternal stress, did it induce long-lasting behavioural effects in the offspring 
and in subsequent generations. Chronic and unpredictable maternal separation induced depressive-like 
behaviours as well as altered behavioural responses to aversive environments during adulthood in the 
separated animals. The male offspring of males subjected to maternal separation also exhibited most of these 
behavioural alterations, even though they were reared normally. In addition, chronic and unpredictable 
maternal separation modified the DNA methylation profile (in the germline) of the separated males in 
promoter regions of several candidate genes (MeCP2, cannabinoid receptor-1 (CB1), corticotrophin releasing 
factor receptor 2 (CRFR2)). Comparable DNA methylation changes were also evident in the brains of their 
offspring and were associated with changes in gene expression (Franklin et al., 2010).  
 
A study by Miller and Sweatt (2007) focused on DNMT and its function in DNA methylation and memory. 
The transcription of DNMTs was found to be upregulated in the rat hippocampus during contextual fear 
conditioning, while inhibition of DNMT blocked memory formation. Furthermore, fear conditioning was 
found to be associated with methylation and subsequent transcriptional repression of the protein phosphatase 
1 gene (PP1), the memory suppressor gene, and demethylation and transcriptional activation of reelin 
(RELN), a synaptic plasticity gene. Thus, methyltransferase and demethylase are both involved in the 
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memory consolidation process. In addition, pharmacological inhibition of DNMT activity blocked normal 
memory consolidation. This study clearly showed the dynamic regulation of DNA methylation in the adult 
nervous system and its critical function in memory formation (Miller and Sweatt 2007). 
 
A number of studies have shown that DNA methylation within the brain plays an integral part in PTSD 
disease aetiology. It is important to note, though, that these DNA methylation patterns differ between 
different brain regions (Ladd-Acosta et al., 2007; Gibbs et al., 2010). A study investigating the association 
between BDNF DNA methylation and PTSD-like behaviour in an adult rat model, compared methylation 
levels in the dorsal and ventral hippocampal tissue, mPFC and BLA (Roth et al., 2011). The researchers 
evaluated DNA methylation patterns in exon IV of BDNF and performed subsequent gene expression 
analysis. They found that psychosocial stress in adulthood resulted in a significant increase in BDNF 
methylation in the dorsal CA1 sub-region. However, in the ventral hippocampus (CA3), stress significantly 
decreased methylation. Furthermore, decreased expression levels of BDNF were evident in both the dorsal 
and ventral CA1 region. The medial prefrontal cortex and basolateral amygdala exhibited no changes in 
BDNF methylation. These results indicate that traumatic stress can induce DNA methylation in certain parts 
of the CNS and that hippocampal dysfunction in response to traumatic stress might be induced by BDNF 
methylation. Furthermore, these results also suggest that altered hippocampal BDNF methylation is one 
mechanism underlying the cognitive deficits typical of PTSD pathophysiology (Roth et al., 2011). 
 
Another study that focused specifically on DNA methylation patterns in the hippocampus in a rat PTSD 
model revealed that maladaptation to traumatic stress is associated with various changes in the methylation 
pattern of the hippocampus. One of the differentially methylated genes identified using this global screening 
method was disks large homolog-associated protein 2 (DLGAP2). DLGAP2 had increased methylation levels 
in a specific site associated with a reduction in DLGAP2 expression in rats with a PTSD-like (maladapted) 
phenotype compared to non-PTSD-like (well-adapted) rats. Proteins of the DLGAP family are enriched in 
the post-synaptic density (PSD) zone, which is regarded as the main region underlying synaptic plasticity. 
The main PSD scaffolding protein, PSD-95, regulates the development, maintenance and plasticity of 
synapses and spines (Han and Kim, 2008) and has also been associated with LTP (Migaud et al. 1998). LTP 
is a model of synaptic plasticity which is proposed to be similar to the plasticity which underlies learning and 
memory (Hölscher 1999; Bliss and Collingridge 1993), the two cognitive processes that are impaired in 
PTSD (Friedman 1997; Vermetten and Bremner, 2002). Alterations in methylation patterns could thus be 
involved in behavioural adaptation to environmental stress and could aid in the identification of possible 
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2.3.1.3 DNA methylation and PTSD: studies in humans  
 
Individuals who suffer from child abuse have a greater risk of developing PTSD and depression in later life 
(Mullen et al., 1996; MacMillan et al., 2001). These individuals are also prone to exacerbated physiological 
responses to stress (Weiss et al., 1999; Heim and Nemeroff, 2001) and corresponding alterations in CNS 
functioning (Liu et al., 1997; Weiss et al., 1999). However, it is not only childhood trauma that alters 
methylation and gene expression patterns; for example, prenatal exposure to maternal stress and adult 
exposure in the form of intimate partner violence (IPV) have also been found to induce lasting methylation 
changes that could affect psychological function in later life. The link between environmental stressors and 
disease pathogenesis wave been extensively investigated in the context of DNA methylation. Table 2.6 
provides a summary of the DNA methylation studies in human subjects that have found associations between 
trauma and/or PTSD and DNA methylation and gene expression profiles in different tissues (as indicated in 
the table under the description of the sample group). 
 
Table 2.6: DNA methylation studies in human subjects that describe associations between trauma, DNA 
methylation profiles, gene expression profiles and PTSD 
Association of DNA methylation with trauma, 
gene expression or PTSD 
Sample group Reference 
Increased SLC6A4 promoter methylation in abused 
males vs. non-abused males 
Iowa adoptee sample (EBV transformed 
lymphoblast cell lines) 
Beach et al. (2010) 
Hypermethylation of CpG1 and CpG3 regions of 
SLC6A4 promoter in women who experienced child 
abuse 
Iowa adoptee sample (EBV transformed 
lymphoblast cell lines) 
Beach et al. (2010) 
Increased methylation of NR3C1 promoter in 
suicide victims with childhood abuse history vs. no 
abuse history and controls 
Post-mortem suicide victims (hippocampal 
tissue) 
McGowan et al. 
(2009) 
Hypermethylation of ALS2 in abused individuals Individuals that suffered severe childhood 
abuse (hippocampal tissue) 
Labonté et al. 
(2012) 
Hypermethylation of SLC6A4 at cg22584138 had a 
protective effect in individuals who experienced a 
higher number of traumatic events  
Detroit Neighbourhood Health Study 
(whole blood) 
Koenen et al. 
(2011) 
Hypermethylation of LINE1 in post- deployment 
controls vs. pre-deployment controls 
US military soldiers deployed to 
Afghanistan or Iraq (serum samples) 
Rusiecki et al. 
(2012) 
Hypomethylation of LINE1 in post-deployment 
cases vs. controls 
US military soldiers deployed to 
Afghanistan or Iraq (serum samples) 
Rusiecki et al. 
(2012) 
Hypermethylation of Alu in pre-deployment cases 
vs. controls 
US military soldiers deployed to 
Afghanistan or Iraq (serum samples) 
Rusiecki et al. 
(2012) 
Hypomethylation of genes with immune-related 
functions in PTSD-affected individuals.  
PTSD-affected and -unaffected individuals 
(blood samples) 
Uddin et al. (2010) 
Hypomethylation of genes with neurogenesis-
related functions in PTSD-unaffected individuals  
PTSD-affected and -unaffected individuals 
(blood samples) 
Uddin et al. (2010) 
Increased global methylation in subjects with PTSD Traumatized African American 
individuals from Atlanta (PBMCs) 
Smith et al. (2011) 
Differential methylation of TPR CLEC9A, APC5, 
ANXA2 and TLR8 in PTSD subjects 
Traumatized African American 
individuals from Atlanta (PBMCs) 
Smith et al. (2011) 
ADCYAP1R1 CpG island methylation directly Traumatized African American Ressler et al. (2011 
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associated with total PTSD symptoms individuals from Atlanta 
PACAP methylation levels associated with PTSD in 
females  
Traumatized African American 
individuals from Atlanta (saliva and blood 
samples) 
Ressler et al. (2011) 
Total PTSD symptoms associated with methylation 
at ADCYAP1R1 CpG island in females 
Traumatized African American 
individuals from Atlanta (saliva and blood 
samples) 
Ressler et al. (2011) 
HTR2A minor A-allele (resulting in loss of CpG 
methylation site at -1,439) associated with disorders 
including PTSD 
Chronic fatigue syndrome patients and 
non-fatigued controls (PBMCs) 
Smith et al. (2008) 
COMT Met/Met genotype associated with increased 
susceptibility to PTSD development and DNA 
methylation at four CpG sites (two sites found 
associated with impaired fear inhibition) 
Community study in African American 
individuals from Atlanta (whole blood) 
Norrholm et al. 
(2013) 
ALS2 - amyotrophic lateral sclerosis 2 gene, ADCYAP1R1 - adenylate cyclase activating polypeptide 1 (pituitary) 
receptor type I gene, ANXA2 - annexin A2 gene, APC5 - anaphase promoting complex subunit 5, gene, BDNF - brain-
derived neurotrophic factor, CLEC9A - C-type lectin domain family 9, COMT - catechol-O-methyltransferase, EBV - 
Epstein-Barr virus, HTR2A - 5-hydroxytryptamine (serotonin) receptor 2A, LINE1 - Long Interspersed Nucleotide 
Element 1, NR3C1 - Glucocorticoid receptor gene, PTSD - posttraumatic stress disorder, SLC6A4 - serotonin 
transporter gene, TLR8 - toll-like receptor 8 gene, TPR - translocated promoter region gene 
2.3.2 MicroRNA (miRNA) 
Please note that the following section contains extracts from a review article that I have written under the 
guidance of my supervisor and co-supervisor and published in 2012 (Malan-Müller S, Hemmings SMJ, 
Seedat S. Big Effects of Small RNAs: A Review of MicroRNAs in Anxiety. Mol Neurobiol (2012) DOI 
10.1007/s12035-012-8374-6). The co-authors, my PhD supervisor and co-supervisor, edited and helped to 
construct the manuscript and agreed that it can be included in my PhD dissertation. More recent research that 
has been published after our review, are also included. Note that the Sections originating from the 
published manuscript will be indicated by quotation (“ ”) marks.  
2.3.2.1 MicroRNAs 
 
“MicroRNAs (miRNAs) are a class of small, noncoding RNAs that have recently drawn interest as 
epigenetic modulators of gene expression in psychiatric disorders (Hunsberger et al., 2009). In 1993, the first 
miRNA, lin-4, was discovered in C. elegans through genetic screening for deficiencies in the temporal 
control of post-embryonic development (Lee et al., 1993). However, it was only in 2001 that the role of 
miRNAs as a new layer of gene regulation was finally appreciated (Lagos-Quintana et al., 2001; Lau et al., 
2001; Lee and Ambros 2001).  
MiRNAs are single-stranded RNA species approximately 22 nucleotides (nt) long that form part of a large 
class of small, non-coding RNAs. miRBase is the major online repository for all miRNA sequences and 
annotation, the most recent version of the database, release 19, contains 21 264 hairpin precursor miRNAs 
entries expressing 25 141 mature miRNA products, in 193 species (Kozomara and Griffiths-Jones 2011). 
Between 1% and 5% of mammalian genes are comprised of miRNAs (Bartel, 2004), making them one of the 
most abundant classes of regulators in the genome (Espinosa-Parrilla and Muiños-Gimeno, 2011). Half of all 
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the miRNAs are expressed from non-protein coding transcripts and the other half from intronic regions of 
protein-coding genes (Saini et al., 2007). MiRNAs are evolutionarily conserved and are involved in 
numerous intricate processes including the stress response (He et al., 2007). They are of particular 
importance in brain functioning and are involved in learning and memory processes (Fiore and Schratt, 
2007) as well as synaptic plasticity (Schratt et al., 2006). Certain miRNAs are ubiquitously expressed (e.g. 
let-7b, miR17-5p and miR21) (Tang et al., 2007) while others have an expression pattern dependent on the 
specific cell type or developmental stage (Brown and Naldini 2009) (e.g. brain and spinal cord-specific 
miR34a (Tang et al., 2007), and miR409-3p in brain development in mice (Krichevsky et al., 2003)).  
The production of mature miRNAs is a complex process; the primary transcript miRNAs (pri-miRNAs) are 
cleaved by the ribonuclease III (Drosha) enzymes and the DiGeorge syndrome critical region gene 8 protein 
(DGCR8) in the nucleus. This cleavage produces a precursor miRNA (pre-miRNA) approximately 70–100 nt 
in length that is actively transported to the cytoplasm by exportin 5. In the cytoplasm the pre-miR is cleaved 
by another RNaseIII enzyme, Dicer, and the trans-activation responsive (TAR) RNA binding protein (TRBP) 
to generate double-stranded miRNAs approximately 22 nt in length. Thereafter, a helicase unwinds the 
dsRNA of the miRNA and one of the strands is degraded while the other (known as the guide strand) 
functions as the mature miRNA. The mature miRNA is incorporated into a miRNA-induced silencing 
complex (miRISC), a complex of proteins that target mRNAs based on sequence complementarity mostly in 
the 3’ untranslated regions (UTRs) (Zhang et al., 2007). In the case of perfect complementarity between the 
miRNA and target mRNA, the target RNA is degraded. In the absence of perfect complementarity, the target 
is not cleaved but is deadenylated which leads to decapping and subsequent exonucleolytic digestion or 
translational repression (through a different mechanism at each translational step, namely initiation, 
elongation and termination) (Kuss and Chen 2008) (Fig. 2.4) (de Kloet et al., 2009). It is important to note 
that not all mRNA targets are directly targeted by miRNAs via binding to the 3’UTR of the mRNA. Indirect 
targets form part of a miRNA-mediated regulatory pathway but do not possess structural affinity for 
miRNAs. However, the expression of these targets is indirectly affected by another target of the miRNA 
(Reyes-Herrera et al., 2011). Parker and Wen (2009) have also shown that indirect targets have a delayed 
response in expression changes over time compared to direct targets (as described for miR-124) (Parker BJ, 
Wen 2009). It is clear that miRNAs do not simply turn genes on and off, but form part of an interconnected 
regulatory network that fine-tunes the expression levels of target genes (Sun and Tsao 2008). Variations in 
target sites could thus result in altered gene expression patterns and ultimately contribute to disease 
susceptibility (Muinos-Gimeno et al., 2009).  




Figure 2.4: Figure depicting the production of mature miRNAs. MicroRNAs (miRNAs) are encoded in the genome, 
their genes usually transcribed by RNA polymerase II. The transcripts undergo splicing and polyadenylation. The pri-
miRNA is processed in the nucleus by the Drosha RNaseIII enzyme and the DGCR8 protein, producing the pre-
miRNA. The pre-miRNA is exported to the cytoplasm by exportin-5 where Dicer and the TRBP cleave the pre-miRNA 
to yield a miRNA duplex (about 22-bp long). One strand is selected to function as a mature miRNA, the other strand is 
in usually degraded. Mature miRNAs are then incorporated in a miRNA-induced silencing complex (miRISC) that 
recognises and binds to the 3’UTR of the target mRNA and represses translation (AGO-argonaute) (Kuss and Chen 
2008) 
Approximately 20% - 30% of all genes are regulated by at least one miRNA (Bartel, 2004; Krek et al., 2005; 
Lewis et al., 2003). However, computational analysis suggests that a single miRNA can target hundreds of 
genes and that one gene can be targeted by more than one miRNA (Yang et al., 2011). Although the 3’ UTR 
of mRNAs is a typical target site of miRNAs, target sites in the coding region have also been documented 
(Duursma et al., 2008; Kloosterman et al., 2005). Nucleotides 2-7 of the miRNA sequence are known as the 
seed region and are the most critical region for target recognition (Brennecke et al., 2005). MiRNA-mediated 
regulation of mRNAs is complicated by the fact that miRNAs are prone to tissue-specific RNA editing. RNA 
editing is a post-transcriptional mechanism whereby some RNA molecules are changed to contain bases not 
originally encoded in the genome (via nucleotide insertion, deletion or modification). Such events can lead to 
altered properties of miRNAs and alternative mRNA: miRNA interactions (Erson et al., 2008).  
In order to gain insight into miRNAs and their functions, it is essential to identify their mRNA targets. This 
step has proven to be computationally challenging. Although great advances have been made in the field of 
miRNA target prediction, with the development of various target-predicting software (Nicolas et al., 2008), 
their false-positive rates of target prediction range between 24% and 70% (Baek et al., 2008; Easow et al., 
2007; Selbach et al., 2008). These high rates emphasize the importance of experimental strategies to validate 
predicted targets in an endeavour to identify genuine miRNA targets and miRNA function (Thomson et al., 
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2011). For more detail on in vitro and   in vivo experimental strategies for miRNA target identification, refer 
to Thomson et al. (2011), Schratt et al. (2006), Pasquinelli et al. (2012) and Karres et al. (2007). 
Recent studies suggest a crucial role for miRNAs in regulating various neurobiological processes, including 
neurogenesis, neurite outgrowth, synaptogenesis and synaptic and neural plasticity (Zhou et al., 2009). Many 
putative miRNA targets are involved in neural development; these include mRNAs that encode proteins 
involved in the maintenance of neuronal function, plasticity of neural networks and specific 
neurodevelopmental and neurodegenerative diseases (Rogaev, 2005). Studies have also shown that miRNAs 
are altered by stress, glucocorticoids and mood stabilisers (Hunsberger et al., 2009), suggesting that miRNAs 
could be vital in the aetiology of anxiety disorders. Hunsberger (2009) suggested that miRNAs could be 
differentially expressed in patients with various psychiatric disorders, indicating that miRNAs may have the 
potential to broaden our understanding of the pathophysiology and therapeutics of anxiety disorders 
(Hunsberger et al., 2009).”  
2.3.2.2 MiRNAs in anxiety as described in animal Models 
 
“MiRNAs are abundantly expressed throughout the brain where they perform important regulatory functions 
in the CNS (Kussand Chen 2008; Sun and Tsao 2008). This suggests a role for miRNAs in stress response 
regulation. Uchida et al. (2008) established and characterized an animal model of vulnerability to repeated 
stress in F344 rats (Uchida et al., 2008). After investigating neuroendocrine and biochemical responses to 
repeated restraint stress (RRS) they found lower levels of glucocorticoid receptor (GR) protein expression in 
the paraventricular nucleus (PVN) in F344 rats compared to control SD rats. Furthermore, they established 
that miR-18a inhibited translation of GR mRNA (in cultured neuronal cells) and that higher expression levels 
of miR-18a were present in F344 rats compared with SD rats in the PVN.  In vitro experiments confirmed 
the results for miR-18a and also established a similar role for miR-124 (Vreugdenhil et al., 2009). Down-
regulation of GR translation via miR-18a may be an important susceptibility mechanism for stress-related 
disorders (Uchida et al., 2008), and F344 rats could therefore be a useful animal model for studying 
vulnerability to repeated stress.  
 
Subsequent work by Uchida et al. (2010) focused on the effects of maternal separation and early life 
adversity on the behavioural response to RRS as well as vulnerability to chronic stress in adult rats (Uchida 
et al., 2010). Maternally separated rats showed increased expression of repressor element-1 silencing 
transcription factor 4 (REST4), a neuron-specific splicing variant of the transcriptional repressor REST. 
REST regulates certain brain-enriched miRNAs postulated to be associated with neuronal functions such as 
brain development and plasticity (Kosik, 2006; Conaco, Vo et al., 2005; Otto et al., 2007). The maternally 
separated rats also showed a marked increase in a variety of REST target gene mRNAs and miRNAs in the 
medial prefrontal cortex (mPFC). The expression of pre-mir132, -124-1, -9-1, -9-3, -212, and -29a as well as 
the mature miR132, -124, -9, and -29a were found to be significantly up-regulated in maternally separated 
rats compared to control rats. Interestingly, mir-132, -124-1, -9-1, -9-3, -212 and -29a all possess an 
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repressor element-1 (RE-1) site within 50 kb of their promoter regions (Otto et al., 2007). The authors 
hypothesised that the differential expression of mRNAs and miRNAs of genes that contain RE-1 might be 
due to alterations in RE-1-mediated gene transcription in the mPFC of maternally separated rats secondary to 
altered REST4 expression. Indeed, results indicated an increased level of expression of genes and miRNAs 
possibly regulated by REST4, such as glutamate receptor subunit (GLUR2), calcium/calmodulin-dependent 
protein kinase II (CAMKIIα) and adenylate cyclase 5 (ADCY5) as well as precursors for mir132, -124 and -
212. These results suggest a role for an REST4-mediated gene network and specific miRNAs acting in the 
mPFC. This study provides additional insights into factors that could influence susceptibility to developing 
mood and anxiety disorders in adulthood following exposure to early life stress (Uchida et al., 2010). 
 
Meerson et al. (2010) predicted that miRNAs mediate stress response regulation through alternative splicing. 
They studied expression profiles of miRNAs in the hippocampus CA1 region and the central amygdala in 
both acute and chronically stressed rats. They found that both acute and chronic immobilization stress 
induced distinct miRNA expression profiles in these two stress-responsive brain regions. MiR-134 and miR-
183 were upregulated in the amygdala following acute stress. MiR-134 was downregulated in the amygdala 
and hippocampus under chronic stress conditions in both the amygdala and CA1. These two miRNAs were 
further investigated as they shared numerous common predicted mRNA targets that were known mediators 
of neuronal stress reactions, including the Serine/arginine-rich splicing factor 2 (SC35). SC35 is upregulated 
in response to stress, promoting the alternative splicing of acetylcholinesterase (AChE) from its synapse-
associated isoform (AChE-S) to the rare soluble form of the protein (AChE-R). MiR-183-mediated 
suppression of SC35 was confirmed in cultured cells. This alternative splicing of AChE affects the local and 
temporal regulation of cholinergic neurotransmission. The authors were able to demonstrate that stress 
altered the expression levels of miR-183 and miR-134. Through regulating splicing factors and their targets, 
these miRNAs were able to modify both alternative splicing and cholinergic neurotransmission under stress 
conditions in the brain, providing a link between the molecular and physiological responses of different brain 
regions to psychological stress (Meerson et al., 2010). 
  
The functional role of miRNAs in regulating stress responses were investigated by Haramati et al. (2011); by 
inactivating the Dicer gene (a key enzyme in miRNA synthesis pathway) they were able to inactivate 
miRNA processing in the central amygdala (Haramati et al., 2011). A sharp increase in anxiety-like 
behaviour was evident in mice lacking Dicer (and thus also mature miRNAs) in their amygdala. In addition, 
acute stress in wild type mice induced differential expression of numerous miRNAs in the amygdala. MiR-
34c, one of the prominent stress-induced miRNAs, was further investigated and found to be strongly 
upregulated by exposure to stress, resulting in reduced symptoms of anxiety in normal mice. Interestingly, 
corticotrophin releasing factor receptor type 1 (CRFR1) mRNA is one of the targets of miR-34c. The authors 
showed that miR-34c elicits its effect on the amygdala by targeting an evolutionarily conserved region in the 
3’UTR of CRFR1 mRNA. The authors postulated that miR-34c downregulates stress-related proteins like 
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CRFR1 and assists in the stress recovery process of these mice. In effect, such miRNAs and their targets may 
unveil new targets for the treatment of stress-related disorders (Haramati et al., 2011). 
 
By 2008 it was established that miRNAs play an important regulatory role in neuronal development, 
however the mechanism of regulation of miRNA expression had not been elucidated. Parsons et al. (2008) 
investigated differential miRNA expression in the hippocampus of four common inbred mouse strains (A/J, 
BALB/cJ, C57BL/ 6J, and DBA/2J) prone to anxiety-like behaviour They identified 11 differentially 
expressed miRNAs. The expression of miR-34a, miR-323, miR-378, and miR-451 correlated with 
behavioural measurements of exploration on the elevated plus maze task (indicative of anxiety levels), with 
less anxious animals displaying more explorative behaviour. MiR-34c and miR-323 expressions correlated 
with anxiety (less explorative behaviour) on the elevated plus maze task and expression of miR-34c, miR-
323, miR-378, and miR-451 correlated with tests of learning and memory (Parsons et al., 2008). While a role 
for miRNAs in synaptic development had previously been proposed (Fiore and Schratt 2007), this study was 
one of the first to demonstrate involvement of miRNAs in anxiety, learning and memory. 
 
Acute and repeated stress affects neural activity in different brain regions (Anisman and Zacharko 1992); 
short term changes in neural transmission and gene regulation (Alfonso et al., 2006; Gao et al., 2006; Xu et 
al., 2004) and longer term changes in structural modification (Cook and Wellman 2004; Donohue et al., 
2006; Magarinos and McEwen 1995) have, in particular, been documented. It is thus plausible that miRNAs 
may be involved in these processes. In a recent study investigating the effects of single or repeated exposures 
to restraint stress on miRNAs in the frontal cortex of CD1 mice, a marked increase in the expression levels 
of various miRNAs after acute stress was found, while only minor changes were observed after repeated 
restraint. The authors hypothesized that acute stress rapidly modulates miRNAs, but that these effects are 
only transient. Northern blot analysis confirmed that after acute restraint an increase in let-7a, miR-9 and 
miR 26-a/b was observed. These changes were found to be region specific, present in the frontal cortex but 
not in the hippocampus, providing evidence that miRNAs in the frontal cortex are involved in the process of 
translating stressful events to alterations in protein expression (Rinaldi et al., 2010).” 
 
A recent study suggested that region-specific miRNA-mediated reprogramming are involved in gene 
expression and epigenomic responses to chronic stress in the brain (Babenko et al., 2012). In this study, rats 
were grouped into the following groups; those exposed to two weeks of daily restraint stress and those that 
received two weeks of daily restraint stress + two weeks of recovery from stress and naïve controls. MiR-186 
and miR-381were up-regulated, whereas miR-709 was downregulated in the cerebellum of the stressed 
animals compared to the controls. Remarkably, mir-709 downregulation persisted after two weeks of 
recovery from stress, suggesting that downregulation of this miRNA in the cerebellum may be involved in 
long-term adaptation to chronic stress. Interestingly, miR-709 showed different expression patterns in the 
cerebellum, hippocampus and PFC. Levels of mir-709 in hippocampus and PFC were unaffected after two 
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weeks of chronic stress and were upregulated in the PFC after two weeks of recovery. These finding 
emphasized the fact the regulation of mir-709 by stress was brain region-specific (Babenko et al., 2012). 
 
Molitoris et al. (2011) described a regulatory feedback loop that involve the miR-17~92 cluster (which 
includes miR-18) and the GR. The GR is a main regulator of neurogenesis and structural plasticity in the 
hippocampus; furthermore Fitzsimons et al. (2012) have previously demonstrated that high levels of 
miRNA-18 are expressed in the hippocampus during early postnatal development and that miRNA-18 
regulates GR protein expression (Vreugdenhil et al., 2009). These results suggest that early postnatal 
hippocampal neurogenesis may be regulated by mir-18 through its repression of GR expression. 
Interestingly, a regulatory feedback loop exists between miRNA-18 and the estrogen-receptor α (ERα) 
(Castellano et al., 2009), suggesting that the sex differences observed in the levels of adult neurogenesis after 
early-life stress (Oomen et al., 2010, 2011) could involve long-lasting changes in miR-18 expression 
(Schouten et al., 2013). 
 
The first study to investigate the connection between miRNAs and PTSD was published in 2013. MiRNA 
profiles from PFC samples from fluoxetine-treated C57BL/6N mice were compared to that of control 
C57BL/6N mice 74 days after they were subjected to either a single electric footshock or mock-treatment. 
Fluoxetine is an antidepressant that has previously been shown to be effective in treating PTSD patients and 
mice suffering from PTSD-like symptoms. The researchers established that the therapeutic action of 
fluoxetine in shocked mice was associated with significant downregualtion of mmu-miR-1971. The authors 
hypothesised that fluoxetine interacts with traumatic stress to modify mmu-miR-1971 expression levels 
(Schmidt et al., 2013). Refer to Table 2.7 for a summary of miRNAs that have been described in animal 
models of anxiety.  
2.3.2.3 MiRNAs in Anxiety as Described in Human Studies  
 
“The role that miRNAs play in synaptic plasticity and neuronal differentiation suggests that miRNAs may be 
involved in the aetiology of numerous psychiatric disorders. Various miRNA expression studies have been 
conducted in schizophrenia patients (post-mortem brain samples) (Beveridge et al., 2008; Beveridge et al., 
2010; Perkins et al., 2007), autism spectrum disorders (bu-Elneel et al., 2008; Talebizadeh et al., 2008), Rett 
syndrome (bu-Elneel et al., 2008) and substance abuse disorders (Chandrasekar and Dreyer 2009). To date, 
there have been few studies of miRNAs in anxiety disorders.  
 
Muiños-Gimeno et al. (2011) selected a panel of SNPs (712 SNPs that covered 325 miRNA regions) to use 
in association studies of panic disorder (Muinos-Gimeno et al., 2011). Their analysis revealed that the SNP 
coverage in miRNA regions is much lower than the rest of the genome. None of these SNPs were located 
within a mature miRNA sequence, which is in line with the reported negative selection at miRNAs and 
miRNA target sites at 3’UTRs (Chen and Rajewsky 2006). This lower SNP density was confirmed by a 
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study that re-sequenced 117 miRNAs in four different human reference populations (Quach et al., 2009). It is 
thus evident that mutations in miRNA binding sites are likely to be deleterious and could have severe 
phenotypic implications. Re-sequencing of 3’UTRs and miRNAs in patients and controls might cast more 
light on the role of miRNA-mediated regulation in the susceptibility to anxiety disorders (Quach et al., 
2009).  
 
In 2011 Muiños-Gimeno et al. investigated the functional role of miRNAs in panic disorder (PD) in a 
Spanish cohort of patients with PD. They examined 712 SNPs that tagged 325 human miRNA regions. Two 
SNPs found to be significantly associated with PD, rs6502892 and rs11763020, were also found to tag 
miRNAs miR-22 and miR-339, respectively. MiRNA-22 was shown to regulate four candidate genes, 
namely brain-derived neurotrophic factor BDNF, serotonin 5-HT2C receptor (HTR2C), monoamine oxidase 
A (MAO-A), and the regulator of G-protein signalling 2 gene (RGS2). Target predicting software proposed 
adenosine receptor A2a (ADORA2A), BDNF, corticotropin releasing hormone receptor 2 (CRHR2) and 
sodium-dependent noradrenaline transporter (SLC6A2) as possible targets of miR-339. In addition, they 
found SNPs associated with PD sub-phenotypes (PD with and without agoraphobia) that tagged miR-138-2, 
miR-148a, miR-488 and miR-491. Functional studies indicated that miR-138-2, miR-148a, and miR-488 
repressed the expression of certain candidate genes for PD in the region of 30% to 60%, including gamma-
aminobutyric acid A receptor, alpha 6 (GABRA6), cholecystokinin B receptor (CCKBR) and 
proopiomelanocortin preproprotein (POMC), respectively (Muiños-Gimeno et al., 2011). Following 
transfection with miR-22 and miR-488, neuroblastoma cells showed altered expression of a subset of 
potential target genes for these miRNAs and genes that might affect physiological pathways related to 
anxiety. An association between rs73531, which tagged the intergenic miR-148a, and age at onset (AAO) (p 
= 0.0007) was observed. The average AAO was 23 years for the GG homozygotes and 30 years for the AG 
heterozygotes and AA homozygotes (Muiños-Gimeno et al., 2011). 
 
Neurotrophin-3 growth factor receptor (NTRK3) was also investigated as a candidate susceptibility factor in 
PD and obsessive-compulsive disorder (OCD). After re-sequencing the 3’UTRs in two different isoforms of 
NTRK3 in PD and OCD patients, they found that in the truncated isoform of NTRK3 (located in a functional 
target site for miR-485-3p) the C allele of rs28521337 was significantly associated with the hoarding 
phenotype of OCD. Additionally they identified two new rare variants, ss102661458 (located in a functional 
target site for miR-765) and ss102661460 (located in a functional target sites for miR-509 and miR-128), in 
the 3’UTR of NTRK3, present in one chromosome of a PD patient (Muinos-Gimeno et al., 2009). MiR-128 is 
a brain-enriched miRNA that is involved in synaptic processing and neuronal differentiation and miR-509 
shares the target site of miR-128, its expression is restricted to the testis (Betel et al., 2008), suggesting 
tissue-dependent regulation of NTRK3 at this site. These two variants resulted in the recovery of gene 
expression by significantly altering the miRNA-mediated regulation of NTRK3. Their data provides evidence 
that miRNAs play a key role in posttranscriptional regulation, in this case allele-specific miRNA regulation 
of NTRK3 in anxiety disorders (Muinos-Gimeno et al., 2009). 




A cross-species approach is another interesting method that has been used to study anxiety and to identify 
genes that regulate anxiety-like behaviour. This approach has enabled researchers to identify a SNP 
(rs817782) in the 3’UTR of the aminolevulinate dehydratase gene (ALAD) that was shown to be associated 
with social phobia (Donner et al., 2011). The rare A allele of rs817782 generated a putative target site for 
both miR-211 and miR-204 within the ALAD 3’-UTR, as predicted by a miRNA target prediction program 
(http://www.patrocles.org) (Donner et al., 2011). The authors previously found that ALAD was expressed at a 
higher level in the hippocampus and periaqueductal grey of six inbred anxious mouse strains. These two 
brain regions together are part of the abnormally sensitive fear network that patients with PD suffer from. 
However, a direct link between this functional ALAD SNP, the putative miRNA target sites (for miR-211 and 
miR-204) and PD has yet to be established (Hovatta et al., 2005).” 
 
Recent studies provide experimental evidence that indicate that miRNA biogenesis occurs locally in the 
vicinity of synapses. Especially, Drosha and DGCR8 (the microprocessor components) and their pri-
miRNAs substrate are particularly enriched in postsynaptic densities (Lugli et al., 2012). This will provide an 
ideal position for miRNAs rapidly respond to synaptic activity and regulate translation. Findings from Lugli 
et al., (2005) support this hypothesis; they demonstrated that postsynaptic densities are highly enriched for 
Dicer and Argonaute 1 (the rate-limiting enzymes in mature miRNA production) and that neuronal activity 
modulate their levels (Lugli et al., 2005). 
 
Researchers were also interested in the role of miRNAs in processes such as LTP. A recent study 
investigating this in rat hippocampus found that LTP induced differential expression of numerous miRNAs, 
with miRNA-188 exhibiting the largest upregulation. This result suggests that miR-188 is involved in the 
fine-tuning of synaptic plasticity in hippocampal neurons (Lee et al., 2012). Table 2.7 provides a list of 
miRNAs, as described in animal and human studies, that are possibly involved in anxiety disorders. 
 
Table 2.7: Summary of microRNAs that are possibly involved in anxiety disorders (adapted from Malan-Müller 
et al., 2012) 
MiRNA Involvement with Anxiety Disorders Species Reference 
Let-7a-1  Upregulated expression in the frontal cortex following acute 
stress 
Down regulated in amygdala after acute and chronic stress 
Mus musculus 
Rattus norvegicus 
Rinaldi et al. 2010 
Meerson et al., 2010 
Let-7b  
 
Increased expression in the hippocampus due to treatment with 
lithium and sodium valproate 
Rattus norvegicus Zhou et al. 2009 
Let-7c  Decreased expression in the hippocampus due to treatment with 
lithium and sodiumvalproate 
Rattus norvegicus Zhou et al. 2009 
miR-1 Upregulated in amygdala under chronic stress and downregulated 
in the hippocampus under acute stress 




Involved in neural lineage differentiation in ESCs 
 
Upregulated expression in the frontal cortex following acute 
stress 
Mus musculus and  in 
vitro cell line 
Mus musculus 
 
Krichevsky et al., 
2006 
 
Rinaldi et al., 2010 




Upregulated expression in the medial pre-frontal cortex following 




Uchida et al., 2010 
 
miR-9-1  
Pre-miRNA upregulated expression in the medial pre-frontal 
cortex following maternal separation  




Uchida et al., 2010 
 
Meerson et al., 2010 
 
miR-9-3  Pre-miRNA upregulated expression in the medial pre-frontal 
cortex following maternal separation 
Rattus norvegicus 
 
Uchida et al., 2010 
miR-17-5p Upregulated in the hippocampus CA1 region under chronic stress 
 




 in vitro cell line 
Meerson et al., 2010 
 
Hebert et al. 2009  
miR-18a 
 
Possible repressor of the glucorcorticoid receptor gene 
in the hypothalamic paraventricular nucleus regulating 
stress responses 
Rattus norvegicus Uchida et al et 
al.,2008 Vreugdenhil 
et al., 2009;  
miR-21 Involved in the control of glial cell differentiation  in vitro cell line Chan et al., 2005 
miR-22  Associated with Panic  
Disorder - Repression of RGS2, 
BDNF, HTR2C, and MAOA 




Decreased expression in the hippocampus due to treatment with 
lithium and sodium valproate 
Rattus norvegicus Zhou et al., 2009 
miR-26a/b  Upregulated expression in the frontal cortex following acute 
stress 
Mus musculus Rinaldi et al. 2010 
miR-29a  Upregulated expression in the medial pre-frontal cortex following 
maternal separation 
Rattus norvegicus Uchida et al., 2010 
miR-30c  
 
Decreased expression in the hippocampus due to treatment with 
lithium and sodium valproate 
Rattus norvegicus Zhou et al., 2009 
miR-34a 
 
Correlation between differential expression of this 
miRNA and behavioural measures for exploration on the elevated 
plus-maze task 
Decreased expression in the hippocampus due to treatment with 






Parsons et al.,2008 
 
 
Zhou et al., 2009 
miR-34c  
 
Correlation between differential expression of this 
miRNA and behavioural measures for anxiety in mice. 
Upregulated by exposure to stress 
Mus musculus Parsons et al.,2008 
Haramati et al., 2011 
miR-124  Upregulated expression in the medial pre-frontal cortex following 
maternal separation 
Rattus norvegicus Uchida et al., 2010 
miR-124-1  Pre-miRNA upregulated expression in the medial pre-frontal 
cortex following maternal separation 
Down regulated in the hippocampus under acute stress. Controls 
neuronal development and 
differentiation 
Rattus norvegicus Uchida et al., 2010 
 
Meerson et al., 2010 
Hebert et al. 2009  
miR-124a Involved in neural lineage differentiation in ESCs 
 
 
Down-Regulates glucocorticoid receptor 
Mus musculus and  in 
vitro cell line 
 
Rattus norvegicus 
Krichevsky et al., 
2006; Lim et al., 
2005; Makeyev et al., 
2007 




Association of an allelic variant in the target site for 
miR-128 in NTRK3 (ss102661458) with Panic Disorder - 
Reduction of NTRK3 repression 
Homo sapiens Muiños-Gimeno et 
al., 2009 
miR-128a  Decreased expression in the hippocampus due to treatment with 
lithium and sodium valproate 
Rattus norvegicus Zhou et al. 2009 
miR-128b  Regulates formation of fear-extinction memory in the infralimbic 
pre-frontal cortex 
Mus musculus Lin et al., 2011 
miR-132 One of the most highly inducible CREB targets, plays a role in  in vitro neural cell line Vo et al., 2005 
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neurite outgrowth and neuronal plasticity 
 
Upregulated expression in the medial pre-frontal cortex following 
maternal separation  
Pre-miRNA upregulated expression in the medial pre-frontal 





Uchida et al. 
2010[87] 
miR-134 Modulates synaptic plasticity in hippocampus 
 
Upregulated expression in the central amygdala and hippocampus 
after acute stress.  
Downregulated expression in the central amygdala and 






Hansen et al. 2007 
 
Meerson et al., 2010 
 
Meerson et al., 2010 
miR-138-2  
 
Associated with age at onset in Panic Disorder - 
Repression of GABRA6 
Homo sapiens Muiños-Gimeno et 
al., 2011 
miR-144  Decreased expression in the hippocampus due to treatmentwith 
lithiumand sodiumvalproate 
Rattus norvegicus Zhou et al., 2009 
miR-148a  
 
Associated with age at onset in Panic Disorder - 
Repression of CCKBR 
Homo sapiens Muiños-Gimeno et 
al., 2011 
miR-183  Upregulated expression in the central amygdala following acute 
stress 
Rattus norvegicus Meerson et al., 2010 
miR-186 Upregulated in the cerebellum of animals subjected to daily 
restrained stress compared to the naïve controls 
Rattus norvegicus Babenko et al., 2012 
miR-204 Association of an allelic variant in the 3’UTR of ALAD with SP Homo sapiens Donner et al., 2008 
miR-208 Upregulated in CA1 region of hippocampus under acute or 
chronic stress 
Rattus norvegicus Meerson et al., 2010 
miR-211 Association of an allelic variant in the 3’UTR of ALAD with SP Homo sapiens Donner et al., 2008 
miR-212  Pre-miRNA upregulated expression in the medial pre-frontal 
cortex following maternal separation 
Rattus norvegicus Uchida et al., 2010 
miR-221  Decreased expression in the hippocampus due to treatment with 
lithium and sodium valproate 
Rattus norvegicus Zhou et al., 2009 
miR-273 Plays a role in neuronal differentiation C.elegans Chang et al., 2004; 
Johnston et al., 2005; 
Johnston et al., 2003 
miR-323  
 
Correlation between differential expression of this 
miRNA and behavioural measures for anxiety in mice 
Mus musculus Parsons et al.,2008 
miR-339  
 
Associated with Panic Disorder Homo sapiens Muiños-Gimeno et 
al., 2011 
miR-376 Upregulated in CA1 region of hippocampus under acute or 
chronic stress 
Rattus norvegicus Meerson et al., 2010 
miR-378 Association between miRNA and behavioural measures 
(exploration, learning and memory) for anxiety in mice  
Mus musculus Parsons et al.,2008 
miR-451 Association between miRNA and behavioural measures 
(exploration, learning and memory) for anxiety in mice  
Mus musculus Parsons et al.,2008 
 
miR-381 Upregulated in the cerebellum of animals subjected to daily 
restrained stress compared to the naïve controls 
















Association of an allelic variant in the target site for 
miR-509 in NTRK3 (ss102661458) with Panic Disorder - 
Reduction of NTRK3 repression 
Homo sapiens Muiños-Gimeno et 
al., 2009 
miR-709 Downregulated in the cerebellum of animals subjected to daily Rattus norvegicus Babenko et al., 2012 
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restrained stress compared to the naïve controls 
miR-765 
 
Association of an allelic variant in the target site for 
miR-765 in NTRK3 (ss102661460) with Panic Disorder - 
Reduction of NTRK3 repression 





Downregulation of this miRNA in PFC is associated with 
therapeutic action of fluoxetine in shocked mice 
Mus musculus Schmidt et al., 2013 
 
3’UTR – three prime untranslated region, CA1 - Cornu Ammonis region 1, ESCs - embryonic stem cells, CREB - cAMP 
response element-binding protein. Please refer to list of abbreviations for full gene names 
 
2.3.2.4 MicroRNAs and pharmacotherapies for anxiety disorders 
 
“The serotonin transporter (SERT) is an important neurotransmitter in the CNS that ensures the reuptake of 
serotonin at the synaptic cleft and regulates serotonin levels in the brain. Defective serotonergic 
neurotransmission has been associated with anxiety, OCD, depression, and suicidal behaviour (van Praag, 
1996a, b). SERT is also a pharmacological target of selective SSRI antidepressants (Torres et al., 2003), one 
of the very effective treatments for various anxiety disorders. A study by Baudry et al. (2010) found that 
SERT is a target of miR-16. After chronically treating mice with the SSRI fluoxetine (Prozac), there was an 
increase in miR-16 levels in serotonergic raphe nuclei that resulted in reduced SERT expression (Baudry et 
al., 2010). These studies clearly confirm the important role of miRNAs in the pathophysiology of anxiety 
disorders. Furthermore, miRNAs presents a novel therapeutic strategy as targets for anxiolytic drugs. Since 
miRNAs play an essential role in regulating numerous stress response pathways, it is imperative that 
miRNAs be evaluated as potential drug targets for anxiety disorders.  
 
Zhou et al. (2009) conducted one of the first studies that demonstrated that miRNAs and their effectors are 
targets of pharmacotherapeutic drugs. Lithium and valproate (VPA) have been found to be effective in 
treating bipolar disorder (BPD). Although not routinely used in the anxiety disorder setting, valproate in 
particular may be useful adjunct in treatment-refractory anxiety disorder patients as well as in those patients 
with a comorbid bipolar disorder and might enhance exposure-based cognitive therapy for anxiety disorders 
and PTSD (Kuriyama et al., 2011). Zhou et al. (2009) found fluctuating levels of various hippocampal 
miRNAs following chronic treatment with mood stabilizers, lithium and VPA. The miRNAs that they were 
able to confirm were let-7b, let-7c, miR-24a, miR-30c, miR-34a, miR-128a, miR-144 and miR-221. The 
predicted effectors of these miRNAs are involved in neurogenesis, neurite outgrowth and signalling of 
extracellular signal-regulated kinase (ERK), phosphatase and tensin homologue deleted from chromosome 
10 (PTEN) and Wnt/ß-catenin pathways (Zhou et al., 2009). Treatment with mood stabilizers such as lithium 
and VPA has been found to increase the expression of genes encoding dipeptidyl-peptidase 10, metabotropic 
glutamate receptor 7 (GRM7) and thyroid hormone receptor ß   in vivo (Zhou et al., 2009). Several of these 
effector-coding genes have previously been described as candidates for susceptibility to the development of 
BPD. The authors went on to investigate the effects of lithium and VPA on the expression of miRNAs and 
their effectors in primary cultures. Primary cultures that received treatments of lithium or VPA showed 
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lowered levels of miR-34a and elevated levels of GRM7 (a predicted effector of miR-34a). In addition, 
treatment with a miR-34a precursor decreased GRM7 levels and treatment with a miR-34a inhibitor 
increased GRM7 levels. These results confirm that endogenous miR-34a regulates the levels of GRM7, 
which may contribute to the therapeutic effects of lithium and VPA on GRM7 (Zhou et al., 2009). Valproate 
has been shown to be effective, particularly as an augmentation strategy, for a number of anxiety disorders, 
including PTSD, panic disorder, GAD and SAD (Zhou et al., 2009).”  
2.4 Treatment of PTSD 
 
Stress-related diseases, such as depression and anxiety disorders, place a heavy health and economic burden 
on society. However, there is a limited range of available pharmacotherapies to treat these disorders and the 
majority of treatments are suboptimal with regard to efficacy and tolerability (Holmes et al., 2003; Kessler et 
al., 2005; Kasper et al., 2010). Several forms of psychotherapy, especially CBT, form part of the current 
recommendations for the treatment of PTSD (Foa et al., 2000), as well as psycho-education and supportive 
measures (Cohen et al., 2004; Oflaz et al., 2008). Another important component in the comprehensive 
treatment of PTSD is the treatment of comorbid conditions, such as mood and substance use disorders.  
 
Several of the current CBT for PTSD are based on regulating the processes of fear extinction (McNally, 
2007; Otto et al., 2007). Exposure-based CBT is the most commonly used approach for PTSD treatment and 
relies on extinction-based methods (Norton and Price, 2007). The therapy is procedurally similar to 
extinction training in animal models of emotional learning (Thyer et al., 1988; Foa and Kozak, 1986; Zarate 
and Agras, 1994). This therapy involves repeatedly exposing the patient to an anxiety-producing stimulus in 
a controlled setting, thereby reducing the uncontrolled fear associated with the anxiety (Foa and Kozak, 
1986). Although exposure-based CBT is effective in the initial phases of PTSD treatment, the CS-no US 
association that is acquired during the fear extinction process has been found to diminish over time. As a 
result, a large proportion of patients with PTSD undergoing this therapy are expected to relapse (Rescorla 
2004). Cumulatively, these findings suggest that exposure-based CBT can, and should, be improved upon, as 
the inhibitory extinction learning seems to fade more rapidly than the excitatory conditioning learning.  
 
Pharmacological strategies for the treatment of established PTSD that target the emotional response or other 
non-cognitive symptoms include SSRIs (Van der Kolk et al., 1994; Connor et al., 1999; Brady et al., 2000; 
Martenyi et al., 2002), other antidepressants (Davidson et al., 1990, 2006; Frank et al., 1988; Onder et al., 
2006), adrenoceptor agonists and antagonists (Peskind et al., 2003; Raskind et al., 2003, 2007; Taylor et al., 
2008) as well as anticonvulsants and antipsychotics (Hageman et al.,2001; Berlin, 2007) (for more detail see 
review by Steckler and Risbrough 2012, Bradley et al., 2013, Jonas et al., 2013 and Table 2.8). 
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Table 2.8: Pharmacotherapies that have been investigated and prescribed for PTSD treatment 
Drug class Drugs References 
Selective serotonin re-
uptake inhibitors (SSRIs) 
fluoxetine, sertraline 
Marshall et al., 2001;Tucker et al., 2001; Davidson et al., 2001; van 
der Kolk et al., 2007; Xu et al., 2011; Panahi et al., 2011; Chen et 
al., 2013 
Serotonin–norepinephrine 
reuptake inhibitors (SNRIs) 
venlafaxine, nefazodone*, 
mirtazapine**, bupropion 
Davidson et al., 2006; Davis et al., 2004; Becker et al., 2007; 
Sonne et al., 2013 




Kosten et al., 1991; Dow et al., 1997; Davidson et al., 1990; 




Shestatzky et al., 1988; Baker et al., 1995; Weizman et al., 1996; 
Connor et al., 2001; Aurora et al., 2010 
Anticonvulsants 
lamotrigine, topiramate, tiagabine, 
divalproex 
Hertzberg et al., 1999; Tucker et al., 2007; Davidson et al., 2007; 
Davis et al., 2008; Bajor et al., 2011; Kozarić-Kovačić et al., 2013 
Benzodiazepines alprazolam, temazepam Braun et al., 1990; Mellman et al., 2002; Hermos et al., 2007 
NMDAR modulators D-cycloserine Heresco-Levy et al., 2002; Litz et al., 2012; Philbert et al., 2013 
Atypical antipsychotics (as 





Padala et al., 2006; Butterfield et al., 2001; Stein et al., 2002; 
Rothbaum et al., 2008; Reich et al., 2004; Hamner et al., 2003; 
Detweiler et al.,2011; Carey et al., 2012; Krishnamurthy et al., 
2013 
Adrenergic inhibitors propranolol, prazosin, 
Pitman et al., 2002; Stein et al., 2007; Hilakivi et al., 1984; Raskind 
et al., 2003; Taylor et al., 2008; Aurora et al., 2010; Poundja et al., 
2012 
Corticosteroids Hydrocortisone Schelling et al., 2001; Wingenfeld et al., 2013 
 
SSRI - selective serotonin re-uptake inhibitors, SNRI - serotonin norepinephrine reuptake inhibitors, TCA - tricyclic 
antidepressants, MAOI - monoamine oxidase inhibitors, NMDA - N-Methyl-D-aspartate. *serotonin reuptake inhibitor 
and a 5-HT2A receptor antagonist, **α2-adrenergic antagonistwith 5-HT2- and 5-HT3-blocking properties, 
***reversible MAOI. 
2.4.1 N-methyl-D-aspartate receptors 
The therapeutic target of interest in this PhD study is the NMDAR, one of the pharmacological targets for 
secondary prevention of PTSD and a major role player in the memory consolidation processes. Activation of 
the NMDARs requires the binding of both glutamate and the co-agonist glycine for efficient opening of the 
calcium channel. Upon opening of the channel, intracellular calcium concentrations increase which activates 
signal transduction pathways critical to the plasticity underlying fear extinction (Myers and Davis, 2002) 
(Fig. 2.4). NMDAR agonists have been investigated in the treatment of PTSD (Ledgerwood et al., 2003; 
2005; Walker et al., 2002; Yang and Lu, 2005; Litz et al., 2012; Philbert et al., 2013). 
 
Administration of NMDAR antagonists (a ligand that binds to the receptor and blocks or dampens agonist-
mediated responses) shortly after predator stress exposure was found to interfere with anxiety-related 
behaviour in rats (Adamec et al., 1999) (Refer to Section 2.1.2.3 Fear conditioning and extinction and 
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Section 2.2.4.1 Gene expression analyses in PTSD animal models, for more detail). Furthermore, a 
preliminary, retrospective study in a group of US military soldiers who had sustained thermal injuries during 
deployment found that those treated with the NMDAR antagonist, ketamine, during hospitalization, had 
lower incidence of developing PTSD (McGhee et al. 2008). Whilst NMDAR antagonists impair memory 
formation and LTP, agonists enhance those processes (see Myers et al., 2011 for a review). These findings 
support the utility of NMDAR subunits as novel pharmacological targets for the treatment of PTSD.  
 
Figure 2.5: Diagram depicting an activated N-methyl-D-aspartate receptor. The receptor contains a glutamate and 
a glycine binding site, activation of the NMDAR requires the binding of both glutamate and a glycine for efficient 
opening of the calcium channel. 
2.4.1.1 D-cycloserine 
 
D-cycloserine (DCS) is an antibiotic and partial NMDAR1 agonist at the glycine site on the NMDAR1 
receptor subunit and has been found to be effective in facilitating extinction learning in rats when 
administered before or immediately after extinction training (Ledgerwood et al., 2003; 2005; Walker et al., 
2002; Yang and Lu, 2005; Philbert et al., 2013). DCS has also been shown to be effective in human trials of 
different anxiety disorders (Ressler et al., 2004; Hofmann et al., 2006; Kushner et al., 2007; Guastella et al., 
2008; Wilhelm et al., 2008; Otto et al., 2010; Storch et al., 2010; Yamamoto et al., 2010; de Kleine et al., 
2012). Administration of DCS has been found to result in generalized extinction of fear (Legderwood et al., 
2005), a characteristic which could be of clinical benefit to PTSD, as the extinction of a single cue might 
generalize to other fear-associated cues simultaneously. This could greatly facilitate therapy for PTSD 
patients for whom many cues trigger fear responses.  
 
DCS treatment has been found to augment exposure therapy (Smits et al., 2013), especially in patients 
suffering from more severe PTSD that require longer treatment (de Kleine et al., 2012). DCS has furthermore 
been shown to reduce the rate of relapse following successful exposure-based CBT (Richardson et al., 2004). 
Yamamoto et al. (2008) subjected rats to SPS, which is incorporated in an animal model of PTSD, and found 
that these rats exhibited impaired fear extinction relative to rats not subjected to SPS (sham rats). The study 
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also showed that DCS administration, in unison with extinction training, improved the impairment of fear 
extinction in SPS rats (Yamamoto et al., 2008).  
 
Efficacy of DCS has especially been demonstrated in patients with maladaptive fear and rodents with prior 
stress exposure (Myers et al., 2011). Systemical injection of DCS as well as infusion into the mPFC, BLA 
and hippocampus of rats has shown to enhance fear memory extinction, suggesting regional specific effects 
(Myers et al., 2011). Interestingly, BDNF Met66 knock-in mice have demonstrated impaired NMDAR 
dependent synaptic plasticity (Ninan et al., 2010) as well as delayed fear extinction; systemic DCS 
administration reversed these effects (Yu et al., 2009). These results suggest that DCS may mediate its 
actions through the BDNF system (Andero and Ressler 2012).  
 
In a study that investigated expression and extinction of fear memory in the lateral amygdala, found that fear 
conditioning resulted in an increase in AMPA/NMDA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic 
acid/ N-methyl-D-aspartate) ratio as well as depression of paired-pulse facilitation (PPF) in neurons of the 
lateral nucleus of amygdala (Lin et al., 2010). The α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid 
receptor (AMPAR) is a non-NMDA-type ionotropic transmembrane glutamate receptor that facilitates fast 
synaptic transmission in the CNS. An increase in the ratio of AMPAR to NMDARs (following high-
frequency stimulation) is one of the key indicators of LTP induction. PPF occurs when postsynaptic 
potentials, evoked by an impulse, are increased when that impulse closely follows a prior impulse; PPF is 
thus a form of short-term synaptic plasticity (Zucker and Regehr 2002). Lin et al., 2010 found that extinction 
training did not affect the conditioning-induced changes in synaptic transmission. Administration of DCS 
before extinction training facilitated extinction and reversed the AMPA/NMDA ratio increase without 
changing the PPF depression. Extinction training significantly increased the amplitude and frequency of 
miniature inhibitory post-synaptic currents and DCS treatment didn’t have an influence on these effects. 
DCS-induced reversal of AMPA/NMDA ratio and the facilitation of fear extinction was blocked by the 
disruption of AMPA receptor endocytosis with a synthetic peptide containing a short C-terminal sequence of 
GluR2 (869YKEGYNVYG877, GluR23Y). Extinction training appears to mainly increase inhibitory 
transmission without altering conditioning-induced excitatory association, whilst DCS (administered before 
extinction training) does not affect inhibitory transmission but reverses the conditioning-induced post-
synaptic memory trace (Lin et al., 2010). 
 
To gain more insight into the molecular function of drugs that potentiate GABAergic or glutamatergic 
systems during extinction, Leslie and Norwood (2013) compared operant extinction with re-extinction to 
investigate the neuropharmacological mechanisms with pre-session chlordiazepoxide (CDP) or post-session 
DCS. Both chlordiazepoxide and DCS facilitated extinction and re-extinction, with CDP showing an earlier 
effect during re-extinction. These results replicate earlier findings that DCS, administered post-session, 
facilitated extinction of food-reinforced behaviour (Shaw et al., 2009). DCS administration prior to 
extinction sessions failed to achieve extinction (Vurbic et al. 2011). The study by Leslie and Norwood 
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(2013) furthermore showed that DCS facilitated re-extinction to a similar extent as the initial extinction and 
that the effect was greater during re-extinction (as was also the case with CDP and re-extinction), although 
the mechanisms of actions of the two drugs on operant extinction are absolutely different (Leslie et al., 
2012). These results of DCS facilitated re-extinction was contrary to other studies that found that re-
extinction is not facilitated by the drug unless a different conditioned stimulus is used (Langton and 
Richardson, 2008, 2010). Leslie and Norwood (2013) hypothesised that after extinction sessions, DCS acts 
on a mechanism that is common to both extinction and re-extinction, such as the mediation of extinction of 
Pavlovian conditioning (Vurbic et al. 2011). These findings, indicating that operant re-extinction may be 
facilitated by DCS post-session administration, have important implications for human clinical use.  
 
The precise mechanisms by which co-administration of DCS reduces the fear triggered by a traumatic 
context remain to be fully elucidated. It has been suggested that DCS may function by increasing the 
efficiency of exposure-based CBT (Norberg et al., 2008; Hofmann et al., 2006; Ressler et al., 2004). Another 
possibility is that when DCS activates the strychnine-insensitive glycine-binding site of the NMDAR, it 
facilitates NMDAR-mediated synaptic potentials and subsequently assists in learning and memory 
(Yamamoto et al., 2010).  
 
2.4.2 Epigenetic drugs 
Since the advent of the phrase ‘personalised medicine’ there have been high expectations that patient-
specific pharmacogenetic data will improve treatment outcomes in neuropsychiatric disorders. However, 
owing to the complexity of transcriptional regulation and the influence of environmental factors and the 
epigenome, simple translation of individual genetic information into personalised treatment is not enough. 
How could pharmacogenetics explain the fact that monozygotic twins, who are both treated for major 
depression with the same drug, exhibit different clinical responses? Why do some patients who suffer from 
recurrent major depression not show the same response to drugs as they did during a previous episode? The 
answers might lie in epigenetics seeing that the dynamic nature of DNA-methylation patterns and histone 
acetylation provide plausible explanations for some of these puzzling pharmacogenetic questions (Holsboer 
2008). 
 
Most of the epigenetic therapies target DNA methylation and histone deacetylation enzymes and several of 
these drugs (mainly developed to treat cancer) have been tested in clinical trials (Szyf 2009). Some DNMT 
inhibitors have been approved for clinical therapy (such as Azacytidine, Decitabine), other are in phase one, 
such as 5-Fluoro-2′-deoxycytidine at phase 1, whilst Zebularine is still in the preclinical phase of 
development (Amatori et al., 2010). Another strategy to achieve demethylation in the brain involves the use 
of histone deacetylase inhibitors (HDACis) (Simonini et al., 2006, Tremolizzo et al., 2002). 
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MicroRNA research provided novel insights into the molecular mechanism underlying the therapeutic effects 
of certain anxiolytic drugs (Zhou et al., 2009; Baudry et al., 2010). In addition, miRNAs also presents novel 
therapeutic targets for the treatment of anxiety disorders, either through directly targeting the miRNA itself 
or by targeting the targets of those miRNAs that have been associated with anxiety disorders (Malan-Müller 
at al., 2012). Please refer Section 2.3.2.4 MicroRNAs and Pharmacotherapies for Anxiety Disorders.  
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3. Methods and Materials 
 
Ethics approval was granted for this study by the Stellenbosch University Research Ethics Committee: 
Animal Care and Use (REC: ACU) (Ref: ACU/2010/006 (A1)). The animal behavioural model used in this 
project was based on the PTSD mouse model described by Siegmund and Wotjak (2007). The animal 
behavioural section of the methods was performed by Ms Lorren Fairbairn as part of her PhD project (PhD 
in Psychiatry, Stellenbosch University, South Africa). For the present study, brain tissue from the left dorsal 
hippocampus (LDH) and peripheral blood samples were utilised. Please refer to Figure 3.1 for an overview 
of the methods used during this project. 
 
 
Figure 3.1: Methods overview flow diagram. Animal behavioural work (1) and animal selection (2) was performed 
by Ms L Fairbairn. n - sample number, ctrl – control, DCS – d-cycloserine, PTSD – posttraumatic stress disorder, LDH 
– left dorsal hippocampus, qPCR – quantitative polymerase chain reaction, miRNA – microRNA 
3.1 Animal studies 
3.1.1 Overview of the PTSD animal model  
Exaggerated implicit fear memories underlying PTSD can be attributed to both associative fear conditioning 
and non-associative sensitization processes (Antelman, 1988; Charney et al., 1993; Sorg and Kalivas, 1995). 
The symptoms associated with the traumatic memory (e.g. flashbacks and avoidance of trauma-related cues) 
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are part of the associative fear component, while those symptoms not associated with the traumatic memory 
(e.g. hyperarousal and exaggerated startle) are the non-associative, sensitised fear component.  
 
Animal models of PTSD, in addition to meeting the criteria for face, construct and predictive validity, should 
also demonstrate that animals exposed to trauma-related stimuli (associative fear) display conditioned 
responses, and that these conditioned (fearful) responses are also elicited following the presentation of a 
novel, non-trauma-related stimuli (thus eliciting non-associative fear). The PTSD animal model used in this 
study was based on a modified PTSD mouse model that was originally described by Siegmund and Wotjak 
(2007), incorporating the associative and non-associative properties of the PTSD phenotype. The model they 
described meets the criteria of construct and predictive validity, and is characterised by utility value 
(Siegmund and Wotjak, 2007). In the current study, ten repetitive footshocks (each lasting one second) over 
a period of one minute was used during fear conditioning instead of the single 2 sec electric footshock 
described by the original model (Siegmund and Wotjak, 2007). No further modifications were done to the 
PTSD evoking model (i.e. the administration of the electric footshocks), the only other modification was that 
male Sprague-Dawley rats were used instead of male C57BL/6N (B6N) or C57BL/6JOla (B6JOla) mice (as 
described by Siegmund and Wotjak (2007)). The main reason for this modification was the fact that the 
animal facility at the current research institution only bred Sprague-Dawley rats and these rats were 
successfully used in other behavioural research projects at the institution. It is therefore believed that the 
animal model still met the criteria of construct and predictive validity, and is characterised by utility value 
(Siegmund and Wotjak, 2007). Rats were bred in the central research facility at the University of 
Stellenbosch. The day of birth was designated as postnatal day (PND) 1. The pups were weaned at PND 21 
and were subjected to regular manual handling to eliminate the possibility of introducing a novel stressor 
(manual handling) during later stages of the model. Animals were housed according to standard laboratory 
conditions as stipulated by the Ethical Guidelines of the University for Housing Experimental Animals. The 
housing room is separate from the location where the surgical procedure, behaviour recordings and 
dissections took place.  
D-cycloserine (DCS) was injected intrahippocampally via a surgical procedure, 30 minutes before the fear 
extinction procedure took place. The surgical implantation was performed on PND 59. Briefly, rats were 
anaesthetised intraperitoneally with a combination of ketamine hydrochloride (Anaket-V, Bayer Healthcare, 
South Africa) and medetomide hydrochloride (Domitor, Pfizer, South Africa) at a dose of 0.1 ml/100 g. 
Anaesthetised rats were then placed in a stereotaxic instrument, and after exposing the skull, an opening was 
drilled at the precise coordinates corresponding to the target area, the dorsal hippocampus, according to co-
ordinates given by the rat brain atlas (http://www.scribd.com/doc/22822097/Rat-Brain-Atlas). Bilateral 
infusions were done (i.e. both sides of the dorsal hippocampus therefore left and right dorsal hippocampus). 
An intracranial indwelling guide cannula was lowered into the opening for DCS or saline intrahippocampal 
infusion at a later stage, and was secured on the skull with dental cement. DCS (Aspen Pharmacare, Durban, 
South Africa) was prepared fresh daily (immediately before administration), by dissolving it in physiological 
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saline to a concentration of 10 μg (Walker et al., 2002). A needle was subsequently inserted into the guide 
cannula for the administration of DCS or saline. After infusion, the needle was left in place for a further two 
minutes to allow diffusion from the tip of the needle into the hippocampus. DCS and saline was administered 
for 30 minutes before initiation of each fear extinction protocol for six consecutive days (PND 62 – PND 67) 
(Walker et al., 2002), during the light phase of the light/dark cycle. The timeline followed for the PTSD 
animal model is shown below in Figure 3.2.  
 
 
Figure 3.2: Experimental schedule for the PTSD animal model illustrating the behavioural procedures 
conducted at various time points. Fear conditioning was performed on PND 61 and consisted of administration of a 
series of 10 single electric footshocks, thereafter, to test for conditioned fear, rats were re-exposed to the shock chamber 
for another 3 min without stimulation. The rats were then placed in neutral chamber, after 3 minutes a tone was 
presented for 1 minute, thereafter rats remained in the chamber for another 60 seconds; this tested for sensitised or non-
associative fear. For the next 6 days (PND 62 – PND 67) rats received intrahippocampal DCS infusion followed by a 
fear extinction paradigm, during which they were re-exposed to the shock chamber for 3 minutes without stimulation to 
test for conditioned fear. Behavioural tests were conducted to evaluate features and symptoms of fear conditioning 
(PND 62, PND 64 and PND 66) and rats were sacrificed on PND 67. DCS – D-cycloserine, dB – decibel, kHz – 
kilohertz, mA – milliampere, PND - postnatal day, sec – second. 
The animals were divided into four experimental groups.  
1. Control + Saline (CS): animals not subjected to fear conditioning and receiving intrahippocampal saline 
injections. (n = 30) 
2. Fear-conditioned + Saline (FS): animals subjected to fear conditioning and receiving intrahippocampal 
saline injections. (n = 30)  
3. Control + D-cycloserine (CD): animals not subjected to fear conditioning and receiving intrahippocampal 
DCS injections. (n = 30) 
4. Fear-conditioned + D-cycloserine (FD): animals subjected to fear conditioning and receiving 
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3.1.2 Fear conditioning, fear extinction and behavioural analyses 
A single electric footshock (shock intensity, 1.5 mA; shock duration, 1 seconds (sec); ten repetitive shocks 
over the period of one minute (min)) was used during fear conditioning and served as the US. The footshock 
was administered via a chamber with a metal grid floor, connected to an electrical current supply. Following 
the footshock stimulation, rats remained in the chamber for an additional 60 sec, after which they were 
returned to their home cages. Control animals were placed in the shock chamber, but did not receive the 
electric footshock. Fear conditioning commenced on PND 61 (Fig. 3.2).  
To test for conditioned or associative fear, the animals were re-exposed to the shock chamber for three 
minutes, without shock application or tone presentation, after which they were returned to their home cages. 
Animals were then placed in a neutral test chamber for three minutes, and a neutral tone (80 dB, 9 kHz) was 
administered; this also tested for sensitised or non-associative fear. The animals remained in the neutral 
chamber for another 60 seconds, before being returned to their home cages. The fear extinction procedure 
was carried out for six consecutive days (from PND 62 – PND 67). On PND 62, 64 and 66, the fear 
extinction protocol was performed prior to the behavioural tests (Fig. 3.2). 
The core features of PTSD were assessed by measuring freezing behaviour during:  
(1) re-exposure to the shock context (associative fear memory) 
(2) exposure to a neutral tone in a novel context ( non-associative fear memory).  
 
Freezing movements are defined as immobility displayed by the animal, except for respiratory movements 
(Holahan and White, 2002).  
  
Additional symptoms of PTSD include emotional blunting, social withdrawal or avoidance (DSM-5, APA 
2013), levels of comorbid depression have also been described (Cryan and Mombereau 2004). The PTSD 
animal model therefore also tested for signs of social withdrawal and stress-coping strategies by using the 
following tests: 
(1) the light/dark (L/D) avoidance test 
(2) the forced swim test (FST) 
(3) the open field test (OF test) 
 
All behavioural assessments were performed between 10h00 and 13h00. 
3.1.2.1 Light/dark avoidance test 
 
The L/D avoidance test was performed on PND 62; the test is based on rodents’ instinctive aversion of 
brightly lit areas and their spontaneous exploratory behaviour in response to mild stressors, i.e. the novel 
environment and light (Crawley and Goodwin, 1980). Upon exposure to an unfamiliar environment or to 
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novel objects, the animal is faced with a natural conflict situation between the initial tendency to avoid the 
unfamiliar (neophobia) and the tendency to explore. An increase in locomotion and time spent in the light 
compartment is typical of anxiolytic behaviour. Decreased locomotion and more time spent in the dark 
compartment are indicative of anxiogenic behaviour (Bourin and Hascoët, 2003). For the purpose of this 
study, the test arena was split in half, resulting in one illuminated and one dark compartment, connected by 
an open doorway. The animals had a habituation time of 5 minutes to eliminate the stress of a new 
environment. Rats were then placed in the middle of the dark compartment and during the 10 minute test, 
end-parameters, such as movement and exploration, were recorded by video camera and analysed with the 
EthoVision XT programme (Noldus, Wageningen, The Netherlands). After completion of the test, animals 
were returned to their home cages. Between each trial, the floor of the arena was cleaned with soap water. 
 
The following parameters were measured: 
 Horizontal locomotion (total distance travelled) 
 Exploration (number of rearings) 
 Relative time spent in dark compartment 
 Relative distance moved in dark compartment 
3.1.2.2 Open field test  
 
The open field (OF) test was performed on PND 64. The test measures behaviours elicited by the placing the 
animal in a novel open space, surrounded by a wall (to prevent escape). The OF test is based on conflicting 
innate tendencies of animals to avoid open and brightly lit spaces and the tendency to explore a novel 
environment. The OF test can also be used to assess basal animal locomotor activity and exploration. 
Animals prefer to spend time around the edges, since they are fearful of the exposed open area, which would 
render them vulnerable to predators. Freezing behaviour and avoiding the centre of the field is indicative of 
“anxiety-like” behaviours (Cryan and Sweeney, 2011), however, numerous other parameters, such as 
distance covered, escape attempts, latency and field area visited can also be measured as a proxy for 
locomotion, exploration and anxiety. In this model, the rat was placed in the bottom right quadrant of the 
board and was left in the novel context for a period of 10 minutes. Behaviour was recorded with a video 
camera and was analysed with the EthoVision XT programme (Noldus Wageningen, The Netherlands). 
 
The following parameters were measured: 
 Time spent in zones  
 Locomotion 
3.1.2.3 Forced swim test 
 
The forced swim test (FST) was performed on PND 66. The FST assesses levels of depression in animal 
models; this model is commonly used to measure the effect of antidepressant drugs on behaviour. It usually 
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comprises of perspex cylinders (about 18 cm in diameter), filled to a height of about 15 cm with ambient (25 
°C) water. Rats are gently placed into the water for a period of 10 min, whereafter they are placed in a warm 
room to dry and returned to their cages. The duration of floating (lack of movement except for necessary 
movement to keep the head above the water), swimming (forward motion through the water, forepaws do not 
break through water surface) and struggling (upright position in the water, forepaws break through water 
surface) can be scored.  
3.1.2.4 Harvesting of rat tissues for use in genetic analyses 
 
After completion of the behavioural tests on PND 66, the rats were sacrificed on PND 67 by decapitation by 
means of a guillotine. This method inflicts the least amount of stress in the animals and also limits 
subsequent effects on mRNA and epigenetic expression in the brain. Decapitation was also necessary in 
order to obtain the brain tissue on which the genetic and epigenetic analyses were done. The left 
hippocampal tissue was then divided into left ventral and left dorsal hippocampal tissues (LVH and LDH, 
respectively). The LDH tissue from all 30 animals from each of the abovementioned groups as well as whole 
blood from each animal was used in the present study for genetic and epigenetic analyses. Due to the high 
level of N-methyl-D-aspartate receptors (NMDARs) (DCS is a partial NMDAR agonist) and the fact that it 
plays a pivotal role in fear extinction and retention processes (Fredrikson et al., 1976; Quirk and Mueller 
2008), the hippocampus was selected as the brain region for direct DCS infusion. The LDH region was used 
in genetic and epigenetic analyses in order to determine the effects of intra-hippocampal DCS administration 
in this brain region.  
3.1.3 Statistical analyses of behavioural data 
In order to determine whether the fear conditioning model was effective in establishing fearful behaviours in 
fear-conditioned animals, statistical analyses were used to determine if there was a significant difference 
between the different treatment groups for each of the following behavioural measurements: 
(1) time spent in the open field and outer regions 
(2) time spent in the light and dark compartments  
(3) duration of freezing in response to the tone in the neutral box  
(4) duration of freezing in the open field test.  
 
In order to determine which treatment groups were significantly different, a one-way analysis of variance 
(ANOVA) and least square (LS) differences (LSD) post-hoc analysis comparing the four treatment groups 
were performed using Statistica v11 (StatSoft, Tulsa, USA). Based on the relative sensitivity of the 
behavioural measurements in detecting successful fear conditioning, animals were selected for behavioural 
subgrouping as described below (see Section 3.1.4).  
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3.1.4 Animal selection based on behavioural data  
Animals display a range of behavioural responses to stressors, with varying degrees of behavioural 
disturbances. It is, therefore, important to distinguish between mal- and well-adapted animals (Cohen et al., 
2003, 2004). Behavioural data were used in subsequent experiments to distinguish between animals that 
were fear-conditioned and exhibited PTSD-like behaviour (maladapted) and animals that were fear-
conditioned, but did not exhibit PTSD-like behaviour (well-adapted).  
In the L/D avoidance test, animals in the FS group spent more time in the dark compartment compared to the 
CS group (p = 0.035), thus indicating that the fear conditioning model was effective in eliciting a fearful 
response. Furthermore, there was a significant difference in the FS group (animals spent more time in the 
dark compartment, typical anxiogenic behaviour) compared to the FD group (animals spent more time 
exploring the light compartment, typical anxiolytic behaviour) (p < 0.001), suggesting that DCS was 
effective in reducing anxiogenic behaviour in fear-conditioned animals (refer to the Section 4.1 for detailed 
behavioural results).  
 
Animals were thus subgrouped, for genetic and epigenetic analyses, based on these results. In addition, the 
selection of animals also took into account the available quantity and quality of RNA that would be 
sufficient for downstream analyses. Twelve animals were selected from the CS group, with a time spent in 
the light closest to the group’s mean time spent in the light value of 311 sec; twelve animals were selected 
from the CD group with a time spent in the light closest to the group’s mean time spent in the light value of 
344.07 sec. Selecting animals with behavioural test measures closest to the group mean values ensured that 
animals with extreme behaviours were not selected in the control group, ensuring the ‘normality’ of the 
control groups. For both the FS and the FD groups, six animals that spent the most time in the light 
compartment were selected as the well-adapted group and six animals that spent the least amount of time in 
the light compartment were selected as maladapted. In addition, an RNA concentration of at least 75 ng/µl 
was required as this is the minimum concentration for next generation RNA sequencing purposes. 
 
Statistical tests were used to determine if there was a significant difference between the FS maladapted 
(FSM) and FD well-adapted (FDW) groups in the L/D avoidance test measurements (since not only the 
animals with extreme behavioural results were selected, but RNA quantity and quality was also considered). 
A one-way analysis of variance (ANOVA) was performed with least square differences (LSD) post-hoc 
analysis to compare the LS means of the L/D avoidance test measurements between the FSM and FDW 
groups.  
 
The 120 animals were divided into four subgroups according to the behavioural test results. For the control 
groups, twelve animals per group were selected (with L/D avoidance test values closest to the group mean) 
and for each of the fear-conditioned groups, six well- and six maladapted animals were selected for further 
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genetic analyses. These groups consisted of 12 CS, 12 CD, 6 FS well-adapted (FSW), 6 FSM, 6 FDW and 6 
FD maladapted (FDM) animals.  
3.2 Nucleic acid isolation  
 
Animals were decapitated on PND 67 (adulthood), at which time the LDH was dissected and whole blood 
collected in EDTA tubes. 500 µl of whole blood was added to 1.3 ml of RNAlaterTM (Ambion, Inc., Austin, 
Texas). Left dorsal hippocampal brain tissue was placed into 1.2 ml of RNAlater. These samples were 
immediately stored at 4 C for 24 hours whereafter the samples were stored at -80 C (to enable long term 
usaage). RNAlaterTM (Ambion, Inc., Austin, Texas) prevents RNA degradation ex vivo and halts further 
changes in gene expression once blood is obtained. 
RNA, micro RNA (miRNA) and DNA fractions were isolated simultaneously but in separate fractions from 
the LDH using the RNeasy
 
Plus Mini Kit (Qiagen, Hilden Germany) in conjunction with the RNeasy 
MinElute
 
Cleanup Kit (Qiagen, Hilden Germany) according to the manufacturer’s instructions. Brain tissue 
samples were lysed by placing the LDH tissues in 2 ml lysing matrix tubes (matrix D, 1.4 mm ceramic 
spheres) (MP Biomedicals, Ohio, USA) that contained 400 µl buffer RLT Plus (lysis buffer) (Qiagen, Hilden 
Germany) and 4 µl β-mercaptoethanol (MERCK, Darmstadt, Germany). Samples were homogenised in the 
FastPrep FP120 cell disrupter (MP Biomedicals, Ohio, USA) for 30 seconds at a time. This was repeated 
three times, and after each 30 second homogenisation step, the tubes were placed on ice. 
 
Total RNA (tRNA) (also containing miRNA within the same fraction) was isolated from rat blood samples 
using the Mouse RiboPure™-Blood RNA Isolation Kit (Ambion®, Texas, USA). Blood samples were 
utilized to correlate gene expression and epigenetic results between brain tissue and blood. 
3.2.1 Nucleic acid quantity and quality assessment 
DNA 
The quantity and quality of the DNA extracted from the LDH was assessed using the NanoDrop™ 1000 
Spectrophotometer V 3.7 (Thermo Scientific, Delaware, USA). The software calculates the concentration 
based on the 260 nm measurement and reports the concentration in ng/µl. The 260/280 nm ratio is used to 
assess the purity of the DNA sample. A ratio of about 1.8 is indicative of pure DNA, values below 1.8 
indicate possible contamination by a protein, phenol or other contaminants that absorb strongly at or near 
280 nm.  
RNA 
The quantity and quality of RNA extracted from both the LDH brain tissue and blood was assessed with the 
RNA Nano 6000 kit (Agilent Technologies, California, USA) on the 2100 Bioanalyzer platform (Agilent 
Technologies, California, USA) according to the manufacturer’s instructions. The Bioanalyzer is a 
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microfluidics-based platform for size determination, quantification and quality control of DNA, RNA, 
proteins and cells. The software displays the RNA quantity in ng/µl. An RNA integrity number (RIN) is used 
to assess the integrity or quality of RNA. RIN values range from 10 (intact) to 1 (totally degraded). An RNA 




The quantity and quality of miRNA (within the purified small RNA fraction) extracted from both the LDH 
brain tissue and blood was assessed with the Agilent small RNA kit (Agilent Technologies, California, USA) 
on the 2100 Bioanalyzer platform (Agilent Technologies, California, USA) according to the manufacturer’s 
instructions. The software displays the percentage of miRNAs within the small RNA fraction and provides 
the concentration as pg/µl.  
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3.3 Gene expression analyses 
 
3.3.1 Next generation RNA sequencing 
Next generation RNA sequencing was performed on the selected 48 LDH RNA samples. Extracted and 
quantified RNA samples were sent to Novartis Institute for Bio-Medical Research, department of Biomarker 
Development (Basel, Switzerland). One microgram (µg) of RNA was used as starting material for the sample 
preparation with the TruSeq RNA Sample Preparation Kit v2 (Illumina, California, USA). The mRNA was 
purified using poly-A selection, followed by chemical fragmentation and complementary DNA (cDNA) 
conversion with random hexamer primers. Second strand synthesis generated double stranded (ds) cDNA 
(Fig. 3.3) for use in TruSeq library construction (Fig. 3.4). 
 
 
Figure 3.3: RNA sample preparation with Illumina TruSeq kit. Starting from large RNA fraction (tRNA minus 
small RNA) ds cDNA products ready for library preparation are created (Adapted from http://www.illumina.com) 
The ds cDNA (generated during RNA sample preparation [Fig. 3.3]) was used to generate blunt-end DNA 
fragments by using different fill-in reactions and exonuclease activity (Fig. 3.4 A). An adenine (A) base was 
added to the blunt ends of each strand (Fig. 3.4 B) in preparation for ligation to the sequencing adapters. The 
3’ end of each adapter has a thymine (T) overhang, which provides a complementary overhang for adapter 
ligation (Fig. 3.4 C) to the A-tailed fragmented cDNA. The adapter sequence contains the full complement of 
the sequencing primer hybridization sites for paired-end multiplexed reads. Purified DNA fragments were 
denatured and PCR-amplified (Fig. 3.4 D) using primers complementary to the adapters. This generates 
enriched libraries that can be pooled and used for cluster generation on the cBot (Illumina, California, USA) 
(an automated system used for clonal cluster generation from single molecule DNA templates in preparation 
for sequencing by synthesis on a next generation sequencing platform) (Fig. 3.5).  
 




Figure 3.4: Adapter ligation and library construction. Double stranded cDNA (Fig. 3.3) was used to generate 
adapter ligated libraries that were used for cluster generation (Adapted from http://www.illumina.com) 
Clusters were generated on the cBot (Illumina, California, USA) on paired end TruSeq v3 flow cells 
(Illumina, California, USA) using the TruSeq PE (Paired-End) Cluster v3-cBot-HS kit (Illumina, California, 
USA) according to the manufacturer’s instructions. During this process, adapter-ligated DNA fragments bind 
to complementary adapter oligomers grafted on the flow cell’s surface (Fig. 3.5 A). Starting from the 
hybridized primer, the templates are copied using 3' extension by incubation with free nucleotides and a high 
fidelity DNA polymerase (Bst), in a process called bridge amplification (Fig. 3.5 B). Thereafter, formamide 
denatures the double-stranded DNA fragments, and the process is repeated (Shendure and Ji, 2008) (fig 3.5 
C). Bridge amplification generates clonal clusters of identical DNA fragments of about 1000 copies each 
(Fig. 3.5 C). The DNA fragments are denatured during the last cycle and a sequencing primer is annealed to 
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each DNA strand (Fig. 3.5 D) (Shendure and Ji, 2008; Tucker et al., 2009). The kit also contains reagents 
that allow cluster resynthesis of the reverse strand, regenerated by bridge amplification within the paired-end 
flow cell. Following resynthesis of the reverse strand, the original forward strand is cleaved and the reverse 
strand is sequenced for the second read. The DNA fragments are denatured during the last cycle and a 
sequencing primer is annealed to a universal sequence that flanks the region of interest (Fig. 3.5 D) 
(Shendure and Ji, 2008; Tucker et al., 2009). 
 
Figure 3.5: Cluster generation. Single DNA fragments are bound to the flow cell and bridge amplification is 
performed to generate clusters of identical molecules that can be sequenced (Adapted from http://www.illumina.com) 
The flow cell, containing the DNA clusters, is subjected to sequencing on the Illumina HiSeq 2000 platform. 
The Illumina platform uses a cyclic reversible termination (CRT) method that involves three steps: 
nucleotide incorporation, fluorescence detection and cleavage. The nucleotides are chemically modified to 
contain a cleavable reverse terminator at their 3’‐OH group that only allows single-base incorporation to 
occur in each cycle. The nucleotides also contain one of four fluorescent labels (Fig. 3.6). After each cycle, 
excess reagents are removed during a washing step and an image is taken of the clusters to identify the 
incorporated fluorescent labelled nucleotide (Fig. 3.6 D). This is followed by unblocking the 3’‐ends of the 
nucleotides and cleaving of the fluorescent labels; the nucleotide incorporation cycle is then repeated (Fig. 
3.6 B - D). Each flow cell has eight independent lanes and each lane contains 300 tiles, which are 
individually photographed. The images are captured by a camera and two lasers detect the four fluorescent 
colours. After the sequencing run, the images are analysed to identify the nucleotides incorporated at each 
position and to determine the sequence of the DNA fragment in each cluster (Fig. 3.6 D). One base is read 
per sequencing cycle, thus the number of cycles equals the read length (Ansorge, 2009; Metzker, 2010; 
Pettersson et al., 2009).  




Figure 3.6: Sequencing by synthesis. The system applies a cyclic reversible termination (CRT) method, three steps are 
involved, namely nucleotide incorporation, fluorescence detection and cleavage (Adapted from 
http://www.illumina.com). 
 
In the present study, two multiplex libraries were created for the 48 samples, with each multiplex library 
containing 24 samples. Each multiplex library was loaded onto four lanes of two separate flow cells 
(therefore eight lanes per multiplex library of 24 samples and 16 lanes in total for the 48 samples) and the 48 
RNA samples were paired end sequenced on the Illumina HiSeq 2000 platform at a read length of 101 bp. 
3.3.2 Differential gene expression analysis 
In order to identify differentially expressed genes, the following comparisons were made: 
a. FSM vs. FDW – to identify differentially expressed genes associated with fear extinction induced by 
DCS  
b. CS vs. FSM – to identify differentially expressed genes associated with the process of fear 
conditioning  
c. FSM vs. FSW – to identify differentially expressed genes associated with fear conditioning as well 
as susceptibility and resilience to developing anxiety disorders 
d. FDM vs. FDW - to identify differentially expressed genes associated with efficacy of the drug or the 
mechanism of effective action 
e. FDW vs. FSW - to identify differentially expressed genes associated with DCS-induced fear 
extinction compared to the “natural” process of fear extinction 
 
The aim of the current study was to determine the molecular mechanisms whereby DCS facilitates fear 
extinction. For this reason, the comparison groups FSM vs. FDW formed a major focus of the current study 
as genes that are differentially expressed between these two groups may be associated with the fear 
extinction process specifically induced by DCS.  




Bioinformatics analyses were performed in collaboration with the South African National Bioinformatics 
Institute (SANBI), University of the Western Cape (UWC). A pipeline was created to analyse the gene 
expression data. The following programs were implemented in the running of the pipeline: 
1. TopHat (http://tophat.cbcb.umd.edu/): a splice junction mapper for RNA-sequencing reads that 
sequentially aligns the sequencing reads to known RefSeq mRNAs. The program then predicts 
combinations of known exons, and finally the remainder of the reference genome of interest, in this 
case the Rattus novergicus rn4 rat reference genome 
(http://support.illumina.com/sequencing/sequencing_software/igenome.ilmn) by using the ultra-
high-throughput short read aligner Bowtie. The mapping results are then analysed by TopHat to 
identify splice junctions between exons. 
2. Bowtie (http://bowtie-bio.sourceforge.net/index.shtml): a short read aligner that aligns short DNA 
sequences (sequencing reads) to the reference genome of interest. 
3. Cuffdiff (http://cufflinks.cbcb.umd.edu/): calculates differential expression within the RNAseq 
samples and between different treatment groups. It assembles the alignments into a parsimonious set 
of transcripts from the aligned RNA-sequencing reads and estimates the relative abundance of these 
transcripts based on how many reads support each one (allowing for biases in library preparation 
protocols). 
4. The Bio-Ontological Relationship Graph (BORG) database (designed by Dr. Gamieldien from 
SANBI, UWC, South Africa) identified biologically relevant genes associated, or predicted to be 
associated, with, fear, anxiety and memory (any factors or phenotypes associated with anxiety or 
PTSD) within the large set of differentially expressed genes identified by Cuffdiff. The BORG 
database integrates hundreds of thousands of curated facts about genes and their known functions, 
disease and phenotype associations, and pathway membership into a large knowledge structure 
known as a semantic network. At the heart of the database are human, rat and mouse genes, which 
are linked to each other and to relevant terms in several bio-ontologies, resulting in a large on-disk 
concept map-like structure. A custom semantic model for PTSD was built into the database by 
linking between terms in different ontologies so that the disorder is described by its known features. 
This ensured that any gene previously annotated as being involved in a phenotype, cellular process, 
or pathway known or hypothesized to be related to PTSD would be prioritised through a novel 
concept called 'guilt by indirect association'. For example, a rat gene whose counterpart in the mouse 
causes an anxiety phenotype (or one of its sub-phenotypes) when knocked out, was selected as a 
candidate in view of the anxiety concept being linked to the PTSD concept in the semantic model. 
The BORG semantic discovery protocol produced a shortlist of differentially expressed genes 
predicted to be involved in fear extinction and PTSD that could be utilised in downstream 
investigations (Fig. 3.7).  




Figure 3.7: The Bio-Ontological Relationship Graph (BORG) database. Diagram illustrating how the biological 
evidence or knowledge is linked in the BORG database and how the semantic model of the disease is built using 
features of the disease (red links).  
3.3.3 Gene enrichment analyses and clustering 
The 42 biologically relevant, differentially expressed genes produced by BORG (fold change ≥ 1.3 and p < 
0.05) were used to perform gene enrichment analyses using the Comparative Toxicogenomics Database 
(CTD) (http://ctdbase.org/tools/analyzer.go). Biological interpretation of large sets of differentially 
expressed genes can be improved by grouping genes together based on their functional similarity (Cline et 
al., 2007). Genes were selected as the input type and the analyses options include ‘enriched diseases’, 
‘enriched GO functional annotations’ or ‘enriched pathways’. For the ‘enriched GO functional annotations’ 
Section, genes can be classified according to ‘biological process’, ‘molecular function’ or ‘cellular 
component ontologies’. Categories were considered overrepresented if p < 0.05. Cytoskape v2.8.3 
(http://www.cytoscape.org) was used to generate visual models of the molecular interaction networks and 
biological pathways. Cytoscape is an open source software platform that can be used to visualize biological 
pathways and molecular interaction networks and integrate these networks with gene expression profiles, 
annotations and other data.  
3.3.4 SYBR Green real-time quantitative PCR gene expression analysis 
From the subset of 42 biologically relevant genes identified by the BORG analyses, nine were selected 
(based on function and fold change) (Table 3.1) for relative real-time qPCR analyses using SYBR Green 
technology on the ABI 7900HT platform (Applied Biosystems, Foster City, CA, USA). This was done in 
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order to determine whether real-time qPCR is a sensitive enough tool to detect these differences in gene 
expression. 
Table 3.1: Genes investigated in the SYBR Green real-time qPCR differential expression analysis. Nine 
biologically relevant differentially expressed genes (selected based on fold change and function) used in the SYBR 
Green real-time qPCR differential expression analysis 
Gene  Name Fold change Function 
SPP1 Secreted phosphoprotein 1  -6.0 Demyelination  
IL1RN Interleukin 1 receptor antagonist  -4.2 Learning or memory  
TRH Thyrotropin releasing hormone  -2.8 Anxiety-related response  
CYBB Cytochrome b-245, beta polypeptide  -2.5 
Abnormal learning or memory; nervous system 
physiology 
MT2A Metallothionein 2A  -2.1 Abnormal learning or memory  
CXCL13 Chemokine (C-X-C motif) ligand 13 -5.2 
Elevation of cytosolic calcium ion 
concentration 
S100A4 S100 calcium binding protein A4 -3.5 
Neuron projection; calcium ion binding; 
calcium-dependent protein binding 
MMP9 Matrix metallopeptidase 9 -2.4 Impaired contextual conditioning behaviour 
NPY Neuropeptide Y  -1.3 
Increased anxiety-related response; abnormal 
depression-related behaviour  
 
Please refer to list of abbreviations for full gene names 
 
The RNA extracted from the LDH and blood was reverse transcribed to cDNA by means of the QuantiTect® 
Reverse Transcription Kit (Qiagen, Hilden Germany) according to the manufacturer’s instructions. A starting 
amount of 300 ng of RNA was used for reverse transcription (RT). cDNA was evaluated on the NanoDrop™ 
1000 Spectrophotometer v3.7 (Thermo Scientific, Delaware, USA) to get a rough estimate of the 
concentration of cDNA. A calibrator sample was prepared by pooling equal amounts of cDNA from each 
sample for the construction of a standard curve. The calibrator cDNA sample was serially diluted 2 fold per 
dilution, to produce a seven-point standard curve, with cDNA concentrations ranging from 800 ng to 12.5 
ng. Each of the LDH and blood cDNA samples was diluted to 200 ng for use in subsequent gradient PCR 
reactions (for annealing temperature optimisation) and real-time qPCR reactions. 
 
Each 25 µl reaction consisted of 1 x KAPA SYBR®FAST Master Mix ABI Prism™ (KAPA Biosystems, 
Massachusetts, USA) and forward and reverse primers (IDT, Iowa, USA) (see Table 2.2 for concentrations). 
Primers were designed and evaluated using the IDT PrimerQuest 
http://eu.idtdna.com/PrimerQuest/Home/Index) and OligoAnalyser tools 
(http://eu.idtdna.com/analyzer/Applications/OligoAnalyzer/). All primers spanned intron-exon boundaries to 
eliminate amplification of possible DNA contaminants. Reference gene primer sequences for β-actin 
(ACTB), cyclophilin A (Cyc A), glyceraldehyde-3-phosphate dehydrogenase (GAPDH) were described by 
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Bonefeld et al. (2008), and primers for phosphoglycerate kinase (Pgk) were described by Langnaese et al. 
(2008). Reference genes were also validated using geNorm and Normfinder, both of which are included in 
GenEx software package v5.4.3 (GenEx [www.multid.se]) (MultiD, Gothenburg, Sweden).  
 
Each sample was analysed in triplicate in order to eliminate technical variability. Following the amplification 
of serial dilutions, a linear plot of the quantification cycle (Cq) versus the log value of the input amount of 
DNA (standard curve) was constructed using ABI’s SDS v.2.3 software (Applied Biosystems, California, 
USA). The PCR efficiency was subsequently calculated from the standard curve of reaction for each 
individual primer set. Software-determined default threshold and baseline values were used. 
 
All Cq values for each primer set were corrected for the PCR efficiency of the particular primer set and 
normalised to the aforementioned reference genes using GenEx software (http://www.gene-
quantification.de/datan.html) (MultiD, Gothenburg, Sweden). Statistical analyses were performed using 
GenEx [www.multid.se] (MultiD, Gothenburg, Sweden) and Statistica v11 (StatSoft, Tulsa, USA). One-way 
ANOVA was performed to determine if there was a significant difference between the least square (LS) 
means of the gene expression fold change between the FDW and FSM animals for each of the primer sets. A 
p-value of ≤ 0.05 was regarded as significant. 
 
Table 3.2: Primers for SYBR Green real-time qPCR differential expression analysis. Primer sequences, melting 
temperatures (Tm), annealing temperatures (Ta) and concentration of primers in each 20 µl SYBR Green real-time 
qPCR reaction.  
Gene  Primer sequences (5’ – 3’) Tm (°C) Ta (°C) 
Final primer 
concentrations (µM) 
SPP1 F TGTGTCCTCTGAAGAAACGG 54.6 
54 0.12 
SPP1 R GGTGAGATTCGTCAGATTCATCC 55.2 
IL1RN F GGGATACTAACCAGAAGACC 51.7 
56 0.2 
IL1RN R CGAAAGTCAATAGGCACC 50.7 
TRH F CCTAACTGGTATCCCTGAATCC 54.3 
61 0.4  
TRH R GATGCTGGCGTTTCTCAG 53.8 
CYBB F CCAGGTATCCAAGCTAGAGTG 53.8 
54 0.2  
CYBB R GTCACAATATTTGTACCAG 45.6 
MMP9 F CCTGTACCGCTATGGTTACACTC 56.9 
58 0.2 
MMP9 R GATGACAATGTCTGCTTCGAGC  56.2 
MT2A F GAACTCTACAGCGATCTCTCG 54.4 
54 0.12 
MT2A R CGAAGCCTCTTTGCAGATG 53.9 
CXCL13 F CTGGACCAAGGCCAAGAAAGC 58.8 
61 0.6 
CXCL13 R CGAGCAGGGATTAAGAAAGGGTG 57.7 
S100A4 F CACAAATACTCAGGCAACGAGG 56.0 
58 0.6 
S100A4 R GCCCAACACTTCATCTGAGGAG 57.7 
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NPY F CAGCCCTGAGACACTGATTTC 55.6 
56 0.2 
NPY R CAACGACAACAAGGGAAATGG 54.6 
ACTB F* TGTCACCAACTGGGACGATA 55.7 
54 0.2  
ACTB R* GGGGTGTTGAAGGTCTCAAA 55 
CYC A F* TATCTGCACTGCCAAGACTGAGTG 58.7 
54 0.2  
CYC A R* CTTCTTGCTGGTCTTGCCATTCC 58.6 
GAPDH F* ACCACAGTCCATGCCATCAC 57.7 
55 0.12  
GAPDH R* TCCACCACCCTGTTGCTGTA 58.6 
PGK F* ATGCAAAGACTGGCCAAGCTAC 58.0 
54 0.2  
PGK R* AGCCACAGCCTCAGCATATTTC 57.6 
 
*Primers designed to amplify regions of the reference genes ACTB, CYC A, GAPDH and PGK. Please refer to the list of 
abbreviations for full gene names 
3.4 Epigenetic analysis 
 
The study of epigenetics investigates the stable alterations in gene expression that are not attributable to 
DNA sequence changes (Bjornsson et al., 2004). We investigated whether DNA methylation and miRNAs 
were driving the differential gene expression detected with the RNA sequencing, and to what extent.  
3.4.1 DNA methylation analysis  
High resolution melt (HRM) analysis was used to investigate DNA methylation status of CpG islands of a 
subset of biologically relevant differentially expressed genes identified with RNA sequencing. The approach 
described by Wojdacz and Dobrovic (2007) was followed. Approximately 300 ng of DNA extracted from 
LDH as well as 300 ng DNA from rat pre-mixed methylation controls (EpigenDx, Massachusetts, USA) 
were subjected to bisulfite conversion using the EZ DNA Methylation-LightningTM Kit (Zymo Research, 
California, USA), according to the manufacturer’s instructions. Bisulfite modification of DNA converts 
unmethylated cytosine residues to uracil, while the methylated cytosines in CpG islands remain unconverted. 
The subset of genes for which real-time qPCR detected differential expression in the LDH (Results Section 
4.2.4, Table 4.10) was analysed using EMBL EMBOSS Cpgplot 
(http://www.ebi.ac.uk/Tools/seqstats/emboss_cpgplot/) to determine which of these genes contained CpG 
islands. We selected these genes for DNA CpG island methylation analysis seeing as real-time qPCR was 
able to detect differential expression in two of these genes, these genes have functions that could contribute 
to PTSD disease pathology and if DNA methylation mediated the differential expression of these genes, 
these combined results would form a strong unit. The nine genes that were investigated for differential 
expression using SYBR Green real-time qPCR, were analysed with EMBL EMBOSS Cpgplot 
(http://www.ebi.ac.uk/Tools/seqstats/emboss_cpgplot/) in order to identify which of the selected genes 
contained CpG islands. CpG island methylation levels were therefore investigated in MT2A, TRH and NPY 
(Table 3.3). NPY contained two predicted CpG islands, the island closest to the transcription start site (TSS) 
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was investigated, as DNA methylation close to the TSS has been shown to prevent transcription factors and 
RNA polymerase from accessing the DNA, resulting in silencing of the gene (Strathdee and Brown, 2002; 
Turner, 2001; Hashimshony et al., 2003; Kass et al., 1997; Venolia and Gartler 1983). Primers for the 
amplification of bisulfite converted DNA were designed using Bisulfite Primer Seeker 12S (Zymo Research) 
(http://www.zymoresearch.com/tools/bisulfite-primer-seeker), a free online primer design tool created 
specifically for methylation analyses. This program designs primers specifically for bisulfite-converted 
sequences (see Table 3.4 for DNA methylation primers).  
 
Table 3.3: CpG island chromosomal positions for MT2A, TRH and NPY 
Gene CpG island position 
MT2A Chromosome 19: 11, 284, 267 – 11, 285, 166 
TRH Chromosome 4: 189, 149, 064 – 189, 149, 408 
NPY Chromosome 4: 144, 235, 298 – 144, 235, 513 Chromosome 4: 144, 235, 974 – 144, 236, 905 
 
MT2A - metallothionein 2A, NPY – neuropeptide Y, TRH - thyrotropin releasing hormone 
 
Real-time qPCR amplification and HRM analyses were carried out sequentially on the Rotor-GeneTM 6000 
(Corbett Research, Mortlake, Australia). Each 25 µl qPCR reaction consisted of the following: 1x Kapa 2G 
Robust HotStart ReadyMix (KAPA Biosystems, Massachusetts, USA), 640 nM of the relevant forward and 
reverse primers (Integrated DNA Technologies (IDT), Iowa, USA), 4 µM SYTO®9 (Invitrogen, California, 
USA), and 2.5 ul (theoretical concentration of 20 ng/ul) of bisulfite-converted LDH DNA and calibration 
standards. Each sample was analysed in triplicate in order to eliminate technical variability. The bisulfite-
treated rat calibration standards (including 100%, 75%, 50%, 25%, 10%, 5% and 0% methylated DNA) 
(EpigenDx, Massachusetts, USA) were included in all the reactions in order to determine the level of CpG 
island methylation within the investigated regions for each sample. The 36-sample rotor on the Rotor-
GeneTM was used and samples were analysed in triplicate, thus the standards were amplified in the first run 
and re-melted in the HRM analyses for the 2nd and 3rd runs with the rest of the samples. The real-time qPCR 
cycling conditions were as follows: 95 °C for 5 min followed by 40 cycles of 95 °C for 10 sec, annealing 
temperature for 30 sec (see Table 2.4 for annealing temperatures of each primer set) and 72 °C for 25 sec. 
HRM analyses were performed at the optimised temperature ramping (see Table 2.3) and fluorescence 
acquisition settings were used as recommended by the manufacturer, with the temperature rising by 0.1 °C/2 
sec. 
 
During the real-time qPCR reaction, the intercalating dye, SYTO®9 (Invitrogen, California, USA), emits 
fluorescent light when it intercalates with the double stranded DNA (dsDNA) as the DNA amplifies 
exponentially during each cycle of the PCR, until it reaches a plateau. The real-time qPCR is followed by a 
HRM step. HRM exploits the differential melting temperature that exists between methylated and 
unmethylated alleles where the change in fluorescence is sequence-specific. The degree of methylation is 
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represented by the C to T content in the amplicon and this will determine the rapidity of melting and release 
of the intercalating dye. Thus, methylation is assessed across the amplified region of the CpG island as a 
whole, instead of at specific sites. The dsDNA products are melted from dsDNA into single-stranded DNA 
(ssDNA) during the HRM step resulting in a high emission of fluorescence from the SYTO®9 dye 
(Invitrogen, California, USA), which slowly decreases as the temperature increases and the dsDNA is melted 
into ssDNA. Normalised melting profiles were generated by the Rotor-GeneTM 6000 (Corbett Research, 
Mortlake, Australia) software (by calculating the ‘line of best fit’ for the region between two normalization 
regions, representing the melting of the PCR product). The algorithm enables direct comparison between 
samples with different starting fluorescence levels. The melting profiles of the LDH DNA samples were 
compared to the profiles of the calibration standards (EpigenDx, Massachusetts, USA) in order to determine 
the percentage methylation of the CpG islands for each sample.  
 
Table 3.4: Primers for DNA methylation analyses. Primers designed for DNA methylation analyses of selected CpG 








56 °C 347 bp 75 °C – 83 °C 
MT2A _Reverse TTACCTATAACACAAAAACAATTAAAATCCATAAC 
TRH_Forward GGGACGTTTTTTTTTTTTTTTGTTTTTTAGTTAGATG 
53 °C 350 bp 72°C – 82 °C 
TRH _Reverse TACCTACGAAATAAAAACTCTACAAAACTTTC 
NPY_Forward GGAGATTAGTAGGTTTAGTAGGTTTAGTAGGTTTAAG 56 °C 
250 bp 71 °C -89 °C 
NPY _Reverse AATCCCRCTACCAAAAAAAAAAATAAAAC  
 
MT2A - metallothionein 2A, NPY – neuropeptide Y, TRH - thyrotropin releasing hormone 
3.4.2 MicroRNA expression analysis  
 
3.4.2.1 Small RNA library preparation  
 
The purified small RNA fraction (containing miRNAs and other small RNAs smaller than 200 nt) extracted 
from the LDH was used for cDNA library preparation with the TruSeq Small RNA Sample Preparation kit 
(Illumina, California, USA) according to the manufacturer’s instructions, with modifications. The TruSeq 
Small RNA Sample Preparation kit protocol was followed for the 3’ and 5’ adapter ligation and reverse 
transcription steps. Normally a minimum of 1 µg of tRNA starting material (or the equivalent amount of 
miRNA found within 1 µg of tRNA) is required for cDNA library preparation. Due to the small size of rat 
LDH brain samples and the fact that we had initially separated the small and large RNA fractions, we had 
limited amounts of miRNA starting material (between 2 ng – 7 ng of miRNA). Subsequently, the PCR 
amplification section of the protocol was modified in order to generate sufficient product for use in the 
sequencing reaction. Instead of the TruSeq Small RNA Sample Preparation kit, we used a high fidelity 
polymerase, Velocity DNA polymerase (Bioline, London, UK), and increased the PCR cycle numbers from 
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the suggested 11 cycles to 20 cycles. Velocity DNA polymerase was chosen for a number of reasons: first, it 
has a high thermostability as well as 3’- 5’ proofreading exonuclease activities; second, the polymerase has 
an error-rate of 4.4 x 10-7, thus providing a 50-fold higher fidelity than Thermus aquaticus DNA polymerase 
(as determined by Mo (1991) and Fujii (1999)); third, Velocity exhibits high amplification rates (up to 66 
bp/s or 15s/kb) and produces higher yields than most commercially available enzymes. The TruSeq PCR mix 
(PML) was replaced with 2.5 U Velocity DNA polymerase (Bioline, London, UK), 1 x HI-Fi buffer 
(containing 10mM Mg2+) (Bioline, London, UK) and 1.4 mM deoxynucleotide triphosphates (dNTPs) 
(Bioline, London, UK). RNA PCR primer (RP1) and RNA PCR indexes from the TruSeq Small RNA 
Sample Preparation Kit (Illumina, California, USA) were used in the PCR reaction as indicated by the 
manufacturer’s instructions. This adapted protocol was developed and optimised by using real-time qPCR 
and SYTO®9 (Invitrogen, California, USA) to determine the optimum PCR cycle number when DNA 
amplification is within the exponential phase.  
 
Adapted PCR protocol for small RNA library preparation 
 
After attempting amplification of the limited starting amount of small RNAs with the PCR mix (PML) from 
the TruSeq Small RNA Sample Preparation kit (Illumina, California, USA), another high fidelity real-time 
qPCR mix was investigated. The TruSeq PCR mix (PML) was replaced with 2.5 U Velocity DNA 
polymerase (Bioline, London, UK), 1 x HI-Fi buffer (containing 10mM Mg2+) (Bioline, London, UK) and 
1.4 mM dNTPs (Bioline, London, UK) and 4 µM SYTO®9 (Invitrogen, California, USA). RP1 and RNA 
PCR indexes from the TruSeq Small RNA Sample Preparation kit (Illumina, California, USA) were used in 
the PCR reaction as indicated by the manufacturer’s instructions. The sample 1 contained 1.3 ng and sample 
2 contained 24.3 ng of miRNA starting material which was used and amplified with the adapted protocol on 
the Rotor-GeneTM 6000 (Corbett Research, Mortlake, Australia) with the following cycle conditions: 98 °C 
for 2 min, 98°C for 30 sec, followed by 45 cycles of 60°C for 30 sec and 72°C for 20 sec, with final 
elongation at 72°C for 10 min. The Cq value of sample 1 was 15 and sample 2 had a Cq value of 12, where 
sample 1 reached the exponential phase of amplification around cycle 18 whereas sample 2 at cycle 14 (Fig. 
3.8) 
3.4.2.2 MicroRNA sequencing 
 
The amplified libraries were size-selected (to ensure that the miRNA fraction was captured) using the Pippin 
Prep DNA size selection system with a 2% agarose gel (Sage Science, Massachusetts, USA). The Pippin 
Prep is a preparative electrophoresis platform that separates and extracts user-defined sizes of DNA 
fragments. The size of the adapters are 118 bp in total and miRNAs range in size from 18 bp – 25 bp, thus a 
final size of between 136 bp - 143 bp is expected for miRNA libraries. The size selection range of 132 bp – 
156 bp was set slightly beyond these minimal ranges to ensure all possible miRNAs were included). The 12 
size-selected library preparations were loaded onto the MiSeq® System (Illumina, California, USA), where 
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cluster generation and sequencing was performed over three consecutive single-read runs (all 12 samples 
were sequenced on three machines) using MiSeq Reagent Kits V2 for 50 cycles (Illumina, California, USA).  
 
Figure 3.8: Real-time qPCR amplification curves generated during adapted PCR protocol for small RNA library 
preparation. Real-time qPCR amplification curves of test sample 1 and 2 using Velocity DNA polymerase, 1 x HI-Fi 
buffer and SYTO®9 dye 
3.4.2.3 Bioinformatics analyses to identify differentially expressed miRNAs 
 
Bioinformatics analyses were performed in collaboration with SANBI, UWC. A pipeline was created to 
analyse the miRNA expression data to identify differentially expressed miRNAs between the FDW and FSM 
groups, consisting of the following programs and analysis tools: 
1. Novoalign (novocraft.com) was used to trim adapter sequences and to map the short reads to the rn4 
Rattus novergicus reference genome 
(http://support.illumina.com/sequencing/sequencing_software/igenome.ilmn)  
2. The generalized fold change count facility (GFOLD) (Feng et al., 2012) was used to count the reads 
that mapped to known miRNA gene coordinates (from miRbase [http://www.mirbase.org/]). 100 000 
iterations were performed during the sampling phase and a significant p-value cut-off of 0.05 was 
selected in order to identify differentially expressed miRNAs with GFOLD  
3.4.3 Identifying mRNA targets of the differentially expressed miRNAs 
The next step was to determine whether the significantly differentially expressed miRNAs targeted any of 
the differentially expressed genes identified following RNAseq analysis, in order to determine if the 
miRNAs mediated differential gene expression. Ingenuity Pathway Analysis (IPA) 
(http://www.ingenuity.com/) software was used for target enrichment analysis. First, functions of the 
differentially expressed miRNAs were predicted based on the functions of the genes they targeted. Second, 
IPA used the differential miRNA and gene expression data to predict if any of the differentially expressed 
genes were targeted by differentially expressed miRNAs. IPA utilizes miRecords 
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(http://mirecords.umn.edu/miRecords/), TargetScan human (http://www.targetscan.org/) and TarBase 
(http://www.microrna.gr/tarbase) to predict mRNA targets of the differentially expressed miRNAs. 
Additional manual searches were performed on databases that included Rattus norvegicus in the species list 
(these databases were MicroCosm, microrna.org and DIANA lab). Both MicroCosm and microrna.org tools 
use the miRanda algorithm to identify potential miRNA binding sites within a genomic sequence. The 
MicroCosm algorithm uses a weighted scoring system that rewards complementarity at the 5' end of the 
microRNA. The algorithm demands strict complementarity between the miRNA and target mRNA at the 
miRNA seed region and also estimates thermodynamic stability of the target region. Finally, every potential 
3'UTR target site was investigated to determine if the site is conserved in orthologous transcripts from other 
species. For target a site to be conserved, it must be detected by a miRNA (of the same family) at the same 
position in a cross-species untranslated region (UTR) alignment in at least two other species than the species 
of interest (the complete process is depicted in Fig. 3.9). 
 
Figure 3.9: The complete computational prediction protocol incorporated in the MicroCosm prediction tool 
(http://www.ebi.ac.uk/enright-srv/microcosm/htdocs/targets/v5/info.html) 
MicroRNA.org uses miRSVR (miRNA support vector regression) (Betel at al., 2010) as a scoring tool. 
MiRSVR is a regression method that predicts the likelihood that a target mRNA will be down-regulated 
based on sequence and structure features in microRNA/mRNA predicted target sites. MiRSVR thus ranks 
microRNA target sites by a down-regulation score. miRanda, in combination with mirSVR (miRanda-
mirSVR), predicts the extent of miRNA-induced down-regulation at the mRNA or protein levels. 
Importantly, the method identifies a significant number of experimentally determined non-canonical and 
non-conserved sites. MicroCosm thus produced predicted conserved miRNA targets and microRNA.org 
allowed identification of those miRNA targets that were not conserved (Betel at al., 2010).  
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3.4.4  SYBR Green real time qPCR expression analysis of rno-miRNA-31a-5p in LDH 
brain and blood  
Rno-miRNA-31a-5p was one of the significant differentially expressed miRNAs identified with miRNA 
sequencing; furthermore, this miRNA was predicted to target IL1RN mRNA. This was significant to the 
present study, as IL1RN has previously been shown to be involved in learning or memory processes (Palin et 
al., 2004). In the FDW group, IL1RN was downregulated 4-fold compared to the FSM group, and real-time 
qPCR was also sensitive enough to detect this differential expression in the LDH and therefore this miRNA 
was selected to be used in SYBR Green real-time qPCR relative expression analysis as well as functional 
target verification luciferase assays.  
 
To investigate if real-time qPCR analysis could be used to detect differential expression of rno-miRNA-31a-
5p between the FDW and FSM group (in miRNAs extracted from LDH samples as well as tRNA extracted 
from rat blood samples), the All-in-OneTM miRNA qRT-PCR Detection Kit (GeneCopoeia, Maryland, 
USA) in combination with an All-in-OneTM miRNA qPCR primer was used (GeneCopoeia, Maryland, 
USA). The kit quantitatively measures miRNAs with the of use real-time qPCR technology. The 
experimental procedure includes three main steps, namely (1) poly-A tail addition: poly-A polymerase adds 
poly-A tails to 3’ miRNA ends; (2) cDNA Synthesis: M-MLV RTase and a unique Oligo-dT Adaptor Primer 
is used to reverse-transcribe the poly-A miRNAs; (3) qPCR: SYBR Green qPCR specifically amplifies and 
detects the reverse transcribed miRNA (the miRNA-specific forward primer is used with the Universal 
Adaptor Primer).  
 
The small nuclear RNA (snRNA) component of U6 small nuclear ribonucleoprotein (snRNP) was used as 
internal reference for normalisation of the miRNA expression data. It is an RNA-protein complex that 
combines with other snRNPs, unmodified pre-mRNA, and various other proteins to assemble a spliceosome. 
It is commonly used for normalisation of miRNA expression analysis due to its stable expression 
(Takamizawa et al. 2004; Choonget al. 2007; Corney et al. 2007; Pineles et al. 2007) and was supplied with 
the All-in-OneTM miRNA qPCR Primer. This real-time PCR method is more specific and sensitive, requires 
less sample material and is less time-consuming compared to traditional hybridization-based miRNA 
detection methods, such as Northern blot analysis.  
  
The 25µl reverse transcription (RT) reaction consisted of 2.5 U Poly A Polymerase, 1µl RTase Mix, 1 x 
PAP/RT Buffer (all aforementioned products were from GeneCopoeia, Maryland, USA) and 200 ng of LDH 
miRNA or 200 ng of blood tRNA. After cDNA conversion, a calibrator sample was prepared (a separate 
calibrator sample for LDH and blood samples) by pooling equal amounts of cDNA from each sample for the 
construction of a standard curve (this was done separately for the LDH cDNA and the blood cDNA). The 
calibrator cDNA samples were serially diluted 2 fold per dilution, to produce a seven-point standard curve, 
with cDNA concentrations ranging from 750 ng to 11.7 ng. Amplification of rno-mir-31a-5p and snRNA U6 
internal reference gene was performed separately. Each 10µl qPCR reaction consisted of 1 x KAPA 
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SYBR®FAST Master Mix ABI Prism™ (KAPA Biosystems, Massachusetts, USA), 0.2 µM All-in-One 
miRNA-31a-5p qPCR Primer or 0.2 µM snRNA U6 internal reference gene primer (miRNA-31a-5p and 
snRNA U6 were amplified in separate reactions) (GeneCopoeia, Maryland, USA), 0.2 µM Universal 
Adaptor PCR Primer (GeneCopoeia, Maryland, USA) and first-strand cDNA (200 ng). The miRNA-31a-5p -
specific forward primer (GeneCopoeia, Maryland, USA) and snRNA U6 internal reference (GeneCopoeia, 
Maryland, USA) was designed by GeneCopoeia.  
 
MiRNA-31a-5p and snRNA U6 qPCR amplification were performed during the same run on the ABI 
7900HT platform (Applied Biosystems, Foster City, CA, USA). Each sample was analysed in triplicate in 
order to eliminate technical variability. Following the amplification of the serially diluted samples, a linear 
plot of the threshold cycle (Cq) versus the log value of the input amount of DNA (standard curve) was 
constructed for each primer pair using ABI’s SDS v2.3 software (Applied Biosystems, California, USA). 
The efficiency of each reaction (per primer set) was also determined from the standard curve of that reaction. 
Default threshold and baseline values were used as determined by the SDS v2.3 software. All Cq values, for 
each primer pair, were corrected for the calculated PCR efficiency and normalised to the reference gene, 
snRNA U6 using GenEx software v5.4.3 (http://www.gene-quantification.de/datan.html) (MultiD, 
Gothenburg, Sweden). Statistical analyses were performed using the appropriate statistical software, such as 
GenEx [www.multid.se] (MultiD, Gothenburg, Sweden) and Statistica v11 (StatSoft, Tulsa, USA). One-way 
ANOVA was performed to determine if there was a significant difference between the least square (LS) 
means of the gene expression fold change between the FDW and FSM animals for each of the primer sets. A 
p-value of ≤ 0.05 was regarded as significant.  
3.4.5 Functional analysis of miRNA-target interaction  
It is important to determine if a particular miRNA elicits a direct or indirect effect on the mRNA target as 
predicted by different software programs. In order to determine whether miR-31a-5p interacts directly with 
the predicted target gene, IL1RN, a luciferase reporter assay was performed, using the GLuc-ONTM Promoter 
Reporter Clones assay kit (GeneCopoeia, Maryland, USA). Each pEZX-MT05 promoter clone contains a ~1-
1.5 kb insert that corresponds to the 5'-flanking sequence located approximately 1-1.5 kb upstream of 3' UTR 
sequences of the target gene, in this case IL1RN. This insert is placed downstream of the Gaussia Luciferase 
(GLuc) reporter gene (Fig. 3.10). According to the manufacturer-provided user manual, the putative cis-
acting enhancer elements are expected to exist in the cloned promoter region. The luciferase activity 
observed during the reporter assay should thus closely resemble actual promoter regulation of these genes 
within human cells. Secreted Alkaline Phosphatase (SEAP), located on the same vector as GLuc, is a 
secondary reporter gene used for transfection normalization. Following co-transfection of the miRNA 
precursor clone (Fig. 3.11) and the promoter reporter clone, a decrease in luciferase activity is expected if the 
miRNA interacts with the predicted mRNA target. Co-transfection with the negative controls (scrambled 
mRNA target sequence and scrambled miRNA sequence) should not result in lowered luciferase activity.  




Figure 3.10: The pEZX-MT05 GLuc-ONTM Promoter Reporter Clone. A 3' UTR region of IL1RN was inserted 
downstream of the GLuc reporter gene (in the region depicted as miR Target in the diagram). A chimeric mRNA was 
subsequently transcribed, driven by SV40 promoter, consisting of the GLuc and the IL1RN 3' UTR target sequence. In 
addition to GLuc, a SEAP reporter, driven by a CMV promoter, is also cloned into the same vector (pEZX-MT05) and 
serves as the internal control. The dual-reporter vector system enables transfection-normalization for accurate across-
sample comparison. 3’UTR – 3’ untranslated region, Ampicillin – ampicillin resistance gene, CMV – cytomegalovirus, 
GLuc - Gaussia Luciferase, IL1RN - interleukin 1 receptor antagonist, Neomycin - neomycin resistance gene, SEAP - 
Secreted Alkaline Phosphatase, SV40 - Simian virus 40, pUC Ori- pUC plasmid origin of replication 
 
Figure 3.11: The pEZX-MR04 GFP miRNA precursor clone. The precursor of rno-mir-31a-5p was cloned 
downstream of an eGFP construct and a CMV promotor. AmpR – ampicillin resistance gene, bla – beta- lactamase, 
CMV – cytomegalovirus, eGFP - enhanced green fluorescent protein, hPGK – human phosphoglycerate kinase I 
promoter (for puromycin selection), miRNA – miRNA precursor sequence, pUC Ori- pUC plasmid origin of 
replication, PUROR - puromycin resistance gene, SV40 poly A - Simian virus 40 poly A  
 
Human Embryonic Kidney 293 (HEK 293) cells (obtained from our laboratory) were maintained in 
Dulbecco's Modification of Eagle's Medium (DMEM) (Lonza, Basel Switzerland) supplemented with 1 % 
nonessential amino acids, 10 % fetal bovine serum (Sigma, Missouri, USA), 100 U/mL penicillin and 100 
mg/mL streptomycin (Lonza, Basel Switzerland) (Appendix I). The cells were maintained at 37 °C with 5 % 
CO2 and subcultured every other day. Cells between passage 15 and 18 were used for luciferase experiments. 
The GLuc-ONTM Promoter Reporter Clone containing the IL1RN mRNA target region specific for rno-mir-
31a-5p as well as the precursor sequence of rno-mir-31a-5p was purchased from GeneCopoeia. 
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The day before the transfection assay, 1 x 104cells were seeded into a 6-well culture tray containing  
3 ml DMEM (complete media) (Appendix I) per well, the cells were grown for 24 hours to reach a 
confluency of 70–75%, cells were co-transfected with 150 ng GLuc-ONTM Promoter Reporter Clone for 
IL1RN (GeneCopoeia, Maryland, USA) and 150 ng miR-31a-5p precursor clone (GeneCopoeia, Maryland, 
USA) in serum-free media (Appendix I) in a 6-well culture tray using HiPerFect Transfection Reagent 
(Qiagen, Hilden Germany) and following the traditional protocol for transfection of adherent cells with 
miRNA, according to the manufacturer’s instructions (Qiagen, Hilden Germany). Negative control assays 
included the following co-transfections: (1) 150 ng of the miR-31a-5p precursor clone and 150 ng of a 
scrambled control reporter clone; (2) 150 ng of a scrambled miR precursor control and 150 ng of the IL1RN 
reporter clone; (3) 150 ng of IL1RN reporter clone and no miR-31a-5p precursor clone (negative control to 
test if any endogenous miRNAs are targeting the IL1RN mRNA target region). A positive control (EF1A-
PG04 media) was provided in the kit by the manufacturer (GeneCopoeia, Maryland, USA). After about 24 
hours the media was removed and replaced with fresh DMEM (complete media) (Appendix I). About 72 
hours after transfection, cell culture media was collected and assayed for both GLuc and SEAP luciferase 
signal, simultaneously on the same white 96-well plate and according to the manufacturer’s instructions 
(GeneCopoeia, Maryland, USA). For the GLuc assay, the GL-S Buffer was used for more stable activity. 
Each sample was analysed in duplicate and the experiment was repeated to ensure reproducibility.  
 
When comparing GLuc activities of multiple transfected cell samples, signal normalization is necessary. 
SEAP signal was used as an internal standard control and signal normalization (ratio of GLuc and SEAP 
activities) eliminated the impact of transfection efficiency variations; thus the normalized GLuc activities of 
the different samples more accurately reflected the true biological events. The ratio of luminescence 
intensities (RLU, Relative Light Unit) of the GLuc over SEAP was calculated and the normalized GLuc 
activity (GLuc/SEAP ratio) was used to compare the different co-transfections (as described in the paragraph 
above).  
 
In order to determine whether rno-miR-31a-5p targeted IL1RN in vitro, the co-transfection of the rno-miR-
31a-5p precursor clone and the IL1RN promoter reporter clone had to show significantly lower luciferase 
activity compared to the negative control co-transfections. A mixed model repeated measures ANOVA was 
performed using Statistica v11 (StatSoft, Tulsa, USA) to determine if there were statistically significant 
differences. 
  




4.1 PTSD animal model  
Animals were subjected to several behavioural tests following fear conditioning and fear extinction, to 
evaluate their anxiety-like phenotypes (refer to Methods Sections 3.1.2 and 3.1.3) and to group the animals 
in well-adapted (WA) and maladapted (MA) groups (refer to Methods Sections 3.1.4). One of these tests was 
the L/D avoidance test. Statistical analysis (ANOVA F-test) of behavioural data showed that there were 
significant group differences in the time spent in the dark (p < 0.05) (Fig. 4.1 A). Post-hoc analysis revealed 
that the FS group spent significantly more time in the dark compartment (indicative of fearful behaviour) 
compared to the CS and the FD groups that spent more time in the light compartment (indicative of non-
fearful behaviour) (p < 0.05) (Fig. 4.1 B) (Table 4.1). These results from the L/D avoidance test indicate that 
fear conditioning was effective in eliciting a fearful response in FS group and that a fear extinction effect 
was evident in the FD group. The difference in the time spent exploring the light compartment was also 
statistically significant between the CS and CD groups. This suggested that in the absence of fear 
conditioning, the drug still elicited an effect on behaviour. However, after sub-group selection for the CD 
and CS groups, whereupon 12 animals with behavioural values closest to the group mean were selected, 
there were no statistically significant group differences, suggesting that outliers may have caused this 
spurious result.  
We therefore concluded that the L/D avoidance test was the most sensitive behavioural test, compared to the 
OF and FST, to detect the effects of fear conditioning and fear extinction in the present study. Since 30 
animals per treatment group were used in the behavioural analysis, it provided more statistical power as well 
as confidence in the data. Behavioural data from the L/D avoidance test were subsequently used as selection 
criteria for the WA and MA subgroups within the FS and FD groups. 
 
After subgrouping the FD and FS animals into WA and MA groups, statistical analyses (ANOVA F-test) 
were performed on the L/D avoidance test behavioural data to determine if there was indeed a significant 
difference between the WA and MA groups and between the FSM and FDW groups. We also wanted to 
confirm that these subgroups were appropriate for downstream genetic and epigenetic analyses. There was a 
statistically significant difference in the time spent in the dark compartment between the WA and MA groups 
in the L/D avoidance test (p < 0.05) (Fig. 4.1 C): WA animals spent significantly less time in the dark 
compartment compared to MA animals. Post-hoc analysis indicated that there was a statistically significant 
difference in the time spent in the dark compartment between the two focus groups, FDW and FSM, as well 
as among all other subgroups, except between FSW and FDM (Table 4.2). The post-hoc analysis accounts 
for multiple comparisons.  
 
Furthermore, a significant interaction effect between treatment group (FS or FD) and WA or MA status was 
found (p = 0.00087) (Fig. 4.1 D). This implies that the combination of these factors results in more extreme 
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values than if a single factor had been considered. Figure 4.1 D shows that the combination of DCS 
administration and WA status resulted in less time spent in the dark in the L/D avoidance test, compared to 










Figure 4.1: Statistical analyses of L/D avoidance test results. (A) There was a statistically significant group 
difference in the time spent in the dark compartment for the four treatment groups (p = 0.01). One-way ANOVA 
results for the L/D avoidance test shows the time spent in the dark compartment (y-axis) for all treatment groups (x-
axis). (B) A statistically significant difference was evident in the time spent in the dark compartment between the 
FS group compared to the FD group (p < 0.001). One-way ANOVA and post-hoc test results for the L/D avoidance 
test shows the time spent in the dark compartment (y-axis) for the FS and the FD groups (x-axis). (C) There was a 
statistically significant difference in the time spent in the dark compartment between the WA and MA subgroups 
(p = 0.00). One-way ANOVA results for the L/D avoidance test shows the time spent in the dark compartment (y-axis) 
for the WA and MA subgroups (x-axis). (D) An interaction effect was evident between the MA or WA status and 
group status (FS or FD) which had an effect on the L/D avoidance test results (p < 0.001). F-test results for the L/D 
avoidance test shows the time spent in the dark compartment (y-axis) for the FSW, FDW, FSM, FDW groups (x-axis). 
ANOVA – analysis of variance, L/D – light/dark, FS – fear-conditioned + saline, FD – fear-conditioned + DCS, WA – 
well-adapted, MA – maladapted, FSM - fear-conditioned + saline maladapted, FDW - fear-conditioned + DCS well-
adapted. * indicate significant p-values (p < 0.001) 
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Table 4.1: LSD post-hoc analysis test results for the L/D avoidance test for the four treatment groups. P-values < 
0.05 in red show statistically significant differences in mean values for the time spent in the dark compartment for each 
treatment group. Statistically significant differences were evident between all groups, except between CD and FD 
 Group {1} 288.63 {2} 254.07 {3} 315.10 {4} 263.60 
1 CS  0.007020 0.036150 0.047284 
2 CD 0.007020  0.000004 0.450616 
3 FS 0.036150 0.000004  0.000070 
4 FD 0.047284 0.450616 0.000070  
 
LSD - Least Significant Difference, L/D – light/dark, CS – control + saline, CD – control + DCS, FS – fear-conditioned + saline, FD 
– fear-conditioned + DCS 
Table 4.2: LSD post-hoc analysis test results for the L/D avoidance test for the fear-conditioned subgroups. P-
values < 0.05 in red show statistically significant differences in mean values for the time spent in the dark compartment 
for each of the WA and MA subgroups 
 Group Status {1} - 290.67 {2} - 346.50 {3} - 200.67 {4} - 309.67 
1 FS WA  0.000011 0.000000 0.062203 
2 FS MA 0.000011  0.000000 0.001049 
3 FD WA 0.000000 0.000000  0.000000 
4 FD MA 0.062203 0.001049 0.000000  
 
LSD - Least Significant Difference, L/D – light/dark, FS – fear-conditioned + saline, FD – fear-conditioned + DCS, WA – well-
adapted, MA - maladapted 
4.2 Gene expression analyses 
 
4.2.1 Next generation RNA sequencing 
The paired-end sequencing data from the two flow cells sequenced on the Illumina HiSeq 2000 platform 
yielded an average of about 60 million reads per sample. The quality of the sequencing data was very high as 
illustrated by the phred scores that were mostly ≥ 30 (Fig. 4.2). Phred score (Q) is the log transformation of 
error rate (P) at each base calling position. Q = -10log10P. A phred score of 30 thus denotes 1 error per 1000 
nucleotides and a score of 20 denotes 1 error per 100 nucleotides. An average of 99.96% of the reads could 
be mapped to the Rattus novergicus rn4 rat reference genome 
((http://support.illumina.com/sequencing/sequencing_software/igenome.ilmn). Among the mapped 
sequences, approximately 56.90% of the read pairs were uniquely mapped to the reference genome. These 
reads were used to estimate transcript expression of all 48 samples (consisteing of 12 CS, 12 CD, 6 FSM, 6 
FSW, 6 FDW and 6 FDM animals). Cufflinks measures transcript abundances in Fragments Per Kilobase of 
exon per Million fragments mapped (FPKM). Of the 16 491 annotated genes, 13 676 (82.93%) transcripts 
had FPKM values higher than 0 and 7 479 (45.35%) transcripts had FPKM values higher than 5. In order to 
identify a gene or transcript as differentially expressed, Cuffdiff tests the observed log-fold-change in its 
expression against the null hypothesis of no change (i.e. the true log-fold-change is zero). Genes with log2 
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(fold change values) ≥ 1.3 and p < 0.05 were considered as significantly up-regulated while those with log2 
(fold change values) ≤ 0.5 and p < 0.05 were regarded as significantly down-regulated and investigation of 
these genes was thus taken further.  
A. Flow cell one 
 
B. Flow cell two 
 
Figure 4.2: Distribution of phred (Q) score in reads for flow cell one (A) and flow cell two (B). The x-axis indicates 
the bp position in the 101 bp read and the y-axis indicates the phred score at each position. The phred scores are usually 
lower at the start and end points and should be trimmed if the per base quality score is below 20. Due to the high quality 
of the sequencing data, no end trimming was required 
4.2.2 Differential gene expression analyses 
Bioinformatics analyses of the RNAseq data detected a total 93 genes that were statistically significant 
downregulated in the FDW compared to the FSM group, of which 42 were predicted to have biologically 
relevant functions by the BORG analysis tool. Only one gene, cysteine-rich angiogenic inducer 61 (CYR61) 
was found to be overexpressed in the FDW group compared to the FSM group, however it was not assessed 
as being biologically relevant by the BORG analysis tool in the present study. Table 4.3 provides a summary 
of the genes that were differentially expressed between the different subgroups; it also indicates how many 
genes were predicted to be biologically relevant by BORG analysis. Table 4.4 contains the 42 biologically 
relevant genes that were differentially expressed between FDW and FSM animals, the gene expression fold 
changes (negative fold changes indicate that genes were down-regulated in the FDW group compared to the 
FSM group) as well as functions of the differentially expressed genes as predicted by the BORG analyses. 
Refer to Appendix II, Table II.1 for the differentially expressed genes between the other treatment groups 
(mentioned in Table 4.3). 
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Table 4.3: Summary of differential gene expression results for the different treatment groups. The total number of 
overexpressed (fold change ≥ 1.3 and p < 0.05) and under-expressed (fold change ≤ 0.5 and p < 0.05) genes identified 
with Cuffdiff as well as biologically relevant differentially expressed genes identified with BORG analyses among the 
various treatment groups  


















Total over-expressed genes 1 0 6 5 0 0 
BORG over-expressed genes 0 0 3 3 0 0 
Total under-expressed genes 93 2 1 1 0 364 
BORG under-expressed genes 42 1 0 0 0 95 
 
FSM - fear-conditioned + saline maladapted, FDW – fear-conditioned + DCS well-adapted, CS – control saline, FSW – fear-
conditioned + saline well-adapted, FDM – fear-conditioned + DCS maladapted, CD – control + DCS 
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Table 4.4: Biologically relevant differentially expressed genes. The 42 biologically relevant genes (pertaining to fear, anxiety and PTSD, as identified by BORG analyses tool) that 
were significantly differentially expressed between the FDW compared to the FSM group; negative fold changes indicate that genes were down-regulated in the FDW group 
compared to the FSM group. Functions were predicted by the BORG analyses tool 
Gene Name Fold change Function 
SPP1 Secreted phosphoprotein 1  -6.00 Demyelination (Chiocchetti et al., 2005) (http://www.ncbi.nlm.nih.gov/pubmed/15885319) 
CXCL13 Chemokine (C-X-C motif) ligand 13 -5.21 Elevation of cytosolic calcium ion concentration (GO:0007204) / Immune response (GO:0006955) 
(http://www.ncbi.nlm.nih.gov/pubmed/22075990)/ Inflammatory response (Camon et al., 2004) 
CLEC7A C-type lectin domain family 7, member 
A 
-5.20 Cytokine regulation (Camon et al., 2004) 
IL1RN Interleukin 1 receptor antagonist  -4.19 Learning or memory (http://www.ncbi.nlm.nih.gov/pubmed/15050649) (Palin et al., 2004) 
C6 Complement component C6  -4.15 Neurodegenerative disease pathway (http://www.ncbi.nlm.nih.gov/pubmed/19594883) 
CD8A CD8a molecule  -3.96 Abnormal myelination (http://www.ncbi.nlm.nih.gov/pubmed/22075990 ) 
MSR1 Macrophage scavenger receptor 1  -3.80 Amyloid beta deposits (http://www.ncbi.nlm.nih.gov/pubmed/22075990) 
S100A4 S100 calcium binding protein A4 -3.47 Neuron projection (GO:0043005) (http://www.ncbi.nlm.nih.gov/pubmed/15101091) / calcium-dependent 
protein binding (GO:0048306) (http://www.ncbi.nlm.nih.gov/pubmed/8878885) / calcium ion binding 
(GO:0005509) (http://www.ncbi.nlm.nih.gov/pubmed/2357224) 
(http://www.ncbi.nlm.nih.gov/pubmed/15101091) 
S100A9 S100 calcium binding protein A9 -3.45 Calcium ion binding(GO:0005509) / antioxidant activity (GO:0016209) (Camon et al., 2004) /chronic 
inflammatory response (GO:0002544) (http://www.ncbi.nlm.nih.gov/pubmed/8343166) 
F10 Coagulation factor X -3.42 Calcium ion binding (GO:0005509) (Camon et al., 2004) / coagulation cascade pathway (PW:0000474) 
(http://www.ncbi.nlm.nih.gov/pubmed/10048754) (http://www.ncbi.nlm.nih.gov/pubmed/12356487) / 
complement system pathway (PW:0000502) (Petri et al., 2011) 
GPNMB Glycoprotein (transmembrane) nmb  -3.13 Neuron degeneration (http://www.ncbi.nlm.nih.gov/pubmed/22075990) 
LBP Lipopolysaccharide binding protein  -3.04 Cytokine production (Camon et al., 2004) 
HMOX1 Heme oxygenase (decycling) 1 -2.99 Negative regulation of neuron apoptotic process (GO:0043524) 
(http://www.ncbi.nlm.nih.gov/pubmed/19177228) / response to oxidative stress (GO:0006979) 
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(http://www.ncbi.nlm.nih.gov/pubmed/17020887) / increased inflammatory response (MP:0001846) 
(http://www.ncbi.nlm.nih.gov/pubmed/22075990) 
ST14 Suppressor of tumorigenicity 14 protein -2.81 Abnormal neural tube morphology/development (http://www.ncbi.nlm.nih.gov/pubmed/22075990) 
TRH Thyrotropin releasing hormone  -2.80 Abnormal pituitary gland development (http://www.ncbi.nlm.nih.gov/pubmed/22075990) 
ITGAL Integrin, alpha L -2.74 Abnormal inflammatory response (MP:0001845) (Camon et al., 2004) / Positive regulation of calcium-
mediated signalling (GO:0050850) (http://www.ncbi.nlm.nih.gov/pubmed/8117278) 
LYZ2 Lysozyme 2 -2.64 Altered response to CNS ischemic injury (http://www.ncbi.nlm.nih.gov/pubmed/22075990) 
A2M Alpha-2-macroglobulin  -2.53 Neurodegenerative disease pathway (Blacker et al., 1998) 
CYBB Cytochrome b-245, beta polypeptide  -2.51 Oxidative stress (Datla and Griendling 2010; Tyagi et al., 2011) / Nervous system physiology 
(GO:0030425) (http://www.ncbi.nlm.nih.gov/pubmed/17027166) (GO:0043025) 
(http://www.ncbi.nlm.nih.gov/pubmed/17027166) 
MMP9 Matrix metallopeptidase 9  -2.42 Impaired contextual conditioning behaviour (http://www.ncbi.nlm.nih.gov/pubmed/22075990) 
NCF1 Neutrophil cytosolic factor 1  -2.24 Abnormal spatial learning / impaired cued conditioning behaviour 
(http://www.ncbi.nlm.nih.gov/pubmed/22075990) 
S100A3 S100 calcium binding protein A3 -2.21 Calcium ion binding (GO:0005509) (Camon et al., 2004) 
C1QC Complement C1q subcomponent 
subunit C 
-2.18 Neurodegenerative disease pathway (http://www.ncbi.nlm.nih.gov/pubmed/19594883) 
RRM2 Ribonucleoside-diphosphate reductase 
subunit M2  
-2.13 p53/stress response signalling pathway (Petri et al., 2011) 
MT2A Metallothionein 2A  -2.10 Abnormal learning/memory/conditioning (http://www.ncbi.nlm.nih.gov/pubmed/22075990) 
PTPRC Protein tyrosine phosphatase receptor 
type, C  
-2.02 Abnormal myelination (http://www.ncbi.nlm.nih.gov/pubmed/22075990) 
TSPO Translocator protein -1.97 Response to pain (http://www.ncbi.nlm.nih.gov/pubmed/19555675)  
RAC2 Ras-related C3 botulinum toxin 
substrate 2  
-1.92 Axon guidance (GO:0007411) (Camon et al., 2004) 
VIM Vimentin  -1.87 Increased anxiety-related response / abnormal nervous system morphology 
(http://www.ncbi.nlm.nih.gov/pubmed/22075990) 
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C1QB Complement C1q subcomponent 
subunit B  
-1.87 Neurodegenerative disease pathway (http://www.ncbi.nlm.nih.gov/pubmed/19594883) 
CTSC Cathepsin C  -1.79 Decreased prepulse inhibition (http://www.ncbi.nlm.nih.gov/pubmed/22075990) 
CP Ceruloplasmin (glycoprotein) -1.76 Abnormal neuron morphology (http://www.ncbi.nlm.nih.gov/pubmed/22075990) 
C1S Complement component 1, s 
subcomponent 
-1.64 Calcium ion binding (Camon et al., 2004)/ glial cell differentiation 
(http://www.ncbi.nlm.nih.gov/pubmed/9524231) 
CD4 Cd4 molecule  -1.64 Demyelination / brain inflammation (http://www.ncbi.nlm.nih.gov/pubmed/22075990) 
CHRDL1 Chordin-like 1 -1.61 Neuron differentiation (GO:0030182) (http://www.ncbi.nlm.nih.gov/pubmed/14684875) 
C1QA Complement component 1, q 
subcomponent, A chain  
-1.60 Neurodegenerative disease pathway (Petri et al., 2011) and seizures 
(http://www.ncbi.nlm.nih.gov/pubmed/22075990) 
FCER1G Fc fragment of IgE, high affinity I, 
receptor for; gamma polypeptide  
-1.57 Cytokine regulation (Camon et al., 2004) 
CD44 Cd44 molecule  -1.55 Abnormal spinal nerve morphology, abnormal synaptic transmission 
(http://www.ncbi.nlm.nih.gov/pubmed/22075990) 
CD74 Cd74 molecule, major 
histocompatibility complex, class II 
invariant chain 
-1.48 Cytokine regulation (Camon et al., 2004) 
LCP1 Ceruloplasmin  -1.41 Calcium ion binding (GO:0005509) (http://www.ncbi.nlm.nih.gov/pubmed/2378651) / T cell activation 
involved in immune response (GO:0002286) (Camon et al., 2004) 
LGALS3BP Lectin, galactoside-binding, soluble, 3  -1.34 Inflammatory response (Wang et al., 2011) 
NPY Neuropeptide Y  -1.30 Increased anxiety-related response (http://www.ncbi.nlm.nih.gov/pubmed/22075990), neuropeptide Y 
metabolic pathway (http://www.ncbi.nlm.nih.gov/pubmed/16046456), abnormal depression-related 
behaviour (http://www.ncbi.nlm.nih.gov/pubmed/14757324)  
 
FDW – fear-conditioned + DCS well-adapted, FSM - fear-conditioned + saline maladapted, BORG - Bio-Ontological Relationship Graph
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4.2.3 Gene Ontology enrichment analyses for differentially expressed genes 
The set of 42 biologically relevant genes differentially expressed between the FDW compared to the FSM 
group were further analysed to identify shared or common functional categories between these genes, based 
on gene ontology terms. Statistically significant (p<0.05) over-expressed GO terms and pathways associated 
with the downregulated genes were identified using the Comparative Toxicogenomics Database (CTD) 
functional enrichment tool (http://ctdbase.org/tools/analyzer.go) (Davis et al., 2013). Integrative network 
diagrams were constructed with Cytoskape 2.8.3 (http://www.cytoscape.org) to create a more insightful view 
of the relationships between annotation categories. Functional categories of biological process (Table 4.5, 
Figs. 4.3, 4.4, 4.5), disease (Table 4.6, 4.7, Figs. 4.6 – 4.8), molecular function (Table 4.8, Figs. 4.9, 4.10) 
and enriched biochemical pathways (including KEGG and REACTOME biochemical pathways terms) 
(Table 4.9, Figs. 4.11, 4.12) were identified, only for the 42 biologically relevant genes. 
4.2.3.1 Biological processes associated with biologically relevant differentially expressed genes 
Biological processes that were overrepresented in the differentially expressed gene set include immune 
response, positive regulation of response to stimulus, responses to stress, developmental processes, cellular 
responses to stimulus and signal transduction. Other important associated processes that may be involved in 
anxiety-related pathologies include locomotion, complement activation, behaviour and negative regulation of 
glutamate secretion. Table 4.5 indicates the sets of genes associated with each process. Figure 4.3 indicates 
the number of genes associated with each process, and Figures 4.4, 4.5 indicate genes that share roles in 
certain processes.  
 
Table 4.5: Biologically relevant differentially expressed genes in the LDH of FDW vs. FSM animals that were 
associated with the gene ontology (GO) biological process terms (p < 0.05) (as determined by CTD) 





Immune response 24 9.21E-21 A2M, C1QA, C1QB, C1QC, C1S, C6, CD4, CD44, 
CD74, CD8A, CLEC7A, CTSC, CXCL13, CYBB, 
FCER1G, HMOX1, IL1RN, ITGAL, LBP, LCP1, 
MT2A, NCF1, PTPRC, S100A9 
Positive regulation of 
response to stimulus 
22 7.61E-18 A2M, C1QA, C1QB, C1QC, C1S, C6, CD4, CD44, 
CD74, CD8A, CLEC7A, CXCL13, F10, FCER1G, 
HMOX1, IL1RN, ITGAL, LBP, NPY, PTPRC, 
S100A4, S100A9 
Response to stress 28 7.48E-17 A2M, C1QA, C1QB, C1QC, C1S, C6, CD4, CD44, 
CD74, CD8A, CLEC7A, CXCL13, CYBB, F10, 
FCER1G, HMOX1, IL1RN, ITGAL, LBP, 
LGALS3BP, MT2A, NCF1, PTPRC, RAC2, S100A9, 
SPP1, TRH, TSPO 
Developmental process 24 3.49E-08 A2M, C1QB, C1QC, C6, CD4, CD44, CD74, CD8A, 
CHRDL1, CTSC, CXCL13, GPNMB, HMOX1, 
IL1RN, LCP1, MMP9, MSR1, NPY, PTPRC, RAC2, 
S100A4, SPP1, TSPO, VIM 
Locomotion 14 2.48E-07 CD4, CD74, CXCL13, F10, FCER1G, HMOX1, 
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ITGAL, LBP, MMP9, PTPRC, RAC2, S100A9, 
SPP1, TSPO 
Complement activation 6 3.53E-07 A2M, C1QA, C1QB, C1QC, C1S, C6 
Cellular response to stimulus 24 6.23E-07 A2M, CD4, CD44, CD74, CD8A, CHRDL1, 
CLEC7A, CXCL13, F10, FCER1G, HMOX1, 
IL1RN, ITGAL, LBP, LGALS3BP, MT2A, NPY, 
PTPRC, RAC2, S100A4, S100A9, SPP1, TRH, 
TSPO 
Signal transduction 22 7.35E-07 A2M, CD4, CD44, CD74, CD8A, CHRDL1, 
CLEC7A, CXCL13, F10, FCER1G, HMOX1, 
IL1RN, ITGAL, LBP, LGALS3BP, MT2A, NPY, 
PTPRC, RAC2, S100A4, S100A9, TRH 
Response to chemical 
stimulus 
18 3.36E-06 CD44, CD74, CLEC7A, CTSC, CXCL13, FCER1G, 
HMOX1, IL1RN, LBP, MSR1, MT2A, NPY, PTPRC, 
RAC2, S100A9, SPP1, TRH, TSPO 
Cell differentiation 16 1.09E-04 A2M, C1QC, CD4, CD74, CD8A, CHRDL1, 
GPNMB, MMP9, MSR1, NPY, PTPRC, RAC2, 
S100A4, SPP1, TSPO, VIM 
Ion homeostasis 7 4.67E-03 CP, CXCL13, HMOX1, MT2A, PTPRC, S100A9, 
TSPO 
Positive regulation of 
calcium-mediated signalling 
3 6.18E-03 CD4, CD8A, ITGAL 
Behavior 7 6.29E-03 CD74, CXCL13, IL1RN, LBP, NPY, TRH, TSPO 
Immune system development 7 1.35E-02 C1QC, CD4, CD74, CD8A, CXCL13, MMP9, 
PTPRC 
Negative regulation of 
response to stimulus 
8 1.48E-02 A2M, CD44, CD74, CXCL13, HMOX1, IL1RN, 
PTPRC, SPP1 
Reactive oxygen species 
metabolic process 
4 3.06E-02 CYBB, NCF1, RAC2, TSPO 
Negative regulation of 
glutamate secretion 
2 4.15E-02 IL1RN, TRH 
 
LDH – left dorsal hippocampus, FDW – fear-conditioned + DCS well-adapted, FSM – fear-conditioned + saline maladapted, CTD – 












Figure 4.3: Main biological process gene ontology (GO) terms associated with the biologically relevant 
differentially expressed genes. The x-axis shows the main biological processes and the y-axis indicates the number of 
genes enriched for each biological process 
Integrative network analysis was originally performed with all the above-mentioned biological processes 
depicted in the network (Fig. 4.4), however, due to the large number of genes associated with certain 
processes (immune response, response to stress, developmental process etc.), this network was visually 
complex. A subset of the biological processes (which included some of the more relevant biological 
processes that had fewer associated genes) was, therefore, selected to construct a simpler integrative network 





































Figure 4.4: Integrative network diagram depicting the common biological processes associated with, and shared 
between, the biologically relevant differentially expressed genes in the FDW vs. FSM groups. Biological processes 









Figure 4.5: Integrative network diagram depicting a selected subset of the common biological processes 
associated with, and shared between, the biologically relevant differentially expressed genes in the FDW vs. FSM 
groups. Biological processes are represented using large blue circles; genes associated with one, two, three, four, five 
and six processes are represented using grey, green, blue, yellow, pink and orange circles, respectively. Refer to Table 
4.4 for full gene names and Table 4.5 and Fig. 4.3 for biological process GO terms not included in the network. FDW – 
fear-conditioned + DCS well-adapted, FSM – fear-conditioned + saline maladapted 
4.2.3.2 Diseases associated with biologically relevant differentially expressed genes 
 
In order to identify differentially expressed genes that could play a role in PTSD or anxiety disorders, a 
search for significantly associated disease terms was conducted. CTD gene–disease relationships include 
curated and inferred relationships. Curated gene-disease relationships are based on published literature 
curated by CTD or derived from the Online Mendelian Inheritance in Man (OMIM) database. Inferred 
relationships are those based on CTD-curated chemical–gene interactions, for example, where gene A 
directly interacts with chemical B, and chemical B has a curated relationship with disease C, gene A will 
have an inferred relationship with disease C (via chemical B). 
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The biologically relevant differentially expressed genes, identified with RNAseq, were imported into CTD to 
identify the significantly associated GO disease terms. Significantly associated disease terms included, but 
were not limited to, nervous system diseases, mental disorders, cognitive disorders and neurodegenerative 
disorders, digestive system diseases and metabolic diseases. Genes that are associated with nervous system 
diseases, mental disorders, cognitive disorders and neurodegenerative disorders could be involved in fear 
extinction and fear conditioning processes, as well as anxiety related pathologies. In addition, other 
overrepresented disease terms, such as cardiovascular diseases, digestive system diseases and metabolic 
diseases could facilitate our understanding of co-morbidity and indicate which genes may explain certain 
disorders co-morbid with PTSD. Table 4.6 shows the subsets of genes significantly associated with different 
disease terms. 
Table 4.6: Biologically relevant differentially expressed genes in the LDH of FDW vs. FSM animals that were 
associated with the gene ontology (GO) disease terms (p<0.05) (as determined by CTD) 







17 4.02E-14 C1QA, C1QB, C1S, C6, CD4, CD8A, CP, CTSC, CYBB, 
FCER1G, HMOX1, IL1RN, MMP9, NCF1, PTPRC, RAC2, 
SPP1 
Cardiovascular Diseases 18 1.02E-13 C1QB, C1S, C6, CTSC, CYBB, F10, HMOX1, IL1RN, ITGAL, 
MMP9, MT2A, NCF1, NPY, RAC2, S100A4, SPP1, TRH, VIM 
Digestive System 
Diseases 
17 9.06E-11 A2M, C1S, CD44, CD74, CP, CTSC, GPNMB, HMOX1, IL1RN, 
LBP, MMP9, MT2A, PTPRC, RRM2, S100A4, S100A9, SPP1 
Central Nervous System 
Diseases 
12 1.72E-06 A2M, CP, CYBB, HMOX1, IL1RN, MMP9, NCF1, NPY, 
S100A4, SPP1, TRH, VIM 
Nervous System 
Diseases 
16 2.28E-06 A2M, CD4, CD44, CP, CYBB, HMOX1, IL1RN, MMP9, NCF1, 
NPY, PTPRC, S100A4, SPP1, TRH, TSPO, VIM 
Brain Diseases 11 7.06E-06 A2M, CP, CYBB, HMOX1, IL1RN, MMP9, NCF1, NPY, 
S100A4, SPP1, TRH 
Hypersensitivity 7 1.59E-05 C1QA, C1S, CTSC, FCER1G, HMOX1, MMP9, SPP1 
Diabetes Mellitus 7 1.63E-05 CP, CYBB, HMOX1, IL1RN, MMP9, NCF1, SPP1 
Metabolic Diseases 11 4.00E-05 C6, CP, CYBB, HMOX1, LBP, MMP9, NCF1, PTPRC, SPP1, 
TRH, VIM 




5 6.61E-04 A2M, CP, HMOX1, NPY, TRH 
Pain 4 2.42E-03 IL1RN, MMP9, TRH, VIM 
Pancreatic Diseases 4 5.43E-03 CD44, HMOX1, MMP9, SPP1 
Mental Disorders 8 1.83E-02 A2M, CP, HMOX1, IL1RN, LCP1, MMP9, NPY, TRH 
Nerve Degeneration 3 4.61E-02 CD4, CD44, CP 
 
LDH – left dorsal hippocampus, FDW – fear-conditioned + DCS well-adapted, FSM – fear-conditioned + saline maladapted, CTD – 









Figure 4.6 indicates the number of genes associated with each disease term, with the highest number of genes 
being associated with cardiovascular diseases, immune system diseases, nervous system diseases, and 
digestive system diseases. 
 
Figure 4.6: Main disease gene ontology (GO) terms associated with the biologically-relevant differentially 
expressed genes. The x-axis represents the main GO disease terms and the y-axis indicates the number of genes 
enriched for each disease 
Figure 4.7 illustrates which group of genes are associated with each disease term, showing sets of genes that 









































Figure 4.7: Integrative network diagram depicting a selected subset of the common diseases associated with and 
shared between the biologically-relevant differentially expressed genes in the FDW vs. FSM groups. Diseases are 
represented using large blue circles; one, two, three, four, five, six, seven, eight, nine, eleven and twelve diseases are 
represented using grey, green, blue, yellow, pink, orange, red, light pink, purple mint green and olive green 
respectively. Refer to Table 4.4 for full gene names and Table 4.6 and Fig. 4.6 for disease terms not included in the 
network 
Venn diagrams were also constructed to compare the differentially expressed gene list to genes with inferred 
relationships (based on CTD-curated chemical–gene interactions, refer to Section 3.3.3 for a more detailed 
explanation) with anxiety disorders and PTSD (Fig. 4.8). From the 42 biologically relevant differentially 
expressed genes identified, 21 genes had inferred associations with anxiety disorder and 21 genes had 
inferred associations with both anxiety disorders and PTSD (Fig. 4.8, Table 4.7).  
  




Figure 4.8: Venn diagram depicting the biologically relevant differentially expressed genes (between FDW and 
FSM groups) that had inferred relationships with PTSD, anxiety disorders or both.  
DEG – differentially expressed genes, PTSD - posttraumatic stress disorder, CTD - Comparative Toxicogenomics Database 
 
Table 4.7: Genes with inferred relationships with anxiety disorders alone, and with both anxiety disorders and 
PTSD (as determined by CTD) 
Disorders Genes 
Anxiety disorders A2M, C1QA, C1QB, C1QC, C1S, CD4, CHRDL1, CLEC7A, CXCL13, FCER1G, 
GPNMB, IL1RN, ITGAL, LBP, LCP1, MSR1, PTPRC, RAC2, S100A3, S100A4, ST14 
Anxiety disorders and 
PTSD 
C6, CD44, CD74, CD8A, CP, CTSC, CYBB, F10, HMOX1, LGALS3BP, LYZ2, MMP9, 
MT2A, NCF1, NPY, RRM2, S100A9, SPP1, TRH, TSPO, VIM 
 
PTSD - posttraumatic stress disorder, CTD - Comparative Toxicogenomics Database. Refer to Table 4.4 for full gene 
names 
 
4.2.3.3 Molecular functions associated with biologically relevant differentially expressed genes 
Gene enrichment analysis was also conducted to identify the molecular functions associated with and shared 
between the 42 biologically relevant genes that were downregulated in the FDW group. Table 4.8 show the 








Table 4.8: Biologically relevant differentially expressed genes in the LDH of FDW vs. FSM animals that were 
associated with the gene ontology (GO) molecular function terms (p<0.05) (as determined by CTD) 





Protein binding 34 1.34E-12 A2M, C1QA, C1QB, C1S, C6, CD4, CD44, CD74, CD8A, CLEC7A, CP, 
CTSC, CXCL13, CYBB, F10, FCER1G, GPNMB, HMOX1, IL1RN, 
ITGAL, LBP, LCP1, MMP9, MSR1, MT2A, NCF1, NPY, PTPRC, RRM2, 
S100A4, S100A9, SPP1, TRH, VIM 
Binding 37 8.77E-10 A2M, C1QA, C1QB, C1S, C6, CD4, CD44, CD74, CD8A, CLEC7A, CP, 
CTSC, CXCL13, CYBB, F10, FCER1G, GPNMB, HMOX1, IL1RN, 
ITGAL, LBP, LCP1, MMP9, MSR1, MT2A, NCF1, NPY, PTPRC, RAC2, 
RRM2, S100A3, S100A4, S100A9, SPP1, TRH, TSPO, VIM 
Receptor binding 13 9.65E-07 CD4, CD74, CD8A, CLEC7A, CXCL13, GPNMB, IL1RN, LBP, NPY, 
S100A4, S100A9, SPP1, TRH 
MHC protein binding 4 2.00E-05 CD4, CD74, CD8A, CLEC7A 
Identical protein binding 11 2.29E-05 C1QB, C1S, CD4, CD74, CD8A, CTSC, HMOX1, LCP1, MMP9, 
S100A4, VIM 
Receptor activity 11 2.03E-03 CD4, CD44, CD74, CD8A, CLEC7A, FCER1G, LGALS3BP, MSR1, 
NPY, PTPRC, TSPO 
Molecular transducer activity 11 3.56E-03 CD4, CD44, CD74, CD8A, CLEC7A, FCER1G, HMOX1, NPY, PTPRC, 
S100A9, TSPO 
Signal transducer activity 11 3.56E-03 CD4, CD44, CD74, CD8A, CLEC7A, FCER1G, HMOX1, NPY, PTPRC, 
S100A9, TSPO 
Ion binding 20 7.93E-03 C1S, CD4, CLEC7A, CP, CTSC, CXCL13, CYBB, F10, GPNMB, 
HMOX1, ITGAL, LCP1, MMP9, MT2A, NCF1, RAC2, RRM2, S100A3, 
S100A4, S100A9 
MHC class II protein binding 2 2.77E-02 CD4, CD74 
Signaling receptor activity 9 3.62E-02 CD4, CD44, CD74, CD8A, CLEC7A, FCER1G, NPY, PTPRC, TSPO 
 
LDH – left dorsal hippocampus, FDW – fear-conditioned + DCS well-adapted, FSM – fear-conditioned + saline maladapted, CTD – 
Comparative Toxicogenomics Database. Refer to Table 4.4 for full gene names 
 
Figure 4.9 illustrates the number of genes for each enriched molecular function. The highest number of genes 






















Figure 4.9: Main molecular function GO terms associated with the biologically relevant differentially expressed 
genes. The x-axis represents the main molecular functions and the y-axis indicates the number of genes enriched for 
each molecular function 
Figure 4.10 indicates which subsets of genes share a common molecular function. The CD4 gene was found 














































Figure 4.10: Integrative network diagram depicting selected subset of the molecular functions that are shared 
between the biologically relevant genes that were differentially expressed between the FDW vs. FSM groups. 
Molecular functions are represented using square blue blocks; one, two, three, four, five, six, eight, nine and ten 
molecular functions are represented using grey, green, blue, yellow, pink, orange, purple and mint green circles, 
respectively. Refer to Table 4.4 for full gene names and Table 4.8 for molecular function GO terms not included in the 
network. FDW – fear-conditioned + DCS well-adapted, FSM – fear-conditioned + saline maladapted 
4.2.3.4 Biochemical pathways associated with biologically relevant differentially expressed genes 
 
The comparative toxicogenomics database (CTD) contains KEGG and REACTOME pathway data that 
represent the current knowledge on the molecular interaction and reaction networks. These networks are 
integrated with genes, chemicals and diseases in CTD to provide insights into molecular networks that may 
be associated with different genes. Table 4.9 contains subsets of biologically relevant differentially expressed 
genes associated with different pathways. 
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Table 4.9: Biologically relevant differentially expressed genes in the LDH of FDW vs. FSM animals that were 
associated with KEGG and REACTOME biochemical pathways (p<0.05) 





Immune System 18 1.24E-14 C1QA, C1QB, C1QC, C1S, C6, CD4, CD44, CD74, CD8A, 




7 1.37E-10 A2M, C1QA, C1QB, C1QC, C1S, C6, F10 
Staphylococcus aureus 
infection 
5 4.22E-07 C1QA, C1QB, C1QC, C1S, ITGAL 




5 1.83E-05 CYBB, ITGAL, MMP9, NCF1, RAC2 
Systemic lupus 
erythematosus 
5 4.13E-05 C1QA, C1QB, C1QC, C1S, C6 
Phagosome 5 1.05E-04 CLEC7A, CYBB, MSR1, NCF1, RAC2 
Primary 
immunodeficiency 
3 8.16E-04 CD4, CD8A, PTPRC 
Cell adhesion molecules 
(CAMs) 
4 1.44E-03 CD4, CD8A, ITGAL, PTPRC 
Tuberculosis 4 4.22E-03 CD74, CLEC7A, FCER1G, LBP 
Antigen processing and 
presentation 
3 7.12E-03 CD4, CD74, CD8A 
Hematopoietic cell 
lineage 
3 1.05E-02 CD4, CD44, CD8A 
Fc gamma R-mediated 
phagocytosis 
3 1.40E-02 NCF1, PTPRC, RAC2 





3 1.67E-02 C1QA, C1QB, C1QC 
Hemostasis 5 1.79E-02 A2M, F10, FCER1G, ITGAL, RAC2 
T cell receptor signaling 
pathway 
3 1.97E-02 CD4, CD8A, PTPRC 
Natural killer cell 
mediated cytotoxicity 
3 4.32E-02 FCER1G, ITGAL, RAC2 
 
KEGG - Kyoto Encyclopedia of Genes and Genomes, LDH – left dorsal hippocampus, FDW – fear-conditioned + DCS well-adapted, 
FSM – fear-conditioned + saline maladapted, CTD – Comparative Toxicogenomics Database. Refer to Table 4.4 for full gene names 
 
  




Figure 4.11 illustrates the number of genes associated with each enriched pathway. Pathways involved in the 
immune system, signal transduction, complement and coagulation cascades as well as hemostasis (the 
process which causes bleeding to stop) had the biggest number of associated genes. Figure 4.12 indicates the 
subsets of genes that share a common biological pathway.  
 
 
Figure 4.11: Main biochemical pathways associated with the biologically relevant differentially expressed genes 
based on KEGG and REACTOME search results. The x-axis shows the main pathways and the y-axis indicates the 


















































Figure 4.12: Integrative network diagram depicting the pathways that are shared between the biologically 
relevant genes that were differentially expressed between the FDW vs. FSM groups. Different pathways are 
represented using large blue circles and one, two, three, four and five, six and seven pathways are represented using 
grey, green, blue, yellow, pink, orange and red circles, respectively. FDW – fear-conditioned + DCS well-adapted, FSM 
– fear-conditioned + saline maladapted. Refer to Table 4.4 for full gene names 
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4.2.4 SYBR Green real-time quantitative PCR gene expression analyses 
 SYBR Green real-time quantitative PCR (qPCR) gene expression analysis was performed to determine if 
this technique would be sensitive enough to detect differential expression of a subset of the statistically 
significant differentially expressed genes identified during the RNAseq analysis. The same LDH cDNA that 
was used for RNAseq, as well as cDNA derived from blood samples were used in the analysis. Real-time 
qPCR analysis was able to detect significant downregulation of six genes (of the nine genes tested) in the 
LDH of FDW compared to the FSM animals (Table 4.10). Metallothionein 2A (MT2A) showed a trend 
towards significant downregulation in the LDH cDNA FDW group with a p-value of 0.06.  
Table 4.10: The nine genes (selected based on fold change and function) investigated with SYBR Green real-time 
qPCR for differential expression in the LDH and blood between FSM and FDW animals 
Differential expression in left dorsal hippocampus  
Gene  Name ANOVA F-
test p-values 
Function 
SPP1 Secreted phosphoprotein 1  0.1 Demyelination  
CXCL13 Chemokine (C-X-C motif) ligand 
13 
0.04 Elevation of cytosolic calcium ion concentration / 
Immune response  
CYBB Cytochrome b-245, beta 
polypeptide  
0.03 Oxidative stress / Nervous system physiology 
IL1RN Interleukin 1 receptor antagonist  0.05 Learning or memory  
S100A4 S100 calcium binding protein A4 0.02 Neuron projection / Calcium ion binding / 
Calcium-dependent protein binding 
TRH Thyrotropin releasing hormone  0.05 Abnormal pituitary gland development 
MMP9 Matrix metallopeptidase 9 0.33 Impaired contextual conditioning behaviour 
MT2A* Metallothionein 2A    0.06 * Abnormal learning/memory/conditioning 
NPY Neuropeptide Y  0.91 
Increased anxiety-related response, abnormal 
depression-related behaviour  
Differential expression in blood  
MMP9 Matrix metallopeptidase 9 0.02 Impaired contextual conditioning behaviour 
 
P-values for six significant differentially expressed genes in the LDH, and one gene in the blood (ANOVA F-tests p < 
0.05) are indicated in red. Only data for the significantly differentially expressed gene in blood, MMP9 is indicated. 
LDH – left dorsal hippocampus, FSM – fear-conditioned + saline maladapted, FDW – fear-conditioned + DCS well-
adapted, qPCR – quantitative PCR, ANOVA – analysis of variance. *MT2A p-value showed a trend towards a 
significant difference in gene expression between FDW and FSM  
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4.3 DNA Methylation Analysis 
 
The subset of genes for which SYBR Green real-time qPCR was used to investigate differential expression 
in the LDH (Table 4.10, p < 0.05) was analysed using EMBL EMBOSS Cpgplot 
(http://www.ebi.ac.uk/Tools/seqstats/emboss_cpgplot/) to determine which of these genes contained CpG 
islands. We selected these genes based on the following (1) for two of the genes (TRH and MT2A) qPCR 
detected differential expression (MT2A showed a trend towards significanctly lower expression in the FDW 
vs. FSM group), (2) these genes have functions that could contribute to PTSD disease pathology (NPY has 
especially been implicated in anxiety disorders) and (3) if DNA methylation mediated the differential 
expression of these genes, results from the RNAseq, real-time qPCR and CpG island methylation would 
form a strong unit.  
 
CpG islands were identified in MT2A, TRH and NPY. The DNA extracted from LDH as well as 
commercially available DNA standards (including 100%, 75%, 50%, 25%, 10%, 5% and 0% methylated 
DNA) from rat pre-mixed methylation controls, were subjected to bisulfite conversion. This was followed by 
real-time qPCR amplification and HRM analyses to determine the percentage methylation at each CpG 
island for each sample. 
There were no significant differences in DNA methylation levels between the FDW and FSM groups in the 
screened CpG islands. For the MT2A CpG island the HRM melting profile of one of the FDW samples 
corresponded to that of the 5% methylated standard; the profiles of all the other samples however, 
corresponded to the 0% methylated standard and were thus unmethylated (Fig. 4.13 A - C). HRM melting 
profiles of NPY and TRH CpG islands all corresponded to the 0% methylation standard and were also 
unmethylated (Fig. 4.13 D - G). In conclusion, there were no significant differences in methylation levels 
between the FDW and FSM groups in the investigated MT2A, NPY and TRH CpG islands and therefore 















MT2A CpG island mehtylation HRM melting profiles 
A. HRM melting profile for DNA methylation standards for the MT2A CpG island 
 
B. HRM melting profiles for FSM and FDW samples for the MT2A CpG island, showing 0% , 5% and 10% 











C. HRM melting profiles for one FDW sample for the MT2A CpG island, showing 0% , 5% and 10% methylated 















E. HRM melting profiles for FSM and FDW samples for the NPY CpG island, showing 0% , 5% and 10% 






F. HRM melting profile for DNA methylation standards for the TRH CpG island 
 
 





G. HRM melting profiles for FSM and FDW samples for the TRH CpG island, showing 0% , 5% and 10% 
methylated standards. The FSM and FDW samples correspond to the 0% methylated standard 
 
 
Figure 4. 13: HRM CpG island methylation analysis for MT2A, NPY and TRH. Figures show normalised HRM 
melt profiles for DNA methylation standards (ranging from 100% methylated to 0% methylated DNA) and the FDW 
and FSM samples for each gene. The x- axis shows the melting temperature range in °C and the y – axis shows 
normalised fluorescence values. HRM – high resolution melt, FSM – fear-conditioned + saline maladapted, FDW – 
fear-conditioned + DCS well-adapted, MT2A - metallothionein 2A, NPY - neuropeptide Y, TRH - thyrotropin releasing 
hormone 
 
4.4  MicroRNA analysis 
 
4.4.1 MicroRNA sequencing data analysis 
The sequencing data from the three flow cells sequenced on the MiSeq® platforms yielded between 654 000 
– 4 998 000 reads per sample, with an average of 1.9 million reads per sample. The quality of the sequencing 
data was high as illustrated by the high phred scores (mostly ≥ 30) (Fig. 4.14). Table 4.11 shows the number 
of reads generated for each sample as well as the number of reads which could be mapped to the Rattus 
novergicus rn4 rat reference genome. Data analysis of the miRNA sequencing data, using GFOLD 
(generalized fold change) count facility (Feng et al., 2012) (which only uses data from mapped reads), 
revealed 23 statistically significant differentially expressed miRNAs between the FDW and FSM groups 
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(Table 4.12). Three of these miRNAs were overexpressed and 20 were underexpressed in the FDW group 
compared to the FSM group.  
Table 4.11: Total amounts of miRNA sequencing reads and number of reads mapped to the reference genome 
(Rattus novergicus rn4) for each sample 
Sample Total amount of sequencing reads Numer and % of reads mapped to the 
reference genome 
FDW 1 7 249 534 79 721 (1.10%) 
FDW 2 23 321 721 11 129 939 (47.72%) 
FDW 3 6 227 221 2 041 530 (32.78%) 
FDW 4 7 803 393 4 275 386 (54.79%) 
FDW 5 3 737 149 1 473 210 (39.42%) 
FDW 6 3 410 516 1 843 431 (54.05%) 
FSM 1 4 016 154 198 989 (4.95%) 
FSM 2 9 929 794 575 982 (5.80%) 
FSM 3 15 840 090 223 005 (1.41%) 
FSM 4 3 465 502 241 319 (6.96%) 
FSM 5 9 356 673 1 466 464 (15.67%) 
FSM 6 3 905 285 2 103 946 (53.87%) 
 
FDW – fear-conditioned + D-cycloserine well-adapted, FSM – fear-conditioned + saline maladapted 
 
 
Figure 4.14: Distribution of phred (Q) score in reads. The x-axis indicates the bp position in the 50 bp read and 
the y-axis indicates the phred score at each position. The phred scores are usually lower at the start and end points 
and should be trimmed if the per base quality score is below 20  
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Table 4.12: Statistically significant differentially expressed miRNAs between the FDW and FSM groups as 
identified by GFOLD (generalized fold change) count facility (Feng et al., 2012). Positive fold change values 
indicate miRNAs that were upregulated in the FDW vs. FSM and negative values indicate downregulated miRNAs in 
FDW vs. FSM 
Gene Symbol miRNA Fold Change Associations of interest to the study 
MI0000932 rno-mir-187-3p 1.27 ↑ following ECT treatment in Ms rat model (O'Connor et al., 2013) 
MI0000872 rno-mir-31a-5p 1.1 ↑ in NSCs vs. MN (Wei et al., 2010) 
   ↓following differentiation of adipose-derived stem cells (Wei et al., 
2010) 
   ↑ in NSC vs. MN (Wei et al., 2010) 
MI0015412 rno-mir-31b 1.08  
MI0015476 rno-mir-3120 -1.50 Mirror miRNA located in neuronal cell bodies (Scott et al., 2012) 
MI0021852 rno-mir-6328 -1.47  
MI0006168 rno-mir-488-3p -0.94 Hsa-mir-488 tagged SNPs associated with different panic disorder 
phenotypes (Muiños-Gimeno et al., 2011) 
MI0012585 rno-mir-490-3p -1.11 ↑ in liver and serum of alcoholic steatohepatitis (Chen et al., 2013) 
↑ in insulin resistant adipocytes of mice (Ling et al., 2009) 
MI0012590 rno-mir-362-5p -1.59  
MI0012606 rno-mir-665 -1.55  






MI0000963 rno-mir-223-3p -1.71 
 
 
MI0000917 rno-mir-144-3p -1.55 
 
↑ hippocampal expression following chronic lithium and sodium 
valproate treatment in rats (Zhou et al., 2009) 
   ↑ following KET treatment in Ms rat model (O'Connor et al., 2013) 
   ↓ following FLU treatment in Ms rat model (O'Connor et al., 2013) 
MI0000922 rno-mir-153-3p -1.24 
 
 
MI0000842 rno-miR-10b-5p -1.40 
 
↓ following KET treatment in Ms rat model (O'Connor et al., 2013) 
MI0000850 rno-miR-21-5p -1.29 
 
Glial cell differentiation (Chan et al., 2005) 
MI0000620 rno-mir-339-3p -1.48 
 
Hso-mir-339 tagged SNPs associated with panic disorder (Muiños-
Gimeno et al., 2011) 
   5p ↓ following KET treatment in Ms rat model (O'Connor et al., 
2013) 
   3p ↑ following ECT treatment in Ms rat model (O'Connor et al., 
2013) 
   5p ↓ following ECT treatment in Ms rat model (O'Connor et al., 
2013) 
MI0000936 rno-mir-193-3p -1.77 
 
↓ following ECT treatment in Ms rat model (O'Connor et al., 2013) 
Stellenbosch University  https://scholar.sun.ac.za
120 
 
MI0015405 rno-mir-3549 -1.78  





3p ↓ following KET treatment in Ms rat model (O'Connor et al., 
2013) 
   5p↑ following KET treatment in Ms rat model (O'Connor et al., 
2013) 
   3p ↓ following ECT treatment in MS rat model (O'Connor et al., 
2013) 
   5p ↑ following ECT treatment in Ms rat model (O'Connor et al., 
2013) 
MI0001731 rno-mir-451-5p -1.90 
 
Expression of mmu-miR-451 correlated with behavioural measures 
for exploration on the elevated plus-maze task and learning and 
memory measures (Parsons et al., 2008) 
 
   ↓ following FLU treatment in Ms rat model (O'Connor et al., 2013) 
   ↓ following KET treatment in Ms rat model (O'Connor et al., 2013) 
   ↓ following ECT treatment in Ms rat model (O'Connor et al., 2013) 
MI0006121 rno-mir-879-5p -1.70 
 
 
With regards to miRNA nomenclature, 3p and 5p indicates that the mature miRNA originated either from the 3’ or the 
5’ arm. Hsa – Homo sapiens, rno - Rattus norvegicus, mmu – Mus musculus, SNP – single nucleotide polymorphism, 
NSC – neuronal stem cells, MSC – mature stem cells, MN – motor neurons, ECT - electroconvulsive shock therapy, Ms 
- maternal separation, FLU – fluoxetine, KET – ketamine, mir – miRNA, ↓ - downregulated, ↑ - upregulated 
 
4.4.2 MicroRNA target enrichment analysis 
Ingenuity pathway analysis (IPA) software program was used to perform miRNA target enrichment analysis, 
facilitating the identification of common networks shared between the differentially expressed miRNAs, 
based on the functions of their mRNA targets (Table 4.13). Furthermore, miRNA expression data was 
integrated with RNAseq expression profiles of biologically relevant differentially expressed genes (of the 
current study) to identify possible miRNA targets within this gene set (Table 4.14). IPA utilizes miRecords 
(http://mirecords.umn.edu/miRecords/), TargetScan human (http://www.targetscan.org/) and TarBase 
(http://www.microrna.gr/tarbase) to predict mRNA targets of the differentially expressed miRNAs. 
Additional manual searches were performed on databases that included Rattus norvegicus in the species list 
(MicroCosm, microrna.org and DIANA lab). Two miRNAs, rno-mir-187-3p and rno-mir-31a-5p, were 
significantly upregulated and were predicted to target several genes that were downregulated in the 
biologically relevant differentially expressed gene set (Table 4.14, Fig. 4.15).  
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Table 4.13: Common functions shared between differentially expressed miRNAs, based on the functions of their 
mRNA targets as predicted by Ingenuity Pathway Analysis (IPA). 
Top Functions Number of 
miRNAs 
MiRNAs in Network 
Reproductive system disease, Cellular 
movement, Hair and skin 
development and function 
11 mir-31a, mir-193, miR-144-3p, miR-153, 
miR-187-3p, miR-193a-3p, miR-31a-5p, 
miR-31b, miR-3549, 
miR-490-3p, miR- 665 
Cancer, Tumor morphology, 
Cardiovascular system development 
and function 
9 mir-214, miR-10b-5p, miR-21-5p, miR-223-3p, 
miR-3120,miR-33-5p, miR-362-5p, miR-451, 
miR-488-3p, miR-879-5p 
 
Table 4.14: Differentially expressed miRNAs, as identified by GFOLD, and their predicted mRNA targets, 
within the 42 biologically relevant differentially expressed gene set, as predicted by different software programs. 
Expression pairing show the direction of miRNA:mRNA expression regulation. Negative log-2 fold values denote 
down-regulated and positive values denote up-regulated miRNAs in the FDW group compared to the FSM group 











rno-mir-187 rno-mir-187-3p  1.273 
TargetScan 
human 
Moderate (predicted) ↑↓ A2M 
rno-mir-187 rno-mir-187-3p 1.273 
TargetScan 
human 
High (predicted) ↑↓ C1S 
rno-mir-187 rno-mir-187-3p 1.273 
TargetScan 
human 
Moderate (predicted) ↑↓ S100A4 
rno-mir-187 rno-mir-187-3p 1.273 
MicroCosm 
 
Moderate (predicted) ↑↓ CD4 
rno-mir-187 rno-mir-187-3p 1.273 
MicroCosm 
microRNA.org 
Moderate (predicted) ↑↓ CD44 
       
rno-mir-193 rno-mir-193-3p -1.770 
TargetScan 
human 
Moderate (predicted) ↓↓ C1QC 
rno-mir-193 rno-mir-193-3p -1.770 
MicroCosm 
microRNA.org 
Moderate (predicted) ↓↓ S100A4 







Moderate (predicted) ↓↓ TSPO 
rno-mir-19b-1 rno-mir-19b-1-3p -0.206 microRNA.org Moderate (predicted) ↓↓ CXCL13 
rno-mir-19b-1 rno-mir-19b-1-3p -0.206 microRNA.org Moderate (predicted) ↓↓ RRM2 
rno-mir-144 rno-mir-144-3p -0.259 
MicroCosm 
microRNA.org 
Moderate (predicted) ↓↓ GPNMB 
rno-mir-144 rno-mir-144-3p -0.259 
MicroCosm 
 
Moderate (predicted) ↓↓ ANXA3 
rno-mir-153 rno-mir-153-3p -0.259 
MicroCosm 
 
Moderate (predicted) ↓↓ GPNMB 
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rno-mir-153 rno-mir-153-3p -0.259 
MicroCosm 
microRNA.org 
Moderate (predicted) ↓↓ C1S 
rno-miR-219-1 rno-miR-219-1-5p -0.541 microRNA.org Low (predicted) ↓↓ IL1RN 
rno-miR-219-1 rno-miR-219-1-5p -0.541 microRNA.org Low (predicted) ↓↓ CTSC 
rno-mir-223 rno-mir-223-3p -1.715 
TargetScan 
human 
Moderate (predicted) ↓↓ CD44 
rno-mir-223 rno-mir-223-3p -1.715 
TargetScan 
human 
Moderate (predicted) ↓↓ MSR1 









rno-mir-223 rno-mir-223-3p -1.715 microrna.org Moderate (predicted) ↓↓ PTPRC 
rno-mir-223 rno-mir-223-3p -1.715 microrna.org Moderate (predicted) ↓↓ CHRDL1 
rno-mir-31a rno-mir-31a-5p 1.097 
TargetScan 
human 
Moderate (predicted) ↑↓ IL1RN 
rno-mir-31a rno-mir-31a-5p 1.097 
TargetScan 
human 
Moderate (predicted) ↑↓ RAC2 
rno-mir-31a rno-mir-31a-5p 1.097 MicroCosm Moderate (predicted) ↑↓ HMOX1 
rno-mir-3120 rno-mir-3120 -1.502 
TargetScan 
human 
High (predicted) ↓↓ MSR1 
rno-mir-33 rno-mir-33-5p -1.409 
TargetScan 
human 
Moderate (predicted) ↓↓ MSR1 
rno-mir-33 rno-mir-33-5p -1.409 
TargetScan 
human 
High (predicted) ↓↓ SPP1 
rno-mir-33 rno-mir-33-5p -1.409 MicroCosm Moderate (predicted) ↓↓ NPY 
rno-mir-33 rno-mir-33-5p -1.409 MicroCosm Moderate (predicted) ↓↓ SAT 
rno-mir-339 rno-mir-339-3p -1.475 MicroCosm Moderate (predicted) ↓↓ LYZ2 
rno-mir-339 rno-mir-339-3p -1.475 MicroCosm Moderate (predicted) ↓↓ MMP9 
rno-mir-339 rno-mir-339-3p -1.475 MicroCosm Moderate (predicted) ↓↓ RAC2 
rno-mir-362 rno-mir-362-5p -1.586 
TargetScan 
human 
Moderate (predicted) ↓↓ CTSC 
rno-mir-362 rno-mir-362-5p -1.586 
TargetScan 
human 
Moderate (predicted) ↓↓ LCP1 
rno-mir-451 rno-mir-451-5p -0.750 MicroCosm Moderate (predicted) ↓↓ PTPRC 
rno-mir-488 rno-mir-488-3p -0.945 
TargetScan 
human 
Moderate (predicted) ↓↓ CTSC 
rno-mir-488 rno-mir-488-3p -0.945 
TargetScan 
human 
High (predicted) ↓↓ S100A3 




High (predicted) ↓↓ VIM 
rno-mir-488 rno-mir-488-3p -0.945 microrna.org Moderate (predicted) ↓↓ RMR2 
rno-mir-490 rno-mir-490-3p -1.114 
TargetScan 
human 
High (predicted) ↓↓ CHRDL1 
rno-mir-490 rno-mir-490-3p -1.114 TargetScan Moderate (predicted) ↓↓ GPNMB 




rno-mir-665 rno-mir-665 -1.549 
TargetScan 
human 
High (predicted) ↓↓ CD4 
rno-mir-665 rno-mir-665 -1.549 
TargetScan 
human 
Moderate (predicted) ↓↓ CP 
rno-mir-665 rno-mir-665 -1.549 
TargetScan 
human 
Moderate (predicted) ↓↓ MSR1 
rno-mir-879 rno-mir-879-5p -1.701 
TargetScan 
human 
High (predicted) ↓↓ CXCL13 
rno-mir-879 rno-mir-879-5p -1.701 
TargetScan 
human 
Moderate (predicted) ↓↓ LCP1 
rno-mir-879 rno-mir-879-5p -1.701 MicroCosm Moderate (predicted) ↓↓ CLEC7A 
 
FDW – fear-conditioned + DCS well-adapted, GFOLD - generalized fold change count facility, rno - Rattus norvegicus, mir – 
miRNA, ↓ shows downregulation, ↑ shows upregulation, Refer to Table 4.4 for full mRNA target gene names 
 
 
Figure 4.15: Integrative miRNA target enrichment. Integrative target enrichment diagram depicting the 
upregulated miRNAs in red circles and the downregulated genes (from the RNAseq data) predicted to be 
targeted by the upregulated miRNAs, in green circles. HMOX - heme oxygenase (decycling) 1, RAC2 - ras-related 
C3 botulinum toxin substrate 2, IL1RN - interleukin 1 receptor antagonist, CD4 - T cell surface glycoprotein CD4 
molecule, S100A4 - S100 calcium binding protein A4, C1S - complement component 1, s subcomponent, A2M - Alpha-
2-macroglobulin, mir – miRNA, rno - Rattus norvegicus, mir - miRNA   
  
Stellenbosch University  https://scholar.sun.ac.za
124 
 
4.4.3 SYBR Green real-time qPCR expression analysis for rno-miRNA-31a-5p in LDH 
and blood  
Rno-miRNA-31a-5p was one of the significantly upregulated miRNAs identified in the miRNA sequencing 
analyses and was selected to be used for SYBR Green real-time qPCR expression analysis. This particular 
miRNA was selected for the following reasons: (1) its potential association with anxiety related traits (Parsons 
et al., 2012), (2) it is predicted to target IL1RN, which was four-fold downregulated in the FDW vs. FSM 
group and (3) its target gene, IL1RN, is also predicted to be involved in learning or memory processes (Palin et 
al., 2004). The aim was to determine whether SYBR Green real-time qPCR is sensitive enough to detect 
differential expression of this miRNA in the LDH and in blood samples between FDW and FSM animals. The 
small nuclear RNA (snRNA) component of U6 small nuclear ribonucleoprotein (snRNP) was used for 
normalisation. SYBR Green real-time qPCR expression was not able to detect a significant difference in the 
expression level of rno-miRNA-31a-5p between FDW and FSM animals in either the LDH cDNA (p = 0.35) 
or blood cDNA (p = 0.65) samples (ANOVA F-test). 
4.4.4 Functional analysis of miRNA-target interaction 
In order to determine whether rno-miR-31a-5p directly targeted IL1RN, as predicted by the software programs, 
a luciferase reporter assay was performed, using the GLuc-ONTM Promoter Reporter Clones assay kit. Results 
from the mixed model repeated measures ANOVA indicated that co-transfection of a promoter clone 
containing the 3' UTR sequence of IL1RN and the rno-miR-31a-5p precursor clone, resulted in significantly 
lower luciferase activity compared to co-transfection of the miRNA precursor clone and a scrambled 3’ UTR 
control clone (p < 0.05) (Fig. 4.15). This suggested that rno-miR-31a-5p did bind to the mRNA target region 
of IL1RN. However, when the luciferase signal was compared to that of the other negative controls, namely 
the scrambled miRNA precursor clone + IL1RN promoter reporter clone and the IL1RN promoter reporter 
clone without any miRNA precursor, no statistically significant differences were detected in the luciferase 
signals. 




Figure 4.16: Functional luciferase analysis of miRNA-target interaction. Relative light units (RLU) of GLuc signal 
normalised to SEAP signal for each of the four different co-transfections into HEK 293 cells. HEK 293 cells co-
transfected with the rno-miR-31a-5p precursor clone and IL1RN promoter reporter clone, showed significantly lower 
luciferase activity (18.16 ± 5.7) compared to cells co-transfected with the rno-miR-31a-5p precursor clone and a 
scrambled 3’ UTR control clone (103.32 ± 12.655) (* p < 0.05) (mixed model repeated measures ANOVA). The data 
shown are the means ± SEM (standard error of the mean) of two independent experiments performed in duplicate. GLuc 
- Gaussia luciferase, SEAP - secreted Alkaline Phosphatase, RLU – relative light units, HEK 293 cells - Human 
Embryonic Kidney 293 cells, rno-miR31a-5p - rno-miR-31a-5p precursor clone, IL1RN - Interleukin 1 receptor 
antagonist promoter reporter clone, scr 3’ UTR – scrambled three prime untranslated region negative control reporter 
clone, scr miR – scrambled miRNA negative control precursor clone.  




The current study investigated the molecular mechanisms underlying DCS-facilitated fear extinction in a 
PTSD animal model by investigating gene expression and epigenetic profiles in the LDH of male Sprague 
Dawley rats. The key findings of the study were firstly that co-administration of DCS and behavioural fear 
extinction downregulates genes that facilitate neuroinflammation, namely immune system genes, 
proinflammatory genes and genes involved in oxidative stress. Secondly, co-administration of DCS and 
behavioural fear extinction downregulated genes that are associated with processes in anxiety- and stress-
related disorders, such as PTSD, as well as genes that are associated with disorders that often occur 
comorbidly with PTSD. In addition, DCS was found to downregulate genes that are involved in fear and 
anxiety, such as TRH (Wittmann et al., 2009; Lisowski et al., 2013), CYBB (Nair et al., 2011; Rammal et al., 
2008; Hovatta et al., 2005; Masood et al., 2008; Schiavone et al., 2009), and genes transcribing S100 
proteins (Ackermann et al., 2006). Moreover, DCS downregulated genes implicated in learning and memory, 
such as IL1RN (Oprica et al., 2005; Spulber et al. 2009) and TRH (Aguilar-Valles et al., 2007).  
Epigenetic analyses indicated that CpG island DNA methylation of the investigated genes, did not mediate 
differential expression of those genes. Co-administration of DCS and behavioural fear extinction did, 
however, result in differential miRNA expression, and functional analysis suggested that the differential gene 
expression induced by DCS may have been mediated through differential expression of miRNAs.  
The following paragraphs will briefly discuss the animal behavioural data. At this juncture, it should be 
noted that the animal behavioural data was not the focus of the current study, and was conducted by a fellow 
student. This is followed by a discussion of the GO enrichment analyses results and a more focussed 
discussion on a subset of the 42 biologically relevant differentially expressed genes, including those genes 
exhibiting the largest fold changes, genes for which differential expression was replicated using real-time 
qPCR as well as genes that have been described in literature to be involved in learning, memory and 
neuroinflammation. The chapter concludes with a discussion of the epigenetic results, including DNA 
methylation analysis, miRNA expression analysis as well as miRNA and gene expression correlation and 
functional miRNA analysis.  
5.1 Central and peripheral effectors of the stress system 
 
In order to adequately interpret molecular results from studies on stress-related disorders, it is imperative to 
understand the stress process and the downstream effects that stress elicits on an organism as a whole. The 
major CNS effectors of the stress system include hormones involved in the HPA axis (corticotropin-releasing 
hormone, arginine and vasopressin) and the pro-opiomelanocortin-derived peptides (α-melanocyte 
stimulating hormone, β-endorphin and norepinephrine which is produced in the locus coeruleus and 
autonomic norepinephrine centres in the brainstem) (Chrousos and Gold 1992; Charmandari et al., 2005). 
The main peripheral effectors are glucocorticoids, regulated by the HPA axis, and the catecholamines 
(epinephrine and norepinephrine), regulated by the systemic and adrenomedullary sympathetic nervous 
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system. These effectors target several systems, including the executive, cognitive, reward, fear and growth 
systems, and reproductive and thyroid hormone axes (Chrousos and Gold 1992; Chrousos, 1998), the 
circadian centres of the brain (Chrousos 2007; Vgontzas et al., 2003, 2004, 2007), gastrointestinal (Chrousos 
2007; Taché and Bonas 2007), cardiorespiratory (Blanchard et al., 1990; Fredrikson and Matthews 1990; 
Georgiades and Fredrikson 2000; Buckley et al., 2001), metabolic (Goodwin et al., 2005; Lauterbach et al., 
2005; Trief et al., 2006; Qureshi et al., 2009; Boyko et al., 2010; Pietrzak et al., 2012; Lukaschek et al., 
2013; Dedert et al., 2010), and immune systems (Chrousos 1995; Chrousos 2000; Karalis et al., 1991; 
Elenkov et al., 2008). Dysregulation of the basal activity of this stress system could therefore result in a 
multitude of psychiatric, behavioural as well as somatic pathological conditions (Fig. 5.1). Throughout the 
discussion, the reader will be referred to Figure 5.1, which illustrates how stress and other factors, such as 
genetic variation, influences the stress system and different target tissues, which could ultimately lead to the 
development of various pathological conditions.  
 
 
Figure 5.1: Chronic stress interacts with multiple environmental and genetic factors which subsequently 
influence the levels of various hormones and neurotransmitters. Altered profiles of hormones and neurotransmitters 
may ultimately contribute to the development of various diseases, such as metabolic syndrome, sleep disturbances, 
osteoporosis, inflammatory diseases, cardiovascular and neurovascular diseases and problems with the reproductive 
system. ABP – arterial blood pressure, ACTH - adrenocorticotropin hormone, APR – acute-phase reactants, AVP - 
arginine vasopressin, CRH - corticotropin-releasing hormone, iCRH – immune CRH, E – epinephrine (adrenalin), E2 – 
estradiol, GH – growth hormone, HPA - hypothalamic–pituitary–adrenal, IGF-I – insulin-like growth factor I, IL-6 – 
interleukin 6, LC – locus coeruleus, LH – luteinizing hormone, NE – norepinephrine, T – testosterone, TG - 
triglycerides (adapted from Chrousos, 2009) 
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5.2  PTSD animal model 
 
The L/D avoidance test was compared to the other behavioural tests performed, namely the FST (forced 
swim test) and the OF tests, and was found to be the most sensitive behavioural test to detect the effects of 
fear conditioning and fear extinction. The L/D avoidance test showed statistically significant differences 
between the FS group and the CS group (fear conditioning), where the FS animals displayed more fearful 
behaviour than the CS animals. Furthermore, in the L/D avoidance test there was a statistically significant 
difference between the FS and FD animals (fear extinction). The other behavioural tests (FS test and the OF 
tests) either did not show statistically significant differences between all the aforementioned group 
comparisons or the differences were less significant compared to the L/D avoidance tests.  
 
The results from the L/D avoidance test were thus subsequently used as the behavioural test on which to base 
the selection of well-adapted (WA) and maladapted (MA) subgroups within the fear-conditioned + saline 
(FS) and fear-conditioned + DCS (FD) groups. Statistical analyses of the L/D avoidance test behavioural 
data showed that there was a statistically significant difference between the FS group and all the other 
groups, with the FS group spending significantly more time in the dark compartment (Fig. 4.1A, Table 4.1, 
Section 4.1), indicative of anxiogenic or stress-related behaviour (Bourin and Hascoët, 2003). These results 
suggest that the modified animal model had face validity; where the model reproduced symptoms associated 
with the human syndrome (such as avoidance). Furthermore, based on the results from the L/D avoidance 
test, the fear conditioning paradigm used in the present study was successful in eliciting a significant fearful 
response in the fear-conditioned animals compared to animals that were not fear-conditioned. This indicated 
construct validity of the modified animal model as the L/D avoidance test measured what it was intended to 
measure, namely anxiety and stress-related behaviour. There was also a statistically significant difference 
detected between the control + saline (CS) group compared to all the other groups (Fig. 4.1A, Table 4.1, 
Section 4.1), where the CS group spent significantly more time in dark compartment. The significant 
difference between the CS and the CD was an unexpected result, as, in human studies, DCS is known to only 
elicit its anxiolytic effects when co-administered with behavioural fear extinction/CBT (Smits et al., 2013; de 
Kleine et al., 2012; Richardson et al., 2004). One explanation could be that outliers may have caused this 
effect, since after sub-group selection for the CD and CS groups, where 12 animals with behavioural values 
closest to the group mean were selected, there were no statistically significant group differences.  
 
There were no statistically significant differences in the time spent in the dark compartment between the CD 
and FD groups (Fig. 4.1A, Table 4.1, Section 4.1). This result might suggest that the fear extinction induced 
by the co-administration of DCS and behavioural fear extinction was effective to such an extent that the 
animals in this group had behavioural parameters similar to those of the control group.  
 
Furthermore, statistical analyses of the behavioural data of the WA and MA groups confirmed that there was 
indeed a statistical significant difference between MA and WA animals (Fig. 4.1 C, Table 4.2, Section 4.1); 
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WA animals spent significantly less time in the dark compartment. Furthermore, FDW animals spent 
significantly less time in the dark compartment compared to the FSM animals, which served as confirmation 
that the behavioural test used to group the animals into subgroups (the L/D avoidance test), was indeed 
suitable and that the phenotypes of these two subgroups can be utilized for correlations with downstream 
genetic and epigenetic results pertaining to fear conditioning and extinction. Another statistically significant 
difference was observed between the FSW and FDW animals (Fig. 4.1 D, Table 4.2, Section 4.1), where the 
FDW animals exhibited more anxiolytic behaviour compared to the FSW animals, indicating that co-
administration of DCS and fear extinction was more effective in extinguishing fear than fear extinction 
alone. 
5.3  Differential gene expression analysis 
Next generation RNA sequencing data was analysed using bioinformatics tools (TopHat, Bowtie, Cuffdiff 
and BORG analysis tool) and the following between-group gene expression profiles were compared (Table 
5.1):  
Table 5.1: Different treatment groups that were used in the between-group gene expression profile comparisons 
Groups Processes associated with genes differentially expressed between groups  
FSM vs. CS fear conditioning in fear-conditioned compared to control animals 
FSW vs. FSM fear conditioning that could pertain to resilience or susceptibility to stress 
FDW vs. FDM efficacy of the drug in fear conditioning or resistance to the drug 
FDW vs. FSM fear extinction induced by DCS 
FDW vs. FSW fear extinction induced by DCS as opposed to the “natural” process of fear extinction 
CD vs. CS effects of DCS in the absence of fear conditioning and behavioural fear extinction 
 
FSM - fear-conditioned + saline maladapted, CS - control + saline, FSW - fear-conditioned + saline well-adapted, FSM 
- fear-conditioned + saline maladapted, FDW - fear-conditioned + DCS well-adapted, FDM - fear-conditioned + D-
cycloserine maladapted 
 
Bio-ontological relationship graph (BORG) analysis was used to identify biologically relevant genes that 
could be associated with processes relating to fear conditioning, fear extinction, anxiety, memory and stress 
(i.e. any phenotypes associated with anxiety or PTSD). The main comparison group in the current study was 
FDW vs. FSM. From the total of 93 genes that were downregulated in the FDW group compared to the FSM 
group, 42 genes were identified as biologically relevant for the purposes of the present study. Only one gene, 
CYR61, was upregulated in the FDW group compared to the FSM group, however the BORG analysis did not 
detect this gene as biologically relevant. The general functions of the protein transcribed by this gene 
(provided by RefSeq 2011) is to promote the adhesion of endothelial cells and it also plays a role in cell 
proliferation, differentiation, angiogenesis, apoptosis and extracellular matrix formation 
(http://www.ncbi.nlm.nih.gov/gene?cmd=Retrieve&dopt=full_report&list_uids=3491). The current study 
hypothesised that some of these biologically relevant, differentially expressed genes, are possibly involved in 
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the fear extinction process, as there were no significantly differentially expressed genes between the CS and 
CD animals, suggesting that DCS administration in the absence of fear conditioning and behavioural fear 
extinction, did not induce differential gene expression.  
 
In the FSW vs. FSM comparison (which would identify genes possibly involved in the “natural” process of 
fear extinction), three of the genes that were overexpressed in the FSW group compared to the FSM group, 
were found to be downregulated in the FDW group compared to the FSM. Initially, this result appeared to be 
counterintuitive, as both of these groups are well-adapted but in the FSW group these three genes are 
upregulated whereas in the FDW these same three genes are downregulated relative to the FSM group. 
However, when comparing the FDW to the FSW group, the same three genes, together with 32 other genes, 
were found to be downregulated in the FDW group compared to the FSW group (Table II.1, Appendix II). 
Genes that are differentially expressed between these groups (FDW vs. FSW) point to genes associated with 
DCS induced fear extinction pathway compared to the “natural” fear extinction pathway. It is therefore 
hypothesised that DCS-induced fear extinction possibly incorporates different genes and/or pathways 
compared to the “natural” processes of fear extinction. Furthermore, with reference to the L/D avoidance test 
results (Fig. 4.1 and Table 4.2, Section 4.1), where the FDW animals spent significantly less time in the dark 
compartment compared to the FSW animals, it is hypothesised that DCS administration in conjunction with 
the behavioural fear extinction (in the FDW group) was more effective in extinguishing fear compared to the 
behavioural fear extinction alone (in the FSW group).  
 
One gene, CXCL13, was found to be biologically relevant and significantly downregulated in the FSM group 
compared to the CS groups. This was an unexpected result, as this gene was also found to be downregulated 
in the FDW vs. FSM groups, the FDW vs. FSW groups, the FDW vs. CS groups and the FSM vs. FSW 
groups. The fact that we see this gene differentially expressed between FDW vs. FSM as well as FDW vs. 
FSW suggests that this gene may be associated with a DCS-induced fear extinction pathway that is distinct 
from the “natural” fear extinction pathway.  
 
Biological interpretation of large sets of differentially expressed genes can be improved by grouping genes 
together based on their functional similarity (Cline et al., 2007). Therefore, in the current study, GO 
enrichment analyses were performed to gain insight into the biological processes, diseases, molecular 
functions and pathways that these genes were associated with or involved in. Biologically relevant genes that 
were differentially expressed in FDW compared to FSM rats will be discussed in the following way: firstly 
the GO data will be discussed with regards to biological processes, diseases, molecular functions and 
pathways, after which the focus will be narrowed down to specific genes.  
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5.3.1 DCS downregulates immune system genes and proinflammatory molecules that 
facilitate neuroinflammation 
The most enriched biological process in our dataset was immune response (p = 9.21E-21), with 24 of the 
biologically relevant differentially expressed genes associated with this process (Table 4.5, Figs. 4.3 – 4.5). 
Included in this set of genes were genes that transcribe complement components (C6, C1QB, C1S, C1QA), 
glycoproteins (CD4, CD44), cytokines (IL1RN), lipopolysaccharide-binding protein (LBP), alpha-2-
macroglobulin (A2M), and cytochromes (CYBB). In addition, seven of the differentially expressed genes 
were also associated with the process of immune system development. The importance of the 
interrelationship between the CNS and immune systems has become more apparent in recent years and is 
best illustrated in the context of the innate immune system. The innate immune system is genetically 
programmed to respond to specific pathogen-derived or other danger signals. It sets a signal transduction 
cascade in motion which results in the release of proinflammatory cytokines and chemokines that neutralize 
pathogens and initiate tissue repair (Jones and Thomsen 2013). Research has shown that immune functioning 
is affected in individuals suffering from PTSD (Watson et al., 1993; Arranz et al., 2007). This has been 
attributed to the continuous state of sympathetic hyperarousal which is typical of the disorder (Wong et al., 
2000; Geracioti et al., 2001; Paulus and Stein, 2006). Previously published gene expression analyses have 
also detected dysregulated expression of immune-related genes (Zieker et al., 2007; Yehuda et al., 2009; 
Glatt et al., 2013; Neylan et al., 2011).  
Appropriate immune responses are vital for survival; however, dysregulated inflammatory and oxidative 
stress responses may result in cellular injury and even cell death (Lee et al., 2001; Marques et al., 2003; 
Andersen, 2004; Hovatta et al., 2010). Subsequently, cellular injury produces excess toxic substances which 
promote further inflammatory cascades and additional cellular toxicity (Licinio and Wong, 1997, 2003). 
CNS inflammation does not only originate in response to bacterial or viral infection, but could also develop 
as a consequence of endogenous neurotoxin production or variations in the protein oxidation and reduction 
balance, such as those occurring during the aging process, and neurodegenerative and autoimmune disorders 
(Glass et al., 2010; Bhat and Steinman, 2009). Furthermore, four of the biologically relevant differentially 
expressed genes in the present study were associated with the reactive oxygen species metabolic process 
biological process GO term (Table 4.5, Section 4.2.3.1). Increased oxidative stress could result in further 
increased inflammatory responses.  
Recent research has indicated that the immune system has functions within the CNS beyond that of 
inflammation and neuroprotection, providing evidence for the involvement of immune system mediators in 
central behavioural functions including adult neurogenesis and processes underlying synaptic plasticity (such 
as learning and memory) (Khairova et al., 2009; McAfoose and Baune, 2009; Ransohoff, 2009; Yirmiya and 
Goshen, 2011). The involvement of the immune system in the response to psychological stress, apart from 
infectious or physical injury, has initiated a paradigm shift with regards to the understanding of the 
interrelations of immune system, brain and behaviour (Kioussis and Pachnis, 2009; McAfoose and Baune, 
2009; Besedovsky and Del Rey, 2011; Molina-Holgado and Molina-Holgado, 2010; Schwartz and Shechter, 
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2010). According to this emerging model, the immune and nervous systems evolved together and they share 
numerous cellular, molecular and genetic mechanisms (such as gene regulation, cellular communication, 
signalling and supracellular organization). The model also states that the cascades that are induced (under 
normal conditions or in response to physical, psychological or infectious challenges) are tightly regulated, 
and aid in the maintenance of sufficient metabolic, adaptational and defensive functions. Lastly, the model 
states that the brain is supported by the immune system; where sufficient immune functioning is essential for 
learning and memory under basal conditions, and supports optimal stress-coping responses (Meffert and 
Baltimore, 2005; Kioussis and Pachnis, 2009; Besedovsky and Del Rey, 2011; Molina-Holgado and Molina-
Holgado, 2010; Schwartz and Shechter, 2010; Su et al., 2010; Yirmiya and Goshen, 2011).  
There is a growing body of literature that describes how acute and chronic stress contribute to the activation 
of the innate immune system, causing peripheral inflammation, which has been found to be associated with 
early morbidity and mortality (Elenkov et al., 2005; Fransson et al., 2010; Wassel et al., 2010; Gianaros and 
Manuck, 2010; Seeman et al., 2010). PTSD is one of the disorders that has been found to be associated with 
higher CNS reactivity, increased inflammation and a deteriorating state of health (Baker et al., 2003, 2012). 
Pre-clinical research has shed light on the functions of immune cells (such as astrocytes and microglia), 
proinflammatory cytokines (including IL-6 and IL-1), and tumor necrosis factor alpha (TNF-α) in vital brain 
functions such as learning and memory. These factors interact with neuronal glutamate and GABA signalling 
to control long-term potentiation (LTP) and facilitate neurogenesis. Therefore, the immune system could 
contribute to the resolution or exacerbation of fear memories following exposure to a trauma (Tambuyzer et 
al., 2009; Verkhratsky, 2010; Yirmiya and Goshen, 2011). Furthermore, pre-clinical research provides 
evidence to suggest that, in the context of stress, components of the acquired immune system, such as 
protective T cells, can be transported to the CSF blood brain barrier (BBB) interface by means of molecules 
such as chemokines and glucocorticoids (Lewitus et al., 2008; Ransohoff, 2009). These protective T cells are 
hypothesized to have a neuroprotective function during conditions of infection, injury or emotional or 
psychological stress (Miller, 2009; Schwartz and Shechter, 2010).  
The results from the current study correlate with previous research that has found PTSD to be associated 
with dysregulated expression profiles of immune-related genes (Zieker et al., 2007; Yehuda et al., 2009; 
Glatt et al., 2013; Neylan et al., 2011). Additionally, in light of the functions of immune cells in learning and 
memory, it can be postulated that co-administration of DCS and behavioural fear extinction induces the 
downregulation of these immune-related and proinflammatory genes, and therefore attenuates 
neuroinflammation and learning and memory deficits, which contributes to the facilitation of fear extinction. 
In addition to several complement components being associated with the immune response process, results 
from GO analysis indicated that six genes were also associated with the complement activation process. The 
complement components that were downregulated in the FDW group compared to the FSM group were 
mostly from the classical complement pathway (C1QA, C1QB, C1QC and C1S). The other complement 
component, C6 (part of the alternative complement pathway), was also part of the list of genes associated 
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with the process of cell death. The complement system forms an essential part of the innate immune system. 
It provides defence against pathogens and initiates inflammatory responses (Frank and Fries 1991; Finehout 
et al., 2005; Coleman et al., 1989). Complement components are proinflammatory mediators and if the 
induced inflammatory response is dysregulated, it could result in tissue damage. The complement system has 
therefore been implicated in the pathology of several neurodegenerative disorders such as Parkinson’s 
disease (PD) (Yamada et al., 1992; McGeer and McGeer 2004), Alzheimer’s disease (AD) (May et al., 1989, 
1990; Gasque et al., 2000; Tuppo and Arias 2005), multiple sclerosis (MS) (Kornek et al., 2003; Sellebjerg et 
al., 1998) and Pick’s disease (Morgan and Gasque 1996, 1997). Expression levels of the classical 
complement cascade have also been found to be significantly higher in the hippocampus and temporal cortex 
of AD cases compared to controls (Shen et al., 1997), suggesting that neuroinflammation in these brain 
regions could contribute to the pathology of this neurodegenerative disorder.  
More recent literature indicates that the complement system can also remodel and repair brain tissue by 
removing toxic protein deposits and facilitating phagocytosis of necrosed or apoptotic neurons via the 
microglia (Gasque et al., 2000). The complement system can thus elicit potentially threatening responses in 
the CNS, resulting in neuroinflammation, but can also induce positive effects in terms of repair and 
maintenance of brain tissue (Gasque et al., 2000). During the early stages of these brain disorders, the 
complement system may have a beneficial function (Osaka et al., 1999; Mukherjee et al., 2001, 2008), 
whereas in chronic CNS disorders, inflammation induced by these complement components is detrimental to 
neurons, as neuronal cells are not able to regulate non-specific complement component actions (Singhrao et 
al., 2000). In order to determine if upregulation of the complement system was associated with increased 
levels of anxiety, Kulkarni et al. (2011) administered an in-vitro inhibitor of complement activation to 
APPswePS1δE9 mice (transgenic mice with increased levels of anxiety, usually used to model neurological 
disorders, specifically Alzheimer’s disease). Administration of this inhibitor of the complement system was 
shown to attenuate anxiety in this model of AD; inhibition of the complement system thus had an anxiolytic 
effect in these animals (Kulkarni et al., 2011). In the context of DCS-induced fear extinction in the current 
study, one of the proposed processes whereby DCS facilitated fear extinction is by downregulating genes 
that transcribe complement components, thus reducing neuroinflammation and subsequent neuronal damage 
and ultimately eliciting an anxiolytic effect.  
5.3.2 DCS downregulates genes associated with behavioural processes implicated in 
stress-related disorders 
Another enriched biological process of interest is behaviour, defined by the database as “the internally 
coordinated responses (actions or inactions) of whole living organisms (individuals or groups) to internal or 
external stimuli”. Seven genes were associated with this process (p = 6.29E-03) (Table 4.5, Figs. 4.3 – 4.5, 
Section 4.2.3.1). Although the behavioural functions of CD74, CXCL13 and LBP were associated with 
cellular behaviour, including neutrophil and T cell chemotaxis, the other genes enriched in this process were 
associated with behavioural responses such as memory, adult feeding, adult locomotory behaviour, eating 
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behaviour, circadian cycle and behavioural response to pain. It has been well documented that memory 
processes are impaired in PTSD (DSM-V, APA 2012; Elzinga and Bremner 2002; Layton and Krikorian 
2002). Moreover, research has shown that NMDAR-dependent plasticity is crucial for spatial learning and 
memory (Morris 1981; Morris et al., 1982). In the current study, DCS administration may have facilitated 
NMDAR-dependent plasticity, as DCS is a partial NMDAR1 agonist at the glycine site, and indirectly 
increases glutamatergic activity which subsequently facilitates neuroplasticity, and therefore also learning 
and memory. Furthermore, co-administration of DCS and behavioural fear extinction downregulates genes 
that have been shown to interfere with memory consolidation, such as IL1RN, (Spulber et al. 2009) and in 
this regard DCS may contribute to improved learning and memory, and ultimately to fear extinction. With 
regards to feeding and eating behaviours, the associated genes could help to explain the comorbidity 
between eating disorders (EDs) and anxiety disorders (Bulik et al., 2000; Brewerton et al., 1995; 
Swinbourne and Touyz 2007) and eating disorders and PTSD (Brewerton 1999, 2007). In addition, several 
studies have also shown an association between trauma and EDs (Perkins and Luster 1999; Ackard and 
Neumark-Sztainer 2002; Fonseca et al., 2002; Wonderlich et al., 2000).  
Circadian cycle was also amongst the GO enriched behavioural responses affected by DCS administration. 
Sleep disturbances are common amongst PTSD patients (Lavie et al., 2001); sleep-related symptoms of 
PTSD are included in the DSM-5 (APA, 2013) as diagnostic criteria where the traumatic events are often re-
experienced in the form of nightmares and the initiation and maintenance of sleep is problematic (which is 
part of the hyperarousal symptom cluster of the disorder). Although the current study did not include an 
assessment of disturbances in circadian rhythms, it can be postulated that DCS induces gene expression 
changes that are associated with alterations in circadian rhythms, and as such may alleviate some of the sleep 
disturbances associated with PTSD. Further analysis is however required to establish this proposed effect of 
DCS.  
With regards to the process of behavioural response to pain, DCS has previously been shown to reduce 
neuropathic pain (caused by nerve injury, characterized by spontaneous pain and exaggerated responses to 
painful (hyperalgesia) and non-painful stimuli (allodynia)) in rats with spared nerve injury (SNI) 
(Millecamps et al., 2007). Daily oral administration of DCS was found to reduce sensitivity of the injured 
limb in a dose-dependent manner. Direct infusion of DCS into the mPFC or the amygdala resulted in the 
acute reduction of sensitivity to painful stimuli in SNI rats. This effect was mimicked by NMDA and glycine 
and blocked by HA−966 (a glycine-recognition site antagonist). This led the authors to conclude that limbic 
NMDA-mediated circuitry facilitates a long-term decrease in neuropathic pain behaviour by enhancing the 
extinction of pain-related memories, thereby facilitating antinociceptive properties for neuropathic pain 
through manipulation of prefrontal neuronal properties (Millecamps et al., 2007). In this context, the 
downregulation of genes in the FDW group compared to the FSM group that are associated with behavioural 
response to pain, concurs with previous findings of NMDA-mediated decreases in neuropathic pain (Boyce 
et al., 1999; Chizh et al., 2001; Parsons et al., 2001; Millecamps et al., 2007; Kayser et al., 2011), it is 
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furthermore proposed that DCS might possibly facilitate the extinction of fear memories and pain-related 
memories in a similar fashion. 
Research suggests that, amongst other things, PTSD is characterised by cytokine dysregulation, with 
decreased anti-inflammatory responses and increased proinflammatory responses, resulting in a state of 
heightened inflammation. This may result in comorbid immune related symptoms such as fatigue, malaise 
and altered patterns in sleep and appetite (Silverman et al., 2005; Dunn et al., 2006; Sternberg 2006). Results 
from the current study indicate that co-administration of DCS and behavioural fear extinction decrease 
expression of certain proinflammatory genes and genes involved in inflammatory responses (such as certain 
complement component genes, SPP1,MMPs, S100 genes etc.). Furthermore, GO enrichment showed that 
differentially expressed genes between these two treatment groups were associated with immune-related 
processes and diseases as well as behavioural responses relating to sleep patterns and appetite. It is thus 
possible that one of the main molecular mechanisms whereby DCS facilitated fear extinction in this study 
was by regulating genes involved in the immune system. 
5.3.3 DCS downregulates genes that are associated with disorders that co-occur with 
PTSD 
Gene ontology enrichment for diseases associated with the genes that were differentially expressed in 
response to co-administration of DCS and behavioural fear extinction, not only indicates diseases associated 
with the pathology and processes in question in the present study (fear extinction, anxiety, memory, learning, 
neurocognition etc.), but also identifies genes that could help to explain the comorbidity between PTSD and 
other disorders. The most significantly enriched GO disease term was immune system diseases (p = 4.02E-
14), with 17 associated genes (Table 4.6, Figs. 4.6, 4.7, Section 4.2.3.2). Once again, numerous genes that 
transcribe complement components were associated with this particular disease term, as well as 
glycoproteins (CD4), cytokines (IL1RN), cytochromes (CYBB) and metallopeptidase (MMP9). Together with 
results from previous GO enrichment analyses (relating to enriched biological process terms, where immune 
response was the most enriched biological process), this association with immune system diseases 
underscores one of the main effects elicited by DCS, namely its immunological effect, whereby it 
downregulates immune-related genes and genes that transcribe proinflammatory molecules that mediate 
chronic inflammation, neuroinflammation, disease progression and cellular destruction. 
The second most significant GO disease term was cardiovascular diseases (p = 1.02E-13), with 18 of the 
biologically relevant differentially expressed genes associated with this GO term. As illustrated in Fig. 5.1, 
Section 5.1, stress and other factors, such as genetic variation, can influence the stress system and different 
target tissues, which could ultimately lead to the development of various pathological conditions, including 
the cardiorespiratory systems (Blanchard et al., 1990; Fredrikson and Matthews 1990; Georgiades and 
Fredrikson 2000; Buckley et al., 2001). Research has found that PTSD patients are at increased risk for 
cardiovascular disease (Boscarino, 2008; Kessler, 2000; Schnurr et al., 2003; Kang et al., 2006; Boscarino et 
al., 2006; Kubzansky et al., 2009; Kubzansky et al., 2007). Furthermore, a recent study found that PTSD was 
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associated with ischemic changes on exercise treadmill tests, a result that was independent of traditional 
cardiac risk factors, C-reactive protein, and several health behaviors and psychosocial risk factors. The 
association remained significant even after patients with prior cardiovascular disease were excluded. Turner 
et al. (2013) suggested that additional mechanisms that could link PTSD and ischemia should be explored 
further. The authors mentioned that inflammation could be one of the factors that are involved as it has been 
shown to play a key role in the pathogenesis of cardiovascular disease. In addition, studies have shown that 
PTSD patients have elevated levels of multiple inflammatory biomarkers, as well as greater induction of 
inflammation in response to acute stress (Gill et al., 2009). Results from the present study correlate well with 
these findings, where several biologically relevant differentially expressed genes were found to be associated 
with GO terms such as immune response, immune system development, and immune system diseases.  
The third most significant GO disease term associated with 17 of the biologically relevant differentially 
expressed genes, was digestive system diseases (p = 9.06E-11). In addition there were also 11 genes 
associated with the metabolic diseases GO term (p = 4.00E-05) (CTD defined metabolic diseases as diseases 
caused by an abnormal metabolic process, which could be congenital due to inherited enzyme abnormality 
(metabolism or inborn errors) or acquired due to disease of an endocrine organ or failure of a metabolically 
important organ such as the liver (according to STEDMAN, 26th edition) (Haqq et al., 2005)) and seven with 
diabetes mellitus (p = 1.63E-05), with some overlap noted between these three GO terms (Table 4.6, Figs. 
4.6, 4.7).  
The results from the present study correlate well with what has been described in literature. PTSD has been 
found to be significantly associated with a risk of diabetes (Goodwin et al., 2005; Lauterbach et al., 2005; 
Trief et al., 2006; Qureshi et al., 2009; Boyko et al., 2010; Pietrzak et al., 2012; Lukaschek et al., 2013) and 
hyperlipidemia (Solter et al., 2002; Karlovic et al., 2004; Maia et al., 2008; Dedert et al., 2010). Not only is 
PTSD associated with an increased risk for diabetes, but there is a strong association between diabetes and 
severe psychological distress (Egede et al., 2012) and experience of traumatic events (Mooy et al., 2000; 
Kumari et al., 2004). The stress response system includes the central and peripheral nervous systems, the 
immunological system and the endocrine system; it is thus possible that all these systems could 
concomitantly contribute to the progression from traumatic psychological stress to type 2 diabetes (Pickup et 
al., 2004; Black, 2006; Baker et al., 2012; O'Donovan et al., 2012; Lukaschek et al., 2013). However, it 
should also be noted that due to the cross-sectional nature of some of these studies, researchers were not 
always able to discern whether diabetes preceded the onset of PTSD or only developed later. A meta-analysis 
however found that depression was associated with a 60% increased risk of developing type 2 diabetes, 
whereas type 2 diabetes was only associated with a modest increased risk of depression (Mezuk et al., 2008).  
The functional role of insulin in the brain’s structural responses to stressors should not be overlooked. Insulin 
deficiencies result in a decrease in the number of dentate gyrus neurons which leads to increased dendrite 
remodelling of CA3 neurons (in the hippocampus) (Lisowski et al., 2013). This effect was found to be 
further accelerated following repeated restraint stress in two mice strains, bred for high and low swim stress-
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induced analgesia (Lisowski et al., 2013). Furthermore, the combination of stress and hyperglycemia leads to 
increased oxidative stress in the brain, which could ultimately contribute to impaired neural function in 
conditions of chronic stress and diabetes (Lisowski et al., 2013). Additionally, negative health behaviours, 
such as substance abuse, smoking and eating disorders, as well as heightened levels of inflammation are 
commonly associated with PTSD and these factors may converge in their contribution to an increased risk 
for developing diabetes in humans (Rod et al., 2009).  
Other diseases that were enriched in our set of differentially expressed genes were nervous system diseases 
(p = 2.28E-06) with 16 genes associated with this GO term. According to CTD nervous system diseases 
includes diseases of the central and peripheral nervous system, including disorders of the brain, spinal cord, 
cranial nerves, peripheral nerves, nerve roots, autonomic nervous system, neuromuscular junction, and 
muscle. Twenty of the differentially expressed biologically relevant genes were associated with nervous 
system diseases, with most of the genes being associated with central nervous system diseases and a few 
with peripheral nervous system diseases (Table 4.6, Figs. 4.7, Section 4.2.3.2). Central nervous system 
diseases include diseases of any component of the brain (including the cerebral hemispheres, diencephalon, 
brain stem, and cerebellum) or the spinal cord. Peripheral nervous system diseases include diseases of the 
peripheral nerves external to the brain and spinal cord, which includes diseases of the nerve roots, ganglia, 
plexi, autonomic nerves, sensory nerves, and motor nerves.  
The CTD was mined for more specific disease terms (by searching for each gene’s specifically associated 
diseases). Some of the main nervous system diseases that were associated with the gene set (that was 
enriched for the nervous system diseases GO term) were memory disorders, learning disorders, pain, 
neurotoxicity syndromes, Alzheimer’s disease, Parkinson’s disease and dementia. Some of these diseases 
were also enriched in the disease GO search, such as pain, mental disorders (including Alzheimer’s disease, 
learning disorders, cognition disorders, autistic disorder, depressive disorders, anxiety disorders, narcolepsy, 
amnesia) and neurodegenerative diseases (including Alzheimer’s disease, Parkinson’s disease, etc.). Genes 
associated with these disorders were downregulated in the FDW animals compared to the FSM animals. It is 
therefore hypothesised that in the current study DCS facilitated the downregulation of genes involved in 
learning and memory disorders, which may have subsequently assisted the fear extinction process.  
In PTSD, memory failure (specifically relating to memories of the traumatic event) is characterized as a 
symptom of avoidance (Horowitz, 1986; Horowitz & Reidbord, 1992; Larson et al., 2013). These 
dissociative memory problems are not defined to be neurological in nature by the diagnostic guidelines, and 
objective neuropsychological findings are not required in order to meet this criterion. Instead, diagnosis 
mostly relies on clinical observation and subjective complaint (Larson et al., 2013). However, research has 
shown that PTSD does in actual fact elicit neurological sequelae, which can be observed on brain imaging 
scans. PTSD can furthermore result in subsequent memory impairment, which can be confirmed by 
psychometric assessments (Larson et al., 2013). A decrease in hippocampal volume (Emdad et al., 2006; 
Woodward et al., 2009) and hippocampal connectivity (Daniels et al., 2010) and impaired performance on 
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memory testing (Daniels et al., 2010; Emdad et al., 2006; Woodward et al., 2009; Larson et al., 2013) has 
been observed in individuals with PTSD. In the current study, differential expression of genes associated 
with learning and memory disorders are in accordance with previous findings regarding PTSD, as well as 
the understanding of the psychopathology of the disorder, since PTSD affects processes of learning and 
memory (Milad et al., 2009; LeDoux et al., 1988; Goldstein et al., 1987; Sutker et al., 1990, 1991). DCS has 
been shown to facilitate fear extinction (Ledgerwood et al., 2003; 2005; Walker et al., 2002; Yang and Lu, 
2005), a process that also involves learning and memory processes (Berman and Dudai 2001; Bouton 2002; 
Myers and Davis 2002). Therefore, this study illustrates that co-administration of DCS and behavioural fear 
extinction facilitated fear extinction by regulating genes involved in learning and memory processes. 
Results from the current study found that DCS downregulated genes previously associated with Alzheimer’s 
disease. This corresponds to what has previously been described in literature, where a direct relationship was 
found between experiential trauma in Alzheimer’s disease and the rate of decline in Alzheimer’s disease, as 
well as between previous life trauma and Alzheimer’s disease onset (Burnes and Burnette 2013). 
Subsequently, it has been hypothesized that PTSD and correlates of PTSD could be mediators of 
Alzheimer’s disease status, in a model recently described by Burnes and Burnette (2013). Moreover, research 
has shown some convergence of the neuroanatomical changes in individuals with trauma histories with 
cognitive and emotional disturbance and persons with Alzheimer’s disease (Qureshi et al., 2011). This 
suggests that early trauma may mediate neuroanatomical alterations which increase susceptibility or 
vulnerability to Alzheimer’s disease (Burnes and Burnette 2013). In the current study, administration of DCS 
in the fear-conditioned group facilitated the downregulation of genes that have previously been associated 
with Alzheimer’s disease. Literature has also shown associations between dysregulated NMDAR trafficking 
and neuropsychiatric disorders, such as Alzheimer’s disease (Lau et al., 2007), which is consistent with the 
critical role of glutamatergic neurotransmission during learning, memory formation and neuronal plasticity 
(Zhao et al., 2005; Nakazawa et al., 2006; Gardoni et al., 2009). In addition, Tsai et al. (1999) found that 
DCS administration (100 mg/day) significantly improved scores on the cognitive subscale of the Alzheimer's 
Disease Assessment Scale (improvement of 3.0 points). The current study therefore supports the hypotheses 
that there are common mechanisms involved in the pathologies of PTSD and Alzheimer’s disease; we 
furthermore propose that DCS functions by altering the expression of genes involved in these common 
mechanisms.  
Another hypothesis incorporates the important role of stress, brain inflammation and cerebrovascular 
alterations, all contributing in varying degrees to the cause and progression of various brain disorders. These 
disorders include, but are not limited to, affective and anxiety disorders, PTSD, traumatic brain disorder, 
schizophrenia, autism and numerous neurodegenerative diseases such as Parkinson's and Alzheimer's 
disease, multiple sclerosis, amyotrophic lateral sclerosis and HIV-associated dementia (Saetre et al., 2007; 
Dantzer et al., 2008, 2009; Miller et al., 2009; Glass et al., 2010; Tansey and Goldberg 2010; Bauer et al., 
2010; Saavedra et al., 2011). With regards to Parkinson’s disease, anxiety disturbances were found to be 
much more common in diseased patients compared to healthy or comparably disabled elderly controls, where 
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anxiety disturbances occurred in up to 40% of Parkinson’s disease patients (Nuti et al., 2004; Stein et al., 
1990; Pontone et al., 2009). This frequent co-occurrence of anxiety and Parkinson’s disease has led 
researchers to believe that these disorders may share certain etiological processes (Stein et al., 1990; Siemers 
et al., 1993; Menza et al., 1993; Noble, 2000; Gravius et al., 2010; Naviaux, 2013). It has also been 
established that excessive, uncontrolled inflammation in the CNS plays a critical role in the pathophysiology 
of numerous psychiatric and neurodegenerative disorders, such as major depression, schizophrenia, PTSD, 
Parkinson’s and Alzheimer’s disease, HIV-associated dementia and traumatic brain injury (Fassbender et al., 
2004; Hope et al, 2009; Miller et al, 2009; Rivest, 2009). Results from the current study show that genes that 
have previously been associated with Parkinson’s disease were downregulated in the FDW group compared 
to the FSM group, suggesting that there might be common pathogenic processes involved in these two 
disorders. Numerous proinflammatory genes were also downregulated in the FDW group, suggesting that 
DCS has the potential to attenuate these effects of neuroinflammation and other shared mechanisms that 
could contribute to disease progression.  
Research has shown that PTSD often co-occurs with chronic pain. Furthermore, PTSD severity was found to 
correlate with the severity of chronic pain (White and Fuastman 1989; Hickling et al., 1992; Chibnall et al., 
1994; Beckham et al., 1997; Shipherd et al., 2007; Defrin et al., 2008). It has been suggested that PTSD 
patients display intense and extensive chronic pain, hyposensitivity to pain together with hyper-reactivity to 
suprathreshold harmful stimuli (Defrin et al., 2008). This could be due to the particular emotional 
interpretation and response to painful stimuli by PTSD subjects. These findings could also be attributed to 
altered sensory processing in PTSD patients (Defrin et al., 2008). Findings also suggest that in certain 
chronic pain patients (i.e., those classified as dysfunctional) the object of fear may be associated with prior 
traumatic and painful injury (Beck et al., 2001); these dysfunctional pain patients are also more vulnerable to 
developing PTSD (Asmundson et al., 2000). The current study found not only that the differentially 
expressed gene set was enrichment for the biological process of behavioural response to pain, but also 
detected pain as a GO enriched disease term and as a nervous system disorder. In an earlier section of this 
chapter, NMDAR-mediated reduction of neuropathic pain was discussed in detail (Section 5.3.2). In light of 
that research and the research discussed above, it can be hypothesised that co-administration of DCS and 
behavioural fear extinction in the current study may have facilitated relief from pain, (including neuropathic 
pain that could have been experienced in the current model), through downregulating certain genes 
associated with pain and the response to pain. This suggests that DCS may have facilitated fear extinction by 
reducing pain and thereby diminishing the reminder of the prior, possibly painful (electric footshock) 
trauma.  
By downregulating genes that are both associated with PTSD pathologies and comorbid disorders of PTSD, 
DCS might be able to facilitate fear extinction whilst alleviating symptoms of these additional disorders. 
Identifying genes that are common between PTSD and these disorders can thus shed light on the molecular 
underpinnings of comorbidity or disease associations and could furthermore identify novel drug targets that 
facilitate better treatment of PTSD and these disorders. 
Stellenbosch University  https://scholar.sun.ac.za
140 
 
5.3.3.1 DCS downregulates genes that have inferred associations with anxiety disorders and PTSD 
 
In order to determine how many, and which, of the 42 biologically relevant differentially expressed genes 
have previously been implicated in PTSD and anxiety disorders, Venn diagrams were constructed using the 
myGeneVenn CTD tool (http://ctdbase.org/tools/myGeneVenn.go). These diagrams also showed that within 
the database there was a total of 6 816 genes with inferred (or indirect) associations with both PTSD and 
anxiety disorders. The database contained 12 506 genes that have only been found to be associated with 
anxiety disorders and 50 that have been found to be associated only with PTSD. The database also reported 
that 21 of the 42 differentially expressed genes have an inferred association with only anxiety disorders and 
21 of the differentially expressed genes have inferred associations with both anxiety disorders and PTSD 
(Fig. 4.8, Table 4.7 Section 4.2.3.2). These results point to the possible efficacy of DCS for the treatment of 
anxiety disorders and stress-related disorders (Ressler et al., 2004; Hofmann et al., 2006; Kushner et al., 
2007; Guastella et al., 2008; Wilhelm et al., 2008; Otto et al., 2010; Storch et al., 2010; Yamamoto et al., 
2010; de Kleine et al., 2012). 
5.3.3.2 Contributions of neuronal injury to neuropsychiatric disease 
 
In light of the preceding discussions, it is important to discuss allostasis and its contribution to the 
development of disease. Allostasis is the process whereby physiologic systems adapt to meet the demands of 
external stressors. Allostatic load is the cost of repeated exposure to heightened or inconsistent 
neuroendocrine responses following exposure to stressful environmental challenges. Moreover, different 
types of stress can result in distinct patterns of CNS-neuroendocrine activation, whereby sustained stress 
yields neuroendocrine alterations that differ to those of acute stress (McEwen and Stellar 1993; Henninger 
1995; McEwen, 2008). Figure 5.2 illustrates how genetic and environmental influences interact and impact 
on allostatic load. Allostatic load, together with chronic stress, trauma, inflammation and impaired cerebral 
circulation, could eventually result in neuronal dysfunction and injury which contributes to the development 
of neuropsychiatric disease, including PTSD. Results generated by the current study correlate well with the 
model, described by McEwen, (2008), which explains how neuronal injury leads to neuropsychiatric disease. 
In the present study, intrahippocampal DCS administration (together with behavioural fear extinction) had an 
anxiolytic effect on the animals, DCS downregulated proinflammatory genes and DCS resulted in 
differential expression of genes that are associated with affective, stress-related, cognitive and 
neurodegenerative diseases. 




Figure 5.2: Diagram illustrating the mechanisms of neuronal injury leading to neuropsychiatric disease. Genetic 
and environmental factors interact with each other which could result in the failure of compensatory mechanisms to 
maintain homeostasis. This, in turn, contributes to increased allostatic load on the CNS which translates into 
pathological reactivity to stress, uncontrolled inflammation and alterations in blood flow, ultimately resulting in 
variable degrees of neuronal dysfunction and injury. Various combinations of these alterations and their CNS 
localization affect different regulatory systems. The initiation, development and combinations of particular affective, 
stress-related, psychotic, cognitive and neurodegenerative diseases of the brain, is dependent on individual 
vulnerability, the combination of pathological factors, the localization of the neuronal injury, and the regulatory 
mechanisms affected. BBB – brain blood barrier, CNS – central nervous system, HIV - human immunodeficiency virus, 
PTSD – posttraumatic stress disorder (Adapted from McEwen, 2008 and Saavedra et al., 2011). 
5.3.3.3 Neuroinflammation and its effects on neurogenesis and memory 
 
The discussion below provides some explanation of how inflammation facilitates neuronal dysfunction. The 
majority of the genes discussed in the following sections are involved in the immune system, oxidative stress 
response and inflammation. Dysregulated inflammatory and oxidative stress responses may result in cellular 
injury and even cell death (Lee et al., 2001; Marques et al., 2003; Andersen, 2004; Hovatta et al., 2010). In 
addition, cellular injury produces excess toxic substances which promote further inflammatory cascades and 
additional cellular toxicity (Licinio and Wong, 1997, 2003). CNS inflammation does not only originate in 
response to bacterial or viral infection, but could also develop as a consequence of endogenous neurotoxin 
production or variations in the protein oxidation and reduction balance, such as those occurring during the 
aging process, and neurodegenerative, and autoimmune disorders (Glass et al., 2010; Bhat and Steinman, 
2009). Models describing the interrelations of the immune system, brain and behaviour have described that 
the brain is supported by the immune system; where sufficient immune functioning is essential for learning 
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and memory under basal conditions, and supports an optimal stress-coping response (Meffert and Baltimore, 
2005; Kioussis and Pachnis, 2009; Besedovsky and Del Rey, 2011; Molina-Holgado and Molina-Holgado, 
2010; Schwartz and Shechter, 2010; Su et al., 2010; Yirmiya and Goshen, 2011). 
One of the proposed mechanisms whereby neuoinflammation mediates neuronal dysfunction is via the 
inflammatory mediators, such as the cytokines, interleukin 1beta (IL-1β), interleukin 6 (IL-6) and tumor 
necrosis factor alpha (TNFα). All of these cytokines are released by macrophages, peripheral immune cells 
and microglia (in the CNS), during the early acute phase defence reaction against invading pathogens. These 
cytokines are robustly stimulated by molecules associated with pathogens, such as lipopolysaccharide (LPS) 
and viral nucleic acids that bind to toll-like receptors (TLRs) and activate the NFкβ pathway (Fig. 5.3). 
These cytokines also interact with neuronal glutamate GABA signalling to modulate LTP (Tambuyzer et al., 
2009; Verkhratsky, 2010; Yirmiya and Goshen, 2011). Microglia play a vital role in the innate immune 
system in the brain and respond rapidly to stimuli such as infection or injury (Hanisch and Kettenmann 
2007). Upon activation (induced by cell damage), microglia migrate to the site of infarct, where they clear 
damaged neurons or other cellular components. However, in the absence of injury, microglia provide 
surveillance of the environment and trophic support to healthy neurons (Kettenmann et al., 2011). However, 
stress-induced signalling molecules and glucocorticoids induce a proinflammatory response in microglia 
which may lead to aberrant activation in the absence of infection or injuries (Nair and Bonneau, 2006; 
Hanisch and Kettenmann 2007).  
 
Figure 5.3: One of the proposed pathways whereby neuroinflammation mediates neuronal dysfunction. Pathways that regulate 
and secrete IL-1β and other neuroactive cytokines, and the effects of these cytokines on the nervous system. Regulation of IL-6, 
TNFα and IL-1β is primarily via the NFкβ pathway through transcriptional activation. Inactive pro-IL-1β (as well as pro-IL-18 — 
not shown) requires further processing by the inflammasome component caspase-1. Endogenous stimulants include extracellular 
ATP and bacterial LPS. There are many other endogenous and exogenous inflammatory mediators that cause acute inflammation via 
other TLR subtypes and additional components of the inflammasome (not shown). Studies have shown that stress-stimulated and 
exogenously administered IL-1β decrease memory in the conditioned fear and water maze paradigms (Buchanan et al., 2008; Goshen 
et al., 2007; Pugh et al., 1999) (Jones and Thomsen 2013). 
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Numerous studies have demonstrated the key role of IL-1β as a stress-sensitive neurohormone (Goshen and 
Yirmiya, 2009). Following a period of intense stress, IL-1β levels were found to be increased in 
hypothalamus and other brain areas (Nguyen et al., 2000). Stress-induced IL-1β release has been implicated 
in reduced cognitive performance, as both exogenously administered and stress-stimulated IL-1β resulted in 
reduced memory in the conditioned fear and water maze paradigms (Buchanan et al., 2008; Goshen et al., 
2007; Pugh et al., 1999). Studies have furthermore shown that the anti-neurogenic action of stress is ablated 
in knockout mice lacking the receptor for IL-1β (IL-1RI) (Goshen et al., 2008; Koo and Duman, 2008). The 
anti-neurogenic action was also inhibited following the administration of IL1RN in wild-type animals 
(Goshen et al., 2008; Koo and Duman, 2008).  
However, it is not only excess CNS IL-1 signalling that elicits negative effects on memory tasks, earlier 
studies have shown that deficits in CNS IL-1 signalling also has a negative effect on memory. During the 
maintenance phase of LTP, there is a strong and sustained increase in the levels of IL1β (Balschun et al., 
2004; Schneider et al., 1998). Long-term potentiation at the synaptic level is believed to underlie memory 
consolidation (Bliss and Lømo, 1973; Teyler, 1987). Accordingly, researchers have found that elevated 
levels of IL1RN, which blocks the binding of IL-1β, impair learning (Oprica et al., 2005) and interferes with 
the memory consolidation process (especially in the hippocampus) (Spulber et al. 2009). These findings, 
together with earlier research showing that IL1 receptor blocking interferes with the BDNF-ERK1/2 pathway 
(which mediates the effects of BDNF on synaptic plasticity, nuclear signalling, and memory formation 
(Finkbeiner et al., 1997; Gottschalk et al., 1999; Blanquet 2000; Pizzorusso et al., 2000; Alonso et al., 
2002a,b)), suggests that physiological levels of IL1 are essential in learning and long-term memory 
consolidation. Additionally, blocking of IL-1R-mediated signalling, through intracerebroventricular (ICV) 
administration of IL1RN, significantly impaired memory in the Morris water-maze and in the passive 
avoidance test in rats (Yirmiya et al., 2002). It was also proposed that IL1RN elicits a possible direct effect 
on hippocampal function, in view of findings that exogenous IL1RN exerts agonist activity in the 
hippocampus, independent of IL-1RI (Loscher et al., 2003). This study found that  in vitro stimulation of 
synaptosomes with IL1RN mimicked the effects of IL-1β by decreasing glutamate release and increasing c-
Jun N-terminal kinases (JNK) phosphorylation. These effects were maintained in mice with defective IL-1 
type I receptor (IL-1RI). Furthermore, IL1RN mimicked the IL-1β inhibitory effect on long-term potentiation 
(LTP) in the hippocampus (Loscher et al., 2003). 
It has been established that IL-1β is involved in the modulation of anxiety, exerting either anxiogenic 
(Connor et al., 1998; Montkowski et al., 1997), or anxiolytic (Montkowski et al., 1997) effects, depending on 
the dose (Oprica et al., 2005; Goshen et al., 2007). It was subsequently proposed that IL-1β has a modulatory 
effect on anxiety, where higher levels of IL-1β are anxiogenic and low levels of IL-1β or a deficit in 
available IL-1Rs, seem to have anxiolytic effects (Oprica et al., 2005; Goshen et al., 2007). Therefore, it is 
proposed that neuroinflammation, induced under stressful conditions, could mediate neuronal dysfunction 
through decreased neurogenesis and hippocampal memory, via dysregulation of the levels of IL-1β in the 
microglia.  
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It is however not only IL-1β that affects the neuronal functioning, but studies have also investigated the 
effects of IL-6. In a study by Raison et al. (2010) where 24 patients were treated with IFN-α (which induces 
inflammation), they found significantly increased CSF IL-6 levels. These levels were negatively correlated 
with concentrations of the serotonin metabolite, 5-hydroxyindoleacetic acid (5-HIAA) in the CSF (Raison et 
al., 2009). The authors proposed that, based on pre-clinical research, increased CSF IL-6 may have elicited 
direct as well as indirect effects on serotonin and impaired growth of neuronal progenitor cells (Dunn, 2006; 
Monje et al., 2003; Song et al., 1999). 
Another important factor that influences neuroinflammation is oxidative stress. During oxidative stress, an 
excess of oxidants damage or modify biological macromolecules such as lipids, proteins and DNA 
(Scapagnini et al., 2012; Ng et al., 2008; Salim et al., 2012; Anderson et al., 2013). This excess could be as a 
result of increased oxidant production, decreased oxidant elimination, defective antioxidant defences, or a 
combination of these factors (Scapagnini et al., 2012; Ng et al., 2008; Salim et al., 2012; Anderson et al., 
2013). The brain is particularly vulnerable to oxidative stress due to high levels of peroxidizable 
polyunsaturated fatty acids, high oxygen utilization and limited anti-oxidation mechanisms (Scapagnini et 
al., 2012; Ng et al., 2008). It has been suggested that oxidative stress contributes to the aetiology of various 
psychiatric disorders, including anxiety disorders, depression, and alcohol use disorder (Hovatta et al., 2010). 
Oxidative stress could results in neuroinflammation through the activation of microglia, which increase 
oxidative stress through the production of proinflammatory cytokines and nitric oxide (NO) (Scapagnini et 
al., 2012; Ng et al., 2008; Salim et al., 2012; Anderson et al., 2013). In turn, these proinflammatory cytokines 
and high NO levels may promote further reactive oxygen species (ROS) formation, which ultimately results 
in the damage of membrane phospholipids and their membrane-bound monoamine neurotransmitter 
receptors (which depletes endogenous antioxidants). Increased ROS products could result in enhanced 
microglial activation and increase proinflammatory production via NF-κB stimulation (Salim et al., 2012). 
This, in turn, maintains oxidative injury (Salim et al., 2012), creating a potential pathological positive 
feedback loop in some psychiatric disorders (Scapagnini et al., 2012; Ng et al., 2008; Salim et al., 2012; 
Anderson et al., 2013). 
In the Sections that follow, reference will be made to the effects of neuroinflammation on neurogenesis and 
hippocampal memory, and its possible contribution to neuronal dysfunction in the context of PTSD.  
5.3.4 DCS downregulates genes that are associated with protein, receptor and ion 
binding molecular functions 
Protein binding was the molecular function that was most enriched in the set of differentially expressed 
genes (p = 1.34E-12), with 34 genes associated with this function (Table 4.8, Figs. 4.9, 4.10 Section 4.2.3.3). 
The database defines this function as “Interacting selectively and non-covalently with any protein or protein 
complex (a complex of two or more proteins that may include other nonprotein molecules)”. This definition 
is very broad, which could explain why so many genes were associated with it. Individual protein-binding 
terms associated with the differentially expressed genes included (but were not limited to) enzyme binding, 
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receptor binding, ion binding, calcium-dependent protein binding, tumor necrosis factor binding, MHC class-
I protein binding, protein homodimerization activity, RAGE (receptor for advanced glycation end products) 
receptor binding, G-protein coupled receptor binding, protein kinase binding, chemokine activation as well 
as receptor agonist activity. Some of these individual terms were also detected to be enriched molecular 
functions within our gene set, such as receptor binding, ion binding, calcium ion binding and MHC protein 
binding. 
Most of these molecular functions should be investigated and explained by looking at the NMDA receptor 
and its activation, since DCS is a partial NMDAR1 agonist. NMDAR activation is a relatively complex 
process, since binding of both glutamate and glycine is required to open the ion channel and allow calcium 
entry (Fig. 2.5 Section 2.4.1). The ion-channel is blocked by magnesium (voltage-dependently) and this 
block is removed by depolarization (McBain and Mayer 1994). Continued activation of the NMDA receptor 
promotes signalling to the nucleus (through calcium signalling pathways), which ultimately results in CREB 
phosphorylation, gene activation and long-term synaptic plasticity (which underlies learning and memory) 
(Schwarcz 2001). However, excess glutamate could lead to overstimulation of NMDA receptors, resulting in 
excess intracellular calcium, which has been shown to cause excitotoxicity, a process whereby nerve cells are 
damaged and die due to excessive stimulation by neurotransmitters such as glutamate. It is one of the process 
whereby neurons die in various CNS disorders (Schwarcz 2001). A fine balance of neurotransmitters, as well 
as calcium ion levels, is thus required for optimal neuronal function (Kemp and McKernan 2002). Therefore, 
the detection of differentially expressed genes with functions in ion binding, specifically calcium ion 
binding, suggests that DCS regulates the expression of genes that could help to maintain the homeostatic 
balance of calcium ions and prevent excitotoxicity, whilst ensuring optimal levels for sufficient neuronal 
functioning, learning and memory.  
Receptor for Advanced Glycation Endproducts (RAGE) binding was another enriched protein binding 
molecular function, detected in the current study. RAGE is part of the immunoglobulin superfamily and is a 
transmembrane receptor (Neeper et al., 1992) that has the ability to bind advanced glycation endproducts 
(AGE), including mainly glycoproteins and glycans (Schmidt et al., 1995; Bierhaus et al., 1998). RAGE has 
also been implicated in inflammation through its binding to S100A12 (of the calgranulin family) (Hofmann 
et al., 1999; Marenholz et al., 2004) in mice macrophages (Schmidt et al., 2000), resulting in increased levels 
of IL-1β and TNF-α (factors involved in inflammation). Interestingly, one of the other protein binding 
molecular functions associated with the differentially expressed genes, was TNF binding. RAGE cross-
linking of peptides and proteins results in irreversible tissue damage (Bierhaus et al., 2001). It also activates 
cell types such as macrophages, monocytes, vascular smooth muscle cells and cardiac fibroblasts, which 
consequently generate ROS. Interaction between RAGE and its ligands is believed to result in the activation 
of proinflammatory genes (Bierhaus et al., 2001). Research has shown that RAGE plays an important role in 
the process of ageing and age-related degenerative diseases (Park et al., 1998; Schmidt et al., 2000). In 
addition, elevated levels of RAGE ligands have been detected in diabetes and other chronic disorders, 
leading researchers to hypothesize that this receptor has a causative effect in various inflammatory diseases 
Stellenbosch University  https://scholar.sun.ac.za
146 
 
such as diabetic complications, Alzheimer's disease and even some tumors (Park et al., 1998). In the present 
study, DCS downregulated genes associated with RAGE receptor binding, which may have resulted in 
reduced levels of TNF. This suggests that this is one of the mechanisms whereby DCS attenuates 
neuroinflammation, tissue damage, and possibly also learning and memory deficits, which may have 
contributed to the facilitation of fear extinction. This correlates with other findings in the present study, 
where DCS induced a reduction in the expression of immune system and proinflammatory genes as well as 
genes that have been associated with other inflammatory diseases, such as Alzheimer’s disease and diabetes. 
5.3.5 DCS downregulates genes that are associated with immune system-related and 
complement activation pathways  
The immune system pathway was the most enriched biochemical pathway associated with the genes that 
were differentially expressed between FDW and FSM (p = 1.24E-14), with 18 biologically relevant genes 
associated with this pathway (Table 4.9, Figs. 4.11, 4.12, Section 4.2.3.4). The second most enriched 
pathway (associated with the biologically relevant differentially expressed genes) was complement and 
coagulation cascades (p = 1.37E-10). The results for the immune system and complement pathways correlate 
with the earlier results from the current study, where immune response and complement activation pathways 
were part of the enriched GO biological processes, as well as with the enriched GO disease terms, where 
immune system diseases were enriched. This emphasises the important effects that DCS elicits on 
immunological and complement processes and pathways and how they contribute to the facilitation of fear 
extinction. 
Other enriched pathways associated with the biologically relevant, differentially expressed genes included 
the following pathways: leukocyte transendothelial migration, phagosome, Fc gamma receptor-mediated 
phagocytosis, signal transduction, systemic lupus erythematosus, hemostasis, antigen processing and 
presentation, cell adhesion molecules, T cell receptor signalling pathway and primary immunodeficiency. 
Most of these pathways are involved in or associated with the immune response or inflammation. During 
migration of leukocytes, the leukocytes bind to endothelial cell adhesion molecules (CAM) and subsequently 
migrate across the vascular endothelium. Migration of leukocytes from the blood into tissues is essential for 
immune surveillance and inflammation (Worthylake and Burridge, 2001). Phagocytosis is the process 
whereby phagocytes engulf relatively large particles (> 0.5 µm) and forms an internal phagosome. The 
process of phagocytosis is primarily involved in the uptake and degradation of infectious agents and 
senescent cells. Furthermore, phagocytosis participates in the immune response, inflammation, development 
and tissue remodelling. The innate immune response is initiated following phagocytosis of pathogens by 
macrophages; this in turn activates the adaptive response (Silverstein, 1995; Allen and Aderem 1996). 
Research has also shown that by presenting antigens derived from phagocytized apoptotic cells, dendritic 
cells are capable of stimulating class I–restricted CD8+ cytotoxic T lymphocytes (Albert et al., 1998), 
facilitating the presentation of self-antigens, leading to the breaking of tolerance and subsequent activation of 
autoimmune disease (Casciola-Rosen et al., 1994).  
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Furthermore, one of the other enriched pathways associated with the biologically relevant differentially 
expressed genes, was systemic lupus erythematosus (an autoimmune disease). It was therefore proposed that 
the phagosome pathway was activated due to dendritic cells that presented antigens from phagocytized 
apoptotic cells (cell death was one of the enriched biological processes which was probably the end-result 
from inflammation and proinflammatory responses in the LDH in response to fear conditioning); this may 
have facilitated the activation of autoimmune responses. In the present study, DCS downregulated genes 
associated with the phagosomal pathway (including genes that transcribe proteins that initiate phagocytosis, 
such as CLEC7A and phagocytic receptors, such as MSR1 as well as a regulatory subunit of the phagocytic 
NADPH oxidase, RAC2) thereby attenuating increased inflammatory responses, subsequent 
neuroinflammation and associated memory end learning deficits, which may have facilitated fear extinction.  
5.3.6 DCS downregulates genes that have previously been implicated in learning, 
memory, fear and anxiety  
This Section will focus on those genes that exhibited the largest fold changes between the FDW and FSM 
animals as well as genes that were previously found to be associated with fear, anxiety and PTSD. In 
addition, this section will focus on genes that exhibited differential expression with real time qPCR analyses 
(which included genes with large fold changes as well as genes previously implicated in anxiety disorders), 
thereby verifying the gene expression data from the RNAseq. Lastly, this Section also discusses a selection 
of biologically relevant differentially expressed genes that have previously been implicated in fear, anxiety, 
learning, memory and other neurocognitive diseases. 
5.3.6.1 SPP1 
 
The gene that had the biggest fold change between the FDW and FSM groups was secreted osteopontin or 
phosphoprotein 1 (SPP1), which was downregulated about six-fold in the FDW group (Table 4.4, Section 
4.2.2, refer to Tables 4.5 – 4.9 for GO enrichment results under Section 4.2.3). This highly glycosylated 
multifunctional phosphoprotein functions as a free cytokine in body fluids (Gravallese 2003) and influences 
adhesion, migration, cell survival, and inflammation (Denhardt et al., 2001a, 2001b; Scatena et al., 2007). 
Furthermore, this gene was proposed to act as a novel regulator of myelination and remyelination (Selvaraju 
et al., 2004). Osteopontin has the ability to regulate pathways that are involved in the development of distinct 
effector T helper cells (TH) cells, including TH1 and TH17 cells by interacting with cytokines and their 
receptors (Steinman 2008; Cantor and Shinohara 2009). Osteopontin is expressed in numerous tissues and 
cell types, including inflammatory cells and in the CNS (such as in primary sensory neurons in the 
mesencephalic Vth nucleus, the vestibular, auditory, trigeminal, and dorsal root ganglia (Loez et al., 1995; 
Ishikawa et al., 2000) as well as in the olfactory bulb, the cerebellum, and the brainstem (Shin et al., 1999)).  
Osteopontin has also been found to be present below the plasma membrane in association with the 
intracellular domain of CD44 (Zohar et al., 2000) (interestingly, the CD44 gene was also downregulated in 
the FDW group). In addition to being upregulated in many peripheral tissues following injury such as 
Stellenbosch University  https://scholar.sun.ac.za
148 
 
ischemia (Ellison et al., 1998; Wang et al., 1998; Lee et al., 1999; Choi et al., 2007) or spinal cord injury 
(Hashimoto et al., 2007), osteopontin has also been shown to be upregulated in various brain disorders, 
kainite-induced seizures (Kim et al., 2002), cryolesions (Shin et al., 2005), HIV-induced CNS dysfunction 
(Burdo et al., 2008) and experimental autoimmune encephalomyelitis (EAE) (Chabas et al., 2001). 
Osteopontin has been reported to be protective against ischemic brain injury (Noiri et al., 1999; Denhardt et 
al., 2001a, 2001b; Meller et al., 2005), however it was also shown to promote inflammation and exacerbate 
autoimmune diseases (Cantor, 1995; O’Regan et al., 2000a), such as EAE (Chabas et al., 2001) and multiple 
sclerosis (Steinman 2008). Furthermore, increased plasma levels of osteopontin have previously been 
associated with obesity-associated insulin resistance in mice, osteopontin-promoting inflammation and 
macrophage accumulation in adipose tissue (Nomiyama et al., 2007).  
In a recent study, a unique CCR2+CCR5+ T cell population was found to be enriched in the CSF of patients 
with exacerbated MS (Sato et al., 2012). The authors found that this T cell population was specifically 
involved in the autoimmune pathology of MS. Interestingly, they found that the CCR2+CCR5+ T cells 
produced a large amount of osteopontin (at both the mRNA and the protein levels) and MMP9 (Sato et al., 
2012) (which is discussed in detail in Section 5.3.6.7), which was previously found to be abundantly 
expressed in active MS lesions (Chabas et al., 2001). In addition to being an adhesion molecule, osteopontin 
also promotes the survival of activated T cells and production of proinflammatory cytokines by antigen 
presenting cells (Denhardt et al., 2001). Denhardt et al., proposed that osteopontin (produced by the 
CCR2+CCR5+ T cells) would promote the survival of these T cells in the CNS, leading to further enrichment 
of T cell population in the CSF. The authors furthermore proposed that CCR2+CCR5+ T cells capable of 
producing MMP9 and osteopontin, have a greater ability to invade the brain parenchyma (consisting of 
neurons and glial cells) (Sato et al., 2012).  
In the current study it could be hypothesised that downregulation of SPP1, which transcribes osteopontin, in 
the FDW group compared to the FSM group, may have attenuated neuroinflammation, by downregulating 
harmful T cell populations and the production of proinflammatory cytokines. This decrease in 
neuroinflammation in the FDW group could subsequently have contributed to neurogenesis and increased 
hippocampal memory (as discussed in 5.3.3.3, also refer to the model in Fig. 5.2) which possibly contributed 
to facilitate fear extinction.  
Additionally, if expression levels of SPP1 in LDH are also reflected systemically, SPP1 expression could be 
one of the genes mediating comorbid metabolic diseases such as diabetes. Metabolic diseases were one of the 
enriched diseases detected in this study, and SPP1 was found to be associated with this disease. 
5.3.6.2 CXCL13 
Decreased levels of the chemokine (C-X-C motif) ligand 13 (CXCL13) were observed in the LDH of FDW 
compared to FSM animals. It was more than five-fold downregulated in the FDW animals and was the 
second most downregulated gene in the FDW group (Table 4.4, Section 4.2.3 and refer to Tables 4.5 – 4.9, 
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Section 4.2.3 for GO enrichment results). Differential expression of this gene was also detected with SYBR 
Green real-time qPCR analysis in the LDH of the rats. Differential expression of this gene was also detected 
in some of the other between-group comparisons (refer to Section 5.3 for a detailed discussion). CXCL13 is 
a potent lymphoid chemokine that is constitutively expressed in secondary lymphoid tissue (Cyster et al., 
2000) and is one of the chemokines that plays a role in the migration of B cells within the follicular dendritic 
cell-rich area which and is critical for antigen scanning (Brandes et al., 2000; Pereira et al., 2010). B cells 
have an important function in the humoral immune response in neuroinflammation and perform the role of 
antigen-presenting cells for T cells (Pashenkov et al., 2003).  
In chronic inflammatory CNS diseases, CXCL13 has been shown to play a role in the formation of ectopic 
lymphoid tissues within the CNS (Serafini et al., 2004; Magliozzi et al., 2004). Furthermore, elevated levels 
of CXCL13 were detected in the CSF of patients with MS, neuroborreliosis and other neurological 
inflammatory diseases (Aloisi et al., 2008; Krumbholz et al., 2006; Rupprecht et al., 2009; Brettschneider et 
al., 2010; Khademi et al., 2011). Levels of CXCL13 mRNA were also found to be increased in actively 
demyelinating MS lesions (Krumbholz et al., 2006). A recent study implicates CXCL13 as the major 
determinant for B cell recruitment to the CNS in different neuroinflammatory diseases (including clinically 
isolated syndrome, MS, Lyme neuroborreliosis and patients with other inflammatory neurological diseases) 
(Kowarik et al., 2012). The authors furthermore state that elevated levels of CXCL13 in the CSF reflects a 
strong humoral immune response in the CNS, rather than being a marker specific for a particular disease 
entity (Kowarik et al., 2012).  
It is thus proposed that, in the current study, that co-administration of DCS and behavioural fear extinction 
in the FDW animals resulted in the downregulation of this indicator of enhanced immune activation, 
CXCL13. This indicated that DCS counteracted excessive immune system responses and subsequent 
neuroinflammation and possible neurodegeneration in the LDH. This effect, together with other effects 
elicited by DCS, possibly contributed to effective fear extinction. 
5.3.6.3 CLEC7A 
 
The gene that transcribes the C-type lectin domain family 7, member A (CLEC7A), also known as Dectin-1, 
was more than five-fold downregulated in the FDW compared to the FSM animals (Table 4.4, Section 4.2.2 
and refer to Tables 4.5 – 4.9 Section 4.2.3 for GO enrichment results). CLEC7A is a C-type lectin domain 
family member and microglia marker gene that recognizes glucans (Langmann et al., 2009) and has been 
found to be associated with inflammatory responses (Israelsson et al., 2009). It is a membrane-associated 
surface glycoprotein that is part of the pattern recognition receptors (PRRs). CLEC7A can stimulate the 
release of proinflammatory mediators and other cellular responses such as phagocytosis and respiratory burst 
(also termed oxidative burst, is the rapid release of reactive oxygen species, such as superoxide radical and 
hydrogen peroxide), in collaboration with TLR-2 (Brown et al., 2002; Gantner et al., 2003). This gene has 
been found to be upregulated in lysosomal storage disorder, a neurodegenerative disease that is characterised 
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by astrogliosis and neuroinflammation (Ballabio and Gieselmann 2009). A study by Shah et al. (2008) 
showed that CLEC7A is expressed on the surface of murine primary microglia, and engagement of the 
receptor with β-glucans results in increased tyrosine phosphorylation of spleen tyrosine kinase, which is a 
hallmark feature of the CLEC7A/Dectin-1 signalling pathway. Furthermore, they showed that CLEC7A 
mediates phagocytosis of β-glucan particles and facilitates subsequent intracellular production of ROS (Shah 
et al., 2008). However, it was found that β-glucan-mediated microglial activation did not result in significant 
production of cytokines or chemokines (as is typically found in macrophages and dendritic cells), thus, the 
interaction of microglial CLEC7A with glucan elicits a unique immunological response.  
 
Expression of CLEC7A was also shown to be increased in the mouse neocortex in animal models of closed 
traumatic brain injury (Israelsson et al., 2009; Israelsson et al., 2010) and an Alzheimer’s disease animal 
model (Israelsson et al., 2010), illustrating that a response elicited by CLEC7A is not limited to only 
responses to yeasts and fungal pathogens. Furthermore, blockade of CLEC7A significantly reduced the 
incidence and severity of arthritis in SKG mice (mice that are genetically prone to develop autoimmune 
arthritis) (Yoshitomi et al., 2005). There is growing evidence that the release and detection of alarmins, or 
endogenous ligands, by the innate immune system significantly contributes to the failure to resolve 
inflammation in chronic inflammatory diseases (Lotze Tracey 2005; Scheibner et al., 2006; Okamura et al., 
2001; Ohashi et al., 2000; Shelton et al., 2008). Therefore the identification of innate immune receptors and 
their ligands is critical for intervening in chronic inflammatory responses. A recent study aimed to identify 
whether an endogenously generated inflammatory ligand exists that could trigger superoxide radicals (O2-) 
production through CLEC7A in atherosclerosis, a chronic inflammatory disease characterized by lipid 
accumulation in macrophage foam cells in the artery wall (Thiagarajan et al., 2013). Their results revealed 
that vimentin is an endogenous, activating ligand for Dectin-1 and that it induces NADPH oxidase (NOX) 
activity to produce O2- in a Dectin-1-dependent manner (in primary human monocytes) (Thiagarajan et al., 
2013). In the present study, gene expression levels of vimentin, CLEC7A and NOX2 (CYBB) were all 
downregulated in the FDW vs. FSM animals. It can therefore be hypothesised that decreased levels vimentin 
resulted in lower levels of CLEC7A and NOX2, subsequently leading to lower levels of O2-, which could 
decrease oxidative stress and inflammation. 
Although the current study investigated gene expression patterns in the LDH, it could be hypothesised that 
CLEC7A may facilitate neuroinflammation in response to fear conditioning or exposure to stress, in a similar 
fashion as that described in atherosclerosis in human monocytes. Moreover, the current study detected a 1.8 
fold downregulation of vimentin in the FDW compared to FSM animals as well as a 2.5 fold downregulation 
of NOX2 (also known as CYBB) in the FDW compared to FSM animals. 
 In the current study, CLEC7A was downregulated in the FDW group compared to the FSM group and it is 
hypothesised that downregulation of its alarmin, vimentin, resulted in reduced activation of CLEC7A. This 
could have, in turn, impeded NOX activity, ultimately resulting in decreased O2
-. This may have prevented 
further proinflammatory responses in the LDH (since high levels of O2
- could lead to toxic effects) which 
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possibly contributed to neurogenesis and hippocampal memory (as discussed in 5.3.3.3 and illustrated in 
Fig. 5.3). DCS administration can enhance consolidation and retrieval of memory (Quartermain et al., 1994; 
Gabriele and Packard 2007) and in the present study DCS was co-administered with behavioural fear 
extinction. It is therefore proposed that co-administration of DCS and behavioural fear extinction may have 
facilitated consolidation and retrieval of extinction memories thereby facilitating the process of fear 
extinction. Furthermore, the hippocampus is one of the structures that play a role in consolidation of 
extinction (Cammarota et al., 2005); as the LDH was the site of injection, this may have further facilitated 
the fear extinction process. 
5.3.6.4 IL1RN 
 
The antagonist of the interleukin 1 receptor (IL1RN) was downregulated four-fold in the FDW compared to 
FSM group (Table 4.4, Section 4.2.2 and refer to Tables 4.5 – 4.9 Section 4.2.3 for GO enrichment results). 
Differential expression of this gene was also detected with SYBR Green real-time qPCR analysis in the LDH 
of the rats. Interleukin 1 (IL1) is one of the most important and predominant proinflammatory cytokines 
(Dinarello, 1998). The IL-1 system is composed of two known agonists, IL-1alpha (IL-1α) and IL-1beta (IL-
1β), and their levels are regulated by the endogenous IL1RN. There is, however, a very narrow margin 
between clinical benefit and unacceptable toxicity when it comes to the levels of IL1 in humans (Dinarello, 
1998). Both IL1 and IL1RN are released from glia and microglia and act on neuronal and glial receptors 
(Molina-Holgado et al. 2003; Tsakiri et al. 2008).  
 
During the maintenance phase of LTP, there is a strong and sustained increase in the levels of IL1β 
(Balschun et al., 2004; Schneider et al., 1998). Long-term potentiation at the synaptic level is believed to 
underlie memory consolidation (Bliss and Lømo, 1973; Teyler, 1987). Accordingly, researchers have found 
that elevated levels of IL1RN, which blocks the binding of IL-1β, impair learning (Oprica et al., 2005) and 
interferes with the memory consolidation process (especially in the hippocampus) (Spulber et al. 2009). 
These findings, together with earlier research showing that IL1 receptor blockage interferes with the BDNF-
ERK1/2 pathway (which mediates the effects of BDNF on synaptic plasticity, nuclear signalling, and 
memory formation (Finkbeiner et al., 1997; Gottschalk et al., 1999; Blanquet 2000; Pizzorusso et al., 2000; 
Alonso et al., 2002a,b)), suggests that physiologically appropriate levels of IL1 are essential in learning and 
long-term memory consolidation (refer to Section 5.3.3.3 and Fig. 5.3). 
The current study therefore hypothesised that neuroinflammation, induced under stressful conditions such as 
fear conditioning could mediate neuronal dysfunction through decreased neurogenesis and hippocampal 
memory (pertaining to consolidation and retrieval of extinction memories), which may be induced by 
dysregulated levels of IL-1β in the microglia. In the present study, lower levels of the IL1RN gene were 
detected in the in FDW group compared to the FSM group. Since overexpression of IL1RN impairs IL1 
signalling in the brain, which could result in subsequent impairments in neurogenesis, learning and 
hippocampal memory (refer to Section 5.3.3.3 and Fig. 5.3) (especially hippocampal consolidation of 
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extinction memories), downregulation of this gene is therefore hypothesised to attenuate these impaired 
neuronal processes and may possibly assist in the fear extinction process.  
5.3.6.5 FCER1G 
 
The gene that encodes the gamma chain of the IgE receptor CD23, FCER1G, was downregulated about 1.5 
fold in the FDW group compared to the FSM group (Table 4.4, Section 4.2.2 and refer to Tables 4.5 – 4.9 
Section 4.2.3 for GO enrichment results). This gene has also been found to be upregulated in the brains of 
neuromyelitis optica (NMO), Parkinson diseases (PD) and amyotrophic lateral sclerosis (ALS) patients 
compared to a universal control (Satoh et al., 2008). Following further bioinformatics analyses (to analyse 
molecular interaction on the curated knowledge database) Satoh et al. (2008) proposed that the up-regulated 
genes in NMO brain lesions were possibly transcriptionally regulated by NFkB and B-lymphocyte-induced 
maturation protein-1 (Satoh et al., 2008). NF-kB is an essential regulator of innate and adaptive immune 
responses, cell proliferation, and apoptosis (Li and Verma 2002), and it also regulates the expression of 
various proinflammatory target genes (Kumar et al., 2004). Furthermore, studies have found that the stress-
induced upregulation of NF-κB complex in the hippocampus may contribute to the impaired physiological 
and behavioural processes in stress-related disorders (Cohen et al., 2011). In a study that investigated gene 
expression profiles of immune/inflammation-related genes in the aging brain, FCER1G was found to be 
significantly upregulated throughout the aging brain, including the hippocampus, and the authors 
hypothesised that the extensive innate immune activation they observed in their study may increase 
vulnerability to cognitive decline and neurodegeneration (Cribbs et al., 2012). This suggests that activation 
of immune system genes and proinflammatory genes, induced in response to exposure to stress, could 
contribute to cognitive decline and neurodegeneration. 
 
A recent study, using a mouse model of chronic mild stress (CMS) found that FCER1G was downregulated 
in the prefrontal cortices (PFC) of WA (well-adapted) animals (the low swim stress-induced analgesia [LA] 
mice exhibiting low stress responses) (Lisowski et al., 2013). Furthermore, GO enrichment analysis by 
Lisowski et al. (2013) revealed that FCER1G was associated with the following GO terms (as indicated by 
the Expression Analysis Systemic Explorer program): signal transduction, response to stress, immune 
response and behavioural response to external stimulus, regulation of apoptosis or cell death as well as signal 
transducer activity, receptor activity or GPCR (Lisowski et al., 2013). This corresponds to enrichment 
analysis results from the present study, where this gene was associated with enriched GO terms such as 
immune system disorders, immune response, cell death, response to stimuli and signal transduction.  
In the current study, FCER1G downregulation may have facilitated fear extinction in the LDH in a similar 
fashion as has been observed in the PFC in the study by Lisowski et al. (2013). Furthermore, in light of its 
increased expression in autoimmune diseases (such as NMO, PD, and ALS), the current study hypothesises 
that downregulation of FCER1G (possibly facilitated by NF-kB) in the FDW compared to the FSM group, 
may have attenuated neuroinflammation in the LDH, which possibly mediated hippocampal memory 
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(especially hippocampal consolidation of extinction memories) and neurogenesis (refer to Section 5.3.3.3 




Thyrotropin releasing hormone gene (TRH) was found to be 2.8 fold downregulated in the FDW group 
relative to the FSM group (Table 4.4, Section 4.2.2 and refer to Tables 4.5 – 4.9 Section 4.2.3 for GO 
enrichment results). Differential expression of this gene was also detected with SYBR Green real-time qPCR 
analysis in the LDH of the rats. TRH was the first hypothalamic hormone to be isolated (Nillni and Sevarino 
1999). It is a neuropeptide and is the central regulator of the hypothalamic-pituitary-thyroid (HPT) axis 
(Boler et al., 1969). Produced in the paraventricular nucleus of hypothalamus, TRH stimulates the anterior 
pituitary to synthesise and secrete thyroid-stimulating hormone (TSH), which subsequently stimulates the 
synthesis and release of thyroid hormones (Dietrich et al., 2012). TRH is widely distributed in various brain 
regions (such as the limbic, hypothalamic, cortical and spinal regions) and exerts a range of effects as a 
neurotransmitter or neuromodulator (Nillni and Sevarino 1999). It is also present in numerous peripheral 
tissues and is therefore implicated in diverse physiological functions. The traditional role of TRH is to 
regulate metabolic homeostasis, which also extends to its neurobiological functions, namely the promotion of 
homeostasis in the CNS (Gary et al., 2003). TRH can elicit endogenous antidepressant effects, has 
neuroprotective as well as anti-epileptic properties and is one of several co-transmitters within glutamatergic 
neurons (Kubek et al., 1989; Low et al., 1989; Hrabovszky and Liposits 2008). Furthermore, TRH was 
shown to be involved in the pathophysiology of various neuropsychiatric disorders (Sattin, 1999).  
 
Exogenous administration of TRH has been shown to elicit anxiolytic effects (Vogel et al., 1980 Horita, 
1998; Prokai, 2002). Fear-conditioned rats have been shown to exhibit decreased acoustic startle and 
freezing responses following ICV TRH injection into the amygdala. However, it was shown that, using this 
paradigm, the HPT was not activated (Thompson and Rosen, 2000). To this end, TRH decreased acoustic 
startle and freezing responses, but had a limited effect on fear conditioning and active avoidance (Thompson 
and Rosen, 2000). The authors suggested that the results may be due to the effects of TRH on motor activity 
and arousal, independent of its effects on fear. Following these results, doubt was shed on the ability of TRH 
to truly reduce fear. It could therefore be deduced that endogenously produced TRH and exogenously 
administered TRH, utilise different mechanisms to elicit responses and a fine balance is required in order to 
maintain homeostasis. Furthermore, hippocampal TRH neurons have been shown to be involved in spatial 
learning and memory processes, whereas in the amygdala, TRH has an anxiolytic role (Guilar-Valles et al., 
2007).  
Cholinergic transmission is activated by TRH (Sabbatini et al., 1998) through the activation of cortical 
(Horita et al., 1986) and septohippocampal (Lamour et al.,1985) cholinergic neurons, thereby inducing 
release of acetylcholine (ACh) in the hippocampus (Hutson et al.,1990; Itoh et al., 1994). In the 
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hippocampus, TRH has the ability to affect glutamatergic and GABAergic neurotransmitter systems 
(Ishihara et al., 1992; Stocca and Nistri, 1995). Due to its ability to influence hormones and transmitters that 
form part of the HPA axis, it is hypothesised that dysregulation of TRH could contribute to dysregulation of 
the HPA axis. 
Lisowski et al. (2013) found increased expression levels of this gene in MA animals (the high swim stress-
induced analgesia [HA] mice, exhibiting increased stress responses) in a CMS animal model. Another study 
has shown that the ventral hippocampus, another major projection area of TRH neurons, is involved in 
anxiety-like behaviour; the presumed stimulatory actions of TRH axons in these areas seem to promote stress 
responses and increase anxiety (Wittmann et al., 2009).  
In the current study we hypothesise that DCS-induced downregulation of TRH in the FDW group might have 
reduced stress responses in the animals (similar to what was seen in the study by Lisowski et al. (2013)). 
Furthermore, in light of the fact that TRH regulates hormones and transmitters (especially in the 
hippocampus) involved in the functioning of the HPA axis, and the fact that PTSD is characterised by 
dysregulation of the HPA axis, it is hypothesised that increased TRH in response to stress might further 
contribute to the dysregulation of the HPA axis. Therefore, it is hypothesised that by downregulating TRH in 
the FDW animals, DCS may possibly have facilitated appropriate HPA axis regulation which may have 
enabled a more normal stress response in the FDW group. 
5.3.6.7 MMP9  
 
Expression levels of the matrix metallopeptidase 9 gene (MMP9), also known as gelatinase B, were more 
than two-fold lower in the FDW compared to the FSM animals (Table 4.4, Section 4.2.2 and refer to Tables 
4.5 – 4.9 Section 4.2.3 for GO enrichment results). Downregulated expression of this gene was also detected 
in the blood samples of FDW compared to FSM animals with SYBR Green real-time qPCR analysis. Matrix 
metalloproteinases are a family of secreted, cell-surface zinc- and calcium-dependent endopeptidases that 
catalyse the proteolysis of the extracellular matrix (ECM) and associated proteins (Dzwonek et al., 2004; 
Kaczmarek et al., 2002; Wright and Harding, 2004). Numerous studies have implicated MMPs in damage 
and repair in the brain under pathological conditions (Yong et al., 2005; Milward et al., 2007). In addition, 
MMP9 has also been shown to be involved in learning and memory processes (Nagy et al., 2006; Meighan et 
al., 2006, 2007; Wright et al., 2007). Inhibition of MMPs in the lateral ventricles (Meighan et al., 2006) or 
dorsal hippocampus (Wright et al., 2007), has been found to result in suppressed spatial learning. Also, the 
induction and stability of LTP is abolished in response to MMP9 blockade or broad MMP inhibitors 
(Meighan et al., 2007; Nagy et al., 2006). Impairment in contextual fear conditioning was observed in MMP9 
knockout mice (Nagy et al., 2006) and MMP9 and MMP3 have been shown to have a critical function in 
inhibitory avoidance learning (Nagy et al., 2007; Olson et al., 2008).  
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While the studies above emphasised the beneficial roles of MMPs in the development and normal physiology 
of the healthy CNS, results from the current study regarding MMP9 expression appear to contradict the 
aforementioned results, since MMP9 was found to be downregulated in the FDW animals. However, 
numerous studies utilise knockout animal models in order to determine the function of a particular gene. 
However, as was illustrated for numerous proteins or genes expressed in the brain, there is a very delicate 
balance between physiologically appropriate levels and levels that contribute to disease pathology. Under 
normal developmental and physiological conditions in the healthy CNS, specific MMP members are 
discretely expressed, however, the simultaneous upregulation of several MMP members at high levels have 
been observed during disease states; this synchronised upregulation tend to promote disease progression even 
further (Agrawal et al., 2008).  
 
Increased levels of active MMP9 protein were observed in MS patients compared to controls (Leppert et al., 
1998; Liuzzi et al., 2002; Fainardi et al., 2006) and elevated serum levels of MMP9 in MS patients correlated 
with the increased lesions as detected by magnetic resonance imaging (MRI) (Lee et al., 1999; Waubant et 
al., 1999). In addition, MMP9 serum levels have been found to rise progressively when patients convert from 
clinically isolated syndromes (a first demyelinating event, where MS diagnosis has not yet been confirmed) 
to the clinical diagnosis of MS (Correale et al., 2003). High expression levels of MMPs can furthermore 
mediate apoptosis of neural cells which results in tissue injury and subsequent neurodegeneration (Yonget 
al., 2001). Furthermore, MMPs have been implicated in the involvement in processes that promote 
neuroinflammation (Gijbels et al., 1993). A recent study found a unique CCR2+CCR5+ T cell population to 
be enriched in the CSF of patients with exacerbated MS (Sato et al., 2012). The authors found that this T cell 
population was specifically involved in the autoimmune pathology of MS. In comparison to other T cell 
populations, the CCR2+CCR5+ T cells have an exceptional ability to produce MMP9. Since MMP9 has the 
ability to disrupt the glia limitans (the outermost layer of neural tissue, it works in concert with other CNS 
components, such as BBB to regulate movement of small molecules and cells into the brain parenchyma), 
the authors speculated that they may have the potential to destroy the integrity of the BBB and trigger an 
inflammatory pathology cascade. An  in vitro model of glia limitans has also shown that the MMP9–
producing CCR2+CCR5+ T cells were indeed superior to the other T cells in their ability to cross the  in vitro 
model of glia limitans (Sato et al., 2012). 
Increased neuroinflammation is one of the contributing factors to CNS disease pathologies (including PTSD) 
(McEwen, 2008 and Saavedra et al., 2011). In the present study, is has been postulated that DCS possibly 
attenuates excessive inflammatory responses in the LDH by downregulating genes involved in inflammatory 
and oxidative stress responses. Interestingly, MMP9 has been found to be induced by various 
proinflammatory cytokines: TNF-α and IL-1α significantly induced MMP9 synthesis and secretion in 
mesenchymal stem cells-derived osteoprogenitors (Ben David et al., 2008). Similar results were found in the 
brain, where IL-1β was found to be a key regulator of neuronal MMP9 in culture and it mediated the 
upregulation of MMP9 following CNS trauma in mice (Vecil et al., 2000).  
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Taken together, the aforementioned studies illustrate that there is a delicate balance of MMP levels, 
including that of MMP9, that must be preserved in the CNS to maintain homeostasis. In the current study the 
expression of MMP9 was downregulated in the FDW group. It is hypothesised that in the present study 
administration of DCS alleviated neuroinflammation by downregulating genes involved in inflammatory and 
oxidative stress responses. This possibly resulted in lower levels of inflammatory cytokines and since MMP9 
is induced by cytokines, it is hypothesised that decreased levels of cytokines possibly resulted in lower levels 
of MMP9 in the FDW animals compared to the FSM animals. Furthermore, since high expression levels of 
MMPs can mediate apoptosis of neural cells, resulting in tissue injury and subsequent neurodegeneration 
(Yonget al., 2001), it is hypothesised that in the present study, DCS may possibly have prevented neuronal 
apoptosis and degeneration in the LDH by downregulating MMP9. This, together with the other effects 
mediated through the co-administration of DCS and behavioural fear extinction, may have facilitated the 
fear extinction process.  
The current study was also able to detect decreased levels of MMP9 in the blood samples of the FDW 
animals compared to FSM animals, which is in accordance with MS studies that found these perturbations in 
serum (Correale et al., 2003). Sato et al. (2012) showed that MMP9 expressing T cell populations in the CSF 
compromised the integrity of the BBB and was able to cross it and enter the CNS. Disruption of the BBB can 
also enable T cells to invade into the parenchyma and cause further CNS inflammation (Engelhardt, 2010). It 
is therefore hypothesised that in the present study, exposure to stress induced a systemic inflammatory 
response whereby MMP9 was upregulated (possibly through specific T cell populations) (enabling the 
detection of MMP9 in the blood of the rats). It is further hypothesised that, in a similar fashion as described 
by Sato et al. (2012), increased MMP9 might have compromised the integrity of the BBB, enabling MMP9 
to enter the CNS and induce further neuroinflammation and cell destruction. Expression levels of MMP9 in 
the blood may therefore possibly be used as a screening tool to detect corresponding levels of MMP9 in the 
brain. In addition, in the context of anxiety, MMP9 levels may even be used to identify individuals 
susceptible to excessive neuroinflammatory responses and neurodegeneration and the possible development 
of anxiety disorders or PTSD, following exposure to a traumatic event. 
5.3.6.8 CYBB 
 
Expression levels of the cytochrome b-245, beta polypeptide gene, CYBB (also known as NADPH Oxidase 2 
[NOX2]), was 2.5 fold downregulated in the FDW compared to the FSM group (Table 4.4, Section 4.2.2 and 
refer to Tables 4.5 – 4.9 Section 4.2.3 for GO enrichment results). Differential expression of this gene was 
also detected with SYBR Green real-time qPCR analysis in the LDH of the rats. CYBB is a key component 
of the innate host defence system (Leto and Geiszt 2006). One of its primary functions is O2- and ROS 
production in order to induce oxidative burst (explained in Section 5.3.6.3) in phagocytes, which enables 
digestion of engulfed bacteria (Datla and Griendling 2010; Wang et al., 2008; Tyagi et al., 2011; Brown and 
Griendling 2009; Lambeth et al., 2008).  
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However, CYBB is also widely distributed in non-phagocytic cells (Garrido et al., 2009; Sorce and Krause 
2009). CYBB is distributed in somatodendritic and axonal profiles in the hippocampus, prefrontal cortex and 
nucleus tractus solitarius (NTS) (Wang et al., 2004). NTS dysregulation not only disrupts cardiorespiratory 
homeostasis, leading to hypertension, but it was also proposed to be involved in anxiety and mood disorders 
(such as depression, PTSD, panic disorder etc.) (Liu et al., 2012). Anxiety and mood disorders have been 
closely linked to CYBB-mediated oxidative stress, especially following social isolation (Nair et al., 2011; 
Rammal et al., 2008; Hovatta et al., 2005; Masood et al., 2008; Schiavone et al., 2009). Indeed, a growing 
body of literature supports the hypothesis that CYBB-derived ROS is involved in the pathophysiology of 
anxiety and bipolar disorders (Gard 2004; Sorce and Krause, 2009; Inaba et al., 2009; Andreazza et al., 2009; 
Tsaluchidu et al., 2008; Yumru et al., 2009; Steckert et al., 2010).  
Furthermore, in an animal model of AD, mice that were CYBB-deficient did not develop oxidative stress, 
cerebrovascular dysfunction, or behavioural deficits associated with AD (Park et al., 2008). A lack of CYBB 
(mice lacking NOX2) was also associated with improved cognitive performance (as measured by the spatial-
memory task). Genetic inactivation of CYBB counteracts oxidative stress and vascular dysfunction, therefore 
Park et al. (2008) hypothesised that cerebrovascular dysfunction, induced by CYBB-derived radicals, may 
have a role in the neuronal dysfunction underlying the cognitive impairments in Alzheimer’s disease (Park et 
al., 2008).  
The renin-angiotensin system (RAS) and its active peptide angiotensin II (AngII) are not only actively 
involved in hypertension but also play a major role in mood and anxiety disorders. Studies have revealed that 
CYBB-induced ROS production in the brain was mediated by the AngII peptide (Wang et al., 2004; Hirooka 
et al., 2011; Sorce and Krause 2009; Inaba et al., 2009; Zimmerman, 2011; Wang et al., 2008). Moreover, 
continuous activation of RAS in the brain impairs cognitive functions through CYBB-derived ROS (Inaba et 
al., 2009). Two subtypes of AngII receptors, namely, AT1R and AT2R, mediate the effects of AngII 
(Nguyen Dinh Cat et al., 2011). Furthermore, AT1Rs was found to be highly expressed in the HPA axis 
(Karamyan and Speth 2008) and to contribute to the majority of harmful effects induced by AngII (such as 
hypertension, heart failure and mood disorders (Phillips et al., 2008; Davisson et al., 2006)). Considerable 
evidence points to the involvement of AngII in anxiety disorders, which is mediated by the effects of AngII 
in the HPA and sympatho-adrenal axis (Shelton, 2007), as AngII in the brain was associated with higher 
HPA axis activity as well as enhanced responses to stress and anxiety (Pavel et al., 2008). In context of the 
current study, it is therefore hypothesised that decreased AngII may result in lower levels of CYBB-induced 
ROS, which could lead to lower levels of oxidative stress and inflammation. As continuous activation of 
RAS through CYBB-derived ROS impairs cognitive functions, a decrease could attenuate cognitive 
impairment. 
In the current study, expression levels of CYBB were found to be downregulated in the FDW compared to the 
FSM animals. Stress has been shown to increase oxidative stress in the brain (Zieker et al., 2007), we 
therefore propose that in the current PTSD animal model, conditioned fear may have resulted in increased 
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oxidative stress in the fear conditioned animals. Given the functional role of CYBB in immunity and ROS 
production, and that CYBB-induced ROS (possibly mediated by the AngII’s effect on the HPA axis, as 
explained above) is proposed to be involved in the pathophysiology of anxiety disorders, it is proposed that, 
in the FDW group, the co-administration of DCS and behavioural fear extinction resulted in the 
downregulation of CYBB (which may have been mediated through AngII and AT1Rs), this possibly resulted 
in decreased levels of ROS, oxidative stress and further proinflammatory reactions (induced by ROS). This 
possible decrease in cytokines may have facilitated increased hippocampal memory and neurogenesis 
(through the mechanisms proposed in Section 5.3.3.3 and Fig. 5.3). Furthermore, since ROS may mediate 
neuronal cell death, it is hypothesised that downregulation of CYBB may have attenuated neuronal damage 
in the LDH (a brain region involved in fear) and may have contributed to fear extinction. 
5.3.6.9 S100A3, S100A4 and S100A9 
 
Three other genes that were downregulated in the FDW group belonged to the family of S100 calcium 
binding proteins. These genes were S100A3, S100A4 and S100A9, which were 2.2, 3.5 and 3.5 fold 
downregulated respectively (Table 4.4, Section 4.2.2 and refer to Tables 4.5 – 4.9 Section 4.2.3 for GO 
enrichment results). Differential expression of S100A4 was also detected with SYBR Green real-time qPCR 
analysis in the LDH of the rats. S100 proteins are involved in growth, differentiation, cell division and 
survival; the majority of the S100 proteins’ functions are calcium-dependent, with the exception of a few 
calcium-independent functions (Santamaria-Kisiel et al., 2006). Due to their vast array of functions, S100 
proteins are implicated in various physiological and pathological conditions such as inflammation, arthritis 
and inflammation-associated cancer (Gebhardt et al., 2006; Senolt et al., 2006; Foell et al., 2007). In the 
nervous system, S100 proteins have intracellular functions, where they are involved in the regulation of 
synaptic vesicle trafficking (Benfenati et al., 2004), cell survival and differentiation (Arcuri et al 2005). S100 
proteins also have extracellular functions, where they interact mainly with RAGE (Donato, 2003). S100 
proteins are released by glial cells following insults to the CNS. Furthermore, increased levels of S100 
protein have been detected in serum in several neurological pathologies, including head injury, stroke and 
neurodegenerative diseases (Donato, 2001). S100 proteins are also part of the group of alarmins or ligands 
that bind to the TLR class of pattern recognition receptors which has been shown to contribute to chronic 
inflammation (Lotze et al., 2004; Scheibner et al., 2006; Okamura et al., 2001; Ohashi et al., 2000; Shelton et 
al., 2008). 
 
S100A3 and S100A4 have been associated with cancer and are part of one of the subgroups that is associated 
with neoplasias (the formation of an abnormal mass of tissue) (Marenholz et al., 2004). S100A4 is secreted 
and act in a cytokine-like manner (Newton and Hogg 1998). Furthermore, high levels of S100A4 in white 
matter astrocytes were found to elicit a negative effect on astrocyte neurite growth, whereas extracellular 
application of S100A4 induced extensive growth of dorsal root ganglion cell neurites on white matter 
astrocytes (Fang et al., 2006). S100A4 was also found to display angiogenic effects (Ambartsumian et al., 
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2001). Multimeric forms of S100 proteins appear to be associated with extracellular activity of these 
proteins. S100A4 (Novitskaya et al., 2000) is one of the assemblies that is larger than dimers and such 
polymeric forms of S100 proteins are proposed to trigger aggregation of the receptor RAGE, thereby 
activating intracellular signalling cascades (Moroz et al., 2002). As discussed earlier, RAGE cross-linking of 
peptides and proteins results in irreversible tissue damage (refer to Section 5.3.4) and activates cell types 
such as macrophages, monocytes, vascular smooth muscle cells and cardiac fibroblasts, which consequently 
generates reactive oxygen species (ROS). Interaction between RAGE and its ligands is believed to result in 
the activation of proinflammatory genes (refer to Section 5.3.4) (Bierhaus et al., 2001).  
S100A9 is secreted and acts in a cytokine-like fashion. It is predominantly expressed in phagocytes and is 
strongly associated with proinflammatory functions (Ryckman et al., 2003). It primarily occurs in the 
extracellular space, where it acts as a chemotactic molecule to mediate proinflammatory signals (Marenholz 
et al., 2004). The S100A8/A9 heterodimer was shown to act as a chemotactic molecule in inflammation 
(Newton et al., 1998), and S100A9 has been implicated in inflammatory disorders (such as rheumatoid 
arthritis, chronic bronchitis, and cystic fibrosis).  
S100 proteins display different effects in cultured neuronal and glial cells, depending on their extracellular 
concentrations. They elicit trophic effects when they are present in the nanomolar range, and toxic effects in 
the micromolar range (Adami et al., 2004; Reali et al., 2005; Businaro et al., 2006). Similarly, dose-
dependent effects have been described for the effect of S100 proteins on learning and memory in rodents 
(Donato 2001). High doses of antibodies that bind to S100 proteins have been shown to impair LTP 
(Rebaudo et al., 2000) and induce amnesia for passive avoidance in chicks (O’Dowd et al., 1997), however 
at ultralow doses, these antibodies have the opposite effects (Epstein et al., 2003, 2006). High levels of S100 
protein in the brain has detrimental effects on memory function, therefore it is thought that increased levels 
of S100 protein in the brain of Alzheimer’s patients may be associated with some cognitive deficits 
associated with Alzheimer’s disease (Korfias et al., 2006).  
Numerous studies have suggested a role for S100 proteins in anxiety. In S100 protein knockout mice, 
decreased anxiety-related behaviour was evident in avoidance-approach tests, suggesting a role for these 
proteins in the modulation of fear and anxiety (Ackermann et al., 2006). Other studies have showed that 
restraint stress increases S100 protein levels in serum (Scaccianoce et al., 2004) and exposure to predator 
stress (odour) transiently increases S100 protein levels in CSF of adult rats (Margis et al., 2004). 
Furthermore, increased concentrations of S100b protein in serum were associated with anxiety-like 
behaviour in adult male rats following exposure to electric shocks and weekly sessions of situational 
reminders (Diehl et al., 2007). 
Considering the literature discussed above, it is clear that the S100 proteins, especially S100A4 and S100A9, 
are involved in inflammatory processes as well as in the modulation of fear and anxiety. In the present study, 
downregulation of S100A3, S100A4 and S100A9 expression was detected in the FDW compared to the FSM 
group. In light of the cytokine-like actions of S100A4 and S100A9 and their proinflammatory functions, it is 
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proposed that downregulation of these genes in the FDW group may have resulted in reduced levels of 
inflammation in the LDH. Furthermore, since S100A4 is a RAGE ligand and RAGE cross-linking of peptides 
results in ROS generation as well as tissue damage, it is hypothesised that downregulation of S100A4 may 
have attenuated tissue damage in the LDH. It is therefore hypothesised that downregulation of S100A4 and 
S100A9 possibly contributed to the fear extinction process by decreasing neuroinflammation, attenuating 
tissue damage and possibly by supporting hippocampal memory and neurogenesis (through the mechanisms 
proposed in Section 5.3.3.3 and Fig. 5.3).  
5.3.6.10  NPY 
 
Neuropeptide Y was another gene that was differentially expressed, with a 1.3 fold downregulation in the 
FDW compared to the FSM group (Table 4.4, Section 4.2.2 and refer to Tables 4.5 – 4.9 Section 4.2.3 for 
GO enrichment results). Even though NPY didn’t have a big fold change in the current study, it was included 
in the discussion due to the fact that numerous studies have implicated NPY in anxiety disorders and PTSD 
(Munglani et al., 1996; Husum et al., 2002; Sah and Geracioti 2013; Serova et al., 2013). It is one of the most 
abundant and evolutionary conserved peptides in the CNS (Larhammar 1996a, 1996b). NPY has been shown 
to be involved in the regulation of hormone synthesis and release, feeding, memory, anti-anxiety action and 
circadian rhythms (Heilig and Widerlöv, 1995). Experimental studies in model organisms implicate NPY and 
its receptors in several pathological disorders, including obesity, anxiety-related disorders, depression and 
epilepsy or seizures (Klapstein and Colmers 1997; Munglani et al., 1996; Wahlestedt and Reis 1993). NPY 
modulates excitatory synaptic neurotransmission in the hippocampus by acting at Y2 receptors and 
subsequently inhibiting glutamate release onto pyramidal cells (Colmers and Bleakman 1994; Greber et al., 
1994; Schwarzer et al., 1998). One of the most important properties of endogenous NPY is its anxiolytic 
effects (Heilig, 1995). Several animal models of fear or anxiety have illustrated that the effects of centrally 
administered NPY were similar to those observed with typical anxiolytic drugs (Heilig et al., 1989; Heilig et 
al., 1993; Broqua et al., 1995; Sajdyk et al., 1999).  
 
In the present study, reduced levels of NPY gene expression were noted in the FDW animals relative to the 
FSM animals, which initially appeared to contradict the previously discussed literature. However, literature 
has also shown that, depending on the site of administration, NPY may have beneficial or detrimental effects 
on cognitive processing. They found that, when administered directly into the dorsal hippocampus, NPY 
administration resulted in enhanced learning and memory, whereas direct administration into the ventral 
hippocampus, amygdala and septum, resulted in amnestic effects (Redrobe et al., 1999; Flood et al., 1987, 
1989). Furthermore, the endogenous response of NPY to stressful events and the effects of exogenous 
administration of NPY following stressful events appear to be different. A study by Krysiak et al. (2000) 
showed that conditioned fear resulted in increased levels of NPY in the amygdala, nucleus accumbens and 
the hypothalamus (Krysiak et al., 2000). Another study also found that single immobilisation stress increased 
mRNA levels of NPY in the superior cervical ganglia and stellate ganglia of the adrenal medulla of rats 
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(Nankova et al., 1996). In addition, repeated electroconvulsive stimulation has been shown to result in a 
long-term increase in hippocampal NPY neurotransmission (Husum et al., 2000; Madsen et al., 2000; Mathé 
et al., 1998; Greisen et al., 1997; Zachrisson et al., 1995; Mikkelsen et al., 1994).  
A major link between the immune and nervous systems is the sympathetic nervous system (SNS) (Felten and 
Olschowka, 1987). Activation of the SNS results not only in the release of catecholamines (CA), such as NE 
and epinephrine, but also results in the release of NPY and other neuropeptides (Lundberg et al., 1989). This 
CA and NPY releasing pattern also occurs in sympathetic nerve fibers that terminate in lymphatic tissues 
(Felten et al., 1985), providing a functional anatomical link for a role of NPY in SNS-mediated 
immunomodulation. Indeed, studies have demonstrated various effects of NPY on several immunological 
parameters. Furthermore, stress is one of the physiological conditions that leads to SNS activation. The fact 
that NPY is released during stress via the SNS provides the basis for this peptide’s function in stress-induced 
immune alterations (Bedoui et al., 2003).  
NPY is also regarded as a neuroimmune transmitter that fine-tunes immunological functions (Bedoui et al., 
2003). Studies have shown that NPY can directly increase the release of oxygen radicals (De la Fuente et al., 
1993) to modulate inflammatory paw edema via interaction with Y1 and Y5 receptors (Dimitrijevic et al., 
2002). It was also established that NPY elicits proinflammatory effects on antigen-presenting cells 
(Prod’homme et al., 2006). In mice neutrophils, NPY resulted in increased levels of IL-1β (De la Fuente et 
al., 2001) and in mice T cells; it resulted in increased levels of IFN-γ (Levite et al., 1998). This dysregulation 
in the levels of IL-1β and IFN-γ may possibly mediate decreased neurogenesis and hippocampal memory 
(through the mechanisms proposed in Section 5.3.3.3 and Fig. 5.3). 
Therefore, we hypothesise that downregulation of NPY expression in the FDW compared to FSM groups 
may have attenuated the detrimental effects of ROS and neuroinflammation on neurogenesis and memory 
processes in the LDH, possibly through regulating levels of IL-1β and IFN-γ. This may possibly have 
contributed to the extinction of conditioned fear.  
5.3.6.11  MT2A 
 
Metallothionein 2A was downregulated about two-fold in the FDW compared to the FSM group (Table 4.4, 
Section 4.2.2 and refer to Tables 4.5 – 4.9 Section 4.2.3 for GO enrichment results). Although differential 
expression of this gene was not statistically significant in the SYBR Green real-time qPCR analysis in the 
LDH of the rats, a p-value of 0.06 indicated a trend towards a significant difference in expression (also 
showing lower levels of expression in FDW vs. FSM animals). Metallothionein (MT) is an enigmatic 
protein. Its physiological functions, especially in the CNS, are still under intense investigation 50 years after 
its discovery. Various studies have investigated this protein in order to associate its known biochemical 
properties of metal binding and free radical scavenging to the intricate workings of brain (West et al., 2008). 
To this end, MT1 and MT2 genes were found to be co-ordinately regulated by metals and glucocorticoids in 
mice (Searle et al., 1984; Yagle and Palmiter, 1985). Gene expression of MT2 can be metal-induced by a 
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process that is mediated through the action of short cis-acting DNA sequences, which are metal-responsive 
elements. Expression can also be induced by glucocorticoid-responsive elements (GREs) which induce 
MT2A expression in response to glucocorticoids (Karin et al., 1984b; Kelly et al., 1997). It has been 
proposed that increased levels of MT2, in response to inflammatory factors, are likely facilitated by 
cytokines, such as IL-6, through signal transducer and activator of transcription (STAT) factors (Lee et al., 
1999). STAT is one of the components of the JAK-STAT signalling pathway; this pathway transmits 
information from chemical signals outside the cell, through the cell membrane, and into gene promoters on 
the DNA, resulting in DNA transcription and activity in the cell (Aaronson and Horvath 2002). However, it 
is possible that not only IL-6 and STAT, but multiple stress, inflammation and oxidative stress signals 
participate in the induction of MT genes (West et al., 2008). 
 
Results from knockout studies indicate that MT-1/2 null mice displayed impairment in spatial learning and 
memory. Upon further investigation, the authors found that the MT-1/2 knockout-induced impairment was 
not due to learning per se, but more likely due to impairments in memory or attention processes (Levin et al., 
2006). Studies have also shown that the expression of MT-1/2 proteins is highly inducible in response to 
various stimuli, such as hormones, cytokines, metals, oxidative agents, inflammation and stress (Bremner, 
1987b; Sato and Bremner, 1993).  
 
MT2 plays an important function in the brain’s response to different onslaughts and damage (Allan and 
Rothwell, 2001). Levels of MT-1/2 in the brain have been found to be upregulated by psychogenic stress 
(Hidalgo et al., 1990), by the administration of glutamate analogues (Acarin et al., 1999; Dalton et al., 1995), 
cryogenic injury (Penkowa et al., 1999a,c), or by stroke or ischemia (Campagne et al., 1999, 2000; Neal et 
al., 1996; Tang et al., 2002; Trendelenburg et al., 2002). In addition, levels of MT-1/2 in the brain have also 
been consistently reported to be increased in Alzheimer’s disease (Duguid et al., 1989; Uchida, 1994; Adlard 
et al., 1998; Chuah and Getchell, 1999; Zambenedetti et al., 1998), multiple sclerosis (Lock et al., 2002; 
Penkowa et al., 2003b) and aging (Suzuki et al., 1994). 
 
Since MT2A expression can be induced in response to glucocorticoids, it is hypothesised that in the current 
study, dysregulation of glucocorticoids, due to HPA axis alterations that occur in response to stress, may 
have resulted in increased MT2A expression. Furthermore, MT2A expression is proposed to be even further 
induced through inflammatory factors, such as IL-6 (through STAT, which is one of the components of the 
JAK-STAT signalling pathway). It has been proposed that MT2A is upregulated in order to manage neuronal 
damage (Penkowa et al., 2001, 2003a; Giralt et al., 2002b; Penkowa et al., 1999b; Penkowa and Hidalgo, 
2000) and to decrease oxidative stress, inflammation and apoptosis in the CNS (Kang et al., 1997; Kondo et 
al., 1995; Lazo et al., 1995; Youn et al., 2002). However, the exact mechanism whereby these processes are 
facilitated remains to be fully elucidated (West et al., 2008). It is therefore also proposed that a fine balance 
in the amount of MT2A is probably required in order to maintain homeostasis in the CNS, therefore simple 
upregulation or downregulation may not fully explain the involvement of the gene in disease pathology, as is 
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the case with MT2A, where increased expression is observed in response to oxidative stress, however 
administration of MT2A elicits antioxidant properties (Andrews, 2000; Sato and Bremner, 1993). Therefore, 
in the present study, the downregulation of MT2A in the FDW compared to FSM animals is hypothesised to 
be a marker of lower neuroinflammation and oxidative stress. MT2A is hypothesised to be downregulated as 
a result of the decreased levels of inflammation and inflammatory cytokines which can be attributed to the 
downregulation of other proinflammatory genes and ROS inducing agents (induced by co-administration of 
DCS and behavioural fear extinction, as discussed throughout this chapter).  
 
5.3.6.12  Summary of differential gene expression induced by co-administration of DCS and 
behavioural fear extinction 
 
In summary, differential gene expression analyses in the current study revealed that one of the main effects 
of co-administration of intrahippocampal DCS and behavioural fear extinction was the downregulation of 
immune system genes and genes transcribing proinflammatory molecules as well as molecules involved in 
oxidative stress. By mediating the downregulation of these genes, DCS may have attenuated 
neuroinflammation and subsequent neuronal damage and impairment in hippocampal memory. Since 
differential expression of the aforementioned genes were detected between FDW and FSM animals, but not 
between CS and CD animals, it is hypothesised that the combination of behavioural fear extinction and DCS 
administration facilitated these expression changes. Furthermore, all of the genes discussed above, were also 
found to be significantly downregulated in the FDW vs. FSW groups (except MMP9). Genes that are 
differentially expressed between these groups (FDW vs. FSW) point to genes associated with DCS induced 
fear extinction pathway compared to the “natural” fear extinction pathway (seen in animals resilient to fear 
conditioning). It is therefore hypothesised that DCS-induced fear extinction possibly incorporates different 
genes and pathways compared to the “natural” processes of fear extinction. Concomitantly, these gene 
expression alterations may have mediated optimal neuronal functioning, plasticity, learning and memory 
which contributed to the fear extinction process in this animal model. This study therefore highlights the 
intimate connections between regulatory structures, specifically those of the neural and immune systems, and 
their importance in PTSD and anxiety disorder pathology and fear extinction.  
5.3.7 SYBR Green real-time quantitative PCR gene expression analysis 
Real-time qPCR is routinely used to verify next generation sequencing data (Nagalakshmi et al., 2008), 
however this technique is not without limitations. Technical aspects that could influence the final results 
include template quality, the reverse transcription (RT) step, subjectivity in data analysis and reporting 
(Bustin and Nolan 2004; Altar et al., 2009), selection of reference genes (Schmittgen and Zakrajsek 2000; 
Martínez-Beamonte et al., 2011), generation of false negatives and primer–dimers (Altar et al., 2009). It is 
also not known whether qPCR is the most effective means of validating RNAseq data: qPCR produces 
expression data relative to stably expressed reference genes, whereas RNA sequencing data (that generated a 
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sufficient number of reads) provides a more absolute representation of the transcriptome. Furthermore, next 
generation sequencing platforms have the capacity to generate millions of reads per sample, enabling this 
very sensitive technique to detect transcripts with low expression levels or slight differences in expression 
levels. Finally, next generation sequencing has the ultimate advantage of being able to identify novel 
transcripts (Git et al., 2010). However, since real-time qPCR is a much more cost-effective and simple 
screening method, its sensitivity to validate RNAseq results, in both LDH and blood samples of the rats, was 
investigated. Blood samples were investigated as they provide a less invasive means of obtaining genetic 
material and studies have shown comparable gene expression profiles in PBMCs and brain samples for 
certain genes (van Heerden et al., 2009). 
 
Relative gene expression analysis was performed on the same LDH cDNA used for RNAseq as well as blood 
cDNA from these samples. A subset of genes was selected for real time qPCR validation. These genes were 
selected based on the fact that they were statistically significant differentially expressed between FDW and 
FSM animals (fold changes ≥ 1.3 and p < 0.05); furthermore, high fold changes were detected during 
RNAseq analysis and these genes have been implicated in fear, learning, memory and anxiety in previous 
research. Statistically significant differential expression of five (CXCL13, CYBB, IL1RN, S100A4 and TRH) 
of the nine investigated genes could be detected using SYBR Green real-time qPCR in the rat LDH samples. 
Differential expression of MMP9 was not detected in the LDH samples, but it was the only gene for which 
SYBR Green real-time qPCR could detect significant differential expression in the rat blood samples (Table 
4.10). A trend towards a significant difference in expression levels between the groups was detected for 
MT2A (p = 0.06). Significant differential expression of SPP1 and NPY could not be detected with SYBR 
Green real-time qPCR.  
 
One explanation for not being able to detect differential expression for SPP1 and NPY with SYBR Green 
real-time qPCR in the LDH might be the small sample sizes (six rats per group), resulting in reduced 
statistical power to detect differences. A possible explanation for not detecting differential expression of 
CXCL13 and MT2A in the blood RNA, is the fact that expression of these genes are probably tissue-specific, 
since CXCL13 and MT2A could not be amplified in blood cDNA, suggesting very low or undetectable levels 
of these genes in blood. Indeed, the online repository, nextprot BETA, indicated that, based on previous 
microarray data, mRNA expression of CXCL13 has not been detected in blood 
(http://www.nextprot.org/db/entry/NX_O43927/expression#a-ts-line-322). However, the repository indicated 
that prior microarray studies have detected mRNA expression levels of MT2A in blood 
(http://www.nextprot.org/db/entry/NX_P02795/expression#a-ts-line-322).  
 
Expression of the other genes in the blood cDNA was, however, detectable with SYBR Green real-time 
qPCR. Furthermore, gene expression differences in the brain (induced by intrahippocampal DCS 
administration) are not necessarily reflected in the blood (might be a tissue specific change), and lastly, the 
small sample size of six rats per group, reduced statistical power to detect differences.  




These results indicate that qPCR can be used as a sensitive screening tool to detect differential expression of 
CXCL13, CYBB, IL1RN, S100A4 and TRH in LDH samples and MMP9 in blood samples between mal- and 
well- adapted animals in this specific animal model of PTSD. However, in the present study it was found that 
SYBR Green real-time qPCR will not necessarily detect all the differentially expressed genes identified in 
RNAseq analysis. 
 
5.4  DNA Methylation Analysis 
Epigenetic elements are one of the factors that mediate changes in gene expression. This study investigated 
whether differential DNA CpG island methylation facilitated the differential expression observed in the RNA 
sequencing data for MT2A, NPY and TRH. These genes were selected from the set of genes that were 
investigated with SYBR Green real-time PCR, based on the fact that they contained CpG islands and that 
they were associated with particular fear, anxiety and memory GO terms (any factors or phenotypes 
associated with anxiety/PTSD) initially identified during BORG analyses. Neuropeptide Y has also been well 
studied in anxiety disorders and PTSD, and differential methylation of NPY CpG islands have been 
investigated in obesity studies (Crujeiras et al., 2013); in the light of recent studies suggesting comorbidity of 
metabolic disorders and PTSD, NPY CpG island methylation was investigated since it could provide a 
potential link between the pathologies.  
No differences in CpG island methylation levels in any of the genes were detected between the FDW and 
FSM groups. Methylation levels were between 0% and 5% in both groups (Fig. 4.13 Section 4.3). It can 
therefore be concluded that different levels of methylation of these CpG islands between the two treatment 
groups did not mediate the differential expression of these genes. However, other forms of methylation could 
still contribute to the observed differences in expression. The CpG islands investigated were all in close 
proximity to the TSS, therefore methylation of these islands would be expected to influence initiation of 
transcription. However, gene body methylation, which does not necessarily block transcription and may 
stimulate transcription elongation (Moarefi and Chedin 2011), may have mediated the observed differential 
expression. This warrants further investigation. It is also possible that some of the other differentially 
expressed genes that were not screened for differential DNA CpG island methylation were in fact regulated 
by CpG island methylation. This should be investigated in future studies. Furthermore, other epigenetic 
regulators could have facilitated the observed differential gene expression, such as acetylation, methylation, 
phosphorylation, ubiquitination and sumoylation of histone proteins and non-coding RNA-mediated 
alterations (such as micro-RNAs (miRNAs) and small interfering RNAs (siRNAs)) (Yehuda and Bierer 
2009). The effect of differentially expressed miRNAs on gene expression was investigated in the present 
study, and will be discussed in the following section. 
5.5  MicroRNA expression analysis 
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MicroRNAs extracted from the LDH of the rats were sequenced by means of next generation sequencing 
technologies to identify miRNAs that were differentially expressed between the FDW and FSM animals. 
Differentially expressed miRNAs were further investigated to identify miRNAs that may have mediated the 
differential gene expression observed between FDW and FSM animals. 
5.5.1 Differential miRNA expression 
The overall quality of the sequencing reads that were generated from the miRNA cDNA was very high. 
However, when these reads were mapped to the reference genome there were four FSM and one FDW 
sample that had very few reads that could be mapped to the reference genome (Table 4.11 Section 4.4.1). 
This could not be attributed to the quality of the sequencing reads or the number of reads generated (Fig. 
4.14). The Basic Local Alignment Search Tool (BLAST) was used to determine the origin of reads that could 
not be mapped to the reference genome. Results indicated that the RNA PCR primer and certain RNA PCR 
Primer Indexes formed a duplex which was subsequently amplified and sequenced. This was probably due to 
the limited amount of available miRNAs in the LDH which could be amplified, together with the fact that the 
PCR cycle numbers were increased during the adapted protocol. Due to the very limited starting amount of 
miRNAs in the LDH, the adapted protocol was one of the only means of obtaining enough material to 
sequence. Indeed, the protocol was effective in amplifying six samples that could be sequenced and mapped 
sufficiently to the reference genome. It was, however, not as successful in the other six samples. 
Although this did not affect the GFOLD analysis itself, as the program only incorporates mapped reads in its 
analysis, due to the differences of mappable reads between the samples, it is likely to have resulted in sub-
optimal statistical power to detect differentially expressed miRNAs. When the analysis was repeated using 
only the samples that had a higher number of mappable reads, the same results were generated by GFOLD, 
therefore providing more confidence in the results generated. 
GFOLD analyses detected 23 miRNAs that were differentially expressed between FDW and FSM groups 
(Table 4.12, Section 4.4.1). Of these, three miRNAs were overexpressed in the FDW group compared to the 
FSM group. Typically, if a miRNA is upregulated, the expression of its direct mRNA target (based on 
sequence homology) is expected to be downregulated (due to endonucleotic cleavage or repression of 
translation or deadenylation of the mRNA target) (Kuss and Chen 2008). There is also the possibility of 
indirect targets, however we identified the mRNA targets of the differentially expressed miRNAs solely on 
sequence similarity, and therefore indirect targets were not included or investigated in this study. 
Subsequently, the study only focussed on those miRNAs that were upregulated in the FDW group that could 
mediate the downregulation of the genes identified in the FDW. 
However, pairing of the differentially expressed miRNA data and the biologically relevant differentially 
expressed genes (using IPA target filter and manual searches), identified miRNAs that were downregulated 
and predicted targeted genes that were also downregulated in this study (which is not in line with the basic 
theory of miRNA regulated gene expression, where downregulation of the miRNA usually results in 
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upregulation of the target gene) (Table 4.14, Section 4.4.2). This could be attributed to the fact that these 
miRNA:mRNA interactions are predicted mostly based on sequence similarity and do not take different 
biological or environmental factors (such as tissue differences, developmental stages, stress exposure or drug 
administration) into account. Since miRNA expression differs between cell types, tissues, developmental 
stages (Brown and Naldini 2009; Tang et al., 2007; Krichevsky et al., 2003), in response to stress exposure 
(Rinaldi et al., 2010; Meerson et al., 2010) or drug administration (Zhou et al., 2009) and also due to the 
complex nature of miRNA:mRNA interactions (where one miRNA can target numerous genes and one gene 
can be targeted by numerous miRNAs), it could be hypothesised that, even though those miRNAs are 
predicted to target those genes, in the context of fear conditioning and extinction of adult male Sprague 
Dawley rats, those miRNAs may not target those predicted mRNA targets in the LDH following DCS 
administration. Furthermore, other factors also influence the expression levels of genes, and even if some of 
these downregulated miRNAs possibly resulted in upregulation of their mRNA target genes, other factors, 
such as DNA methylation and posttranscriptional modifications of histone proteins, including acetylation, 
methylation, phosphorylation, ubiquitination and sumoylation, could ultimately have resulted in 
downregulation of these genes. 
5.5.1.1 Functions of differentially expressed miRNAs based on functions of their mRNA targets 
 
After identification of differentially expressed miRNAs in the LDH of the rats, it was important to determine 
the possible functions of these miRNAs, especially in the context of fear and anxiety. These functions can be 
deduced based on the functions of their predicted mRNA targets or by consulting the literature for previously 
described functions. One of the main associated functions, as predicted by IPA, was reproductive system 
disease (Table 4.13, Section 4.4.2), with 11 miRNAs that had predicted mRNA targets that were associated 
with this function. As mentioned above, these predictions mostly rely on sequence similarity and free energy, 
and do not take the biological context into account. The reason for the particular enrichment of reproductive 
system disease is not clear, as there is not direct connection with the current PTSD animal model. It was also 
not know whether the rats in the current study suffered from any reproductive system diseases.  
 
Another function that was associated with the predicted mRNA targets of differentially expressed miRNAs 
identified in the LDH was cardiovascular system development and function (Table 4.13, Section 4.4.2). With 
reference to the model described in Fig. 5.1 (Section 5.1) and previously published research, other disease 
pathologies that may develop due to chronic stress are atherosclerosis and cardiovascular disease (Kang et 
al., 2006; Boscarino et al., 2008). MiRNAs are expressed in a temporal-spatial fashion in the cardiovascular 
system. They have recently emerged as important modulators of cardiovascular development (Cordes and 
Srivastava 2009) and angiogenesis (Suárez and Sessa 2009). Dysregulation of miRNA expression is 
associated with cardiac hypertrophy, cardiac arrhythmias and arterial stenosis (Latronico and Condorelli 
2009). One of the differentially expressed miRNAs identified in the current study that was associated with 
cardiovascular system development and function is rno-mir-10b-5p. Research has shown that 
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downregulation of miR-10a in athero-susceptible regions in swine may contribute to endothelial 
proinflammatory signalling, which could ultimately result in atherosclerosis (Fang et al., 2010). In the 
present study this miRNA was downregulated in the FDW animals. It can therefore be hypothesised that 
DCS not only decreases neuroinflammation (which possibly contributed to hippocampal memory and fear 
extinction), but may also decrease endothelial proinflammatory signalling and lower the possibility of 
atherosclerosis. This reduction in proinflammatory signalling could also, in turn, possibly contribute to lower 
neuroinflammation (if these proinflammatory signalling molecules are able to cross the BBB). 
Together, these results indicate that several miRNAs that were found to be downregulated in the FDW group 
are associated with cardiovascular system development and function, and have been previously described to 
be associated with numerous cardiovascular diseases. Although these miRNAs are not directly implicated in 
fear extinction processes, they shed light on how fear conditioning and stress alters miRNA expression 
which could modulate the development of secondary pathologies, such as cardiovascular disease. 
5.5.1.2 Functions of differentially expressed miRNAs implicated in fear extinction or CNS 
functions 
 
Studies that have detected differential expression of the same miRNAs found to be differentially expressed in 
the present study were studies that investigated (i) the effects of antidepressants (rno-mir-144-3p) (Zhou et 
al., 2009) or electroconvulsive shock therapy (ECT) on miRNA expression in a maternal separation model 
(rno-mir-187-3p, rno-mir-33-5p, rno-mir-144-3p, rno-miR-10b-5p, rno-mir-339-3p, rno-mir-193-3p, rno-
miR-219-1-5p and rno-mir-451-5p) (O'Connor et al., 2013), (ii) miRNAs that tagged SNPs that were found 
to be associated with panic disorder (rno-mir-488-3p and rno-mir-339-3p) (Muiños-Gimeno et al., 2011), or 
(iii) comparative expression profiles of miRNAs in neural stem cells and motor neurons in rat embryonic 
spinal cord (rno-mir-31a-5p) (Wei et al., 2010) (Table 4.12, Section 4.4.1).  
Depression is one of the most prevalent co-morbid disorders in PTSD and other anxiety disorders. 
Expression profiles of miRNAs in the current study that correlated with expression profiles of miRNAs in 
studies that have investigated antidepressant treatments; where ECT, ketamine and the SSRI, fluoxetine 
resulted in the differential expression of miRNAs such as rno-mir-187-3p, rno-mir-144-3p, rno-miR-10b-5p, 
rno-mir-193-3p and rno-mir-451-5p (O'Connor et al., 2013). These results may point to miRNAs that could 
be targeted in the treatment of co-morbid depression. Since co-administration of DCS and behavioural fear 
extinction regulated miRNA expression in a similar fashion as certain antidepressant therapies (such as 
ECT, ketamine and the SSRI, fluoxetine), it is hypothesised that differential expression of these miRNAs 
could possibly facilitate the antidepressant effects of DCS previously reported in other studies (Crane 1959, 
1961; Zarate and Manji 2008; Heresco-Levy et al., 2013; Poleszak et al., 2013). D-cycloserine could 
therefore be an attractive therapeutic agent for patients exhibiting both PTSD and comorbid depression.  
Overexpression of miR-144, the miRNA that forms a cluster with miR451 (another downregulated miRNA 
detected in this study) in primary erythroid cells, has been found to significantly increase sensitivity to 
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oxidative stress (Sangokoya et al., 2010). The current study detected decreased levels of expression of rno-
miR-144-3p in the LDH of FDW animals compared to FSM animals. The co-administration of DCS and 
behavioural fear extinction possibly resulted in reduced sensitivity to oxidative stress in the brain, which 
may have been mediated by decreased levels rno-miR-144-3p, therefore protecting the CNS from oxidative 
damage and cell injury, which contributed to optimal neuronal function (Lisowski et al., 2013). 
Downregulation of rno-miR-144-3p by co-administration of DCS and behavioural fear extinction may 
therefore possibly have contributed to fear extinction (possibly facilitated through increased consolidation 
and retrieval of the extinction memories as DCS was infused into the hippocampus, which is a vital region in 
consolidation and retrieval of the extinction memories).  
One of the miRNAs that had a specific function relating to fear extinction, based on previous literature, was 
rno-mir-451-5p. Expression of this miRNA was previously correlated with behavioural measures for 
exploration on the elevated plus maze task and learning and memory measures (Parsons et al., 2008). The 
authors compared miRNA expression profiles between four inbred mouse strains, A/J, BALB/cJ, C57BL/ 6J, 
and DBA/2J, in the hippocampus. The authors did not, however, specify whether up- or downregulation of 
this miRNA correlated with increased or decreased exploration and learning and memory. In the current 
study, rno-mir-451 was significantly downregulated in the FDW group compared to the FSM group. We 
therefore hypothesise that, in the current study, downregulation of rno-mir-451 possibly facilitated increased 
exploration and improved learning and memory. One of the mechanisms whereby DCS thus facilitates fear 
extinction may be through downregulation of rno-mir-451.  
One of the three miRNAs that were upregulated in the FDW group compared to the FSM group was rno-mir-
31a-5p. This miRNA was predicted to target the differentially expressed genes, IL1RN, RAC2 and HMOX, 
from the RNAseq data (Table 4.14 Section 4.4.2). A study that investigated miRNA expression in the 
hippocampi of different inbred mice (C57BL/6 J x DBA/2 J recombinant inbred mice (BXD)) found 
significant correlations between miR-31 (previous nomenclature mir-31a) expression with both blood 
ethanol concentration and a measure of anxiety (as measured by the open field test and light-dark box 
measures), suggesting that this miRNA may be involved in alcohol- or anxiety-related traits (it was, 
however, not clear if up or downregulation of the miRNA was associated with the anxiety, and in which 
strains). KEGG pathway analysis revealed that miR-31 may possibly play a role in adult neurogenesis and 
axon guidance (Parsons et al., 2012). In the current study it is hypothesised that co-administration of DCS 
and behavioural fear extinction possibly resulted in rno-mir-31a upregulation in the FDW group compared 
to the FSM group. This miRNA may have targeted its predicted mRNA target, IL1RN, which may have 
facilitated the downregulation of this gene which, in turn, possibly facilitated neurogenesis, hippocampal 
memory and potentially fear extinction (through means discussed in Sections 5.3.3.3 and 5.3.6.5 and Fig. 5.2 
Section 5.3.3.2). Furthermore, differential expression of this miRNA may be involved in comorbid 
substance-related disorders (possibly by regulating genes that are associated with both substance related 
disorders and anxiety disorders). This hypothesis warrants further investigation.  
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In the current study, rno-mir-19b-1-3p was also downregulated in the FDW compared to the FSW group. 
This miRNA forms part of the miR-17~92 cluster and was found to ubiquitously regulate B-cell, T cell and 
monocyte development (Xiao et al., 2008). Xiao and colleagues found that increased miR-17~92 expressions 
in mice lymphocytes resulted in lymphoproliferative disease and autoimmunity. In the present study, co-
administration of DCS and behavioural fear extinction resulted in decreased levels of rno-mir-19b-1-3p, 
decreasing possible autoimmune responses which could have caused inflammation and subsequent tissue 
destruction. This corresponds with our previous gene expression findings where the autoimmune disease, 
systemic lupus erythematosus, was one of the enriched pathways associated with our biologically relevant 
differentially expressed genes, together with findings that DCS downregulates immune system genes and 
proinflammatory molecules that facilitate neuroinflammation. Therefore one of the possible mechanism 
utilised by DCS to facilitate the downregulation of immune-related genes and hamper neuroinflammation, 
could be through downregulation of rno-mir-19b-1-3p. 
5.5.1.3 Differentially expressed miRNAs that may have facilitated the observed gene expression 
changes 
 
Two miRNAs were upregulated and were predicted to target genes that were found to be downregulated in 
the FDW vs. FSM animals in the current study. Rno-mir-31a-5p was predicted (with moderate confidence, as 
indicated by the prediction programs) to target HMOX1, RAC2 and IL1RN, and rno-mir-187-3p was 
predicted (with moderate confidence) to target CD4, CD44, S100A4 and A2M and a highly confident 
prediction was made for C1S to be targeted by rno-mir-187-3p (Table 4.14 and Fig. 4.15, Section 4.4.2). 
Previous literature has shown that one of the mechanisms whereby certain antidepressant drugs elicit their 
effect is by regulating the levels of miRNAs (Baudry et al., 2010). For example, the administration of the 
SSRI fluoxetine (Prozac) increased the levels of miR-16 in serotonergic raphe nuclei, which resulted in 
reduced SERT expression (Baudry et al., 2010). It is therefore hypothesised that administration of DCS 
modulated the expression of rno-mir-31a-5p and rno-mir-187-3p; the upregulation of these two miRNAs 
may subsequently have resulted in the downregulation of their direct mRNA targets, which possibly 
facilitated or contributed to the fear extinction process, mostly by downregulating genes that mediate 
neuroinflammation, oxidative stress and/or neuronal damage, thereby improving neurogenesis and 
hippocampal memory (through mechanisms described in Section 5.3.3.3 and Fig. 5.3).  
 
The remaining differentially expressed miRNAs may possibly also have been involved in the modulation of 
the observed differential gene expression, through targeting genes that indirectly affected the expression of 
the genes detected to be differentially expressed in this study. This is however difficult to investigate as it is 
not based on sequence complementarity, but pertains to genes that regulate the expression of other genes. 
Furthermore, these miRNA may possibly also have targeted genes that were differentially expressed in the 
current study, but that were not regarded as biologically relevant by the BORG analysis tool.  
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In order to determine if predicted mRNA targets are true targets, in vitro functional analyses should be 
performed. In the current study such analysis was performed (Section 4.4.4) and will be discussed in Section 
5.5.2.  
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5.5.1.4 SYBR Green analysis of rno-miRNA-31a-5p in LDH brain and blood miRNA samples 
 
The upregulated miRNA, rno-miRNA-31a-5p, was selected for SYBR Green real-time qPCR analysis, to 
determine if this technique would be sensitive enough to detect the slight change in expression level in LDH 
and blood samples between the FDW and FSM groups. Rno-miRNA-31a-5p was selected as it was one of 
two miRNAs that were upregulated (therefore it possibly has the ability to downregulate genes identified in 
the RNAseq) and it targeted IL1RN, a gene that was more than four-fold downregulated in FDW vs. FSM 
LDH.  
 
Results indicated that SYBR Green real-time qPCR analysis was not able to detect differential expression of 
rno-miRNA-31a-5p in the LDH or blood samples of the rats. This could be attributed to the fact that the 
SYBR Green real-time qPCR may not be sensitive enough to detect such subtle differences in miRNA 
expression (1.1 fold upregulated), furthermore, sophisticated data analysis tools (GFOLD) had to be 
employed in order to detect this slight difference in expression. GFOLD was used due to the fact that Cuffdiff 
was not able to detect differential expression between the groups, possibly due to the differences in mappable 
reads between samples (as discussed in Section 5.5.1). It is also possible that this expression difference 
induced by DCS is tissue-specific and not detectable in the blood. Once again, the sample size used in this 
analysis was limited, with six animals per comparison group, resulting in less statistical power. 
5.5.2 Functional analysis of miRNA-target interaction 
The predicted interaction between rno-miR-31a-5p and IL1RN was selected for functional verification 
analysis in light of the involvement of IL1RN in learning and long-term memory, and the possible association 
between miR-31a-5p with anxiety-related traits. Co-transfection of a promoter clone containing the 3' UTR 
sequence of IL1RN and the rno-miR-31a-5p precursor clone resulted in significantly lower luciferase activity 
compared to co-transfection of the miRNA precursor and a scrambled target region (Fig. 4.17 Section 4.4.4). 
This suggests that IL1RN was a target of rno-miR-31a-5p. However, when luciferase signal was compared to 
that of the other controls, namely the scrambled miRNA precursor clone + IL1RN target region, and only the 
IL1RN target region alone without any miRNA precursor, there was no statistically significant difference in 
luciferase activity.  
Although the luciferase signal for the co-transfection between rno-miR-31a-5p and IL1RNI was clearly lower 
compared to the negative controls, this difference did not reach statistical significance. This suggests that 
miR-31a-5p may be endogenously expressed in this human embryonic kidney cell line, which targeted the 
IL1RN region, due to the fact that transfection of the IL1RN target region without rno-miR-31a-5p also 
resulted in decreased luciferase signal. Also, other miRNAs that are endogenously expressed in HEK 293 
cells that also target IL1RN (since one gene can be targeted by numerous miRNAs) could have resulted in 
lower luciferase signal (in the control transfection with only the IL1RN target region in the absence of rno-
miR-31a-5p). Also, the experiment was repeated on a separate occasion, therefore two biological repeats 
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were performed (the results presented are the means of the data from the two experiments), therefore the 
small sample size limited the statistical power of the analyses. Furthermore, the interaction between rno-
miR-31a-5p and IL1RN may be more pronounced in the presence of DCS or perhaps other cell stressors 
associated with physical stress (oxidative stress, inflammation, cell stress etc.), since this miRNA was found 
to be upregulated in the FDW group. Future studies could repeat the experiment in the presence of DCS.  
5.5.3 Limitations of the study 
This PTSD animal model provided the opportunity to perform brain-specific genetic analyses in order to 
determine the molecular mechanisms involved in DCS-facilitated fear extinction. It furthermore provided the 
opportunity to correlate gene and miRNA expression results between brain and blood samples. However, due 
to the fact that the blood was stored in RNAlater, DNA extraction proved to be problematic and DNA could 
not be extracted from these samples to correlate DNA methylation results between brain and blood samples. 
Future studies could store a subset of the blood in such a way that would enable DNA extraction or DNA 
extraction should be performed immediately after blood collection.  
Another limitation to the study was the limited amounts of miRNAs that could be obtained from the LDH 
samples. This brain region is quite small and in the present study DNA, RNA and miRNAs were extracted 
simultaneously from one LDH sample. These small amounts of miRNA starting material also gave rise to 
another problem, the formation of duplexes between the RNA PCR primer and the RNA PCR Primer 
Indexes, these duplexes were amplified and sequenced. This in turn resulted in the limited amount of 
miRNAseq reads that could be mapped to the reference genome. This resulted in sub-optimal statistical 
power to detect differentially expressed miRNAs. Furthermore, the number of reads generated during 
sequencing was also relatively low; higher read counts would increase the ability to detect a larger number of 
differentially expressed miRNAs as well as miRNAs that are expressed at low levels. On the other hand, the 
fact that the analyses included six biological repeats (six animals per subgroup) provided some strength to 
the analyses. It should however be kept in mind that this was a pilot study to determine whether sufficient 
amounts of miRNAs could be amplified from such limited starting amounts and that it can be sequenced to 
identify differentially expressed miRNAs that may have mediated the differential gene expression. Therefore 
sequencing was performed on the MiSeq system which only yielded an average of 1.9 million reads per 
sample. Despite these limitations, 23 differentially expressed miRNAs could be identified and follow-up 
sequencing will be performed on a higher throughput platform in order to verify these results, increase the 
read depth and facilitate the detection of a larger number of differentially expressed miRNAs as well as 
miRNAs expressed at low levels.  
Another limitation was the small sample numbers in the sub-groups that were used for SYBR Green real 
time qPCR analyses. Comparing six FDW and six FSM animals with the statistical analyses used for the 
SYBR Green real time qPCR resulted in less statistical power. Another factor that should be kept in mind is 
that this study only investigated gene expression and epigenetic profiles in the LDH of these rats, therefore 
future studies that perform similar investigations in other brain regions should be carried out in order to 
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obtain a holistic and comprehensive representation of the effects of intrahippocampally administered DCS 
throughout the brain and how that might facilitate fear extinction. There are also other epigenetic 
mechanisms that could have contributed to the DCS-induced differential gene expression, such as 
posttranscriptionional modifications of histone proteins (acetylation, phosphorylation, ubiquitination and 
sumoylation) and other non-coding RNA-mediated alterations (such as long noncoding (lcnRNAs) which 
could be investigated in future studies to determine if they may have contributed to the differential gene 








Currently available pharmacotherapies for the treatment of PTSD and stress-related disorders are limited and 
while there are effective treatments, they still fall short with regard to optimal efficacy and tolerability. It is 
therefore important to focus efforts towards the identification of novel anxiolytic drugs and to have a 
thorough understanding of their molecular mechanisms. D-cycloserine has been shown to be effective in 
facilitating fear extinction in animals and humans. It is a tuberculstatic drug that is not approved by the FDA 
for the indication of PTSD but is currently being studied. 
 
This study investigated the molecular mechanisms whereby DCS facilitates fear extinction in an animal 
model of PTSD. By comparing gene expression profiles between FDW and FSM animals, we were able to 
identify 42 genes that were downregulated by the drug and that may underlie the molecular mechanism of 
DCS. One of the main effects of co-administration of intrahippocampal DCS and behavioural fear extinction 
was the downregulation of immune system genes and genes transcribing proinflammatory and oxidative 
stress molecules. These molecules mediate neuroinflammation and subsequently cause neuronal damage; 
DCS thereby attenuates neuroinflammation and subsequent neuronal damage. Additionally, DCS also 
regulates genes involved in learning and memory processes. Concomitantly, these gene expression 
alterations mediate optimal neuronal functioning, plasticity, learning and memory which contribute to the 
fear extinction process. Interestingly, some of the genes that were downregulated by DCS have been 
associated with conditions that co-occur and that have been found to be associated with PTSD, such as 
metabolic diseases, cardiovascular disease, Alzheimer’s and Parkinson’s disease. This indicates that DCS 
may not only be effective in treating PTSD, but also some of its co-morbid disorders. Indeed studies have 
also shown the efficacy of DCS in the treatment of other psychiatric disorders.  
 
Future studies could investigate if differentially expressed genes identified in this animal model may be 
extrapolated to human samples to determine if similar genes, biological processes and pathways are involved 
in fear extinction processes in humans. Furthermore, SYBR Green real-time qPCR could be used to perform 
gene expression analysis in other biologically relevant differentially expressed genes identified in this study. 
This could be followed by CpG island identification of those genes detected with SYBR Green real-time 
qPCR to investigate additional CpG islands for DNA methylation and to determine if this may have 
mediated expression changes in other biologically relevant genes identified during RNAseq. Other 
techniques could also be employed to investigate DNA methylation, such as using methyl sensitive enzymes, 
DNA methylation arrays or bisulfite sequencing.  
 
MicroRNA expression profiles revealed 23 miRNAs that were differentially expressed between the FDW 
and FSM animals. Functional analysis suggested that DCS induced differential gene expression might be 
mediated through miRNAs. This study therefore proposes that the co-administration of DCS and behavioural 
fear extinction was able to facilitate fear extinction in this animal model by regulating genes and miRNAs 
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involved in processes, such as neuroinflammation, learning and memory. In turn, this may have minimised 
neuronal damage and ensured optimal learning and memory functioning during the fear extinction process.  
 
Future studies should include identification of potentially novel miRNAs that may be involved in the fear 
extinction process (by employing different bioinformatics techniques on unmapped sequences). 
Differentially expressed miRNAs identified in this animal model could be extrapolated to human samples to 
determine if similar miRNA families play a role in human fear extinction.  
 
This study elucidated some of the mechanisms that underlie DCS induced fear extinction thereby broadening 
our understanding of the fear extinction process through novel insights into gene and miRNA expression 
profiles, molecular functions and biological pathways that are involved in fear extinction. Furthermore, these 
results may point to novel biological targets that could be explored as therapeutic drug targets (e.g. 









Buffers and solutions 
 
1. Electrophoresis stock solutions 
SB Buffer (20x stock) 
di-Sodium tetraborate decahydrate  38.14 g 
ddH2O to a final volume of 1 litre 
 
Bromophenol Blue 
Bromophenol blue    0.2 % (w/v) 
Glycerol     50 % 
Tris (pH 8)     10 mM  
 
Ethidium Bromide  
Ethidium bromide    500 mg 
ddH2O     50 ml 
 
TE buffer (10 x stock) 
Tris OH     0.1 M (pH 8) 
EDTA (pH 8)     0.01 M  
ddH2O      150 ml 
2. Gels 
1 % Agarose gel 
Agarose     1 g 
SB Buffer (1 x)     100 ml   
 
3. Eukaryotic cell culture media 
Complete growth media 
DMEM (4.5 g/L, with L-glutamine)  196 ml 
Foetal calf serum    20 ml 
Penstrep     2 ml 
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Pre-warm to 37 °C before use 
 
Serum-free media 
DMEM (4.5 g/L, with L-glutamine)  100 ml 
Pre-warm to 37 °C before use 
  




Differentially expressed gene between sub-groups 
 
The focus groups of the current study was FDW vs. FSM; genes differentially expressed between these two 
groups might possibly be involved in DCS-induced fear extinction.  However, other groups were also 
compared during the Cuffdiff analysis and their results are depicted in the table below (Table II.1).  Negative 
fold changes imply that gene expression levels in the first group is lower than that in the second group; 
positive fold changes imply that gene expression levels in the first group is higher than that in the second 
group.  Genes in bold in the FDW vs. FSW comparison are genes that were also downregulated in the FDW 
vs. FSM groups.     
Table II.1: Biologically significant differentially expressed genes between other experimental sub-groups.  
Biologically significant genes that were differentially expressed between FSM and CS groups (as identified by BORG 
analyses); negative fold changes indicate that genes were down-regulated in the FDW group compared to the FSM 
group.  
FSM vs. CS 
Gene Name Fold change 
Cxcl13 C-X-C motif chemokine 13 -6.2112 
FSW vs. FSM 
Gene Name Fold change 
Trh Thyrotropin releasing hormone 3.46987 
Serpina3n Serine (or cysteine) peptidase inhibitor, clade A, member 3N 4.68017 
Cxcl13 Chemokine (C-X-C motif) ligand 13 5.39096 
FDW vs. FDM 
Gene Name Fold change 
Htr2c 5-hydroxytryptamine (serotonin) receptor 2C 2.39421 
Tacr3 Tachykinin receptor 3 2.70281 
FDW vs. FSW 
Gene Name Fold change 
Spp1 Secreted phosphoprotein 1 -8.51347 
Clec7a C-type lectin domain family 7, member A -7.45662 
Msr1 Macrophage scavenger receptor 1 -6.00211 
Ccl2 Chemokine (C-C motif) ligand 2 -5.90184 
Mapk13 Mitogen-activated protein kinase 13 -5.7124 
Il1rn Interleukin 1 receptor antagonist -5.40918 
Ccl3 Chemokine (C-C motif) ligand 3 -5.23823 
Il1b Interleukin 1, beta -5.20524 
Trh Thyrotropin releasing hormone -5.19366 
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Cd8a CD8a molecule -4.9112 
Gpnmb Glycoprotein (transmembrane) nmb -4.82344 
Serpine1 Serpin peptidase inhibitor, clade E (nexin, plasminogen activator 
inhibitor type 1), member 1 
-4.77003 
Gdf15 Growth differentiation factor 15 -4.64086 
Cybb Cytochrome b-245, beta polypeptide -4.50854 
Hspb1 Heat shock 27kDa protein 1 -4.45489 
S100a9 S100 calcium binding protein A9 -4.44037 
Cd36 CD36 molecule (thrombospondin receptor) -4.43935 
Cd14 CD14 molecule -4.42828 
S100a4 S100 calcium binding protein A4 -4.26916 
Lbp Lipopolysaccharide binding protein -4.2255 
Bcl3 B-cell CLL/lymphoma 3 -3.96187 
Pf4 Platelet factor 4 -3.90474 
A2m Alpha-2-macroglobulin -3.66365 
Vim Vimentin -3.61174 
F5 Coagulation factor V (proaccelerin, labile factor) -3.52583 
Ctsc Cathepsin C -3.48689 
Ncf1 Neutrophil cytosolic factor 1 -3.45246 
Mt2A Metallothionein 2A -3.42771 
Slc11a1 Solute carrier family 11 (proton-coupled divalent metal ion transporters), 
member 1 
-3.42324 
Tspo Translocator protein -3.2462 
Tagln Transgelin -3.17222 
Cd44 Cd44 molecule -3.15101 
C3ar1 Complement component 3a receptor 1 -3.13968 
Mt1a Metallothionein 1A -3.09502 
Fcgr2b Fc fragment of IgG, low affinity IIb, receptor (CD32) -3.00999 
Ptprc Protein tyrosine phosphatase receptor type, C -2.99249 
Prlhr Prolactin releasing hormone receptor -2.97606 
Pttg1 Pituitary tumor-transforming 1 -2.95509 
Cp Ceruloplasmin  (glycoprotein) -2.95249 
Spta1 Spectrin, alpha, erythrocytic 1 (elliptocytosis 2) -2.92093 
Cd4 Cd4 molecule -2.91443 
Hpgds Hematopoietic prostaglandin D synthase -2.7878 
Fes Feline sarcoma oncogene -2.68594 
Gldn Gliomedin -2.67487 
Cd300a CD300a molecule -2.65669 
Cd86 CD86 molecule -2.6457 
Espl1 Extra spindle pole bodies homolog 1 (S. cerevisiae) -2.63542 
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S100a3 S100 calcium binding protein A3 -2.62302 
Cdc20 Cell division cycle 20 -2.62129 
S100a10 S100 calcium binding protein A10 -2.53721 
Fcer1g Fc fragment of IgE, high affinity I, receptor for; gamma polypeptide -2.53653 
Fermt3 Fermitin family member 3 -2.53267 
C1qa Complement component 1, q subcomponent, A chain -2.50657 
Spi1 Spleen focus forming virus (SFFV) proviral integration oncogene spi1 -2.49307 
Tyrobp TYRO protein tyrosine kinase binding protein -2.47804 
Irf8 Interferon regulatory factor 8 -2.45074 
Pycard PYD and CARD domain containing -2.42513 
Tlr2 Toll-like receptor 2 -2.37908 
Itga5 Integrin, alpha 5 (fibronectin receptor, alpha polypeptide) -2.31441 
Mafb V-maf musculoaponeurotic fibrosarcoma oncogene homolog B (avian) -2.30377 
Tnfrsf1b Tumor necrosis factor receptor superfamily, member 1B -2.2537 
Lcp1 Plastin-2 -2.24029 
Lgals1 Lectin, galactoside-binding, soluble, 1 -2.22248 
Cd74 Cd74 molecule, major histocompatibility complex, class II invariant 
chain 
-2.2108 
Gadd45a Growth arrest and DNA-damage-inducible, alpha -2.20226 
B4galt1 UDP-Gal:betaGlcNAc beta 1,4- galactosyltransferase, polypeptide 1 -2.06512 
Nlrp3 NLR family, pyrin domain containing 3 -1.97888 
Rbp1 Retinol binding protein 1, cellular -1.96298 
Grn Granulin -1.89918 
Tnfrsf1a Tumor necrosis factor receptor superfamily, member 1A -1.88991 
Serpinf1 Serpin peptidase inhibitor, clade F (alpha-2 antiplasmin, pigment 
epithelium derived factor), member 1 
-1.87216 
Tlr7 Toll-like receptor 7 -1.8502 
Itgam Integrin, alpha M (complement component 3 receptor 3 subunit) -1.846 
Syk Spleen tyrosine kinase -1.83038 
Pla2g4a Phospholipase A2, group IVA (cytosolic, calcium-dependent) -1.80892 
Lyn v-yes-1 Yamaguchi sarcoma viral related oncogene homolog -1.78778 
Tgfb1 Transforming growth factor, beta 1 -1.71818 
Ucp2 Uncoupling protein 2 (mitochondrial, proton carrier) -1.63483 
Csf1r Colony stimulating factor 1 receptor -1.62767 
Shc1 SHC (Src homology 2 domain containing) transforming protein 1 -1.61646 
Tf Transferrin -1.59159 
Npy Neuropeptide Y -1.55933 
Fabp7 Fatty acid binding protein 7, brain -1.55747 
Tmem176b Transmembrane protein 176B -1.53798 
Flna Filamin A, alpha -1.51243 
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Ptafr Platelet-activating factor receptor -1.50641 
Gsn Gelsolin -1.48154 
Cd38 CD38 molecule -1.43933 
Tgm2 Transglutaminase 2, C polypeptide -1.4324 
Nes Nestin -1.42423 
Ncan Neurocan -1.42355 
Ctsl1 Cathepsin L1 -1.42159 
Il17ra Interleukin 17 receptor A -1.42145 
Ifngr1 Interferon gamma receptor 1 -1.39074 
Npc2 Niemann-Pick disease, type C2 -1.34291 
Cxcl13 Chemokine (C-X-C motif) ligand 13 -10.7018 
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